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0.2	Abstract		
Alzheimer’s	disease	(AD)	 is	characterised	by	amyloid	plaques	composed	of	amyloid-beta	(Aß),	
the	cleavage	product	of	the	amyloid	precursor	protein	(APP)	by	the	protease	beta-secretase	(BACE-
1).	Heparan	sulfate	(HS)	inhibits	BACE-1	and	holds	potential	as	a	new	drug	discovery	target;	 in	vivo	
HS	may	act	as	a	brake	on	the	generation	of	Aß	via	regulation	of	BACE-1.	Previous	work	has	identified	
the	 sulfate	 moieties	 in	 HS	 as	 key	 determinants	 in	 the	 efficacy	 of	 BACE-1	 inhibition.	 Structural	
changes	in	HS	are	known	to	occur	with	ageing	and	we	hypothesised	that	these	changes	could	result	
in	reduced	BACE-1	inhibition	and	ultimately	elevated	production	of	Aß.		
	
Strong	 anion	 exchange	 chromatography	 was	 used	 to	 assess	 disaccharide	 composition	 of	 HS	
from	AD	(n=20)	and	age-matched	control	(n=15)	brain	tissue.	TaqMan®	array	profiling	of	HS-related	
genes	was	also	carried	out	to	explore	expression	levels	of	HS-related	genes	that	may	be	responsible	
for	downstream	HS	structural	changes.	HS	purified	from	AD	and	age-matched	control	samples	was	
assessed	 for	 its	 ability	 to	 inhibit	 BACE-1	 using	 FRET-based	 BACE-1	 activity	 assays	 and	 finally,	
manipulation	 of	 endogenous	 HS	 in	 HEKSweAPP	 cells	 with	 RNAi	 was	 carried	 out	 to	 explore	 the	
possibility	of	modulating	generation	of	the	toxic	Aß	species.	
	
HS	 from	AD	 tissue	was	 found	 to	 carry	 a	 significantly	 decreased	proportion	of	 the	di-sulfated	
ΔUA-GlcNS(6S)	 disaccharide	 vs.	 controls	 (p<0.01)	 and	 increased	 levels	 of	 the	 lesser-sulfated	 ΔUA-
GlcNAc(6S)	unit	 vs.	 controls	 (p<0.05).	 Furthermore,	 significantly	more	 total	HS	was	present	within	
control	 brain	 tissue	 (122.3µg/100mg)	 vs.	 AD	 (78.6µg/100mg)	 (p<0.01).	 TaqMan®	 array	 analysis	
revealed	 significant	 alteration	 in	 expression	 of	 HS	 biosynthetic	 genes	 with	 AD	 including	 up-
regulation	of	HS6ST1	 (p<0.05)	and	a	strong	trend	 for	down	regulation	of	HS6ST3,	 coupled	with	up	
regulation	of	SULF1.	These	changes	may	go	some	way	to	explain	changes	in	the	level	of	sulfation	of	
HS	 particularly,	 6-O	 sulfation,	 as	 observed	 by	 structural	 analysis.	Most	 noticeably,	 BACE-1	 activity	
assays	revealed	a	significant	reduction	of	BACE-1	inhibition	efficacy	by	HS	from	AD	patients	(p<0.05).	
In	 addition,	 knockdown	 of	 SULF1	 in	 HEKSweAPP	 cells,	 which	 would	 be	 expected	 to	 elevate	 6-O	
sulfation,	generated	a	significant	reduction	in	Aß.	
	
Our	 observation	 that	 AD	 brain	 HS	 contains	 fewer	 di-sulfated	 ΔUA-GlcNS(6S)	 disaccharides,	
alongside	observed	upstream	gene	expression	changes,	would	be	consistent	with	a	less	sulfated	HS	
chain	 with	 reduced	 ability	 to	 inhibit	 BACE-1	 thus	 generating	 more	 Aß	 as	 observed	 in	 AD.	 The	
observed	 reduction	 in	 BACE-1	 inhibition	 efficacy	 by	 HS	 with	 AD	 confirms	 our	 hypothesis	 that	
structural	 changes	 in	HS	may	contribute	 to	modulating	AD	pathogenesis	 in	patients.	 Finally,	 these	
studies	 support	 the	 idea	 that	 HS-based	 therapeutics	 might	 provide	 the	 basis	 for	 novel	 disease	
modifying	drugs	that	could	prove	beneficial	in	future	efforts	to	treat	an	underlying	cause	of	AD.	
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0.6	Abbreviations
A	
Aβ	–	Amyloid	Beta	
AD	–	Alzheimer’s	disease	
AGRN	–	Agrin	
AMAC	–	2-Aminoacridone	
APP	–	Amyloid	Precursor	
Protein	
	
B	
BACE-1	–	Beta-Site	APP	
Cleaving	Enzyme	
BBB	–	Blood	Brain	Barrier	
BDR	–	Brains	for	Dementia	
Research	
BODIPY	-	4,4-Difluoro-4-Bora-
3a,4a-Diaza-S-Indacene	
	
C	
CBD	–	Cortical	Basal	
Degeneration	
CD44	–	CD44	
CERAD	–	Consortium	to	
Establish	a	Registry	for	
Alzheimer’s	disease	
COL18A1	–	Type	18	Collagen	
CS	–	Chondroitin	Sulfate	
CSF	–	Cerebral	Spinal	Fluid	
CT	–	Computed	Tomography	
	
D	
DEAE	-	Diethylaminoethanol	
DNA	–	Deoxyribonucleic	Acid	
DS	–	Dermatan	Sulfate	
	
E	
EDTA	–	ethylene-di-amine-
tetra-acetic	acid	
EEG	–	Electroencephalogram	
EST	–Expressed	Sequence	Tag	
Analysis	
EXT1	–	Exostose-1	
EXT2	–	Exostose-2	
EXTL3	–	Exostose-like-3	
	
F	
FGF-2	–	Fibroblast	Growth	
Factor-2	
FTDP-17	–	Frontal-Temporal	
Dementia	leading	to	
Parkinsonism	on	chromosome	
17	
	
	
G	
GAG	–	Glycosaminoglycan	
GALT1	–	Galactosyltransferase	
1	
GALT2	–	Galactosyltransferase	
2	
GlcA	–	Glucuronic	acid	
GLCE	–	C5-Epimerase	
GlcNAc	–	N-acetyl-
glucosamine	
GlcNS	–	N-sulfate-glucosamine	
GPC1	–	Glypican-1	
GPC2	–	Glypican-2	
GPC3	–	Glypican-3	
GPC4	–	Glypican-4	
GPC5	–	Glypican-5	
GPC6	–	Glypican-6	
	
H	
HA	–	Hyaluronic	acid	
HS	–	Heparan	Sulfate	
HPLC	–	High	Performance	
Liquid	Chromatography	
HPSE	-	Heparinase	
HS6ST1	–	Heparan	Sulfate	6-O	
Sulfotransferase-1	
HS6ST2	–	Heparan	Sulfate	6-O	
Sulfotransferase-2	
HS6ST3	–	Heparan	Sulfate	6-O	
Sulfotransferase-3	
HS2ST1	–	Heparan	Sulfate	2-O	
Sulfotransferase-1	
HS3ST1	–	Heparan	Sulfate	3-O	
Sulfotransferase-1	
HS3ST2	–	Heparan	Sulfate	3-O	
Sulfotransferase-2	
HS3ST4	–	Heparan	Sulfate	3-O	
Sulfotransferase-4	
HS3ST5	–	Heparan	Sulfate	3-O	
Sulfotransferase-5	
HS3ST6	–	Heparan	Sulfate	3-O	
Sulfotransferase-6	
HSPG	–	Heparan	Sulfate	
Proteoglycan	
HSPG2	–	Perlecan	
	
I	
IdoA	–	Iduronic	Acid	
	
J	
	
K	
KS	–	Keratan	Sulfate	
	
L	
	
M	
MMSE	–	Mini	Mental	State	
Exam	
MPSS	–	Massively	Parallel	
Signature	Sequence	Tag	
Analysis	
MRC	–	Medical	Research	
Council	
MRI	–	Magnetic	Resonance	
Imaging	
MS	–	Mass	Spectrometry	
	
N	
NaCl	–	Sodium	Chloride	
NaOH	–	Sodium	Hydroxide	
NDST1	–	N-Deacetylase/N-
Sulfotransferase-1	
NDST2	–	N-Deacetylase/N-
Sulfotransferase-2	
NDST3	–	N-Deacetylase/N-
Sulfotransferase-3	
NDST4	–	N-Deacetylase/N-
Sulfotransferase-4	
NFTs	–	Neurofibrillary	Tangles	
NIA	–	National	Institute	of	
Ageing	
NIH	–	National	Institute	of	
Health	
NIHR	–	National	Institute	of	
Health	Research	
NRP1	–	Neuropilin-1	
NINCDS-ADRDA	–	National	
Institute	of	Neurological	and	
Communicative	Disorders	and	
Stroke	and	the	Alzheimer’s	
disease	and	Related	Disorders	
Association	
NO	–	Nitric	Oxide	
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O	 	 	
	
P	
PBS	–	Phosphate	Buffered	
Saline	
PET	–	Positron	Emission	
Tomography	
PHF	–	Paired	Helical	Filaments	
PIMH	–	Porcine	Intestinal	
Mucosal	Heparin	
PMD	–	Post	Mortem	Delay	
PSP	–	Progressive	
Supranuclear	Palsy	
	
Q	
	
R	
ROS	–	Reactive	Oxygen	
Species	
RNS	–	Reactive	Nitrogen	
Species	
RNA	–	Ribonucleic	Acid	
RP-HPLC	–	Reverse	Phase	High	
Performance	Liquid	
Chromatography	
RT-PCR	–	Real	Time	
Polymerase	Chain	Reaction	
	
S	
SAGE	–	Serial	Analysis	of	Gene	
Expression	
SAX	–	Strong	Anion	Exchange	
SAX-HPAEC	–	Strong	Anion	
Exchange	–	High	Performance	
Chromatography	
SAXS	–	Small	Angle	X-Ray	
Scattering	
SULF1	–	Sulfatase	1	
SULF2	–	Sulfatase	2	
SDC1	–	Syndecan-1	
SDC2	–	Syndecan-2	
SDC3	–	Syndecan-3	
SDC4	–	Syndecan-4	
SRGN	-	Serglycin	
	
T	
TLC	–	Thin	Layer	
Chromatography	
TBFBR3	–	Beta-glycan	
	
U	
UV	–	Ultraviolet	
	
V	
	
W	
	
X	
XYLT1	–	Xylosyltransferase-1	
XYLT2	–	Xylosyltransferase-2	
	
Y	
	
Z	
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1.	Chapter	1		
1.1	Introduction	to	glycosaminoglycans	
	 	
Glycosaminoglycans	 (GAGs)	 are	 complex	 polysaccharides	 that	 are	 made	 up	 of	 repeating	
units	 of	 disaccharide	 entities	 that	 may	 vary	 in	 their	 sequence,	 linkage	 motif	 and	 modification	
pattern;	 i.e.	 the	degree	of	sulfated	and	acetylated	motifs	 that	may	be	present	along	 the	 length	of	
the	GAG	chain.	The	extent	of	variability	between	members	of	the	GAG	family	is	considerable	and	as	
such	 these	molecules	 are	 found	 to	 be	 involved	 in	mediating	 a	 significant	 proportion	 of	 biological	
processes	and	pathways	within	the	body.	The	size	of	GAG	chains	is	not	well	defined	and	may	be	as	
long	as	25,000	disaccharide	units	in	length	in	the	case	of	hyaluronic	acid	(HA)	(Handel,	et	al.	2005).	
GAGs	 are	 localised	 to	 a	 number	 of	 regions	 of	 the	 cell,	 found	 free	within	 cells,	 but	 also	 bound	 to	
membrane	surfaces	as	proteoglycans	or	 shed	as	a	 soluble	ectodomain	 (Capila	and	Linhardt	2002).	
The	 structural	 diversity	 afforded	 by	 GAG	 chains	 makes	 them	 potent	 modulators	 of	 biological	
functions	 and	 changes	 in	 their	 structure	 (and	hence	binding	 affinity	with	 specific	 protein	 ligands),	
confers	substantial	variation	in	the	efficacy	of	these	physiological	reactions.	As	such,	understanding	
GAG	chain	complexity	and	functionality	offers	a	great	deal	of	insight	into	molecular	mechanisms	and	
indeed	disease	pathogenesis.	 The	heterogeneity	 and	 complex	 regulation	of	GAGs	present	 analysis	
challenges	 resulting	 in	 some	 distinct	 gaps	 in	 our	 understanding	 of	 their	 biology.	 Advances	 in	
carbohydrate	 chemistry	 in	 recent	 years	 however	 has	 alleviated	 some	of	 these	 difficulties	 and	 has	
begun	 to	 allow	 elucidation	 of	 the	 role	 of	 GAG	 chains	 in	 vivo	 with	 respect	 to	 health	 and	 disease	
(Handel,	et	al.	2005).		
	
	 Members	 of	 the	 GAG	 family	 include	 heparan	 sulfate	 (HS),	 chondroitin	 sulfate	 (CS),	
dermatan	sulfate	 (DS)	 (Sugahara,	et	al.	2003),	keratan	sulfate	 (KS)	 (Funderburgh	2000),	hyaluronic	
acid	(HA)	and	heparin	(Capila	and	Linhardt	2002).	These	GAGs	differ	in	their	structural	characteristics	
and	protein	binding	affinities	and	as	such	play	very	different	physiological	roles	within	the	body.		
	
1.2	Heparan	sulfate		
	 HS	is	the	most	ubiquitous	of	the	GAG	chains	and	comprises	between	50%	and	90%	of	total	
endothelial	 proteoglycans	 (PGs)	 (Handel,	 et	 al.	 2005).	 Furthermore,	 HS	 presents	 the	 most	 highly	
heterogeneous	structural	capacity	of	all	GAGs	and	may	exert	its	function	both	on	the	cell	surface,	in	
the	matrix,	 and	 in	 soluble	 form,	making	 its	 role	 within	 the	 body	wide	 and	 varied.	 HS	 consists	 of	
repeating	 disaccharide	 units	 of	 alternating	 glucuronic/iduronic	 acid	 (GlcA/IdoA)	 and	 glucosamine	
(GlcNAc).	 (Esko	 2001).	 One	 or	 more	 HS	 chains	 can	 covalently	 bind	 to	 a	 core	 protein	 forming	 a	
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heparan	sulfate	proteoglycan	(HSPG)	(Bernfield,	et	al.	1999).	HSPGs	play	central	roles	in	both	normal	
physiology	and	development.	Within	the	structure,	variably	sulfated	and	acetylated	motifs	exist	that	
confer	 different	 binding	 properties	 to	 protein	 ligands	 via	 electrostatic	 forces	 of	 attraction.	
Consequently,	 HS	 is	 able	 to	 regulate	 metabolism,	 transport,	 support,	 and	 information	 transfer	
(Bishop,	et	al.	2007).	
	
1.2.1	HS	biosynthesis		
1.2.1.1	HS	chain	initiation	
	
	 The	 biosynthesis	 of	 HS	 has	 been	 more	 conclusively	 understood	 in	 recent	 years	 and	
molecular	 cloning	of	 specific	HS	biosynthetic	enzymes	has	allowed	 scientists	 to	better	understand	
the	 function	 of	 this	 biosynthetic	machinery,	 as	well	 as	 the	 complexity	 and	 regulation	 of	HS	 chain	
production.	HS	chain	biosynthesis	is	 initiated	by	the	formation	of	a	linkage	region	that	links	the	HS	
chain	to	a	core	protein.	The	core	proteins,	which	carry	HS	chains,	 include	syndecan	(SDC),	glypican	
(GPC),	 agrin	 (AGRN),	 perlecan	 (HSPG2)	 and	 collagen	 XVIII	 (COL18A1).	Other	HSPGs	 exist	 that	 only	
carry	 the	HS	chains	under	certain	circumstances	are	 referred	 to	as	“part	 time”	HSPGs	and	 include	
CD44,	 betaglycan	 (TGFBR3)	 and	 testican	 (SPOCK)	 (Parish	 2006).	 The	 relative	 amounts	 of	 these	
proteins	 may	 act	 as	 a	 limiting	 factor	 in	 the	 synthesis	 of	 HS.	 Likewise,	 regulatory	 domains	 within	
these	proteins,	other	than	the	HS	binding	sites	themselves,	may	have	important	regulatory	function	
(Chen	and	Lander	2001).	HS	biosynthesis	begins	with	the	generation	of	a	tetrasaccharide	glucuronic	
acid-galactose-galactose-xylose	linker	region.	Xylotransferase	enzymes,	XYLT	or	XYLT2,	add	xylose	to	
a	 serine	 residue	 on	 the	 core	 HS	 protein	 to	 initiate	 this	 linker	 formation.	 The	 addition	 of	 two	
galactose	residues	by	galactosyltransferases	GALT-1	and	GALT-2	follows	and	the	linker	is	completed	
by	a	final	addition	of	GlcA	via	the	action	of	GlcAT-1	transferase	(Kreuger	and	Kjellen	2012,	Zhang,	et	
al.	1995).	The	linker	region	generated	in	this	instance	for	HS	synthesis	is	identical	to	that	generated	
for	CS.	Elongation	of	the	HS	chain	occurs	via	the	action	of	a	family	of	glycosyltransferases,	EXTLs.	The	
enzymes	work	by	catalysing	the	addition	of	GlcNAc	to	the	non-reducing	end	of	the	tetrasaccharide	
linker	 to	begin	 the	elongation	of	 the	HS	chain.	 	Following	this,	a	polymerase	complex	of	EXT1	and	
EXT2	enzymes	add	alternating	GlcA	and	GlcNAc	residues	to	the	HS	chain.	At	this	point,	the	HS	chain	
becomes	a	substrate	for	chain	modification	by	a	number	of	enzymes	and	addition	of	the	first	GlcNAc	
residue	 limits	 the	 chain	 to	 the	 HS	 pathway.	 These	 enzymes	 are	 numerous	 and	 exhibit	 different	
substrate	specificity,	which	is	not	entirely	understood	as	yet	(Esko	and	Selleck	2002).	Furthermore,	
not	all	of	these	modification	reactions	will	go	to	completion	along	the	HS	chain,	further	conferring	
structural	heterogeneity	between	different	GAG	chains	(Figure	1.1).		
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1.2.1.2	HS	chain	modification	
	
Modification	of	the	HS	chain	begins	with	N-deacetylation/N-sulfation	of	GlcNAc	residues	by	
the	family	of	NDST	enzymes	(NDST1-4).	The	action	of	this	family	is	the	first	committed	reaction	in	HS	
chain	modification	 and	 is	 a	 pre-requisite	 for	 all	 subsequent	modifications	 that	 the	 HS	 chain	may	
undergo.	The	members	of	the	NDST	family	of	enzymes	all	share	reasonably	high	sequence	specificity	
and	 overall	 structure	 however	 the	 ratio	 of	 deacetylase	 and	 sulfotransferase	 activity	 differs	
significantly	 between	 the	 family	 isoforms.	 NDST2	 for	 example,	 exhibits	 a	 higher	 ratio	 of	 N-
deacetylase/N-sulfotransferase	 activities	 vs.	 NDST1.	 Furthermore,	 NDST3	 and	 NDST4	 have	 starkly	
different	ratios	of	activity	compared	to	NDST1	and	NDST2.	NDST3	has	a	much	greater	efficiency	at	
removing	acetyl	groups	at	the	N-	position	whilst	conversely;	NDST4	exhibits	robust	sulfotransferase	
activity	 (Aikawa,	 et	 al.	 2001).	 Interestingly	 whilst	 NDST1	 and	 NDST2	 genes	 are	 expressed	
ubiquitously,	 expression	 of	 NDST3	 and	 NDST4	 genes	 are	 restricted	 to	 the	 adult	 brain	 and	 fetal	
tissues	 (Aikawa	 and	 Esko	 1999,	 Toma,	 et	 al.	 1998).	 The	 differential	 expression	 of	 these	 genes	
alongside	 other	 HS-related	 genes	 would	 suggest	 that	 the	 synthesis	 of	 GAG	 chains	 is	 a	 tightly	
regulated	process	akin	 to	processes	 such	as	 the	 translation	of	 fibroblast	growth	 factors	 like	FGF-2	
(Kevil,	et	al.	1995).		
	
1.2.1.3	HS	domain	structure	
	
Modification	by	the	NDST	enzymes	is	not	carried	out	to	completion	at	all	N-positions	along	
the	HS	chain.	As	a	 result,	N-sulfated	 regions	will	be	 interspersed	with	N-acetylated	 regions,	giving	
rise	to	so-called	“NS-domains”	and	“NA-domains”	respectively	along	the	HS	chain	(Esko	and	Lindahl	
2001,	 Turnbull	 and	 Gallagher	 1991)	 (Figure	 1.1).	 These	 domains	 may	 occur	 in	 a	 multitude	 of	
conformations	 and	 hence	 provide	 the	 HS	 chain	 with	 a	 macroscopic	 structural	 heterogeneity.	
Likewise,	the	level	of	modification	to	individual	disaccharides	within	the	chain	can	vary	substantially.	
Overall,	these	structural	alterations	confer	a	wide	variety	of	protein	ligand	binding	potential.	
	
1.2.1.4			Epimerisation	of	the	HS	chain	
	
Action	of	the	C5-epimerase	enzyme,	GLCE,	follows	modification	by	the	NDST	enzyme	family	
and	 subsequently	 epimerises	 some	 (but	 not	 all)	 of	 the	GlcA	units	 to	 IdoA.	 	 Previous	 research	 has	
indicated	 that	 epimerisation	 in	 this	 fashion	 does	 not	 occur	 on	 those	 units	 that	 are	 already	 O-
sulfated,	nor	those	adjacent	to	O-sulfated	GlcNAc	residues	(Backstrom,	et	al.	1979).	These	findings	
thus	suggest	that	epimerisation	occurs	after	N-deacetylation/N-sulfation	but	before	sulfation	at	the	
6-O	and	3-O	position	(Lindahl,	et	al.	1976).	 Indeed,	 it	has	been	suggested	that	the	extent	to	which	
IdoA	residues	are	generated	along	the	HS	chain	is	restricted	by	the	degree	of	N-deacetylation/N-		
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Figure	1.1:	The	different	stages	in	the	biosynthesis	of	HS.	Diagram	to	show	a	simplified	scheme	of	chain	formation	and	modification	involved	in	the	synthesis	of	HS.	Enzymes	responsible	for	
each	change	are	shown	at	respective	steps.	Formation	of	the	HS	chain	occurs	first	followed	by	considerable	modification	via	a	number	of	different	enzymes.	Abbreviations:	Xyl;	Xylose,	Gal;	
Galactose,	GlcA;	Glucuronic	acid,	GlcNAc;	N-acetylated	glucosamine,	IdoA;	Iduronic	acid,	XYLT1/2;	Xylosyltransferase	1/2,	GALT1/2;	Galactosyltransferase	1/2,	GlcAT1;	Glycosyltransferase	1,	
EXT1/2;	 Exostosin	 Glycosyltransferase	 1/2,	 EXTL;	 Exostosin	 Glycosyltransferase	 Like,	 NDSTs;	 N-Deacetylase/N-Sulfotransferase,	 GLCE;	 C5	 Epimerase,	 HS2ST1;	 Heparan	 sulfate	 2-O	
sulfotransferase,	 HS6ST;	 Heparan	 Sulfate	 6-O	 Sulfotransferase,	 HS3ST;	 Heparan	 Sulfate	 3-O	 Sulfotransferase,	 NS;	 N-sulfated	 GlcN,	 6S;	 6-O-sulfated	 GlcN,	 2S;	 2-O-sulfated	 IdoA,	 3S;	 3-O-
sulfated	GlcN,	Ser;	serine.		
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sulfation	 that	 has	 occurred	 previously	 (Esko	 and	 Selleck	 2002).	 This	 variable	 regulation	 of	
epimerisation	as	evidenced	by	domain	distribution	alongside	NDST	modification	and	expression	of	
the	GLCE	gene	will	further	contribute	to	the	structural	heterogeneity	observed	within	HS.		
	
1.2.1.5	Sulfation	at	the	2-O,	6-O	and	3-O	position	
	
	 Addition	of	further	sulfate	groups	may	occur	at	various	positions	along	the	HS	chain	at	the	
2-O,	6-O	and	3-O	position	by	2-O	sulfotransferases,	6-O	sulfotransferases	and	3-O	sulfotransferases	
respectively.	Addition	of	sulfate	groups	in	this	way	can	occur	in	multiple	locations	on	the	constituent	
HS	residues	(Smeds,	et	al.	2003).	
	
A	2-O	sulfotransferase	enzyme,	HS2ST1	acts	to	transfer	a	sulfate	group	to	the	2-OH	position	
of	 both	 an	 IdoA	 and	 GlcA	 residues;	 however	 shows	 preferential	 efficacy	 for	 the	 IdoA	 (Esko	 and	
Selleck	 2002)	 to	 form	2-OS	 IdoA	 or	 2-OS	GlcA.	 The	 IdoA-2-OS	 residues	 have	 been	 shown	 to	 have	
physiological	 functions	 and	 this	 structural	 motif	 is	 particularly	 important	 for	 the	 stimulation	 of	
growth	factor	mediated	signal	transduction	pathways	(Kreuger,	et	al.	2001).	The	HS2ST1	enzyme	has	
also	been	implicated	in	axon	migration	and	guidance	in	nervous	system	development	(Kinnunen,	et	
al.	2005)	and	knockdown	of	the	HS2ST1	gene	is	compensated	for	with	enhanced	sulfation	at	the	6-O	
position.	In	addition,	research	suggests	that	the	HS2ST1	enzyme	is	able	to	utilise	structural	elements	
along	the	HS	chain	to	distinguish	particular	sulfation	patterns	to	determine	substrate	specificity	(Liu,	
et	al.	2014).	It	is	believed	that	this	may	drive	the	way	and	extent	to	which	the	HS	chain	is	modified.	
Furthermore,	 prominence	of	 2-O	 sulfation	 appears	 to	 be	 somewhat	 linked	with	 the	 extent	 of	 C5-
epimerisation	 and	 N-deacetylation/N-sulfation	 suggesting	 that	 these	 modification	 events	 may	 at	
least	in	some	way	occur	simultaneously	(Esko	and	Selleck	2002).		
	
The	addition	of	a	 sulfate	group	at	 the	6-O	position	has	been	shown	 to	 take	place	via	 the	
action	 of	 three	 6-O	 sulfotransferases,	 HS6ST1,	 HS6ST2	 and	 HS6ST3.	 These	 enzymes	 catalyse	 the	
transfer	of	a	sulfate	group	to	the	GlcNAc/GlcNS	residues	of	the	HS	chain.	The	activity	of	each	isoform	
is	 not	 fully	 understood	 however	 there	 is	 some	 evidence	 that	 each	 family	 member	 has	 different	
specificity	of	action	depending	on	the	nature	of	the	residue	it	acts	upon.	Previous	work	has	indicated	
that	HS6ST1	 prefers	 the	 IdoA-GlcNS	 unit	whilst	 HS6ST2	 shows	 preference	 for	 the	GlcA-GlcNS	 and	
IdoA-GlcNS	 units.	 Finally,	 the	 HS6ST3	 isoform	 will	 act	 on	 either	 residue	 regardless	 of	 substrate	
availability	(Habuchi,	et	al.	2000).		Similarly,	the	3-O	sulfotransferase	family	of	enzymes	is	made	up	
of	7	isoforms.	This	group	is	responsible	for	the	rare	addition	of	a	sulfate	group	to	the	3-OH	position	
of	a	N-sulfated	glucosamine	or	an	N-acetylated	glucosamine	to	form	3-O	glucosamine.	It	is	believed	
that	the	different	isoforms	exhibit	varying	specificity	for	different	substrates	and	the	activity	of	each	
result	in	very	different	structures	of	HS	(Moon,	et	al.	2012).		
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1.2.1.6	Removal	of	sulfate	groups	at	the	6-O	position	
	
In	addition	 to	 those	modification	events	 that	 transfer	a	 sulfate	group	on	 to	 the	HS	chain,	
the	 sulfatase	 family	 of	 enzymes	 (post	 synthetic	modification	 enzymes),	 SULF1	 and	 SULF2	 catalyse	
the	hydrolysis	of	the	sulfate	ester	bond	at	the	carbon-6	position	of	the	GlcNAc	residues	on	the	HS	
chain	 (Morimoto-Tomita,	 et	 al.	 2002,	 Nagamine,	 et	 al.	 2012).	 Previous	 work	 has	 discovered	 that	
removal	 of	 6-O	 sulfate	 groups	 in	 this	 manner	 can	 both	 activate	 and	 attenuate	 important	 cell	
signaling	pathways	within	 the	body	 (Dhoot,	et	al.	2001,	Lai,	et	al.	2003).	The	subtle	changes	 in	HS	
structure	 that	 SULF1	 and	 SULF2	 thus	 afford	 make	 them	 key	 players	 in	 the	 regulation	 of	 key	
physiological	 processes	 such	 as	 cell	 proliferation,	 differentiation	 and	 migration	 (Lamanna,	 et	 al.	
2007).	Studies	 suggest	 that	SULF1	and	SULF2	enzymes	prefer	 the	highly	 sulfated	substrates	of	 the	
tri-sulfated	ΔUA2S-GlcNS6S	and	di-sulfated	ΔUA-GlcNS6S	residues	(Frese,	et	al.	2009,	Lamanna,	et	al.	
2008).		
	
Together,	 the	 action	 of	 these	 biosynthetic	 enzymes	 generates	 HS	 with	 great	 structural	
heterogeneity,	which	in	turn	confers	a	diverse	ligand	binding	capacity	and	thus	functional	repertoire	
within	 the	 body	 (Figure	 1.1).	 	 In	 particular,	 its	 interaction	with	 such	 a	 plethora	 of	 protein	 ligands	
makes	 it	 a	 target	 for	 further	 elucidating	 functional	 mechanisms	 in	 both	 normal	 physiology	 and	
disease	 pathogenesis.	 More	 recently,	 HS	 has	 been	 identified	 as	 a	 key	 mediator	 of	 Alzheimer’s	
pathology	 and	 understanding	 its	 role	 in	 the	 pathogenesis	 of	 this	 neurodegenerative	 disease	may	
prove	fundamental	in	understanding	its	pathological	pathways	and	symptom	onset.	
	
1.3	Alzheimer’s	disease		
1.3.1	Background	
	
Alzheimer’s	disease	(AD)	is	a	neurological	condition	that	leads	to	progressive	degeneration	
of	brain	function	and	is	the	leading	cause	of	dementia	amongst	the	elderly	today	(Allan,	et	al.	2009).	
AD	was	 first	described	 in	1906	by	German	neuropathologist	and	psychiatrist	Alois	Alzheimer	after	
the	death	of	one	of	his	patients	Auguste.	D,	a	fifty	year-old	woman	he	had	been	studying	since	1901	
when	she	came	to	him	presenting	symptoms	of	memory	loss,	disorientation	and	personality	deficits.	
Alzheimer	went	on	to	name	the	condition	and	made	it	a	clinically	recognised	disease	(Berchtold	and	
Cotman	1998).	The	incidence	of	AD	is	rapidly	increasing	and	in	2006	there	were	26.6	million	people	
suffering	from	this	condition	globally.	This	 is	predicted	to	 increase	so	that	by	2050,	1	 in	85	people	
around	 the	world	will	 be	diagnosed	with	AD	 (Brookmeyer,	 et	al.	 2007).	 Indeed,	AD	 is	becoming	a	
rapidly	expanding	burden	for	the	global	economy	and	in	some	instances;	the	cost	of	care	giving	to	
those	afflicted	exceeds	the	capacities	of	some	developing	countries.		
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1.3.2	Diagnosis	
	
	 The	difficulties	associated	with	the	diagnosis	of	AD	may	be	part	of	the	reason	that	to	date	
there	 exists	 no	 curative	 treatment	 for	 this	 condition.	 Detection	 and	 clinical	 diagnosis	 of	 AD	 is	
particularly	challenging	and	currently	only	100%	certain	diagnosis	can	be	achieved	at	post	mortem	
meaning	 treatment	 strategies	 are	 often	 initiated	 too	 late	 on	 in	 disease	 progression.	 There	 are	 a	
number	of	different	medical	criteria	that	can	be	used	to	diagnose	AD	however	the	most	commonly	
used	is	that	of	the	collaborative	efforts	of	the	National	Institute	of	Neurological	and	Communicative	
Disorders	 and	 Stroke	 and	 the	 Alzheimer’s	 disease	 and	 Related	 Disorders	 Association	 (NINCDS-
ADRDA)	(McKhann,	et	al.	1984).	These	criteria	distinguish	between	definite,	probable	and	possible	
cases	 of	 AD.	 Diagnosis	 of	 definite	 AD	 occurs	 when	 both	 the	 clinical	 features	 of	 probable	 AD	 are	
present	 and	 can	 also	 be	 confirmed	 with	 histopathological	 investigation	 at	 biopsy	 or	 autopsy.	
Probable	 AD	 is	 diagnosed	 after	 a	 thorough	 neurophysical	 examination	 of	 the	 individual	 with	 a	
battery	of	 tests.	 The	Mini	Mental	 State	Examination	 (MMSE)	 is	 the	most	widely	used	 test	despite	
criticism	that	it	is	not	suitable	for	the	diagnosis	of	more	mild	forms	of	dementia.	Deficits	in	areas	of	
cognition	 including	 progressive	 deterioration	 in	memory	 in	 the	 absence	 of	 symptoms	 of	 delirium	
coupled	with	onset	between	the	ages	of	40	and	90	are	considered	indicative	of	AD.	Other	symptoms	
that	may	contribute	 to	 the	diagnosis	of	probable	AD	 include	difficulties	with	 language,	perception	
and	trouble	with	activities	important	to	daily	living.	Signs	of	these	deficits	alongside	a	family	history	
of	 dementia	 may	 be	 confirmed	 with	 spinal	 fluid	 examination,	 electroencephalography	 (EEG)	 and	
computerized	tomography	(CT).	Variations	in	the	onset	of	AD,	presentation	of	symptoms	or	clinical	
manifestation	may	 lead	to	the	diagnosis	of	possible	AD	or	 in	those	cases	where	a	secondary	brain	
disease	or	injury	has	been	previously	identified	(Cummings,	et	al.	1998).	
	
No	 laboratory	 test	 currently	 exists	 to	 confirm	 diagnosis	 of	 AD.	 The	 National	 Institute	 on	
Ageing	 (NIA)	 and	 National	 Institute	 of	 Neurological	 and	 Communicative	 Disorders	 and	 Stroke	
(NINCDS)	(Mirra,	et	al.	1993)	have	established	another	set	of	criteria	to	categorise	and	classify	the	
neuropathology	 implicated	 in	 AD.	 These	 require	 the	 presence	 of	 age-adjusted	 neocortical	 plaque	
densities	 but	 do	 not	 distinguish	 between	 plaque	 type	 and	 their	 location	 within	 the	 cortex.	
Furthermore,	the	Consortium	to	Establish	a	Registry	for	Alzheimer’s	disease	(CERAD)	requires	both	
the	 presence	 of	 age-adjusted	 plaque	 densities	 that	 can	 be	 at	 least	 semi-quantified	 and	 a	 clinical	
diagnosis	of	AD	following	extensive	neurological	examination	(Mirra,	et	al.	1991).	Opponents	have	
argued	that	these	criteria	are	falling	behind	in	light	of	the	advances	in	reliable	biomarkers	that	can	
be	used	 in	conjunction	with	Magnetic	Resonance	 Imaging	 (MRI)	 techniques	and	Positron	Emission	
Tomography	 (PET)	 (Dubois,	 et	 al.	 2007).	 Amendments	 to	 these	 criteria	 now	 require	 at	 least	 one	
biomarker	 of	 AD	 alongside	 the	 still	 very	 important	 clinical	 analysis	 of	 cognition.	 The	 use	 of	 MRI	
allows	visualisation	of	atrophy	 in	areas	of	 the	hippocampus	and	the	entorhinal	cortex	and	may	be	
useful	 in	 determining	 the	 rate	 of	 progression	 of	 AD	 and	 the	 extent	 of	 cognitive	 decline	 that	may	
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follow.	Likewise,	 the	use	of	PET-based	 imaging	techniques	has	become	popular	 in	the	diagnosis	of	
AD	as	it	allows	observation	of	glucose	metabolism	within	different	regions	of	the	brain.	A	diminished	
oxygen	 metabolism	 in	 the	 cingulated	 region	 of	 the	 brain	 is	 commonly	 used	 as	 a	 marker	 for	 the	
diagnosis	of	AD.	Indeed,	the	use	of	radiotracers	in	PET	imaging	is	becoming	common	practice	in	not	
just	dementia	diagnosis	but	also	other	types	of	psychiatric	disorders	(Brooks	2009).	Agents	to	detect	
amyloid-plaque	deposits	within	 the	brain	are	 still	 under	development	but	 could	prove	particularly	
beneficial	in	the	early	detection	of	AD	(Salawu,	et	al.	2011).		
	
1.3.2.1	Biomarkers		
	 There	 have	 been	 calls	 for	 a	 combination	 of	 these	 guidelines	 alongside	 the	 use	 of	
biomarkers.	Biomarkers	refer	to	both	fluid	and	imaging	measures	that	may	clarify	the	identification	
of	 AD	 pathology	 in	 patients.	 Presently,	 biomarkers	 are	 divided	 into	 two	 main	 categories;	 1)	 the	
biomarkers	 identifying	 accumulation	 of	 Aβ	 (to	 be	 discussed).	 These	 biomarkers	 include	 disease-
specific	tracer	retention	using	PET	imaging	and	also	low	levels	of	cerebral	spinal	fluid	(CSF)	Aβ42	and	
2)	 biomarkers	 which	 indicate	 the	 presence	 of	 neuronal	 injury	 of	 degeneration.	 These	 include	
elevated	 levels	 of	 CSF	 tau,	 atrophy	 of	 cortices	 as	 determined	 with	 MRI	 and	 decrease	
fluorodeoxyglucose	uptake	on	PET	 in	a	 temporal	 fashion	 (Jack,	et	al.	2011).	Several	other	 types	of	
biomarker	have	been	identified	however	are	yet	to	be	validated	by	the	AD	criteria	as	defined	by	the	
Alzheimer’s	 Association,	 NIA	 and	 National	 Institute	 of	 Health	 (NIH).	 Examples	 include	 diagnosis	
based	on	electroencephalogram	 (Dauwels,	 et	al.	 2010)	 signaling	whereby	 traces	 from	AD	patients	
present	slowing	of	the	EEG,	perturbations	in	EEG	synchrony	and	reduced	complexity	of	overall	signal	
(Dauwels,	 et	 al.	 2010).	 Furthermore,	 studies	 indicate	 that	 implications	 of	 altered	 resting	 state	
functional	network	connectivity	in	patients	suffering	from	AD	may	also	be	invaluable	as	a	marker	of	
this	 disease	 (Buckner,	 et	 al.	 2005).	 Biomarkers	 will	 ultimately	 prove	 the	 most	 useful	 diagnostic	
marker	 for	 AD,	 avoiding	 current	 difficulties	 associated	 with	 somewhat	 subjective	 cognitive	
evaluation	testing.	A	combination	of	these	alongside	pre-established	mental	examination	may	prove	
to	be	optimal	in	the	detection	of	this	type	of	dementia.		
	
1.3.3	Neuropathology	and	pathophysiology	
	
	 There	 are	 two	 fundamental	 hallmarks	 of	 pathology	 associated	 with	 AD,	 the	 presence	 of	
intracellular	neurofibrillary	 tangles	 (NFTs)	 comprised	of	hyperphosphorylated	 tau	and	extracellular	
senile	plaques	composed	of	the	amyloid-beta	peptide	(Aβ)	(Hyman	and	Gomez-Isla	1997).	These	two	
key	features	of	AD	may	also	be	accompanied	by	the	loss	of	synapses	and	degeneration	of	neurons	as	
well	as	granulovascular	degeneration,	AMY	plaques	(non	beta-amyloid	plaque-like	deposits)	(Lippa,	
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et	 al.	 2000)	 and	 amyloid	 angiopathy	 (Cummings,	 et	 al.	 1998)	 (the	 formation	 of	 amyloid	 deposits	
within	the	walls	of	the	blood	vessels	of	the	central	nervous	system	(CNS))	(Revesz,	et	al.	2002).	
	
1.3.3.1	Neurofibrillary	tangles	(NFTs)	
	
		 Some	 studies	 have	 suggested	 that	 the	 presence	 of	NFTs	within	 the	 neurons	 of	 the	 brain	
correlate	 well	 with	 the	 symptoms	 of	 dementia	 (Arriagada,	 et	 al.	 1992).	 AD	 alongside	 other	
conditions	such	as	Corticobasal	Degeneration	(CBD),	Progressive	Supranuclear	Palsy	(PSP)	and	Pick’s	
disease	 make	 up	 a	 group	 of	 neurodegenerative	 diseases	 referred	 to	 as	 tauopathies,	 and	 are	
characterized	by	extensive	neuronal	 loss,	 brain	 atrophy	and	age-progressing	dementia	 (Yue,	 et	 al.	
2011).	 Indeed	 the	 term	 tauopathy	 is	 rather	 a	 generic	 term	 describing	 the	 accumulation	 of	
abnormally	phosphorylated	tau	(Buee,	et	al.	2000).	
	
	 Tau	 (MAPτ)	 is	 a	 microtubule-associated	 protein	 that	 plays	 an	 important	 role	 in	 the	
pathology	 that	accompanies	AD.	 In	 its	normal	 state,	 tau	 is	a	microtubule	binding	protein	 found	 in	
the	 cytoplasm	 of	 cells.	 It	 is	 a	 soluble	 protein	 found	 within	 the	 human	 CNS	 and	 exists	 in	 6	 main	
isoforms.	Tau	plays	an	important	role	in	the	assembly	(Weingarten,	et	al.	1975)	and	stabilisation	of	
axons	 and	 effectively	 acts	 as	 the	 “train	 tracks”	 by	 which	 cell	 transport	 of	 organelles	 such	 as	
mitochondria	and	other	synaptic	components	occurs	along	(Trojanowski	and	Lee	2005).		
	
	 In	 healthy	 individuals,	 tau	 is	 phosphorylated	 dynamically	 in	 a	 process	 that	 enables	 its	
interaction	with	microtubules	and	this	facilitates	axonal	transport.	However	in	tauopathies	like	AD,	
tau	becomes	hyperphosphorylated	(Brunden,	et	al.	2009).	In	this	condition,	already	phosphorylated	
sites	under	healthy	physiological	conditions	are	further	phosphorylated	into	a	hyperphosphorylated	
state.	 Furthermore,	 specific	 additional	 residue	 sites	 including	 a	 proline-directed	 serine/threonine	
sites	 (Buee,	 et	 al.	 2000)	 become	 phosphorylated	 in	 a	 disease-specific	 manner.	 It	 is	 the	
phosphorylation	of	 these	specific	sites	on	microtubules	that	results	 in	a	reduced	affinity	of	 tau	for	
microtubules,	and	coincidently	 causes	 the	protein’s	dissociation,	negatively	 impacting	microtubule	
stability	 (Gotz,	 et	 al.	 2008).	 Rather	 than	 bind	 to	 microtubules,	 tau	 in	 the	 disease	 state,	 forms	
insoluble	deposits.	These	inclusions	are	usually	in	the	form	of	fibrils	and	are	most	commonly	found	
within	the	dendrites	of	neurons	as	well	as	their	cell	bodies	(Figure	1.2).	
	
	 Pathological	tau	inclusions	usually	exist	in	the	form	of	paired	helical	filaments	(PHFs).	These	
filaments	are	held	together	by	strong	disulfide	bonds	that	crosslink	at	several	sites	 to	create	 large	
insoluble	fibrous	inclusions	that	cannot	be	broken	down	easily	(Mazanetz	and	Fischer	2007).	These	
lesions	have	been	found	to	accumulate	with	a	progressive	nature	that	is	both	spatial	and	temporal,	
spreading	systemically	from	the	transentorhinal	cortex,	to	the	limbic	cortical	regions	and	finally	to		
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the	neocortical	areas	(Terry,	et	al.	1991).	In	doing	so,	these	tangles	are	thought	to	contribute	to	the	
degradation	of	neurons	within	the	brain	and	ultimately	compromise	cognitive	function.			
	
1.3.3.2	Amyloid	pathology	
	
	 The	presence	of	insoluble	amyloid	plaques	within	the	brain	forms	a	second	key	hallmark	of	
AD.	 These	 deposits	 are	 formed	 principally	 of	 the	 β-amyloid	 protein	 (Aβ),	 a	 polypeptide	 of	 40-42	
amino	acid	residues	(Glenner	and	Wong	2012).	The	Aβ	protein	is	generated	through	the	cleavage	of	
the	amyloid	precursor	protein	(APP),	a	single-pass	transmembrane	protein	with	a	large	extracellular	
domain.	 APP	 is	 localised	 to	 chromosome	 21;	 the	 chromosome	 found	 in	 triplicate	 in	 those	 with	
Down’s	syndrome,	a	condition	that	invariably	leads	to	the	onset	of	AD	(Kang,	et	al.	1987,	Robakis,	et	
al.	1987).	This	was	the	first	primary	evidence	for	the	role	of	Aβ	as	the	primary	step	in	the	onset	and	
Figure	1.2:	Tau	and	neurodegeneration.	Microtubules	form	the	basis	of	axonal	transport	and	are	made	from	
both	α-	and	β-tubulin.	It	is	these	“railway	tracks”	along	axons	that	provide	structural	support	to	neurons.	Tau	is	
an	 important	microtubule-associated	protein	 that	 stabilises	microtubules	 through	binding	 to	 specific	binding	
sites	 comprised	 of	 18	 amino-acid	 motifs.	 In	 the	 pathological	 condition,	 tau	 becomes	 hyperphosphorylated	
resulting	 in	 reduced	 affinity	 of	 the	 tau	 protein	 for	microtubules,	 ultimately	 leading	 to	 destabilisation	 of	 the	
microtubule.	 Tau	 dissociates	 as	 a	 consequence	 and	 accumulation	 of	 abnormal	 tau	 settles	 in	 the	 neurons.	
Commonly,	these	aggregations	exist	as	paired	helical	filaments	(PHFs).	Following	the	appearance	of	this	fibrous	
pathological	 tau,	 tau	oligomers	and	 insoluble	 tangles	occur	due	 to	 further	proteolytic	processing.	Tau	 in	 this	
pathological	conformation	ultimately	leads	to	neuronal	degeneration	and	cell	death.	Adapted	from	(Mazanetz	
and	Fischer	2007)	
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progression	of	AD	pathogenesis.	The	primary	component	of	amyloid	plaques	within	 the	brain,	 the	
Aβ	 peptide	 is	 formed	 as	 a	 result	 of	 cleavage	 of	 a	 larger	 precursor	 protein	 called	 the	 amyloid	
precursor	 protein	 (APP).	 This	 is	 a	 large	 protein	 that	 is	 made	 in	 the	 cells	 and	 transported	 to	 the	
membrane	where	it	undergoes	cleavage.	The	cleavage	of	APP	can	occur	via	two	pathways.	Most	APP	
is	processed	via	 the	non-amyloidogenic	pathways.	 In	 this	way,	 the	 formation	of	Aβ	 is	not	possible	
and	generation	of	amyloid	plaque	densities	is	precluded.	During	this	process,	APP	is	cleaved	by	a	α-
secretase	at	the	plasma	membrane,	an	enzyme	belonging	to	the	disintegrin	and	metalloproteinase	
family	 (ADAM).	 3	 candidates	 have	 been	 identified	 for	 this	 cleavage	 step;	 ADAM9,	 ADAM10	 and	
ADM17	 (LaFerla,	 et	 al.	 2007).	 Cleavage	 by	 this	 secretase	 occurs	within	 the	 Aβ	 domain	 itself	 thus	
precluding	 the	 generation	 of	 a	 toxic	 Aβ	 domain.	 Two	 fragments	 are	 released,	 a	 large	 sAPPα	
ectodomain	 released	 into	 the	 extracellular	 space	 and	 a	 carboxyl-terminal	 fragment	 (C83)	 that	
remains	within	the	membrane.	Following	this,	γ-secretase	cleaves	the	C83	 fragment	 to	generate	a	
second,	smaller	P3	fragment	(LaFerla,	et	al.	2007)	(Figure	1.3).	
	
	Unprocessed	 APP	 can	 be	 internalised	 into	 early	 endosomes,	 where	 it	 can	 become	 a	
substrate	for	the	β-site	APP-cleaving	enzyme	1	(BACE1)	(these	endosomes	have	the	optimum	pH	for	
BACE-1	 activity).	 Cleavage	 of	 APP	 by	 BACE-1	 results	 in	 a	 sAPPβ	 ectodomain	 and	 C99	 domain	
composed	 of	 the	 first	 99	 amino	 acids	 of	 APP	 that	 is	 retained	 within	 the	membrane.	 C99	 can	 be	
shuttled	back	to	the	endoplasmic	reticulum	(ER)	to	undergo	a	second	cleavage	of	this	C99	fragment	
by	a	γ-secretase	to	release	the	Aβ	peptide.	C99	can	also	be	shuttled	back	to	the	plasma	membrane	
where	the	γ-secretase	is	also	found,	or	finally,	processed	by	γ-secretase	within	the	endosome	itself.		
The	 γ-secretase	 complex	 is	 composed	 of	 presenilin	 1	 or	 2	 (PS1/2),	 anterior	 pharynx	 defective,	
presenilin	enhancer	2	and	nicastrin	(LaFerla,	et	al.	2007).	The	amyloidogenic	pathway	generates	Aβ	
of	40	amino	acids	(Aβ1-40)	most	frequently	however	the	more	toxic	peptide	of	42	amino	acids	(Aβ1-42)	
is	generated	infrequently	at	a	ratio	of	10:1	(Figure	1.3).		
	
Whilst	it	is	now	largely	understood	how	the	amyloid	peptide	is	deposited	within	the	brain,	
there	 is	 still	 much	 to	 learn	 regarding	 plaque	 development	 and	 deposition.	 Currently,	 it	 is	 widely	
understood	 that	 amyloid	 plaques	 are	 derived	 from	 the	 extracellular	 “seeding”	 of	 smaller	 amyloid	
species	(such	as	the	Aβ	peptide	described	above)	followed	by	progressive	deposition	at	this	seeding	
site	 (Hardy	 and	 Higgins	 1992).	 Whilst	 this	 hypothesis	 is	 adequate	 for	 the	 spread	 of	 amyloid	
pathology	 throughout	 the	 brain,	 it	 does	 not	 identify	 differences	 in	morphological	 features	 of	 the	
plaques.	Some	amyloid	plaques	for	example,	referred	to	as	dense	core	plaques,	are	linked	with	the	
stages	of	inflammation	and	can	be	distinguished	by	the	presence	of	activated	microglia	found	within	
the	plaques	(Ard,	et	al.	1996).		This	is	different	to	other	plaque	types	and	so	presents	a	problem	with	
characterisation	of	different	plaque	staging	 that	occurs	with	progression	of	AD.	Diffuse	and	dense	
amyloid	plaques	are	currently	the	most	predominantly	used	terminology	for	different	plaque	types.	
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The	most	popular	hypothesis	 is	 that	amyloid	peptide	deposits	 form	diffuse	plaques	that	over	time	
evolve	into	dense	core	plaques	(Mackenzie,	et	al.	1995).	
Figure	1.3:	APP	processing	pathways.	The	Aβ	peptide	is	derived	from	a	large	precursor	molecule,	the	amyloid	
precursor	 protein	 (APP),	 a	 transmembrane	protein	 that	 can	undergo	proteolytic	 cleavage	 via	 two	pathways.	
More	often,	APP	is	processed	via	the	non-amyloidogenic	pathway	whereby	the	formation	of	the	Aβ	peptide	is	
negated	as	a	result	of	cleavage	by	an	α-secretase	(ADAM9,	10	or	17)	within	the	Aβ	domain	itself.	This	cleavage	
generates	 two	 fragments,	 the	 larger	 sAPPα	 domain	 and	 the	 smaller	 carboxy-terminal	 c83	 domain.	 APP	 not	
cleaved	 in	 this	 manner	 may	 become	 a	 substrate	 for	 a	 β-secretase	 enzyme	 (BACE-1).	 Cleavage	 in	 this	 way	
generates	two	fragments,	a	sAPPβ	ectodomain	and	a	smaller	domain	consisting	of	99	amino	acids	(C99).	C99	
may	 then	 undergo	 further	 cleavage	 by	 the	 γ-secretase	 complex	 (Presenilin	 1,2,	 nicastrin,	 anterior	 pharynx	
defective	 (APH-1)	 and	 presenilin	 enhancer	 2	 (PEN2))	 to	 generate	 the	 Aβ	 peptide	 and	 a	 C59	 domain.	 This	
cleavage	produces	Aβ1-40	and	the	more	amyloidogenic	Aβ1-42	at	a	ratio	of	10:1.		
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Despite	 this,	 there	 are	 still	 a	 great	 number	 of	 unanswered	 questions	 concerning	 why	
plaques	 are	 different	 sizes	 and	 made	 up	 of	 different	 components	 and	 why	 certain	 components	
remain	resistant	to	proteolysis	whilst	others	do	not.	Recent	work	by	D’Andrea	and	Nagele	(D'Andrea	
and	 Nagele	 2010)	 has	 further	 elucidated	 a	 model	 for	 amyloid	 pathology	 within	 the	 brain	 of	 AD	
patients	and	predict	that	the	origin	of	plaques	is	key	in	determining	the	nature	of	the	plaque	found	
there.	
	
This	work	highlights	the	problems	associated	with	describing	any	extracellular	aggregate	as	
an	amyloid	plaque.	Understanding	distinct	morphology	differences	and	localisation	may	help	future	
treatment	strategies	with	a	more	targeted	approach	to	removing	these	 insoluble	protein	buildups.	
Importantly	however,	the	initial	mechanism	that	initiates	the	early	lay	down	of	toxic	Aβ	remains	the	
same	for	all	plaques	 types	and	arguably	 is	ultimately	 the	starting	point	 for	successful	 therapeutics	
against	AD.	
	
There	is	also	some	debate	regarding	the	chain	of	events	that	leads	to	the	development	of	
AD	pathology	whereby	 the	 appearance	of	NFTs,	 composed	of	 hyperphosphorylated	 tau	protein	 is	
not	 known	 to	 either	 precede	 or	 supersede	 the	 appearance	 of	 amyloid	 plaque	 pathology.	 The	
amyloid	 hypothesis	 asserts	 that	 Aβ	 is	 the	 principle	 driving	 influence	 on	 the	 development	 and	
progression	 of	 AD.	 In	 support	 of	 this	 theory,	mutations	 in	 tau-encoding	 proteins	 are	 the	 primary	
cause	of	frontotemporal	dementia	with	Parkinsonism	(FTDP-17)	(Hutton,	et	al.	1998,	Poorkaj,	et	al.	
1998).	This	neurodegenerative	condition	 is	characterised	by	the	presence	of	NFTs	within	the	brain	
but	 notably,	 the	 absence	 of	 any	 kind	 of	 amyloid	 pathology.	 In	 light	 of	 this,	 despite	 considerable	
neurodegeneration	as	induced	by	robust	tau	pathology,	these	effects	are	not	enough	to	induce	the	
characteristic	amyloid	pathology	unique	to	AD.	By	inference,	the	NFTs	composed	of	wild-type	tau,	as	
observed	 in	 patients	 suffering	 from	 AD,	 are	 more	 likely	 to	 have	 been	 deposited	 as	 a	 secondary	
pathology	type	after	important	changes	in	Aβ	metabolism	and	early	amyloid	deposition	and	plaque	
formation	(Hardy,	et	al.	1998).	Furthermore,	mice	transgenic	 for	both	mutant	human	tau	and	APP	
present	accelerated	development	of	NFTs	as	compared	to	mice	that	are	transgenic	for	mutant	tau	
only.	 Amyloid	 burden	 within	 the	 brain	 interestingly	 remains	 unchanged.	 This	 provides	 additional	
evidence	that	changes	in	APP	processing	occur	prior	to	tau	pathology	(Lewis,	et	al.	2001).		
	
Taken	 together,	 this	 evidence	 supports	 the	 notion	 that	 cerebral	 Aβ	 accumulation	 and	
deposition	 is	 the	 fundamental	 influence	 in	 the	 driving	 of	 AD	 pathology.	 Tangle	 formation	 is	 thus	
deemed	a	secondary	pathological	hallmark	that	results	from	an	imbalance	between	the	production	
of	Aβ	and	its	clearance.	Targeting	early	amyloid	peptide	generation	is	an	obvious	target	for	potential	
future	therapeutic	strategies.	One	such	way	this	may	be	achieved	is	via	investigation	of	the	role	of	
GAGs	within	the	amyloid-processing	pathway.	
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1.4	HS	and	Alzheimer’s	disease	
	
	 There	are	numerous	ways	in	which	the	role	of	HS	GAGs	and	their	core	proteins	have	been	
implicated	in	both	the	development	and	persistence	of	the	characteristic	hallmarks	of	AD.	Whether	
they	co-localise	with,	protect,	or	accelerate	the	features	associated	with	this	disease,	the	role	of	HS	
in	AD	is	both	important	and	varied	(Zhang,	et	al.	2014).	Further	understanding	the	role	of	HS	in	AD	in	
this	manner,	may	prove	invaluable	in	elucidating	the	mechanisms	of	the	disease	as	well	as	potential	
for	novel	therapeutic	strategies.		
	
1.4.1	HS	co-localises	with	several	features	of	AD	
	
	 Snow	 and	 colleagues	 were	 among	 the	 first	 to	 discover	 a	 co-localisation	 of	 HSPGs	 and	
various	different	pathological	features	associated	with	AD	using	antibodies	directed	to	HS	GAGs	and	
core	proteins	 (Young,	 et	 al.	 1989).	 This	work	 reported	 the	presence	of	 sulfated	HS	GAG	 chains	 in	
both	neuritic	plaques	and	NFTs,	as	well	as	in	the	presence	of	cerebral	amyloid	angiopathy	(Snow,	et	
al.	1987).	 Interestingly,	the	presence	of	sulfated	GAGs	has	been	reported	 in	several	other	types	of	
amyloidosis,	including	the	amyloid	of	medullary	carcinoma	of	the	thyroid	gland,	inherited	cutaneous	
amyloid	and	senile	cardiac	amyloid.	This	suggests	 that	sulfated	GAGs	may	have	 influence	over	 the	
way	 in	 which	 these	 proteins	 fold,	 such	 that	 amyloid	 displays	 considerable	 beta-pleated	 sheet	
conformation	(Young,	et	al.	1989).	A	theme	in	the	structure	of	PGs	co-localised	with	amyloidosis	has	
also	been	discovered.	It	has	been	reported	that	highly	sulfated	PGs	localise	specifically	with	several	
types	 of	 amyloid	 aggregates,	 including	 amyloid	 fibrils	 and	 PHFs	 suggesting	 that	 the	 structure	 of	
these	 PGs	 is	 of	 great	 importance	 in	 determining	 their	 interaction	with	 the	 amyloid	 protein.	 Such	
specificity,	may	indeed	infer	a	functional	relationship	with	PGs	and	the	persistence	or	function	of	AD	
amyloid	deposits	(Snow,	et	al.	1987).		
	
SDC1-3	and	GPC1	are	examples	of	cell	surface	HSPGs	that	have	been	found	to	be	associated	
with	both	diffuse	and	dense	cerebral	amyloid	plaques	and	NFTs	(Verbeek,	et	al.	1999).	GPC1	is	also	
associated	with	cerebellar	dense	plaques	(van	Horssen,	et	al.	2002)	whilst	SDC1-3	do	not	report	co-
localisation	here.	Similarly,	HSPG2,	an	extracellular	matrix	(ECM)	associated	HSPG	has	been	shown,	
in	a	rat	model	of	AD,	to	accumulate	within	the	amyloid	deposits	indicative	of	Alzheimer’s	pathology	
(Castillo,	 et	al.	1997).	AGRN	has	more	 recently	been	associated	with	amyloid	plaques	at	all	 stages	
also	 (van	 Horssen,	 et	 al.	 2002,	 Verbeek,	 et	 al.	 1999),	 as	 well	 as	 NFTs	 composed	 of	
hyperphosphorylated	tau	protein	(van	Horssen,	et	al.	2003).	 Interestingly,	whilst	COL18A1	has	also	
been	 reported	 to	 co-localise	 with	 dense	 amyloid	 plaques	 and	 amyloid-laden	 vessels,	 positive	
immuno-staining	 for	 COL18A1	 was	 not	 detected	 in	 NFTs	 or	 diffuse	 plaques	 (van	 Horssen,	 et	 al.	
2002).	The	spatial	discrimination	of	these	HSPGs	would	strengthen	a	hypothesis	for	a	functional	role	
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of	HSPGs	 in	AD,	 rather	 than	 simply	a	 coincidental	 spatial	 locality.	 Intensity	of	 staining	of	different	
select	HSPGs	in	different	regions	of	AD	pathology	as	observed	in	these	studies	would	be	suggestive	
of	selective	preference	of	select	HSPGs	to	specific	Aβ	oligomeric	states.	COL18A1	for	example	may	
well	selectively	associate	with	fibrillar	Aβ	over	aggregated	Aβ	found	in	mature	plaques.	
	
The	 HS	 GAG	 chains,	 removed	 from	 their	 HSPG	 core	 protein,	 have	 also	 been	 shown	 to	
extensively	 associate	 with	 the	 pathological	 features	 of	 AD	 in	 a	 number	 of	 regions	 in	 the	 brain,	
suggesting	 it	 is	 not	 only	 the	 HSPGs	 that	 may	 hold	 potential	 as	 a	 modulatory	 factor	 in	 AD	
pathogenesis.	Extensive	positive	 staining	 for	HS	GAGs	 in	all	 types	of	amyloid	plaque	and	NFTs	has	
been	 reported	 and	 may	 again	 point	 towards	 a	 role	 for	 accumulation	 of	 HS	 side	 chains	 in	 either	
response	to	AD	pathology	or	even	as	a	pre-requisite	(Zhan,	et	al.	1995).	 Indeed,	more	recent	work	
has	 shown	 that	 human	 brain	 pericytes,	 when	 cultured	 in	 the	 presence	 of	 Aβ	 protein,	 display	
increased	mRNA	 expression	 of	 both	 the	 genes	 encoding	 the	 AGRN	 and	GPC1	HSPGs.	 In	 addition,	
studies	 showed	 that	 increased	 sulfates	 (as	 labeled	 with	 radioactive	 groups	 for	 detection)	 were	
incorporated	into	the	GAG	chain	fraction	of	the	pericytes	cultured	with	Aβ.	This	work	would	suggest	
that	not	only	 is	 the	presence	of	Aβ	able	 to	modulate	 the	expression	of	HSPGs	–	perhaps	 in	a	self-
perpetuating	 cycle,	 but	 also	 that	 this	 may	 contribute	 to	 the	 accumulation	 and	 co-localisation	 of	
HSPGs	observed	in	AD	lesions	(Timmer,	et	al.	2009).	
	
The	 more	 recent	 development	 of	 more	 sophisticated	 antibodies	 against	 HS	 has	 made	
understanding	the	interaction	of	HS	and	AD	a	little	clearer.	Phage	display	antibodies	including	EV3CE	
and	HS4C3	 that	 specifically	 target	N-sulfated	motifs	 along	 the	HS	 chain,	 and	 RB4EA12	 and	HS4E4	
that	target	partially	N-sulfated	and	N-acetylated	residues	(Bruinsma,	et	al.	2010,	Kurup,	et	al.	2007)	
can	now	more	easily	give	an	indication	of	the	specific	structures	of	HS	co-localised	with	the	features	
of	AD.	For	example,	work	has	shown	that	different	types	of	HS	are	found	to	co-localise	with	AB1-40	
and	AB1-42	peptides	within	diffuse	plaques	(O'Callaghan,	et	al.	2008).	In	addition,	antibodies	to	detect	
highly	N-sulfated	motifs	within	 the	HS	 chain	were	 found	 in	 both	 fibrillar	 (dense)	 and	 non-fibrillar	
(diffuse)	 Aβ	 plaques.	 In	 contrast	 those	 antibodies	 used	 to	 detect	 lower	 degree	 of	 N-sulfation	
displayed	 signaling	 only	 in	 fibrillar	 Aβ	 aggregates	 (Bruinsma,	 et	 al.	 2010).	 	 This	 would	 suggest	
perhaps	that	variable	HS	structure	is	a	key	determinant	in	interaction	with	different	AD	aggregates.		
	
1.4.2	The	role	of	HS	in	AD		
1.4.2.1	HS	and	Aβ	
	
It	has	long	been	established	that	HS	and	amyloidosis	specifically	in	AD	are	linked	in	a	variety	
of	 ways.	 Furthermore,	 studies	 suggest	 it	 is	 not	 only	 spatial	 proximity	 shared	 by	 HSPGs	 and	 AD	
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pathogenesis	but	rather	there	is	a	great	deal	of	evidence	to	suggest	that	PGs	are	potent	enhancers	
of	the	formation	of	Aβ	fibrils,	the	precursor	of	plaques	(Castillo,	et	al.	1997).	AGRN	and	HSPG2	have	
been	 implicated	as	PGs	that	may	bind	to	Aβ	with	high	affinity	 (Castillo,	et	al.	1997,	Cotman,	et	al.	
2000).	 Indeed,	 immunoassays	 revealed	 a	 correlation	between	 increased	binding	 capacity	of	Aβ	 to	
HSPG2	with	 increased	 fibrilisation	of	Aβ1-40	and	Aβ1-42	species	as	well	 as	enhanced	 fibril	 stability	 in	
the	presence	of	HSPG2	(Snow,	et	al.	1994).	Traditionally,	amyloid	plaques	are	believed	to	develop	
from	diffuse	 plaques	 containing	 largely	 non-fibrillar	 Aβ	 into	 classic	 plaques	with	 a	 central	 core	 of	
fibrillar	 Aβ.	 These	 classic	 plaques	 present	 reactive	 astrocytes	 and	 glial	 cells	 around	 the	 densely	
packed	core	of	fibrillar	Aβ	(Dickson	1997,	Selkoe	1991).	AGRN	and	HSPG2	may	thus	be	implicated	in	
the	conversion	of	non-fibrillar	Aβ	 to	 fibrillar	and	 in	doing	so	contribute	 to	 the	development	of	AD	
pathogenesis	 (Snow,	 et	 al.	 1994,	 Verbeek,	 et	 al.	 1997).	 Furthermore,	 both	 free	 HS	 and	 heparin	
chains	 have	 also	 been	 shown	 to	 associate	with	 Aβ	 in	 vitro	 (Bame,	 et	 al.	 1997,	 Buee,	 et	 al.	 1993,	
Leveugle,	et	al.	1994)	via	the	HHQK	domain	at	the	N-terminus	region	of	the	Aβ	peptide	(Giulian,	et	
al.	 1998).	 Likewise,	 an	 N-sulfated	 hexasaccharide	 domain	 within	 HS	 containing	 2-O	 sulfated	 IdoA	
residues	 is	also	known	to	bind	Aβ	and	has	been	demonstrated	 in	 the	human	cerebral	 cortex.	This	
site	 is	 also	 able	 to	 bind	 FGF-2,	 a	 neuroprotective	 growth	 factor	 and	 may	 suggest	 a	 degree	 of	
competition	 between	 Aβ	 and	 FGF-2	 for	 a	 common	HS	 binding	 site	 (Lindahl,	 et	 al.	 1999).	 As	with	
many	other	HS	ligand	binding	interactions,	the	degree	of	sulfation	determines	efficacy	of	interaction	
with	Aβ.	Heparin,	a	highly	sulfated	variant	of	HS	thus	displays	a	much	higher	binding	affinity	to	Aβ	
vs.	a	de-sulfated	form	of	HS	(Lindahl,	et	al.	1999).		
	
Association	of	HSPGs	and	Aβ	in	this	manner	begs	the	question	as	to	whether	the	presence	
of	HS	species	occurs	prior	to	accumulation	of	Aβ	in	the	brain,	or	whether	the	initial	presence	of	Aβ	is	
enhanced	and	prolonged	via	interaction	with	HSPGs	such	as	HSPG2	and	AGRN.	To	go	some	way	to	
answer	this	question,	Snow	and	colleagues	have	reported	the	presence	of	positive	HSPG	staining	in	
diffuse	primitive	plaques	in	the	brains	of	patients	with	Down’s	syndrome,	indicative	of	an	early	role	
in	HSPGs	in	AD	disease	pathogenesis	(Snow,	et	al.	1990).	
	
1.4.2.2	HS	and	APP	
	
Other	 work	 has	 more	 recently	 reported	 that	 both	 the	 HS	 side	 chain	 as	 well	 as	 its	 core	
protein	 is	able	to	 interact	with	the	brain	specific	 isoform	of	APP	 itself,	 the	precursor	of	Aβ,	and	as	
such	may	be	suggestive	of	a	regulatory	role	in	the	production	of	Aβ	(Narindrasorasak,	et	al.	1991).	
The	mechanism	by	which	this	occurs	is	still	unknown	however	recent	evidence	that	APP	may	occur	
in	 a	 CS	 (Shioi,	 et	 al.	 1992,	 Shioi,	 et	 al.	 1993),	 or	 HS	 (Schubert,	 et	 al.	 1988)	 form	may	 indicate	 a	
somewhat	complex	interaction	of	HSPGs	with	AD	pathology	being	that	it	may	interact	with,	mature	
AD	pathology,	smaller	oligomers	and	their	precursors	simultaneously.	Furthermore,	HS	is	known	to	
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interact	 with	 those	 enzymes	 responsible	 for	 the	 processing	 of	 APP	 itself,	 in	 particular	 BACE-1	
(discussed	later)	(Scholefield,	et	al.	2003).		
	
1.4.2.3	HS	and	Tau	
	
Just	 as	 HS	 chains	 have	 been	 shown	 to	 interact	 directly	 with	 the	 amyloid-based	 features	
associated	with	AD,	so	has	this	GAG	been	implicated	in	the	progression	of	tau	pathology	also	seen	in	
patients	with	AD.	Goedert	and	colleagues	in	1996	(Goedert,	et	al.	1996),	after	a	much	earlier	report	
that	 sulfated	 GAGs	 and	NFTs	 are	 closely	 associated	 (Snow,	 et	 al.	 1987),	 found	 that	 sulfated	 GAG	
chains	 may	 be	 able	 to	 induce	 the	 formation	 of	 PHFs	 and	 thus	 induce	 the	 fibrilisation	 of	 mature	
tangles	within	the	brain.	This	work	also	found	that	the	presence	of	sulfated	GAG	chains	might	also	
potentiate	 the	 phosphorylation	 of	 tau	 causing	 it	 to	 dissociate	 from	 the	microtubule.	 In	 addition,	
binding	of	 sulfated	GAGs	chains	 is	believed	 to	occur	across	 the	microtubule	binding	domain	 itself,	
preventing	 the	 association	 of	 tau	 with	 microtubules	 in	 this	 manner	 also	 (Hasegawa,	 et	 al.	 1997)	
(Hernandez,	 et	 al.	 2002).	 In	 doing	 so	 evidence	 has	 been	 put	 forward	 that	 GAG	 chains	 not	 only	
influence	 the	 disassembly	 of	 the	 microtubules,	 but	 also	 potentiate	 the	 polymerisation	 and	
fibrilisation	of	the	tau	and	further	still,	protect	tau	deposits	from	proteolytic	degradation	(Snow	and	
Wight	1989).	Taken	together,	 there	 is	a	strong	case	for	a	role	of	GAGs	 in	the	development	of	tau-
based	pathology	in	AD.		
	
1.4.2.4	Resistance	to	Aβ	degradation	
	
Previous	 studies	 have	 suggested	 that	 certain	 HSPGs	 are	 able	 to	 protect	 Aβ	 species	 from	
protease	degradation	both	 in	vitro	 and	 in	vivo	 and	 that	 in	doing	 so,	may	 suggest	a	mechanism	by	
which	PGs	are	able	to	support	the	accumulation	and	persistence	of	AD	pathology	within	the	brain	of	
patients	(Gupta-Bansal,	et	al.	1995).	It	has	been	suggested	that	the	AGRN	PG	may	be	able	to	do	this	
due	to	the	presence	of	9	separate	follistatin-like	protease	inhibitor	domains	within	its	structure	that	
may	 offer	 a	 protective	mechanism	 against	 the	 degradation	 of	 Aβ	 peptide	when	 co-localised	with	
HSPGs	like	AGRN	(Biroc,	et	al.	1993,	Groffen,	et	al.	1998).		
	
Additional	research	has	suggested	that	HSPGs	may	also	play	a	role	in	protection	against	the	
degradation	of	Aβ	 via	 indirect	 pathways,	 such	 as	 phagocytic	 uptake	 and	degradation	by	microglia	
(known	 to	be	 associated	with	 amyloid	plaques).	 Previous	work	has	 found	 that	 chondroitin	 sulfate	
proteoglycans	(CSPGs)	are	able	to	inhibit	the	degradation	of	Aβ	in	this	manner	however	it	is	not	yet	
certain	whether	HSPGs	 could	play	 a	 similar	 role	 in	 inhibition	of	microglial	Aβ	uptake	and	 removal	
(Shaffer,	et	al.	1995).	Indirectly,	Aβ1-40	has	been	shown	to	inhibit	the	activity	of	heparanase	enzymes,	
and	in	doing	so	may	contribute	to	the	persistence	of	amyloid	plaques	by	blocking	the	degradation	of	
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the	HSPGs	themselves	(Bame,	et	al.	1997).		In	light	of	this,	it	would	seem	that	the	role	of	HS	in	this	
instance	is	something	of	a	negative	one	with	regard	to	its	ability	to	enhance	formation	of	toxic	senile	
plaques	in	Alzheimer’s	patients.	
	
Despite	 this	 evidence	 for	 this	 potentially	 damaging	 role	of	HS	 in	 the	pathogenesis	 of	AD,	
one	might	argue	that	enhancing	the	fibrilisation	of	Aβ	peptides	may	actually	prove	to	be	a	protective	
mechanism.	The	original	amyloid	cascade	hypothesis,	as	proposed	in	1992	(Hardy	and	Higgins	1992),	
originally	proposed	it	was	the	amyloid	plaques	themselves	that	were	the	primary	cause	of	neuronal	
loss	 and	 dementia	 symptoms.	 More	 recently	 however,	 this	 hypothesis	 has	 been	 amended	 to	
account	for	the	smaller	intermediate	Aβ	oligomer	species	that	form	before	mature	plaque	formation	
since	no	real	linear	correlation	was	discovered	between	mature	plaque	deposition	within	the	brain	
and	 the	 onset	 and	 progression	 of	 dementia	 in	 patients	 (Verma,	 et	 al.	 2015).	 Indeed,	 studies	 in	 a	
novel	mouse	model	presenting	a	mutation	in	the	presenilin	1	(PS-1)	gene	revealed	accumulation	of	
Aβ	oligomers	within	neurons	that	impeded	memory	formation	and	led	to	synaptic	dysfunction,	all	in	
the	absence	of	mature	amyloid	plaques	(Zhang,	et	al.	2014).			In	light	of	this,	mature	plaques	within	
the	brain	may	prove	to	be	somewhat	“protective”	in	view	of	the	fact	they	may	actually	be	basins	for	
the	sequestration	of	more	toxic	smaller	oligomer	 intermediates	 (Verma,	et	al.	2015),	analogous	to	
that	of	a	granuloma	in	the	context	of	inflammation.	Subsequently,	in	quickening	the	turnover	of	Aβ	
peptides	to	oligomers	and	ultimately	plaques	densities,	it	may	be	hypothesised	that	this	role	of	HS	is	
indeed	protective	rather	than	damaging,	depending	upon	one’s	view	of	the	relative	toxic	capacities	
of	the	various	amyloid	entities.		
	
1.4.2.5	HS	and	the	uptake	of	Aβ	into	cells	
	
	 As	previously	highlighted,	HS	is	able	to	interact	and	potentially	 influence,	every	feature	of	
pathology	 associated	with	AD.	Whilst	 it	 has	 already	been	 shown	 to	protect	 both	 amyloid	 and	 tau	
from	protease	degradation,	there	is	also	evidence	to	suggest	that	it	is	able	to	mediate	the	uptake	of	
Aβ	 into	 the	 cells	 and	 in	 doing	 so,	 mediate	 the	 effects	 of	 cytotoxicity	 and	 clearance	 of	 this	 toxic	
peptide.	The	pathogenic	species	Aβ	is	able	to	exist	both	outside	and	within	the	cells	themselves	and	
internalisation	mechanisms	allow	the	transfer	of	Aβ	 into	the	cells	to	contribute	to	the	 intracellular	
pools	 present	 there	 (LaFerla,	 et	 al.	 2007).	 Endothelial	 cells,	 neurons	 (Kandimalla,	 et	 al.	 2009),	
different	glial	cells	including	microglia	and	astrocytes	(Nielsen,	et	al.	2010,	Paresce,	et	al.	1996)	and	
smooth	muscle	cells	(Kanekiyo,	et	al.	2012)	are	all	able	to	internalise	Aβ	into	cells	via	the	action	of	
several	membrane	bound	“gateways”	 including	complement	 receptors	 (Fu,	et	al.	2012),	 scavenger	
receptors	(Paresce,	et	al.	1996,	Yang,	et	al.	2011),	toll-like	receptor	(Tahara,	et	al.	2006),	low	density	
lipoprotein	 receptor-related	 protein	 (LRP-1)	 (Kanekiyo,	 et	 al.	 2012)	 and	 transmembrane	 protein	
CD33	 (Griciuc,	 et	 al.	 2013).	 Naturally,	 due	 to	 its	 inherent	 abilities	 to	 bind	 a	 number	 of	 different	
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ligands,	HS	both	as	a	free	GAG	and	anchored	to	a	core	protein	(HSPG)	is	able	to	regulate	uptake	of	
Aβ	 into	the	cell	by	acting	as	a	cell	surface	receptor.	 Indeed,	previous	work	has	found	that	Chinese	
hamster	ovary	cells	(CHO)	deficient	in	HS	(CHO	pgsD-677)	treated	with	Aβ1-40		did	not	display	toxicity	
due	to	uptake	of	the	Aβ	peptide	and	survived	much	better	compared	to	those	wild	type	CHO	cells	
(CHO-WT)	expressing	HS	that	was	able	to	facilitate	the	uptake	of	Aβ	into	cells	(Sandwall,	et	al.	2010).	
	
	 There	is	also	evidence	to	suggest	that	HS	may	play	a	role	in	the	attenuation	of	appropriate	
Aβ	clearance	from	the	brain	via	the	blood	brain	barrier	(BBB).	LRP-1	as	an	example	has	been	shown	
to	act	as	a	cargo	receptor,	 in	which	Aβ	is	able	to	bind	to	the	cell	surface,	become	internalised	and	
consequently	released	at	the	luminal	side	of	the	endothelium	(Deane,	et	al.	2009).	HSPGs	have	been	
shown	to	cooperate	with	LRP1	to	mediate	the	uptake	of	Aβ.	Indeed	knockdown	of	HSPG	expression	
with	heparinase	treatment	suppressed	the	uptake	of	Aβ.	Likewise,	deletion	of	the	Ext-1	gene	(and	
ultimately	 the	 knockdown	of	HS	biosynthesis)	 resulted	 in	 an	 accelerated	 clearance	of	Aβ	 into	 the	
brain	interstitial	fluid	(Liu,	et	al.	2016).	In	this	way,	HSPGs	have	been	shown	to	play	a	role	in	a	critical	
pathway	through	which	Aβ	is	taken	up	by	surrounding	neuronal	cells.		
	
1.4.3	HS	and	BACE-1	
	
	 In	addition,	and	most	importantly	in	the	context	of	this	project,	HS	has	also	been	shown	to	
have	protective	affects	against	the	induction	of	toxic	Aβ	peptides.	Previous	studies	have	discovered	
a	 novel	 interaction	 between	 HS	 and	 the	 BACE-1	 enzyme	 implicated	 in	 the	 formation	 of	 the	 Aβ	
peptide	(Scholefield,	et	al.	2003).	It	has	been	shown	that	HS	can	regulate	and	block	the	cleavage	of	
APP	 via	 its	 interaction	 with	 BACE-1	 and	 in	 doing	 so,	 reduce	 processing	 of	 Aβ.	 Co-localisation	 of	
endogenous	HS	and	BACE-1	was	identified	at	both	the	cell	surface	and	the	Golgi	complex	suggesting	
that	 endogenous	 sources	 of	 HS	may	 be	 responsible	 for	 restricting	 the	 activity	 of	 BACE-1.	 Indeed,	
chlorate	 treatment	 of	 the	 cells	 abolished	 the	 production	 of	 HS	 within	 the	 cells	 and	 resulted	 in	
significantly	 elevated	 generation	 of	 the	 Aβ	 peptide	 within	 cells,	 further	 strengthening	 the	 notion	
that	HS	and	BACE-1	interact	(Scholefield,	et	al.	2003).	
	
	 Work	to	understand	the	mechanisms	by	which	this	inhibition	may	be	conferred	was	carried	
out	 with	 fluorescence	 polarisation	 studies.	 Results	 indicated	 that	 HS	 is	 able	 to	 inhibit	 BACE-1	 by	
preventing	entry	of	 the	 substrate	 to	 the	active	 site	of	 the	BACE-1	enzyme.	 There	 is	 also	evidence	
that	should	the	 ligand	be	pre-bound	to	BACE-1,	HS	 is	able	to	 lock	this	confirmation	 into	the	active	
site	to	prevent	the	APP	substrate	gaining	access	(Scholefield,	et	al.	2003).	In	doing	so,	HS	is	able	to	
prevent	the	interaction	of	APP	with	BACE-1	and	ultimately,	attenuate	the	processing	of	APP	to	form	
the	toxic	Aβ	species	(Figure	1.4).	
	2017	 37	
Figure	 1.4:	 The	 roles	 of	 HS	 in	 Alzheimer’s	 disease.	 	 Aβ	 is	
produced	within	the	ER	and	Golgi	apparatus	and	secreted	out	of	
the	cell.	APP	is	cleaved	predominantly	via	the	α-secretase	enzyme	
to	 form	a	soluble	APPα	fragment	that	 is	secreted	out	of	 the	cell	
and	 an	 83	 amino	 acid	 fragment	 (C83)	 that	 remains	 within	 the	
membrane.	 APP	 that	 is	 not	 cleaved	 may	 be	 internalised	 into	
endosomes.	 Here,	 APP	 may	 be	 cleaved	 by	 the	 BACE-1	 enzyme	
and	results	in	a	C99	fragment	that	remains	within	the	membrane.	
C99	can	also	be	shuttled	back	to	membrane,	or	shuttled	back	to	
the	 ER	 and	 be	 processed	 into	 Aβ	 via	 action	 of	 the	 γ-secretase.	
Extracellular	Aβ	can	bind	to	cell	surface	receptors	such	as	NMDA	
and	 FPRL1	 and	 internalises	Aβ	 into	 endosomes	 for	 degradation.	
Tau	 pathology	 accumulates	 intracellularly	 and	 results	 from	
hyperphosphorylation	 of	 the	 tau	 protein.	 HS	 is	 able	 to	 interact	
with	a	number	of	these	stages.	HS	is	able	to	interact	directly	with	
APP,	the	Aβ	plaques	and	the	mature	amyloid	plaques.	HS	 is	also	
able	to	interact	with	tau	and	the	mature	tau	tangles.	There	is	also	
evidence	 that	 HS	 and	 HSPGs	may	 protect	mature	 plaques	 from	
degradation	and	aid	the	persistence	of	amyloid	pathology.	HS	has	
also	been	shown	to	act	with	LRP1	to	aid	clearance	of	Aβ	from	the	
brain.	
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1.4.3.1	BACE-1	inhibition	efficacy	is	dependent	upon	HS	structure	
	
Importantly,	 the	 efficacy	 of	 BACE-1	 inhibition	 by	 HS	 is	 dependent	 on	 the	 size	 of	 the	 HS	
saccharide	and	also	the	number	of	sulfated	motifs	present	within	the	chain	(Scholefield,	et	al.	2003).	
Heparin	saccharides	of	10	monosaccharide	units	and	higher	were	able	to	inhibit	BACE-1	whilst	their	
smaller	counterparts	were	unable	 to	successfully	 inhibit.	Similarly,	analogues	of	heparin	 that	were	
both	 over-sulfated	 or	 missing	 sulfate	 groups	 altogether	 in	 the	 2-OS	 and	 6-OS	 position	 were	
ineffective	 inhibitors	 of	 BACE-1.	 Taken	 together,	 this	 evidence	 suggests	 that	 specificity	 of	 glycan	
structures	within	HS	 and	 heparin	 is	 key	 in	 determining	 efficacy	 of	 BACE-1	 inhibition.	 Additionally,	
saccharide	 conformation	 changes	 induced	 by	 structural	 modification	may	 also	 be	 responsible	 for	
changes	in	BACE-1	inhibition	potency.	The	suggestion	that	BACE-1	inhibition	is	dependent	upon	the	
structure	 of	 HS	 and	 heparin	 sits	 well	 with	 previous	 work	 that	 the	 structure	 of	 HS	 is	 dynamically	
regulated	by	cells	 in	 response	 to	changing	cellular	environments;	 for	example	neurogenesis	 (Ford-
Perriss,	et	al.	2002).	This	may	go	some	way	to	explaining	the	ability	of	neural	cells	to	modulate	and	
regulate	the	processing	of	APP	in	the	appropriate	sub-cellular	sites	and	further	supports	the	notion	
that	HS	is	implicated	in	the	generation	of	Aβ	within	the	brain	in	normal	physiology	and	ultimately	AD	
(Scholefield,	et	al.	2003).		
	
	 Subsequent	studies	went	on	to	investigate	the	consequence	of	structural	alterations	to	the	
HS	chain	in	an	HS	analogue;	porcine	intestinal	mucosal	heparin	(PIMH).	Changes	to	the	O-sulfation	
and	 N-sulfation/acetylation	 motif	 pattern	 has	 significant	 effects	 on	 BACE-1	 inhibitory	 activity	
whereby	 most	 potent	 therapeutic	 ratios	 (relative	 to	 anticoagulant	 activity)	 were	 achieved	 in	
compounds	containing	NAc	and	6-OS	groups	(Patey,	et	al.	2006).	This	work	again	strongly	implicates	
structural	specificity	of	HS	to	effective	inhibition	of	BACE-1.	Furthermore,	work	in	the	Tg2576	murine	
model	(a	model	over	expressing	a	mutant	form	of	APP),	revealed	that	heparin	and	enoxaparin;	a	low	
molecular	 weight	 analogue	 of	 heparin,	 were	 able	 to	 reduce	 levels	 of	 Aβ	 via	 modulation	 of	 APP	
processing	and	BACE-1	interaction	(Cui,	et	al.	2011).	
	
	 Chemical	 synthesis	 of	 heparin-like	 derivatives	 has	 proven	 extremely	 useful	 in	 the	
subsequent	 investigation	 of	 the	 consequences	 of	 structural	 changes	 within	 the	 HS	 saccharide.	
Schworer	 and	 colleagues	 recently	 created	 a	 library	 of	 16	 hexa-	 to	 dodecasaccharides	 that	 inhibit	
BACE-1.	In	line	with	previous	findings,	most	effective	inhibition	was	achieved	in	those	analogues	of	
larger	unit	length	that	contained	6-O	sulfated	motifs;	octosaccharides	were	found	to	be	the	smallest	
compounds	which	 retained	 potency	 (Schworer,	 et	 al.	 2013).	 Saccharide	 size	 is	 of	 key	 importance	
when	we	consider	their	ability	to	cross	the	BBB.	Should	these	compounds	be	of	therapeutic	viability,	
size	would	be	a	 factor	 in	determining	 their	 success.	 Leveugle	et	 al	 in	 1998	 (Leveugle,	 et	 al.	 1998)	
demonstrated	that	heparin	oligosaccharides	of	12	units	or	smaller	are	able	to	penetrate	the	BBB	and	
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may	 be	 an	 effective	 template	 for	 heparin	 analogue	 derivatives	 in	 the	 future	 should	 this	 be	
successfully	 coupled	with	 appropriate	AD	 therapeutic	 advantage	 as	 described	 above.	 Inhibition	of	
BACE-1	has	been	shown	to	be	most	effective	with	N-acetylated	heparin,	an	analogue	of	heparin	with	
over	 1,000	 fold	 lower	 anticoagulant	 activity	 (Lever	 and	 Page	 2002).	 The	 anticoagulant	 activity	 of	
heparin	would	usually	make	its	use	as	an	AD	therapy	impossible	however	careful	design	of	suitable	
derivatives	in	the	future	could	eliminate	this	side	effect	and	hold	potential	for	the	future	of	BACE-1	
inhibitors	as	a	strategy	against	AD	(Lever	and	Page	2002).	
	
1.5	Changes	to	the	structure	of	HS	occur	with	ageing	
	
	 Recent	 studies	 suggest	 that	 normal	 ageing	 (a	 key	 risk	 factor	 for	 the	 development	 of	 AD)	
may	initiate	changes	in	the	structure	of	HS	and	we	speculate	that	this	could	have	implications	for	the	
interaction	 between	 HS	 and	 BACE-1	 and	 its	 role	 in	 the	 development	 of	 AD	 in	 vivo.	 Studies	 have	
shown	that	GAGs	from	aged	human	hippocampus	present	altered	structural	properties	compared	to	
their	younger	counterparts.	These	structural	differences	were	shown	to	affect	regulation	of	trophic	
factors	despite	having	no	effect	on	Aβ	peptide	toxicity	(Huynh,	et	al.	2012).	Indeed,	altered	levels	of	
specific	HS	biosynthetic	enzymes	are	observed	in	aged	hippocampal	samples	hinting	at	an	upstream	
mechanism	 for	 the	 apparent	 HS	 structural	 diversity	 between	 these	 groups.	 Observed	 down-
regulation	of	the	GLCE	and	HS2ST	genes	and	up-regulation	of	NDST2	and	HS3ST4	genes	may	go	some	
way	to	account	for	the	changes	in	overall	GAG	composition	as	observed	in	this	study	(Huynh,	et	al.	
2012).		
	
The	 brain	 is	 not	 the	 only	 example	where	 ageing	 has	 implications	 on	 the	 structure	 of	HS.	
One	study	by	Keenan	and	colleagues	has	shown	an	age-dependent	decrease	 in	total	HS	within	the	
human	Bruch’s	membrane	–	the	innermost	layer	of	the	choroid,	the	vascular	layer	found	at	the	rear	
of	the	eye.	The	Bruch’s	membrane	is	known	to	thicken	with	age	typically	and	changes	in	the	quantity	
of	HS	with	age	may	go	some	way	to	explain	these	changes,	particularly	 in	the	context	of	 its	 ligand	
binding	affinity	with	complement	factor	H	(CFH)	–	a	key	 inhibitor	of	complement	activation	within	
the	ECM	(Keenan,	et	al.	2014).		
	
Furthermore,	studies	 in	human	aorta	have	found	age-dependent	changes	 in	 the	structure	
of	HS	such	that	binding	to	important	ligands	are	altered	including	FGF2	and	platelet	derived	growth		
factor	A	and	B	(PDGFA/B).	Increased	abundance	of	6-O	sulfation	in	aged	human	aorta	samples	were	
shown	to	be	a	key	driver	 in	altered	 ligand	binding	 in	 this	way	and	 indeed	several	of	 the	biological	
properties	of	the	HS	that	may	be	found	in	this	part	of	the	cardiovascular	system	(Feyzi,	et	al.	1998).	
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Ageing	is	a	naturally	occurring	process	and	one	that	today	is	still	the	top	risk	factor	for	the	
development	 of	 AD.	 Understanding	 therefore	 the	 changes	 HS	 may	 undergo	 in	 this	 physiological	
process	may	too	shed	 light	on	changes	that	may	occur	 in	disease	scenarios.	Altered	 ligand	binding	
affinity	will	naturally	have	huge	downstream	implications	all	over	the	body	and	understanding	the	
key	players	that	drive	these	changes	will	prove	invaluable	in	several	fields	not	limited	to	dementia.	
In	summary,	our	hypothesis	is	that	changes	in	the	structure	of	HS	with	ageing	and	in	dementia	may	
result	 in	 less	 efficient	 interaction	 and	 inhibition	 of	 the	 BACE-1	 enzyme	 resulting	 in	 elevated	
generation	 of	 the	 toxic	 Aβ	 peptide	 and	 ultimately	 the	 onset	 of	 AD.	 HS	 may	 essentially	 act	 as	 a	
naturally	 occurring	 “brake”	 on	 BACE-1	 activity	 that	 is	 removed	 if	 the	 structure	 of	 HS	 is	 altered	
through	ageing	or	in	AD.	Understanding	the	in	vivo	relevance	of	HS	in	ageing	and	dementia	may	thus	
prove	invaluable	in	elucidating	the	mechanisms	of	the	disease	pathogenesis.		
	
1.6	Current	strategies	for	treatment	of	Alzheimer’s	disease	
	
The	 difficulties	 with	 accurate	 diagnosis	 of	 AD	 that	 exist	 currently,	 coupled	 with	 the	
increasing	 life	 expectancy	 and	 increasing	 burden	 of	 AD	 on	 the	 medical	 profession	 mean	 that	
effective	treatment	strategies	are	more	necessary	than	ever.	Currently,	there	exists	no	fully	curative	
treatment	for	AD.	As	such,	all	currently	established	treatments	aim	to	counterbalance	the	symptoms	
of	AD,	in	the	hope	of	managing	the	side	effects	associated	with	this	neurodegenerative	disorder.		
	
1.6.1	Treatments	against	behavioral	and	psychological	symptoms	of	Alzheimer’s	disease	
	
Current	 treatment	 strategies	 include	 those	 that	 tackle	 the	 behavioral	 and	 psychological	
symptoms	 of	 AD.	 Selective	 serotonin	 reuptake	 inhibitors	 (SSRIs)	 like	 fluoxetine,	 sertraline	 and	
citalopram	are	also	clinically	proven	 in	 the	treatment	of	 the	depressive	symptoms	associated	with	
AD	 (Zec	and	Burkett	2008).	 Likewise,	mirtazapine	and	venlafaxine	are	 selective	noradrenaline	and	
serotonin	 inhibitors	 (SNRIs)	 that	 are	 proven	 antidepressants	 that	 may	 be	 used	 to	 treat	 the	
psychological	 symptoms	 of	 AD.	 Furthermore,	 cholinesterase	 inhibitors	 and	memantine	 have	 been	
proven	 to	 improve	 behavioral	 symptoms	 in	 AD	 patients	 (Birks	 2006,	 Farlow	 2002).	 Antipsychotic	
agents	 such	 as	 risperidone	 are	 also	 favoured	 in	 the	 treatment	 of	 psychotic	 symptoms	 including	
aggression	 and	 anxiety	 (Ballard	 and	Corbett	 2010).	 The	use	of	 antipsychotics	 has	 somewhat	 been	
criticised	however	for	worsening	some	symptoms	in	AD	patients.	In	particular,	benzodiazepines,	that	
may	be	prescribed	to	combat	psychotic	symptoms	may	actually	increase	aggression	and	agitation	in	
older	 patients,	 and	 in	 some	 cases	 a	 worsening	 of	 functionality	 (Zec	 and	 Burkett	 2008).	 Taken	
together,	it	is	clear	that	these	strategies	do	go	some	way	to	improve	daily	living	for	patients.	Despite	
this,	 timing	 of	 treatment	 is	 critical	 as	 the	 earlier	 treatment	 is	 initiated	 the	 better	 the	 outcome.	
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Furthermore,	 combinations	 of	 certain	 therapies	 needs	 to	 be	 carefully	 considered	 and	 the	 side	
effects	strictly	monitored	to	ensure	behavioral	therapies	do	not	worsen	AD	pathogenesis.			
	
1.6.1.1	Cholinesterase	Inhibitors	
	
	 Currently	 one	 of	 the	 most	 widely	 used	 therapeutic	 strategies	 is	 that	 of	 cholinesterase	
inhibitors.	The	neuronal	cell	death	that	accompanies	AD	pathogenesis	is	exacerbated	by	the	loss	of	
acetylcholine	 neurons,	 acetylcholine	 synthesis	 and	 degradation	 resulting	 in	 degeneration	 of	
cognitive	abilities	(Bartus,	et	al.	1982).	To	tackle	this,	cholinesterase	inhibitors	are	often	prescribed	
to	slow	the	degradation	of	the	acetylcholine	neurotransmitter	within	the	synaptic	cleft	 in	order	to	
enhance	 its	 persistence	 within	 synapses.	 Currently	 three	 cholinesterase	 inhibitors	 have	 been	
approved	for	the	treatment	of	mild	to	moderate	AD	including,	donepezil	(Pfizer,	New	York,	NY,	USA),	
rivastigmine	 (Novartis,	 Basel,	 Switzerland)	 and	 galantamine	 (Janssen,	 Beersem	 Belgium)	 (Farlow	
2002).	Research	suggests	that	these	drugs	are	effective	in	improving	cognitive	function	and	activities	
of	daily	living	(ADL)	(Birks	2006).	Importantly,	early	treatment	in	the	development	of	AD	is	favoured.	
Research	 has	 shown	 that	 a	 52	 week	 study	 of	 rivastigmine	 administered	 to	 patients	 with	mild	 to	
moderate	 AD	 was	 more	 effective	 in	 patients	 that	 received	 their	 treatment	 immediately	 upon	
diagnosis	 vs.	 those	 who	 started	 6	 months	 later	 (Farlow,	 et	 al.	 2000).	 Naturally,	 the	 difficulties	
associated	with	diagnosis	make	 this	 somewhat	difficult	 to	 ensure	 in	 some	 instances.	Whilst	 these	
drugs	 do	 not	 prevent	 or	 slow	 the	 progression	 of	 AD	 they	 have	 proved	modest,	 and	 consistent	 in	
their	symptomatic	relief	and	functional	living	for	those	with	AD.	
	
1.6.1.2	N-methyl-D-aspartate	antagonists	
	
	 The	drug	memantine	may	be	another	treatment	strategy	for	those	suffering	from	moderate	
to	 severe	 AD	 (Lundbeck,	 Vlabeck,	 Denmark).	 This	 drug	 is	 an	 N-methyl-D-aspartate	 (NMDA)	
antagonist	 that	 has	 been	 shown	 to	 protect	 neurons	 from	 excitotoxicity.	 Trials	 have	 shown	 an	
improvement	in	cognitive	function	and	ADL	in	those	with	severe	AD	treated	for	6	months	(McShane,	
et	al.	2006).	This	drug	has	reported	side	effects	however	of	headaches	and	confusion	and	in	some	
patients,	 agitation	 (Alva	 and	 Cummings	 2008).	 It	 must	 therefore	 be	 prescribed	 with	 care	 and	
caution.		Combination	of	memantine	and	donepezil	however	has	been	shown	to	improve	cognitive	
function	 in	 patients	with	 severe	 AD	 and	may	 prove	 to	 be	 an	 effective	 combination	 however	 this	
improvement	 is	 not	 observed	 in	 those	 suffering	 from	 mild	 to	 moderate	 AD	 (Tariot,	 et	 al.	 2004)	
(Farlow,	et	al.	2010)	thus	strengthening	the	notion	that	timing	of	treatment	is	particularly	important.		
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1.6.2	Treatments	to	modify	the	features	of	Alzheimer’s	disease	
	
	 Directly	tackling	the	pathological	 features	of	AD	 is	another	way	 in	which	research	aims	to	
treat	 this	 disease.	 Directly	 targeting	 the	 Aβ	 and	 tau	 components	 in	 particular	 hope	 to	 not	 only	
prevent	 the	 development	 of	 AD	 but	 also	 ideally	 go	 on	 to	 reduce	 these	 pathological	 features	 and	
treat	AD	 from	 its	 starting	 point.	 Additional	mechanisms	 associated	with	AD	may	 also	 be	 targeted	
including	 inflammation	 (Griffin	 2006),	 iron	 dysregulation	 (Adlard	 and	 Bush	 2006),	 cholesterol	
metabolism	(Stefani	and	Liguri	2009)	and	oxidative	damage	(Reddy,	et	al.	2009).	
	
1.6.2.1	Immunotherapy	
	
	 There	 are	 number	 of	ways	 in	which	one	might	 go	 about	 treating	 the	 features	 of	AD	 and	
immunotherapy	has	proven	to	be	a	particularly	popular	method	in	which	to	do	so.	This	may,	in	part	
be	due	to	the	fact	there	are	a	multitude	of	ways	in	which	immunotherapy	can	be	exploited;	either	to	
directly	attack	and	disassemble	the	aggregated	amyloid	plaques,	induce	the	activation	of	microglial	
cells	and	in	do	so	induce	phagocytosis,	neutralise	the	effects	of	toxic	oligomeric	species	like	Aβ	and	
tau,	aid	in	the	clearance	of	circulating	toxic	peptides	and	finally	immunoglobulin	M	(IgM)	mediated	
hydrolysis	(Yiannopoulou	and	Papageorgiou	2013).		
	
	 Several	trials	have	been	undertaken	to	explore	the	ways	in	which	amyloid	plaque	burden	in	
the	brain	can	be	reduced.	Early	treatment	of	PC	12	cells	with	anti-Aβ	antibodies	has	been	shown	to	
prevent	fibrilisation	of	the	Aβ	peptide	and	in	doing	so	prevents	the	formation	of	amyloid	plaques.	In	
addition	this	treatment	was	shown	to	disaggregate	the	fibrils	already	pre-formed	 in	vitro	(Solomon	
2007,	 Solomon,	 et	 al.	 1997).	 This	 data	 led	 researchers	 to	 prove	 that	 full	 length	 aggregated	Aβ1-42	
antibodies	was	able	to	reduce	plaque	burden	in	a	mouse	model	of	AD	(Schenk,	et	al.	1999).	Success	
in	animals	encouraged	a	human	trial	in	2002	whereby	human	Aβ1-42	(AN-1792)	was	administered	to	
patients	with	the	help	of	a	T-helper	adjuvant	(QS-21)	(adjuvants	are	necessary	to	enhance	and	direct	
a	 specific	 immune	response	 to	vaccine	antigens;	 this	 is	normally	achieved	when	adjuvants	help	 to	
generate	 depots	 to	 trap	 antigens	 at	 the	 site	 of	 injection	 and	 in	 doing	 so,	 slow	 their	 release	 to	
stimulate	 a	 full	 immune	 response).	 This	 trial	 was	 prematurely	 terminated	 however	 due	 to	 the	
occurrence	of	meningoencephalitis	in	a	proportion	of	the	patients	(Gilman	et	al	2005).	
	
	 The	 appearance	 of	 such	 a	 severe	 side	 effect	 prompted	 significant	 re-modeling	 of	
immunotherapy	 strategies.	 Several	 vaccines	 underwent	 modification	 whereby	 the	 amino	 acid	
sequence	 responsible	 for	T-cell	 response	mediated	encephalitis	was	 removed	 in	 favour	of	 just	 the	
small	 number	of	 residues	 that	 are	 able	 to	bind	 to	Aβ.	 These	new	vaccines	 are	 largely	undergoing	
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new	 clinical	 phases	 I	 and	 II	 trials	 in	 the	 hope	 of	more	 successful	 results	 without	 the	 side	 affects	
observed	originally	(Galimberti	and	Scarpini	2011).		
	
Passive	 immunisation	 over	 active	 immunisation	 (as	 described	 above)	 seems	 to	 now	 be	
more	favorable	 in	 light	of	the	adverse	reactions	observed.	One	of	the	most	advanced	examples	of	
this	kind	of	therapy	is	the	Elan/Wyeth	trial	of	AAB-001	(bapineuzumab).	This	Aβ	N-terminal	directed	
antibody	has	been	shown	to	have	the	most	considerable	effect	 in	apoliporotein	E	 (ApoE)	ε4	allele	
non-carrier	patients.	This	success	 led	to	the	 initiation	of	a	phase	III	study	 in	this	subset	of	patients	
only	 with	moderate	 AD	 (Wisniewski	 and	 Konietzko	 2008).	 Eli	 Lilly	 and	 Co.	 (Indianapolis,	 IN,	 USA)	
LY2062430	(solanezumab)	vaccination	against	Aβ	 is	also	currently	under	trial	 (Brody	and	Holtzman	
2008).	 Immunotherapy	 strategies	 including	 DNA	 epitope	 vaccine	 (Qu,	 et	 al.	 2010),	 antibodies	
directed	 against	 the	 BACE-1	 cleavage	 site	 of	 APP	 (Rakover,	 et	 al.	 2007)	 and	mucosal	 vaccination	
(Hara,	et	al.	2011)	all	hold	potential	as	treatments	against	the	pathology	of	AD.		
	
Passive	 vaccination	 in	 this	 context	 requires	 repeat	 exposure	 to	 the	 drug	 that	 naturally	
increases	 the	cost	of	 these	 therapies	 for	patients.	Eliminating	adverse	side	effects	associated	with	
these	therapies	are	also	necessary	if	this	strategy	is	to	be	successful	in	the	treatment	of	AD.		
	
1.6.2.2	Drugs	to	target	tau	pathology	
	
A	 number	 of	 compounds	 have	 been	 tested	 to	 investigate	 their	 ability	 to	 modulate	 tau	
deposition	 in	 patients	 with	 AD.	 Methylene	 blue	 (MB)	 is	 currently	 undergoing	 clinical	 trials	 as	 a	
therapeutic.	The	use	of	this	drug	however	results	in	blue	urine	for	those	who	are	administered	the	
drug,	meaning	clinical	trials	cannot	be	blinded	appropriately.	Despite	this,	cognitive	improvement	in	
those	patients	receiving	MB	treatment	has	been	reported	(Gura	2008).	In	addition,	the	pathways	by	
which	tau	becomes	hyperphosphorylated	have	also	been	targeted,	specifically	the	role	that	kinases	
play	as	a	key	 inducer	of	 this	phosphorylation	event.	Glycogen	synthase	kinase	3	 (GSK3β)	has	been	
found	to	be	a	suitable	phosphorylation	site	 that	could	be	 targeted.	Lithium	 is	able	 to	 inhibit	GSK3	
alongside	 several	 other	 compounds	 including	 pyrazolopyrazines,	 amino-thiazole	 AR-A014418	 and	
sodium	valproate	(Martinez	and	Perez	2008).		Early	research	indicates	compounds	like	lithium	may	
have	disease	modifying	potential	and	may	go	some	way	to	improve	cognitive	function	in	individuals	
who	receive	this	treatment	(Forlenza,	et	al.	2011).		
	
1.6.2.3	Other	therapeutic	approaches	
	
Other	 potential	 approaches	 to	 treatment	 of	 AD	 may	 be	 with	 compounds	 to	 target	 the	
oxidative	damage	that	is	associated	with	AD.	Molecules	such	as	Vitamin	E,	Ginkgo	biloba	and	those	
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foods	containing	natural	polyphenols	such	as	green	tea,	wine	and	blueberries	have	been	suggested	
to	at	least	slow	the	rate	of	cognitive	decline.	Clinical	trials	however	of	high	doses	of	folate,	vitamin	
B6	and	B12	have	yet	to	show	any	 improvement	 in	cognitive	function	or	rate	of	change	 in	patients	
over	an	18-month	 treatment	period	despite	effective	 reduction	 in	homocysteine	 levels	–	a	known	
inducer	 of	 oxidative	 stress	 (Aisen,	 et	 al.	 2002).	 Tumor	 necrosis	 factor	 (TNF)	 inhibitors	 have	 also	
presented	preliminary	success	in	improving	cognitive	decline	in	AD	patients.	Etanercept,	an	already	
FDA-approved	 treatment	 of	 rheumatoid	 arthritis,	 upon	 perispinal	 administration	 reported	 a	
surprisingly	 rapid	 improvement	 in	 cognitive	 function	 in	 AD	 patients.	 This	 potential	 treatment	 still	
requires	 much	 work	 though	 (Griffin	 2008).	 Additionally,	 modulation	 of	 cholesterol	 and	 other	
vascular	 related	 risk	 factors	may	 have	 potential	 as	 therapeutics	 in	 light	 of	 a	 known	 link	 between	
hypercholesterolemia,	 cardiovascular	 disease	 and	 AD.	 Addressing	 issues	 of	 hypertension,	 stroke,	
atrial	 fibrillation	 and	 hyperhomocysteinemia	 may	 prove	 beneficial	 in	 preventing	 the	 onset	 or	
progression	 of	 AD.	 Indeed,	 patients	 who	 received	 statin	 treatment	 presented	 a	 decreased	
prevalence	of	AD	(Jick,	et	al.	2000).	A	recent	trial	however	to	assess	disease	progression	in	patients	
with	mild	to	moderate	AD	who	received	statin	therapy	alongside	donepezil	did	not	yield	satisfying	
results	(Feldman,	et	al.	2006).	Combination	administration	of	these	prophylactic	measures	alongside	
other	AD	medication	may	serve	to	enhance	outcomes	in	patients	by	controlling	known	exaggerators	
of	AD	such	as	inflammation,	cholesterol	etc.		
	
1.6.2.4	Drugs	that	target	Aβ	pathology	of	AD	
	
	 Several	research	efforts	have	attempted	to	target	the	aggregation	of	the	toxic	Aβ	peptide	
and	in	doing	so	slow	the	progression	of	AD	as	a	potential	therapeutic	strategy,	One	Aβ	aggregation	
inhibitor	 in	 particular,	 a	 synthetic	GAG	 3-amino-1-propaneosulfonic	 acid	 (tramiprosate)	 reached	 a	
phase	III	clinical	trial	and	was	found	to	able	to	interfere	with	the	binding	of	GAGs	to	Aβ,	and	in	doing	
so	attenuate	the	aggregation	of	Aβ	into	mature	plaques	(Gauthier,	et	al.	2009).	In	doing	so	however,	
this	drug	was	found	to	promote	the	aggregation	of	abnormal	tau	(and	so	was	discontinued)	(Santa-
Maria,	et	al.	2007)	highlighting	the	complexity	of	developing	inhibitors	of	this	kind,	on	account	of	the	
differing	pathological	features	of	AD.	A	second	drug,	colostrinin	displayed	promising	improvement	in	
MMSE	score	of	patients	with	mild	AD	treated	over	a	15-month	period.	This	promising	early	affect	
however	 was	 not	 maintained	 over	 a	 longer	 treatment	 period	 and	 the	 trial	 was	 discontinued	
(Bilikiewicz	and	Gaus	2004).	Finally	scyllo-inositol,	another	Aβ	targeting	drug	was	shown	to	stabilise	
oligomeric	aggregation	of	Aβ	to	inhibit	the	toxicity	of	the	smaller	Aβ	peptide	in	mouse	hippocampus.	
This	 drug	 however	 has	 not	 proved	 successful	 in	 clinical	 trials	 as	 a	 decisive	 benefit	 of	 the	 therapy	
could	not	be	detected	(Salloway,	et	al.	2011).	Drugs	to	target	the	Aβ	pathway	have	received	most	
attention.	To	date,	much	of	 these	efforts	have	not	proved	successful	at	clinical	 trials,	 (tarenflurbil,	
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tramiprosate	 and	 semagacestat)	 and	 may	 highlight	 a	 difficulty	 in	 moving	 from	 bench	 to	 bedside	
(Gauthier,	et	al.	2009,	Imbimbo	and	Giardina	2011).	
	
1.6.2.5	Drugs	to	target	gamma-secretase	
	
	 Another	 obvious	 target	 for	 potential	 therapeutic	 strategies	 is	 against	 the	 γ-secretase	
enzyme,	the	final	cleavage	enzyme	in	the	APP	processing	pathway	to	form	the	Aβ	peptide.	Targeting	
this	enzyme	could	attenuate	the	formation	of	amyloid	aggregates	as	a	result.	The	problem	with	this	
target	however	is	that	γ-secretase	is	known	to	have	a	great	deal	of	functions	around	the	rest	of	the	
body,	 in	particular,	another	γ-secretase	substrate	 is	notch	receptor	1,	 inhibition	of	which	has	been	
shown	 to	 lead	 to	 severe	 gastrointestinal	 and	 hemopoetic	 side	 effects	making	 its	 success	 negated	
(Wong,	et	al.	2004).	A	trial	drug,	semagacestat	(LY-450139)	has	been	shown	to	reduce	levels	of	Aβ	in	
the	CSF	of	healthy	 individuals	 in	a	dose	dependent	manner	 (Siemers,	 et	al.	2005).	More	 thorough	
clinical	trials	with	this	drug	however	have	not	been	successful	due	to	decreased	cognitive	function	in	
those	 receiving	 treatment;	a	 side	affect	 that	may	well	be	attributed	 to	unwanted	 interaction	with	
notch	receptor	1.	Furthermore	inhibition	of	γ-secretase	alone	may	result	in	elevated	pools	of	the	Aβ	
precursors,	 SAPPβ	 which	 may	 have	 negative	 implications	 on	 cognitive	 function	 (Imbimbo	 and	
Giardina	2011).	
	
1.6.2.6	Drugs	to	potentiate	alpha-secretase		
	
	 In	contrast	to	efforts	to	inhibit	the	activity	of	specific	secretase	enzymes	involved	in	the	APP	
processing	 pathway,	work	 has	 also	 been	 carried	out	 to	potentiate	 the	 activity	 of	 α-secretase,	 the	
secretase	key	 in	 the	driving	of	non-pathological	processing	of	APP.	Enhancing	 turnover	of	APP	via	
this	 pathway	 will	 bypass	 cleavage	 by	 BACE-1	 and	 ultimately	 reduce	 the	 formation	 of	 toxic	 Aβ	
species.	One	drug	currently	being	trialed,	etazolate	(EHT	0202;	Exon	Hit	Therapeutics,	Paris,	France),	
is	 able	 to	 potentiate	 the	 non	 amyloidogenic	 pathway	 and	 in	 doing	 so	 has	 been	 shown	 to	 have	
protective	effects	against	 the	 symptoms	of	AD,	 suggesting	 some	kind	of	disease	modifying	ability.	
Encouragingly,	there	appears	to	be	little	toxic	side	effects	associated	with	administration	of	this	drug	
however	further	trials	are	required	to	assess	if	this	drug	has	efficacy	against	the	pathogenesis	of	AD	
with	prolonged	treatment	(Vellas,	et	al.	2011).	
	
1.6.2.7	Drugs	to	target	BACE-1	
	
	 As	described	previously,	targeting	BACE-1	in	the	APP	processing	pathway	is	an	obvious	drug	
discovery	target,	as	attenuation	of	this	pathway	will	prevent	the	generation	of	the	toxic	Aβ	peptide.	
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Several	 efforts	 have	 been	 made	 to	 target	 BACE-1	 however	 none	 have	 yet	 proved	 successful	 in	
completed	clinical	trials.	This	may	largely	be	because	BACE-1	has	several	physiological	roles	all	over	
the	 body,	 not	 limited	 to	 the	 processing	 of	 APP	 (Yiannopoulou	 and	 Papageorgiou	 2013)	 that	may	
result	 in	 toxicity	 issues	when	 administering	 a	 drug	 that	 inhibits	 BACE-1	 activity	 all	 over	 the	 body.	
Finally	the	active	site	of	BACE-1	is	known	to	be	reasonably	 large	and	as	such,	effective	antagonists	
may	need	to	be	large	in	size	to	fully	inhibit	the	action	of	BACE-1.	As	a	result,	this	may	pose	problems	
for	crossing	the	BBB	as	larger	molecules	are	difficult	to	get	into	the	brain	(John,	et	al.	2011).		
	
Despite	these	potential	difficulties,	the	drug	MK-8931,	a	BACE-1	 inhibitor	has	been	trialed	
by	Merck.	 This	drug	 trial	 reported	a	 reduction	 in	human	plasma	Aβ	 in	 the	CSF	 in	 a	 sustained	and	
dose-dependent	manner	 (Vassar,	 et	 al.	 2009).	 This	 data	 is	 still	 particularly	 preliminary	 and	 future	
trials	would	hope	to	address	whether	BACE-1	inhibition	with	this	drug	can	rescue	cognitive	function	
in	patients	with	AD	(Ghosh,	et	al.	2012).		
	
	 The	current	absence	of	any	curative	treatment	for	AD	 is	testament	to	the	complexity	and	
difficulties	associated	with	designing	successful	therapeutics	against	this	disease.	Largely,	this	seems	
to	be	due	 to	 the	 inherent	difficulty	 in	determining	 an	appropriate	point	 in	disease	progression	 to	
initiate	 treatment.	 Clinical	 trials	 are	 often	 carried	 out	 in	 those	 individuals	 with	 severe	 AD	 and	 as	
such,	 neuronal	 dysfunction	 is	 both	 severe	 and	 in	 most	 cases,	 largely	 irreversible	 (Dubois,	 et	 al.	
2007).	Disease	modifying	compounds	as	described	above	may	prove	more	efficacious	should	they	be	
prescribed	earlier.	Naturally	this	new	design	of	trial	comes	with	its	own	challenges.	However,	recent	
trials	of	aducanumab,	an	antibody	that	targets	amyloid	generation,	has	shown	promising	efficacy	in	
a	phase	I	clinical	trial	 in	which	treatment	 is	given	earlier	than	usual	to	patients,	based	on	MRI	and	
PET	scan	screening.	Establishing	ways	 to	prevent	 the	 formation	of	pathological	 species	such	as	Aβ	
within	the	brain	still	remains	a	promising	target	and	understanding	the	pathways	and	mechanisms	
by	 which	 we	 can	 do	 this	 will	 prove	 invaluable	 in	 generating	 successful	 treatments	 against	 this	
disease.		
	
1.7	Conclusions	
	
There	 seems	 to	 be	 compelling	 evidence	 that	 BACE-1	 is	 still	 an	 important	 drug	 discovery	
target	to	focus	on	in	the	context	of	therapeutic	strategies	against	AD.	Finding	a	way	to	inhibit	BACE-
1	will	prevent	the	formation	of	the	toxic	Aβ	peptides	and	in	doing	so,	prevent	the	accumulation	of	
large	 insoluble	 mature	 amyloid	 plaques.	 Furthermore,	 the	 known	 interaction	 of	 HS	 with	 BACE-1	
provides	the	ideal	template	for	further	understanding	the	way	in	which	it	can	inhibit	the	activity	of	
the	BACE-1	enzyme.	With	this	 in	mind	this	project	aims	to	 further	elucidate	the	structure	of	HS	 in	
the	 brains	 of	 those	 patients	 with	 AD	 relative	 to	 their	 healthy	 age-matched	 counterparts,	 and	
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investigate	 how	 these	 potential	 changes	 in	 structure	 impact	 BACE-1	 inhibition	 efficacy.	
Understanding	 these	 changes	 could	 lead	 the	 way	 in	 the	 future	 design	 of	 chemically	 synthesised	
mimetics	 of	 these	 HS	 compounds	 as	 a	 way	 of	 restoring	 the	 “ideal”	 configuration	 necessary	 for	
efficient	BACE-1	 inhibition.	Preliminary	unpublished	data	has	shown	that	 small	HS	based	mimetics	
are	able	to	cross	the	BBB	and	can	reduce	amyloid	load	within	the	mouse	models	of	AD	without	toxic	
side	effects	(Turnbull	personal	communication).	The	benefit	of	designing	potential	therapies	based	
on	 naturally	 occurring	 structures	 found	 in	 the	 body	 makes	 this	 a	 promising	 starting	 point.	
Furthermore,	this	project	hoped	to	further	understand	the	potential	changes	in	expression	of	those	
genes	 encoding	 HS	 biosynthetic	 enzymes,	 which	 could	 ultimately	 serve	 as	 potential	 diagnostic	
biomarkers	 for	 AD.	 This	 information	 combined	 with	 data	 regarding	 “optimum”	 structures	 of	 HS	
necessary	for	BACE-1	inhibition	may	provide	a	solid	framework	on	which	to	base	future	drug	therapy	
designs	against	this	disease.		
	
1.8	Project	Aims	
	
1. Analyse	 the	 structure	 of	 purified	HS	 from	brain	 tissue	 from	AD	 and	 age-matched	 control	
patients,	as	well	as	old	and	young	mouse	brain	tissue.	Extraction	and	purification	of	HS	to	
determine	possible	age-related	 structural	 changes	of	HS	 that	may	occur	within	 the	brain,	
and	potentially	identify	changes	correlated	with	the	onset	of	AD.	
2. Assess	 the	 expression	 of	 genes	 encoding	 HS	 biosynthetic	 enzymes	 to	 determine	 possible	
differences	 between	 human	 AD	 and	 age-matched	 control	 brain	 samples,	 to	 elucidate	
possible	upstream	mechanisms	for	any	observed	structural	changes	to	HS	with	AD.		
3. Investigate	the	ability	of	HS	samples	from	human	AD	and	age-matched	control	brain	tissue	
to	 regulate	 BACE-1	 to	 identify	 any	 possible	 correlations	 between	 structural	 changes	
observed	in	HS	and	its	ability	to	regulate	BACE-1	activity	effectively.		
4. Study	the	consequences	of	HS	biosynthetic	gene	knockdown.	Explore	whether	knockdown	
of	HS	biosynthetic	genes	has	any	implications	on	the	activity	of	BACE-1	in	cultured	cells.	
5. Study	effects	of	total	gene	knockout	of	selected	HS	biosynthetic	genes	in	mouse	models	on	
both	the	structure	of	HS	and	its	ability	to	regulate	BACE-1.		
6. Carry	 out	 gene	 expression	 profiling	 of	 specific	 enzymes	 involved	 in	 the	 synthesis	 of	 HS	
alongside	with	the	use	of	bioinformatics	to	investigate	public	databases	of	gene	expression	
data	from	AD	patients.	Couple	with	pathway	analysis	networks	to	explore	wider	role	of	HS	
biosynthetic	 genes	 in	 the	 wider	 context	 of	 AD	 pathogenesis	 and	 development.	
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2.	Chapter	2		
2.1	Introduction		
2.1.1	Compositional	analysis	of	HS	
	
In	 recent	decades,	 significant	advances	have	been	made	 in	 the	purification	and	structural	
characterisation	of	both	nucleic	acids	and	proteins.	 Indeed,	recent	emergence	of	 the	genomic	and	
proteomic	 disciplines	 highlights	 the	 success	 with	 which	 we	 can	 now	 explore	 these	 molecules.	
Despite	 this,	 carbohydrate	 analysis	 has	 been	 less	 fruitful,	 perhaps	 in	 part	 due	 to	 the	 inherent	
complexity	of	these	structures.	Much	more	recently	however,	glycobiology	research	has	 led	to	the	
development	of	novel	methods	to	 isolate,	purify	and	characterize	these	structures	and	 in	doing	so	
has	 revealed	 the	 wealth	 of	 structural	 variability	 and	 complexity	 that	 glycan	 structures	 present.	
Indeed,	investigation	of	the	structure	and	function	of	the	glycome	is	now	made	easier	with	advances	
in	 glycoarrays,	 high	 performance	 liquid	 chromatography	 (HPLC),	mass	 spectrometry	 (MS),	 natural	
glycan	libraries	and	synthetic	chemistry	techniques	(Turnbull	and	Field	2007).			
	
The	 complex	 nature	 of	 HS	 itself	 has	 made	 its	 structural	 determination	 one	 of	 the	 most	
challenging	 in	 the	 field	 of	 glycomics.	 The	 linear	 polysaccharide	 chain	 can	 be	modified	 in	multiple	
locations	 and	 in	 a	 number	 of	 ways	 including	 sulfation	 at	 multiple	 positions	 within	 each	
monosaccharide,	 and	N-acetylation,	 resulting	 in	 a	 vast	 degree	 of	 variability	 that	 in	 turn	 confers	 a	
huge	diversity	of	protein	ligand	binding	affinities	(Skidmore,	et	al.	2006).	For	this	reason,	elucidating	
the	 structural	motifs	 that	 underlie	 specific	 protein	 interaction	 properties	 has	 become	 particularly	
important.	 As	 such,	 finding	 ways	 to	 isolate	 HS	 without	 altering	 its	 native	 structure	 has	 proved	
somewhat	challenging.		
	
2.1.1.1	Extraction	and	purification	of	HS	
	
Historically	 chaotropic	 agents	 such	 as	 guanidium	 salts	 in	 an	 appropriate	 buffer	 (that	 can	
disrupt	 the	 hydrogen	 bonds	 between	water	molecules)	 were	 used	 prior	 to	 protease	 digestion	 to	
purify	 HS	 from	 cells	 or	 tissues	 of	 interest.	 This	 was	 carried	 out	 alongside	 addition	 of	 a	 suitable	
detergent	to	facilitate	the	extraction	of	PGs	from	within	membrane	bound	organelles	 (Esko	2001).	
Whilst	this	method	has	no	doubt	proved	very	useful	for	large-scale	purification	of	HS/HSPGs,	it	has	
several	drawbacks,	one	of	which	is	the	lengthy	nature	of	the	protocol.	Not	least	however,	is	also	the	
fact	 that	 the	 chemicals	 used	 can	 remove	 sulfate	 groups	 at	 the	 N-	 position	 along	 the	 HS	 chain	
(Drummond,	et	al.	2001,	Rej,	et	al.	1989).	Recent	work	has	therefore	identified	a	more	streamlined	
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method	of	HS	extraction	from	tissue	that	reduces	product	loss	and	ensures	efficient	purification	of	
the	 native	 structure	 for	 comparative	 analysis.	 Use	 of	 TRIzol®,	 a	 well	 known	
phenol/guanidine/chloroform	 reagent	 used	 more	 commonly	 in	 the	 purification	 of	 DNA	 and	 RNA	
from	 tissue	 (Chomczynski	 and	 Sacchi	 1987),	 has	 been	 found	 to	 successfully	 separate	 PGs	 to	 the	
aqueous	 phase	 making	 it	 a	 suitable	 candidate	 for	 a	 more	 streamlined	 method	 of	 extraction	
(Guimond,	et	al.	2009).		
	
Most	 commonly,	 structural	 composition	 is	 assessed	 following	 disaccharide	 compositional	
analysis	to	obtain	a	profile	of	the	structural	motifs	present	within	HS	(Guimond,	et	al.	2009).	This	is	
then	 followed	 by	 a	 series	 of	 steps	 to	 allow	 analysis	 of	 GAG	 structural	 motifs	 with	 either	 UV	 or	
fluorescence	detection	methods	(Figure	2.1).	The	specificities	by	which	this	may	be	carried	out	vary	
somewhat,	however	the	fundamental	protocol	steps	remain	the	same.		
	
	
	
Figure	2.1:	 Flow	diagram	 to	outline	 the	key	 steps	 involved	 in	 compositional	 analysis	of	GAG	disaccharides.	
Exhaustive	 enzyme	 digestion	 of	 the	 GAG	 chain	 and	 appropriate	 purification	 steps	 followed	 by	 either	 UV	 or	
fluorescent	detection	methods	may	be	employed	to	carry	out	compositional	analysis.	Taken	and	adapted	from	
(Skidmore	et	al.,	2010).	Abbreviation:	SAX-HPAEC:	Strong	Anion	Exchange-	High	Performance	Anion	Exchange	
Chromatography,	UV:	Ultraviolet.	
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2.1.1.2	Depolymerisation	of	the	glycosaminoglycan	chain		
2.1.1.2.1	Enzymatic	digestion	
	
The	 disaccharide	 constituents	 of	 HS/heparin	may	 be	 better	 thought	 of	 as	 their	 “building	
blocks”	and	understanding	the	profile	of	these	units	may	provide	valuable	 insights	 into	the	overall	
structural	 heterogeneity	 of	 this	 GAG.	 Digestion	 of	 long	 chain	 GAGs	 is	 most	 often	 achieved	 via	
exhaustive	 digestion	 with	 bacterial	 lyase	 enzymes,	 heparinase	 I,	 heparinase	 II	 and	 heparinase	 III	
(also	 referred	 to	 as	 heparitinases	 III,	 II	 and	 I	 respectively).	 Addition	 of	 these	 enzymes	 digests	 the	
polysaccharide	chain	and	introduces	a	4,5,	unsaturated	double	bond	at	the	non-reducing	end	of	the	
uronic	acid	 residues,	one	of	 the	units	of	 the	newly	generated	disaccharides	 (the	delta	symbol	Δ	 is	
used	to	 identify	these	disaccharides,	“Δ-disaccharides”).	A	cocktail	of	these	three	enzymes	ensures	
efficient	digestion	owing	to	the	fact	that	each	of	the	heparinase	enzymes	has	its	own	cleavage	site	
specificity	as	shown	in	Table	2.1.	Largely,	heparinase	I	cleaves	the	GAG	chain	at	regions	of	high	levels	
of	sulfation	whilst	heparinase	III	conversely	favors	regions	of	low	sulfation	for	cleavage	(Linhardt,	et	
al.	1990).		
	
Table	2.1:	Enzymes	used	for	digestion	of	heparin	and	HS	into	constituent	disaccharides.	Taken	from	(Skidmore	
et	al.,	2010;	Lindhart	et	al.,	1990).	
Enzyme	(Lyase)	 Sequence	specificity	
Heparinase	I	(Heparitinase	III)	 -GlcNS	(±6S)-α	(1-4)	IdoA	(2S)-	
Heparinase	II	(Heparitinase	II)	 -GlcNR	(±6S)-α	(1-4)	GlcA/IdoA-	
Heparinase	III	(Heparitinase	I)	 GlcNR	(±6S)-α	(1-4)	GlcA-	
	
	
It	 is	 important	 to	 note	 that	 the	 action	 of	 these	 heparinase	 enzymes	 on	 the	 HS/heparin	
chains	ultimately	makes	it	impossible	to	identify	the	nature	of	the	original	uronic	acid	epimer	within	
the	disaccharide,	i.e.	it	is	not	possible	to	distinguish	between	GlcA	and	IdoA	residues.	This	is	a	result	
of	 the	 introduction	 of	 the	 C4-C5	 carbon-carbon	 double	 bond	 at	 the	 non-reducing	 end	 of	 the	
disaccharide.	This	 feature	 is	unavoidable	 in	 the	digestion	of	HS/heparin,	but	 should	be	noted	as	a	
shortcoming	of	this	method	since	epimer	identity	may	prove	crucial	in	understanding	GAG	structure	
heterogeneity	in	tissues/cells	of	interest.	
	 	
2.1.1.2.2	Chemical	degradation	
	
There	are	several	other	means	by	which	GAG	chains	like	HS/heparin	may	be	digested	into	
their	smaller	constituents.	Chemical	digestion	 is	also	a	common	method	for	 this.	For	several	years	
nitrous	acid	digestion	was	a	common	choice	for	the	depolymerisation	of	GAG	chains.	Nitrous	acid	at	
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pH	1.5	is	able	to	rapidly	cleave	at	N-sulfated	GlcN	residues	of	HS/heparin	to	remove	N-sulfate	groups	
and	 yield	 de-N-sulfated	 oligosaccharides.	 As	 such,	 this	 is	 still	 largely	 the	 cheapest	 and	 easiest	
method	 for	generating	unsulfated	oligosaccharides	of	 varying	 lengths	 (Conrad	2001).	N-acetylated	
amino	 sugar	 residues	 of	 these	 chains	 however	 do	 not	 react	 with	 nitrous	 acid	 and	 as	 a	 result,	
digestion	by	this	method	will	not	touch	any	part	of	the	chain	with	an	acetyl	group.	This	hurdle	can	be	
overcome	via	N-deacetylation	of	these	residues	followed	by	further	nitrous	acid	treatment	at	pH	4	
to	 finally	digest	 the	 remaining	de-N-acetylated	chains.	The	process	of	N-deacetylation	was	 initially	
carried	out	via	a	process	termed	hydrazonolysis	(Shaklee	and	Conrad	1984).	This	was	achieved	using	
either	hydrazine	or	 hydrazine	hydrate,	 however	was	 found	 to	 initiate	only	partial	N-deacetylation	
and	caused	degeneration	of	the	GAG	chain	–	an	unfavorable	outcome	for	a	protocol	used	to	assess	
structural	characteristics.	Later,	 it	was	discovered	that	 full	de-N-acetylation	and	degradation	could	
be	 afforded	 by	 the	 use	 of	 a	mixture	 of	 hydrazine	 and	 hydrazine	 sulfate	 instead	 (Yosizawa,	 et	 al.	
1966)	 which	 released	 a	 free	 amino	 in	 place	 of	 the	 acetyl	 group	 that	 could	 then	 be	 attacked	 by	
nitrous	acid	treatment	for	degradation	(Shaklee	and	Conrad	1984).	Despite	the	ease	and	speed	with	
which	 this	 method	 can	 be	 carried	 out,	 nitrous	 acid	 and	 hydrazonolysis	 are	 limited	 to	 lack	 of	
production	of	disaccharides	with	a	 carbon-carbon	double	bond	 that	 can	be	easily	detected	by	UV	
(232nm),	as	is	the	result	with	enzymatic	degradation.	These	do	however	maintain	the	uronic	acids	in	
their	original	configuration	allowing	identification	of	differences	in	GlcA	and	IdoA	content.	
	
UV	 can	 be	 used	 to	 detect	 other	 parts	 of	 the	 disaccharide	 at	 different	 wavelengths	 (e.g.	
210nm)	however	 these	are	not	as	sensitive	as	 the	signal	afforded	by	exploiting	 the	carbon-carbon	
double	 bond.	 Secondly,	 the	 use	 of	 hydrazide	 in	 this	 process	 makes	 the	 C-5	 uronic	 acid	 more	
susceptible	to	epimerisation.	Compositional	analysis	of	polysaccharides	containing	only	one	type	of	
uronic	acid	is	not	hindered	by	this,	however	the	presence	of	both	GlcA	and	IdoA	acid	residues	within	
both	HS/heparin	means	that	recovery	of	the	relative	proportions	of	these	uronic	acid	residues	may	
not	be	a	true	reflection	of	the	native	structure	(Shaklee	and	Conrad	1984).		
	
2.1.1.2.3	Free	radical	degradation	
	
	 Digestion	 of	 GAG	 chains	 by	 free	 radicals	 is	 another	 available	 method.	 Reactive	 oxygen	
species	(ROS)	may	be	described	as	chemically	active	molecules	that	are	generated	as	a	result	of	the	
partial	reduction	of	oxygen.	These	products	are	very	similar	to	reactive	nitrogen	species	(RNS)	that	
are	 identical	 except	 derived	 from	 nitric	 oxide	 (NO)	 based	 reactions	 (Winterbourn	 2008).	 The	
generation	 of	 free	 radicals	 may	 be	 both	 due	 to	 exogenous	 (UV	 radiation	 and	 ionisation)	 and	
endogenous	 (mitochondrial	 respiration,	 enzymes	 that	 produce	 ROS/RNS)	 means	 within	 the	 body	
(Kohen	and	Nyska	2002)	and	can	be	both	beneficial	and	detrimental	to	cells.	Free	radical	exposure	
may	play	a	role	in	pathways	such	as	signal	transduction	and	transcriptional	regulation,	but	may	also	
expose	the	cell	to	intense	oxidative	stress	that	can	be	damaging	(Fialkow,	et	al.	2007).		
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ROS	and	RNS	species	may	be	thought	of	as	free	radicals	that	contain	one	unpaired	electron.	
This	 family	 of	 active	 chemicals	may	 include	 superoxide	 ion	 radicals	 (O2
-),	 peroxyl	 (ROO-),	 hydroxyl	
(OH-),	 alkoxyl	 (Ogishima,	 et	 al.)	 and	NO	 radicals	 (NO-)	 (Kohen	and	Nyska	2002).	 These	 species	 are	
able	 to	 interact	 with	 polysaccharides	 such	 that	 they	 cause	 breakage	 of	 the	 sugar	 backbone	 and	
generate	smaller	fragments	(Duan	and	Kasper	2011).	One	species	in	particular,	the	hydroxyl	radical	
is	the	most	reactive	of	all	the	reactive	oxygen	species.	It	is	able	to	abstract	hydrogen	atoms	from	the	
substrate	in	a	number	of	positions	along	the	polysaccharide	chain.	Most	importantly,	previous	work	
has	 found	 that	 a	 free	 radical	 reaction	 initiated	 by	 a	 mixture	 of	 Cu2+,	 hydrogen	 peroxide	 and	
ascorbate	dramatically	 reduces	the	molecular	weight	of	heparin	by	approximately	a	 third	and	also	
attenuates	its	anti	Xa	activity	by	nearly	a	half.	These	results	suggest	a	regional	selectivity	of	the	Cu2+	
ion	and	heparin	that	can	be	exploited	for	depolymerisation	of	the	GAG	chain	(Liu	and	Perlin	1994).		
	
Furthermore,	 research	 shows	 that	 the	 degree	 of	 depolymerisation	 via	 the	 action	 of	 free	
radicals	 is	dependent	upon	the	 levels	of	sulfation	to	the	GAG	chain.	For	example	hyaluronan	(HA),	
lacking	 sulfate	 groups,	 is	 the	 most	 susceptible	 to	 free	 radical	 attack.	 HS	 however,	 is	 much	 less	
susceptible	 due	 to	 the	 highly	 sulfated	 nature	 of	 this	 sugar	 (Kennett	 and	 Davies	 2007).	 This	
discrimination	of	efficacy	for	free	radical	degradation	for	different	GAGs	does	not	make	it	the	most	
suitable	method	of	depolymerisation,	particularly	 in	this	 instance	for	the	compositional	analysis	of	
HS.		
	
2.2	Heparin/HS	disaccharide	standards	
	
Within	both	heparin	and	HS	structures,	 there	exist	8	“most	common”	disaccharide	motifs	
that	 are	 often	 used	 as	 standards.	 These	 8	 disaccharides	 are	 consistently	 observed	within	 HS	 and	
heparin	GAGs	and	may	therefore	be	used	as	a	commercially	available	comparison	for	identification	
of	 those	 disaccharides	 present	 within	 the	 HS/heparin	 sample	 of	 interest.	 The	 8-disaccharide	
standards	 range	 from	 those	with	 no	 or	 very	 low	 levels	 of	 sulfation	 to	 those	with	 a	much	 greater	
degree	 of	 sulfation.	 In	 its	 simplest	 form,	 there	 are	 3	 positions	 (R1,	 R2	 and	 R3)	 onto	 which	
modifications	to	the	HS/heparin	chain	may	be	made	(Figure	2.2).	A	sulfate	or	hydroxyl	group	may	be	
found	at	position	2	of	the	iduronate	residue	(R1)	or	position	6	of	the	glucosamine	(R2),	and	finally	a	
N-sulfate	or	N-acetyl	group	may	be	added	at	position	2	of	the	glucosamine	(R3)	(Yates,	et	al.	2004).		
	
Modifications	 at	 these	 positions	 may	 occur	 together	 or	 in	 isolation	 and	 as	 such,	 these	
modifications	 open	 up	 a	 great	 variety	 of	 possible	 combinations	 of	 sulfation/acetylation	 that	
ultimately	confer	a	wide	binding	capacity	of	HS/heparin	and	other	protein	ligands.		The	disaccharide	
standards	used	as	authentic	 comparisons	 in	 this	 instance	consist	of	 the	most	commonly	occurring	
varieties	 of	 these	 three	 modification	 patterns	 (Table	 2.2).	 One	 can	 make	 use	 of	 strong	 anion	
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exchange	 high	 performance	 chromatography	 (SAX-HPAEC)	 to	 separate	 these	 standards	 using	 an	
increasing	linear	salt	gradient	to	dissociate	each	standard	from	the	column.		
	
Table	 2.2:	 Structures	 of	 the	 8	 most	 commonly	 occurring	 disaccharide	 components	 within	 HS/heparin	
following	exhaustive	 enzymatic	 digestion	with	heparinase	 I,II	 and	 III	 enzymes.	The	delta	symbol	 represents	
the	presence	of	 the	4,5	unsaturated	carbon-carbon	double	bond.	Abbreviations:	UA,	uronic	acid	 residue;	Ac,	
acetyl;	 GlcNAc,	 N-acetyl	 glucosamine;	 GlcNS,	 glucosamine-N-sulfate;	 H,	 hydrogen;	 2S,	 2-O-sulfate;	 6S,	 6-O-
sulfate;	Sulf,	Sulfate.	Taken	and	adapted	from	(Skidmore,	et	al.	2010)	
	
2.3	Detection	methods	of	heparin/HS	disaccharides	for	analysis	by	strong	anion	
exchange	chromatography		
2.3.1	Detection	by	UV	absorbance	or	fluorescence	
	
The	 chromophore	 of	 the	 unsaturated	 double	 bond	 that	 is	 introduced	 via	 heparinase	
digestion	can	be	detected	optimally	with	UV	absorbance	at	232nm,	making	analysis	of	disaccharide	
composition	relatively	simple.	A	major	drawback	of	this	protocol	however	is	that	the	detection	limit	
Unit	formula	 R1	 R2	 R3	
Δ-UA-GlcNAc	 Ac	 H	 H	
Δ-UA-GlcNAc(6S)	 Ac	 Sulf	 H	
Δ-UA(2S)-GlcNAc	 Ac	 H	 Sulf	
Δ-UA(2S)-GlcNAc(6S)	 Ac	 Sulf	 Sulf	
Δ-UA-GlcNS	 Sulf	 H	 H	
Δ-UA-GlcNS(6S)	 Sulf	 Sulf	 H	
Δ-UA(2S)-GlcNS	 Sulf	 H	 Sulf	
Δ-UA(2S)-GlcNS(6S)	 Sulf	 Sulf	 Sulf	
Figure	2.2:	Simplified	diagram	of	the	repeating	disaccharide	unit	that	make	up	the	HS/heparin	polysaccharide.	
Modification	of	 these	 units	may	 occur	 at	 3	 positions,	 R1,	 R2	 and/or	R3.	A	 sulfate	 or	 hydroxyl	 group	may	be	
present	at	both	the	2	position	of	 iduronate	or	glucosamine	residue	and	a	N-sulfate	or	N-acetyl	group	may	be	
substituted	at	the	6	position	of	the	glucosamine	residue.	Taken	from	(Yates,	et	al.	2004)	
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of	 this	 method	 is	 limited	 to	 the	 low	 nanomolar	 range	 whereby	 approximately	 1-5μg	 of	 starting	
material	is	used	for	HS/heparin	analysis	(Turnbull,	et	al.	1999).	Practically	however,	extraction	of	HS	
cannot	be	achieved	often	in	such	large	quantities	and	a	much	more	sensitive	detection	method	may	
be	needed	for	many	applications.		
	
Labeling	 samples	 of	 interest	with	 an	 appropriate	 fluorophore	 has	 been	widely	 used	 as	 a	
method	to	enhance	sensitivity	and	reduce	detection	limits	for	disaccharide	analysis	without	the	risk	
of	 contaminant	 signal	 as	 is	 common	with	 UV	 detection	 (Skidmore,	 et	 al.	 2006).	 Indeed	work	 has	
been	 carried	 out	 more	 recently	 to	 improve	 sensitivity	 without	 the	 need	 for	 additional	
chromatography	 hardware	 that	 usually	 accompanies	 improved	 detection.	 	 In	 common	 practice,	 a	
fluorophore	may	be	added	to	the	reducing	end	of	the	disaccharide	unit	via	a	Schiff’s	base	reaction	
between	a	nitrogen	containing	functional	group	on	the	fluorophore	(such	as	an	amino	or	hydrazide)	
and	the	carbonyl	group	of	the	reducing	end	of	the	sugar.		
	
Examples	 of	 this	 type	 of	 detection	 include	 addition	 of	 2-aminoacridone,	 a	 small	 amine-
containing	fluorophore,	to	the	reducing	end	of	the	disaccharide	followed	by	detection	with	reverse-
phase	high	performance	liquid	chromatography	(RP-HPLC).	This	fluorophore	is	widely	used	to	label	
any	 carbonyl	 containing	 biomolecule	 and	 has	 reportedly	 improved	 sensitivity	 for	 disaccharide	
analysis	 of	 as	 little	 as	 10ng	 of	 the	 original	 GAG	 (Deakin	 and	 Lyon	 2008).	 Other	 fluorescent-based	
methods	 for	 glycan	 sequencing	 include	 the	 use	 of	 another	 fluorescent	 label,	 anthranilic	 acid,	
followed	by	gel	electrophoresis	to	detect	nmol	levels	of	disaccharide	for	analysis.	This	was	improved	
further	 by	 an	 alternative	 label,	 7-aminonapthalene-1,3-disulfonic	 acid	 to	 improve	 sensitivity	 an	
additional	 ten	 fold	 to	 confer	 detection	 with	 starting	 material	 quantities	 in	 just	 the	 pmol	 range	
(Drummond,	et	al.	2001).		
	
Despite	 the	 undoubted	 improvement	 in	 sensitivity	 and	 detection	 limits	 that	 these	 new	
methodologies	 have	 afforded,	 there	 is	 literature	 to	 suggest	 that	 they	 may	 lack	 the	 ability	 to	
successfully	 resolve	 all	 8	 of	 the	 most	 common	 disaccharide	 standards	 within	 HS/heparin.	 In	
particular,	 RP-HPLC	 has	 more	 recently	 been	 used	 to	 enhance	 separation	 of	 the	 disaccharide	
standards	present	within	HS/heparin	and	also	other	GAGs	such	as	CS,	DS	and	HA.	 In	this	protocol,	
the	GAG	disaccharides	may	be	derivitised	with	a	fluorophore	called	AMAC	and	separated	via	reverse	
phase	HPLC.	As	such,	this	method	became	the	first	of	its	kind	to	facilitate	the	successful	separation	
of	 the	 disaccharide	 standards	 in	 one	 step	 with	 appropriate	 efficiency,	 accuracy	 and	 stability	
(Ambrosius,	et	al.	2008).	
	
2.3.2.Detection	of	BODIPY-tagged	disaccharides	by	fluorescence	
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	 Advances	in	methodology	for	disaccharide	compositional	analysis	have	proved	invaluable	
for	further	understanding	and	characterising	the	structure	and	function	of	GAG	chains.	Much	more	
recently	 however,	 the	 use	 of	 a	 fluorophore,	 BODIPY	 FL	 hydrazide	 (λex	 488nm,	 λem	 520nm)	 has	
become	a	popular	choice	for	detection	of	HS/heparin	disaccharides.	Most	notably,	this	is	due	to	its	
ability	 to	 label	 disaccharides	 that	may	be	 only	 in	 the	 fmol	 	 (10-15	mol)	 range	 in	 terms	of	 quantity	
available.	As	such	this	 is	an	ideal	method	for	the	compositional	analysis	of	HS	from	tissues	such	as	
AD	 patient	 and	 healthy	 aged-matched	 control	 samples	 as	 obtained	 for	 this	 project.	 Only	 small	
amounts	 of	 tissue	 can	 be	 sampled	 at	 any	 one	 time	 and	 high	 sensitivity	 means	 only	 30-80mg	 of	
starting	material	is	required	for	successful	analysis	of	the	disaccharides	present.		
	
The	BODIPY	protocol,	as	first	described	by	Skidmore	and	colleagues	 in	2006	(Skidmore,	et	
al.	2006),	utilises	reductive	amination	(a	process	in	which	a	carbonyl	group	is	converted	to	an	amine	
via	 the	action	of	an	 intermediate	 imine)	 to	 label	 the	disaccharide	of	 interest.	 	 In	 this	 instance	 the	
carbonyl	group	present	on	the	reducing	end	of	the	disaccharide	undergoes	reductive	amination	with	
the	 hydrazide	 group	 present	 on	 the	 fluorophore	 (the	 BODIPY	 tag).	 In	 some	 cases,	 the	 resulting	
conjugate	 may	 be	 stabilised	 by	 reducing	 the	 intermediate	 imine	 to	 an	 amine	 using	 sodium	
borohydride.	When	the	disaccharides	have	been	labeled	they	may	be	separated	through	the	use	of	
strong	anion	exchange	chromatography	(as	with	other	 labeling	methods).	A	 linear	sodium	chloride	
gradient	 can	 successfully	 dissociate	 each	 disaccharide	 from	 the	 column	 and	 each	 peak	 can	 be	
compared	 to	 a	 chromatogram	 generated	 with	 authentic	 disaccharide	 standards	 for	 comparative	
analysis.	As	mentioned	previously,	 the	 identity	of	 the	uronic	acid	residue	within	each	disaccharide	
remains	 unsolved	 with	 this	 method,	 as	 with	 other	 detection	 systems;	 however	 the	 use	 of	 the	
BODIPY	 fluorophore	 undoubtedly	 improves	 the	 speed,	 efficiency	 and	 accuracy	 of	 disaccharide	
compositional	analysis.		
	
For	 this	 project,	 the	use	of	 BODIPY	was	 ideal	 due	 to	 limited	 sources	of	 starting	material.	
Being	 able	 to	 detect	 and	 analyse	 disaccharide	 composition	 at	 low	 levels	 meant	 precious	 human	
tissue	 could	be	used	 for	other	 experiments/assays	without	waste.	Additional	 clean	up	 steps	were	
added	before	and	after	the	addition	of	the	fluorescent	label	to	ensure	clean	chromatograms	with	no	
contaminating	 peaks.	 By	 understanding	 the	 potential	 differences/similarities	 in	 disaccharide	
composition	 between	 the	 HS	 from	 AD	 patients	 and	 age-matched	 controls,	 this	 project	 aimed	 to	
further	elucidate	and	understand	the	consequences	and	functionality	of	altered	HS	structures	within	
the	brains	of	AD	patients	and	its	role	in	the	onset	of	this	disease.		
	
2.4	Changes	in	the	structure	of	glycosaminoglycans	like	HS		
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	 There	are	several	examples	whereby	the	study	of	GAG	structure	has	demonstrated	changes	
in	the	presence	of	a	disease	or	ageing	phenotype.	Specifically	 in	the	context	of	this	project,	recent	
studies	have	 suggested	 that	normal	 ageing	may	 initiate	 changes	 in	 the	 structure	of	HS.	 Studies	 in	
aged	 rat	 myocardium	 have	 recorded	 an	 age-dependent	 increase	 in	 the	 quantity	 of	 HS	 in	 the	
myocardium.	In	addition,	this	change	was	accompanied	by	significantly	increased	6-O	sulfation	and	
some	changes	in	N-	and	2-O	sulfation	also	(Huynh,	et	al.	2012).	In	addition,	studies	have	shown	that	
GAGs	 from	 aged	 human	 hippocampus	 present	 altered	 structural	 properties	 vs.	 their	 younger	
counterparts.	These	structural	differences	were	shown	to	affect	regulation	of	trophic	factors	despite	
having	no	effect	on	Aβ	peptide	toxicity	(Huynh,	et	al.	2012).	In	light	of	this,	we	can	conclude	there	
are	significant	structural	alterations	that	take	place	with	ageing	and	we	might	postulate	that	these	
changes	could	contribute	to	the	AD	phenotype.	
	
		 Indeed,	other	studies	to	look	at	brain	tissue	have	also	recorded	changes	in	the	structure	of	
another	 PG,	 KS	 in	 AD	 patients	 vs.	 age-matched	 controls.	 Lindahl	 and	 colleagues	 reported	 a	
significant	decrease	in	levels	of	highly	sulfated	KS	within	the	cerebral	cortex	of	patients	with	AD	vs.	
age-matched	controls	and	have	suggested	this	may	reflect	a	specific	deficit	in	the	function	of	those	
cells	affected	by	Alzheimer’s	pathology.	Whether	 this	change	 in	 the	structure	of	KS	 is	a	secondary	
effect	 of	 the	 disease	 pathology	 or	 indeed	 an	 upstream	 cause	 of	 the	 deficits	 observed	 with	 this	
disorder	 is	unknown;	however	understanding	the	structure	of	PGs	 in	 this	way	 is	key	 in	elucidating	
links	between	this	complex	sugar	and	disease	pathology	(Lindahl,	et	al.	1996).	
	
Likewise,	 Lindahl	 and	 colleagues	 have	 also	 observed	 a	 slight	 increase	 in	 the	 level	 of	 N-
sulfation	along	the	HS	chain	 in	AD	patients	vs.	age-matched	controls.	This	was	observed	despite	a	
relative	 uniformity	 of	 HS	 profiling	 between	 all	 patient	 samples	 studied;	 however	 more	 work	 is	
needed	to	determine	whether	this	 is	a	cause	of	AD	pathology	or	a	secondary	consequence.	Whilst	
work	has	already	shown	an	 interaction	between	HS	and	BACE-1	 (Scholefield,	2003)	 indicative	of	a	
causative	role	of	HS	in	AD,	there	is	a	great	deal	of	evidence	to	suggest	it	also	has	secondary	roles	in	
disease	progression.	With	this	in	mind,	we	must	also	be	aware	of	the	changes	in	structure	of	HS	and	
how	this	may	alter	interaction	with	the	Aβ	protein	itself	and	the	exacerbation	of	AD	pathology	after	
it	has	been	initiated	(Lindahl,	et	al.	1995).		
	
HS	displays	the	highest	level	of	structural	complexity	of	all	the	GAGs,	which	may	explain	its	
diverse	role	in	so	many	physiological	and	pathological	functions.	Such	interactions	will	be	dependent	
upon	the	distribution	of	charges	along	the	polysaccharide	chain	that	confers	specificity	in	the	way	in	
which	 the	 sugar	 is	 able	 to	 interact	 with	 its	 ligands	 (Lindahl,	 et	 al.	 1995).	 With	 this	 in	 mind,	
understanding	 the	 changes	 in	 the	 structure	 of	HS	will	 be	 of	 key	 importance	 in	 determining	more	
about	 its	 role	 in	 disease.	 Even	 the	 subtlest	 of	 changes	 in	 the	 structure	 of	 this	 GAG	 may	 be	
instrumental	 in	affecting	a	number	of	downstream	processes	associated	with	a	particular	disease.	
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This	project	aimed	to	study	potential	changes	in	the	structure	of	HS	in	the	brains	of	AD	patients	and	
their	healthy	age-matched	control	counterparts.		
2.5	Aims	of	this	chapter	
	
1. Determine	if	there	are	differences	in	the	disaccharide	compositional	profile	of	HS	from	the	
middle	temporal	gyrus	tissue	from	human	AD	and	age-matched	control	patients.		
2. Determine	whether	there	are	global	changes	in	the	degree	of	sulfated	motifs	found	within	
the	HS	 from	 the	middle	 temporal	 gyrus	 tissue	 from	 human	AD	 and	 age-matched	 control	
patients.	
3. Investigate	the	quantity	of	 total	HS	 found	within	middle	temporal	gyrus	brain	tissue	 from	
human	AD	and	age-matched	control	patients.		
4. Determine	whether	 there	are	any	gender-based	differences	 in	 the	overall	 composition	of	
HS	within	human	AD	and	age-matched	control	patients.		
5. Explore	potential	changes	in	the	structure	of	brain	HS	as	above	but	from	young	(3	month)	
and	old	(18month)	old	mice	to	explore	age	as	a	variable	for	HS	structure.	
	
2.6	Methods		
2.6.1	Sample	selection		
2.6.1.1	Ethical	approval	
	
Human	brain	samples	were	 received	 from	the	Oxford	Brain	Bank,	 supported	by	 the	MRC,	
BDR	and	the	NIHR	Oxford	Biomedical	Research	Centre.	All	human	tissue	work	was	carried	out	under	
ethical	 approval	 from	 the	Oxford	 Brain	 Bank	 	 (ref	 number:	 07/0606/85).	 Furthermore,	 all	 human	
tissue	was	acquired,	used	and	disposed	of	appropriately,	according	to	all	environmental,	healthy	and	
safety	laws	as	described	by	the	Human	Tissue	Act	2004.	For	mouse	samples,	all	animals	were	used	in	
accordance	with	 the	Animal	 (Scientific	Procedures)	Act	1986	and	the	EU	Directive	2010/63/EU.	All	
procedures	 were	 performed	 in	 accordance	 with	 the	 UK	 Home	 Office	 Regulation	 of	 Animal	
Experimentation.	
	
2.6.1.2	Selection	of	human	samples	
	
Brain	samples	were	received	from	the	Oxford	Brain	Bank,	supported	by	the	MRC,	BDR	and	
the	 NIHR	 Oxford	 Biomedical	 Research	 Centre.	 Brain	 sampling	 was	 performed	 according	 to	 the	
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Consortium	to	Establish	a	Registry	of	AD	(CERAD).	Two	experimental	groups	were	established;	an	AD	
group	 (n=20)	 of	 10	 females	 and	 10	males	with	 subject	 ages	 ranging	 from	71-	 91	 (mean	 ±S.E.M	 =	
78.85	±	2.11),	and	a	healthy	control	group	(n=15)	of	9	females	and	6	males	with	subject	ages	ranging	
from	75-101	 (mean	±S.E.M	=	86.3±1.6)	 (Table	 2.3).	Post-mortem	delay	 intervals	varied	 from	19.0-
107.0	 and	22.0-120.0hr	 for	AD	patients	 and	healthy	 controls	 respectively.	 Brains	were	 frozen	 and	
200mg/sample	 of	 the	 middle	 temporal	 gyrus	 (BA21)	 dissected.	 Tissues	 were	 immediately	 frozen	
after	dissection	in	dry	ice.		
	
AD	samples	were	selected	based	on	both	a	clinical	and	neuropathological	diagnosis	of	the	
disease.	Difficulties	with	diagnosing	AD	with	100%	accuracy	until	post-mortem	made	it	necessary	to	
confirm	pathology	 after	 death	with	 the	 histologically	 identified	 presence	 of	 AD	pathology.	 CERAD	
criteria	for	disease	progression	were	used	as	a	primary	target	for	sampling	and	those	patients	with	
“definite	AD”	were	 selected	 for	 sampling	with	priority.	Availability	of	 samples	meant	 this	was	not	
possible	in	all	cases;	however	“classical”	AD	pathology	was	confirmed	in	all	AD	patients	selected	for	
this	study.	Braak	staging	was	the	only	confirmed	measure	of	AD	in	some	patients	and	were	selected	
for	when	CERAD	staging	could	not	be	confirmed.	Post	mortem	delay	was	challenging	to	control	for;	
however	sex	of	the	patient,	age	and	diagnosis	were	all	carefully	selected	for.	For	the	control	group,	
age-matched	 samples	were	 selected	with	 a	 similar	 sex	 distribution.	 All	 patients	within	 this	 group	
were	 deemed	 neuropathologically	 normal	 at	 post	 mortem	 and	 in	 all	 but	 2	 exceptions,	 no	
neurological	 or	 psychiatric	 symptoms	 of	 any	 kind	were	 reported	 (Table	 2.4).	 Again,	 post-mortem	
delay	 times	 varied	 somewhat	 for	 this	 cohort	 however	 no	 significant	 statistical	 difference	 (p<0.08,	
Student’s	 t-test))	 was	 found	 for	 post	 mortem	 delay	 between	 the	 two	 groups	 (Figure	 2.3).	
Fortunately,	 the	 structure	 of	 HS	 is	 relatively	 resistant	 to	 this	 variable,	 as	 it	 does	 not	 suffer	
degradation	or	instability	as	readily	as	RNA,	DNA	or	protein.	
	
Brodmann’s	area	21,	or	the	middle	temporal	gyrus,	was	selected	as	a	sample	region	in	this	
instance.	The	middle	temporal	gyrus	is	part	of	the	temporal	cortex	and	is	a	well-documented	area	to	
show	 neuropathological	 and	 neurochemical	 changes	 in	 AD	 (Scheff	 and	 Price	 1993).	 This	 made	
selection	 of	 the	middle	 temporal	 gyrus	 a	 suitable	 candidate	 for	 this	 study,	 as	 it	 was	 desirable	 to	
select	 a	 region	 that	 was	 vulnerable	 to	 the	 onset	 of	 AD	 pathology	 (Figure	 2.4).	 Furthermore,	
bioinformatics	 analysis	 of	 publically	 available	 microarray	 gene	 expression	 profiling	 databases	
highlighted	key	changes	in	the	expression	of	HS-related	genes	with	AD	within	the	middle	temporal	
gyrus	which	supported	the	decision	to	sample	this	area	of	the	brain.	Data	collected	from	this	work	is	
described	 in	 detail	 in	 chapter	 5.	 It	 is	 important	 to	 note,	 previous	 work	 including	 3D	 magnetic	
resonance	 imaging	 (MRI)	 studies	 have	 identified	 the	 hippocampus	 as	 the	 first	 area	 known	 to	 be	
affected	 in	 the	 onset	 of	 AD	 (Zhang,	 et	 al.	 2015).	 In	 particular,	 hippocampal	 atrophy	 has	 been	
observed	 in	 patients	 before	 the	 onset	 of	 symptoms	 (Fox,	 et	 al.	 1996).	 However	 due	 to	 the	 small	
nature	of	this	brain	region,	and	its	primary	role	in	memory	formation	is	a	highly	sought-	after	sample	
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for	studies	like	this	and	was	unavailable	for	this	early	work.	The	middle	temporal	gyrus	is	implicated	
in	AD	pathology	and	is	available	in	relative	abundance	making	it	an	ideal	choice	for	sampling	in	this	
study.	
	
Table	 2.3:	Samples	 selected	 from	 the	Oxford	Brain	Bank	 for	 analysis.	AD	and	age-matched	control	 samples	
were	 selected	 and	 sex,	 age	 and	 post-mortem	 delay	 recorded	 as	 shown	 below.	 Abbreviations:	 PMD,	 Post-
mortem	delay.	
	
	
	
Sex	 Age	(yrs.)	 PMD	(hrs.)	 Group	 Sex	
Age	
(yrs.)	
PMD	(hrs.)	 Group	
F	 72	 85.0	 AD	 F	 79	 31.0	 Ctrl	
F	 83	 19.0	 AD	 F	 89	 59.0	 Ctrl	
F	 71	 22.0	 AD	 F	 85	 40.0	 Ctrl	
F	 86	 72.0	 AD	 F	 87	 52.0	 Ctrl	
F	 89	 30.0	 AD	 F	 88	 27.0	 Ctrl	
F	 67	 107.0	 AD	 F	 101	 37.0	 Ctrl	
F	 68	 49.0	 AD	 F	 88	 62.0	 Ctrl	
F	 91	 49.0	 AD	 F	 83	 52.0	 Ctrl	
F	 70	 84.0	 AD	 F	 84	 31.0	 Ctrl	
F	 93	 80.0	 AD	 M	 93	 120.0	 Ctrl	
M	 78	 77.0	 AD	 M	 75	 45.0	 Ctrl	
M	 86	 50.0	 AD	 M	 86	 31.0	 Ctrl	
M	 85	 65.0	 AD	 M	 82	 22.0	 Ctrl	
M	 88	 24.0	 AD	 M	 88	 31.0	 Ctrl	
M	 88	 72.0	 AD	 M	 86	 28.0	 Ctrl	
M	 70	 79.0	 AD	 	 	 	 	
M	 71	 85.0	 AD	 	 	 	 	
M	 84	 96.0	 AD	 	 	 	 	
M	 66	 42.0	 AD	 	 	 	 	
M	 71	 20.0	 AD	 	 	 	 	
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Figure	2.3:	Post	mortem	delay	in	AD	and	control	samples.	Post	mortem	delay	was	reasonably	varied	between	
AD	 and	 age-matched	 control	 brain	 samples	 however	 no	 significant	 difference	 was	 found	 between	 the	 two	
groups	(p<0.08,	Student's	t-test).	Post-mortem	delay	intervals	varied	from	19.0-107.0hr	and	22.0-120.0hr	for	AD	
patients	and	healthy	controls	respectively.	
	
Figure	2.4:	Brodmann's	areas	of	 the	brain	 labeled	 in	 lateral	view.	Brodmann’s	area	21	 (BA21),	or	the	middle	
temporal	gyrus	is	located	within	the	temporal	cortex	in	the	human	brain.	The	middle	temporal	gyrus	comprises	
most	of	the	lateral	temporal	cortex,	a	region	most	associated	with	language	and	auditory	processing.	Previous	
work	has	 implicated	 this	 area	 in	AD	pathogenesis.	The	BA21	 region	 is	 found	superior	 to	BA20	and	 inferior	 to	
BA40	and	BA41.	
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Table	2.4:	Details	of	clinical	and	neuropathological	diagnosis	of	AD	and	age-matched	control	samples	selected	
for	this	study	as	recorded	by	the	Oxford	Brain	Bank.	Abbreviations:	AD:	Alzheimer’s	disease;	Ctrl:	Control;	VD:	
Vascular	dementia;	CERAD:	Consortium	to	Establish	a	Registry	of	AD.	
	
Group	 Clinical	
Diagnosis	
Neuropathological	Diagnosis	 Group	 Clinical	
Diagnosis	
Neuropathological	
Diagnosis	
AD	 AD	 AD,	Braak	+	Braak	stage	VI	/	AD,	
CERAD	definite	AD	
Ctrl	 No	neurological	
or	psychiatric	
symptoms	
No	neuropathological	or	
normal	ageing	changes	
AD	 AD	 AD,	Braak	+	Braak	stage	VI	/	AD,	
CERAD	definite	AD	
Ctrl	 No	neurological	
or	psychiatric	
symptoms	
No	neuropathological	or	
normal	ageing	changes	
AD	 AD	 AD,	Braak	+	Braak	stage	VI	/	AD,	
CERAD	definite	AD	
Ctrl	 No	neurological	
or	psychiatric	
symptoms	
No	neuropathological	or	
normal	ageing	changes	
AD	 AD	 AD,	Braak	+	Braak	stage	VI	/	AD,	
CERAD	definite	AD	
Ctrl	 Depression	 No	neuropathological	or	
normal	ageing	changes	
AD	 AD	/	vascular	
dementia	
AD,	Braak	+	Braak	stage	VI/	AD,	
CERAD	definite	AD	/	vascular	
disease	
Ctrl	 No	neurological	
or	psychiatric	
symptoms	
No	neuropathological	or	
normal	ageing	changes	
AD	 AD	 AD,	Braak	+	Braak	stage	VI	/	AD,	
CERAD	definite	AD	/	infarction,	
ischaemic	
Ctrl	 Depression	 No	neuropathological	or	
normal	ageing	changes	
AD	 AD,	
hypertension	
AD,	Braak	+	Braak	stage	VI	/	AD,	
CERAD	definite	AD	/	hippocampal	
sclerosis	
Ctrl	 No	neurological	
or	psychiatric	
symptoms	
No	neuropathological	or	
normal	ageing	changes	
AD	 AD	/	
depression,	
vascular	
dementia	
AD,	Braak	+	Braak	stage	VI	/	AD,	
CERAD	definite	AD	
Ctrl	 No	neurological	
or	psychiatric	
symptoms	
No	neuropathological	or	
normal	ageing	changes	
AD	 n/a	 AD,	Braak	+	Braak	stage	VI	/	AD,	
CERAD	definite	AD	
Ctrl	 No	neurological	
or	psychiatric	
symptoms	
No	neuropathological	or	
normal	ageing	changes	
AD	 n/a	 AD,	Braak	+	Braak	stage	VI	/	AD,	
CERAD	definite	AD	
Ctrl	 No	neurological	
or	psychiatric	
symptoms		
No	neuropathological	or	
normal	ageing	changes	
AD	 AD	 AD,	Braak	tangle	stage	VI	 Ctrl	 No	abnormality	
detected	
Cerebrovascular	
arteriolosclerosis	
AD	 AD	 AD,	Braak	tangle	stage	VI	 Ctrl	 No	abnormality	
detected	
Cerebrovascular	disease	/	
mild	cerebrovascular	
atherosclerosis,	moderate	
non-amyloid	SVD	
AD	 Brain	atrophy	/	
vascular	
dementia	/	AD	
Mild	non	amyloid	SVD/	Mild	
cerebrovascular	atherosclerosis/	
Mild	arteriolar	AB-CAA/	AD,	
CERAD	high	density	of	neuritic	
plaques	
Ctrl	 No	abnormality	
detected	
No	abnormality	detected	
AD	 AD,	brain	
atrophy	/	
depressive	
episodes	
AD,	Braak	tangle	stage	VI	 Ctrl	 Malignant	
neoplasm	of	
bronchus	and	
lung	/	no	
abnormality	
detected	
Cerebrovascular	disease	/	
no	abnormality	detected	/	
moderate	non-amyloid	
SVD	/	microinfarcts,	
cerebral	white	matter	/	
microinfarcts,	basal	ganglia	
AD	 AD	 Mild	arteriolar	AB-CAA/	
AD,	Braak	tangle	stage	VI	/	
CERAD	high	density	of	neuritic	
plaques	
Ctrl	 No	abnormality	
detected	
Infarcts	>10mm	in	
diameter	
AD	 AD	/	epilepsy	 AD,	Braak	tangle	stage	VI	 	 	 	
AD	 AD	/	depression	 AD,	Braak	tangle	stage	VI	 	 	 	
AD	 AD	 AD,	Braak	tangle	stage	IV	 	 	 	
AD	 AD	 AD,	Braak	tangle	stage	VI	 	 	 	
AD	 AD	 AD,	Braak	tangle	stage	VI	 	 	 	
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2.6.1.3	Selection	of	old	and	young	mouse	brain	samples	
	
Young	 (3	months,	 n=5)	 and	 old	 (18	months,	 n=5)	 C57Bl/6J	 (female)	mice	 were	 obtained	
from	 Charles	 River	 (France),	 housed	 (4	 per	 cage)	 in	 a	 pathogen	 free	 facility	 at	 the	 University	 of	
Oxford,	UK	under	a	12hr	day-night	cycle	and	 fed	with	standard	chow	and	water	as	 libitum.	 In	 the	
final	two	weeks	of	experiment,	old	mice	were	housed	one	per	cage.	At	appropriate	ages,	mice	were	
culled	 and	 the	 brains	 dissected	 and	 immediately	 snap	 frozen	 before	 sending	 to	 the	 University	 of	
Liverpool	for	analysis.	Whole	brain	HS	was	isolated.	
	
2.6.2	Compositional	analysis	of	HS				 Compositional	 analysis	 of	 HS	 was	 carried	 out	 in	 the	 same	 manner	 for	 both	 human	 and	
mouse	brain	samples.	30mg	of	starting	wet	tissue	was	used	in	both	instances	for	HS	extraction	and	
purification	and	protocols	were	identical	for	both	species.	Optimisation	of	this	protocol	is	detailed	in	
Appendix	A.	
	
2.6.2.1	HS	extraction	and	purification	
	
Extraction	of	HS	from	tissue	was	achieved	using	a	previously	established	protocol	in	the	lab	
and	labeled	with	BODIPY	hydrazide	for	HPLC	analysis	with	fluorescence	detection.	Briefly,	wet	tissue	
(30mg)	was	homogenised	with	a	tissue	grinder	in	1ml	of	TRIzol™	(Life	Technologies)	reagent/100mg	
of	 tissue	 to	 break	 down	 the	 cell	 membranes	 and	 aid	 the	 release	 of	 HS.	 The	 tissue	 was	 then	
incubated	 for	 5	 minutes	 at	 room	 temperature	 and	 transferred	 to	 Eppendorf	 tubes	 and	 0.2ml	
chloroform	 (Sigma)/1ml	 of	 TRIzol™	 added	 before	 shaking	 vigorously	 for	 15s.	 Samples	 were	
centrifuged	at	8000	x	g	for	15	mins	at	4°C.	HSPGs	were	collected	 in	the	upper	aqueous	phase	and	
the	 pellet	 discarded.	 The	 aqueous	 phase	 was	 applied	 to	 a	 diethylaminoethanol	 (DEAE)	 Sephacel	
weak-anion	 exchange	 resin	 (GE	 Healthcare,	 UK)	 (bead	 storage	 ethanol	 pre	 washed	 off	 with	 3x	
washes	with	phosphate	buffered	saline	(PBS),	for	30mg	sample	400μl	of	PBS	and	beads,	assuming	a	
1:1	ratio	of	PBS	to	beads	overnight	and	then	washed	with	10ml	of	PBS,	10ml	of	PBS	(0.25M	NaCl),	pH	
7.4	(x2)	and	eluted	with	2ml	of	PBS	(2M	NaCl),	pH	7.4.	PBS	(2M	NaCl)	fractions	were	then	desalted	
on	a	HiTrap	desalting	column	(GE	Healthcare,	UK)	and	freeze-dried.		
	
Samples	were	 suspended	 in	100mM	sodium	acetate,	0.1mM	calcium	acetate,	pH	7.0	and	
digested	 by	 sequential	 addition	 of	 1.25	mU	 of	 heparinase	 1	 (2hr),	 heparinase	 III	 (2hr)	 and	 finally	
heparinase	II	(Ibex,	Canada)	(2hr)	at	37°C.	This	was	followed	by	addition	of	a	further	1.25	mU	of	each	
enzyme	 for	 incubation	 at	 37°C	 overnight	 (Ibex,	 Canada).	 Samples	 were	 brought	 to	 a	 0.5M	 salt	
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concentration	 and	 heated	 for	 5	 minutes	 at	 95°C	 before	 being	 run	 over	 Pierce	 C18	 spin	 columns	
(Thermo	Scientific).	Columns	were	prepped	and	 run	according	 to	manufacturer’s	 instructions	with	
the	 exception	 that	 flow	 through	 (containing	 HS	 disaccharides)	 was	 kept	 rather	 than	 discarded.	
Samples	were	then	run	over	graphite	spin	columns	(Thermo	Scientific)	to	remove	salt	according	to	
manufacturer’s	preparation	and	run	instructions.		
	
2.6.2.2	BODIPY	labeling	and	HPLC	analysis	with	fluorescence	detection	
	
Disaccharides	were	 labeled	with	BODIPY	hydrazide,	 as	described	previously	 (Skidmore,	 et	
al.	 2006).	 In	 addition	 HS	 disaccharide	 standards	 were	 also	 labeled	 for	 analysis	 by	 HPLC	 as	 a	
comparison.	Samples	were	suspended	in	BODIPY	fluorescent	label	hydrazide	(5mg/ml	in	methanol)	
and	 the	methanol	 removed	 by	 centrifugation	 under	 vacuum.	 Samples	were	 then	 re-suspended	 in	
dimethyl	 sulfoxide	 (DMSO):	 acetic	 acid	 (17:3	 v/v:	 10μl)	 and	 incubated	 in	 the	 dark	 for	 4hr.	 Excess	
BODIPY	 tag	 was	 removed	 using	 aluminium-silica	 thin-layer	 chromatography	 (TLC)	 plates	 (Sigma)	
using	butanol	as	a	mobile	phase.		
	
Finally	samples	underwent	ethanol	precipitation	to	remove	any	unwanted	chemical	species	
that	may	have	co-purified	with	the	HS.	A	saturated	ethanol	solution	was	made	with	sodium	acetate	
(Sigma)	 and	 incubated	 on	 ice	with	 the	 samples	 for	 15	minutes	 before	 being	 centrifuged	 and	 the	
supernatant	 collected.	 Samples	 were	 then	 freeze-dried	 ready	 for	 HPLC	 analysis.	 Labeled	
disaccharides	 were	 re-suspended	 in	 water	 (<1ml)	 and	 loaded	 onto	 a	 Propac	 PA-1	 strong-anion	
exchange	 column	 (4.6x250mm;	 Dionex,	 Leeds,	 UK).	 This	 was	 followed	 by	 elution	 with	 a	 linear	
gradient	of	0-1M	sodium	chloride	and	 isocratic	 sodium	hydroxide	 (150mM)	over	30	min	at	a	 flow	
rate	of	1ml/min	on	a	Shimadzu	HPLC	system.	Peaks	were	detected	with	an	inline	fluorimeter	with	an	
excitation	wavelength	of	λ	=	488nm	and	an	emission	wavelength	of	λ	=	520nm	using	a	Shimadzu	RF-
10AXL	 detector.	 The	 column	 was	 reconditioned	 with	 a	 2M	 NaCl	 wash	 (in	 300mM	 NaOH)	 before	
finally	equilibrating	it	in	150mM	NaOH.		
	
2.6.2.3	Quantification	of	total	HS	within	brain	samples	
	
	 Quantification	 of	 HS	 from	 tissue	 was	 carried	 out	 after	 a	 very	 similar	 extraction	 and	
preparation	process	as	described	above	for	the	disaccharide	compositional	analysis	(Section	2.6.2.1).	
Following	 desalting	 however,	 samples	 underwent	 exhaustive	 enzymatic	 clean	 up	 steps	 to	 remove	
any	 impurities	and	other	GAG	chains	 that	could	contaminate	 the	sample	of	HS.	This	was	achieved	
with	sequential	addition	of	DNAse,	RNAse,	chondroitin	ABC	lyase,	neuraminidase,	keratanase	(Sigma	
Aldrich,	UK)	and	Pronase®	(Roche,	UK)	enzymes	to	remove	DNA,	RNA,	chondroitin,	N-linked	sugars,	
sialic	acids,	KS	and	proteins	respectively.	Enzymes	were	added	in	appropriate	buffers,	as	detailed	in	
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Table	 2.5,	 for	 various	 periods	 of	 time	 at	 37°C,	 and	 after	 addition	 of	 Pronase,	 underwent	 a	 final	
incubation	overnight	at	37°C.	
	
Following	digestion,	 samples	underwent	DEAE	and	desalting	 treatment	 for	a	 second	 time	
(as	 outlined	 in	 section	2.6.2.1),	 to	 remove	 the	enzymes	 and	 salt	 that	were	 introduced	during	 this	
purification	process.	Samples	were	then	digested	with	multiple	heparinases	as	described	above.	This	
was	 followed	 by	 addition	 of	 a	 further	 1.25	mU	 of	 each	 enzyme	 for	 incubation	 at	 37’C	 overnight	
(Ibex,	 Canada).	 Pure	 digested	 HS	was	 then	 quantified	 using	 the	Nano	 Drop	 (Thermo	 Scientific),	 a	
spectrophotometer	set	for	UV	absorbance	at	232nm	to	detect	the	presence	of	the	glycosidic	double	
bond	within	the	HS	disaccharides.	HS	quantification	was	calculated	as	a	total	concentration	and	then	
µg/100mg	 of	 starting	 “wet”	 tissue.	 The	 concentration	 of	 HS	 was	 calculated	 with	 the	 following	
equation.	
A	=	ε	l	c	
(Where	A	=	absorbance	 (at	232nm),	ε	=	molar	absorption,	 (5500	 for	HS)	 l	=	 length	of	solution	 the	
light	passes	through	(0.1)	and	c	=	concentration.	
	
Table	2.5:	Enzymatic	purification	protocol	of	HS	samples	for	total	HS	quanitfication	as	described.	Sequential	
addition	 of	 DNase,	 RNase,	 chondroitin	 ABC	 lyase,	 neuraminidase,	 keratanase	 and	 Pronase®	 enzymes	 were	
added	in	their	respective	buffers	in	the	quantities	described	below.	
Enzyme	 Enzyme	Buffer	 Aliquot	 Incubation	
DNase	 40mM	Tris-acetate	pH	8.0,	6mM	
magnesium	chloride,	10mM	calcium	
chloride.	
1μg/ml	 4hr	
RNase	 10mM	Tris-acetate	pH	8.0,	5mM	EDTA,	
8mM	sodium	acetate,	
0.5mg/ml	 1hr	
chondroitin	ABC	lyase	 100mM	Tris-acetate	pH	8.0	 1.25U	 4hr	
neuraminidase	 50mM	Tris-acetate	pH	7.5	 2.5mU	 4hr	
keratanase	 50mM	Tris-acetate	pH	7.5	 100mU	 4hr	
Pronase®	 100mM	Tris-acetate,	10mM	calcium	
acetate	pH	8.0	
10mg/ml	 Overnight	
	
2.6.3	Statistical	analysis	
	
	 All	data	was	tested	for	normal	distribution	and	differences	between	study	groups	assessed	
with	a	student’s	t-	test.	Compositional	analysis	of	HS	structures	from	both	human	and	mouse	brain	
samples	are	expressed	as	bar	graphs	showing	peak	areas	as	a	percentage	of	total	HS	analysed.	Error	
bars	represent	standard	error	of	the	mean	(S.E.M).	
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2.7	Results		
2.7.1	Human	HS	samples	-	Alzheimer’s	disease	vs.	healthy	age-matched	controls		
2.7.1.1	Disaccharide	peak	analysis	
	
	 HS	from	all	brain	samples	(middle	temporal	gyrus,	BA21);	 	(20	AD	patients	and	15	healthy	
age-matched	controls)	was	extracted	and	underwent	exhaustive	heparinase	digestion	in	preparation	
for	disaccharide	compositional	analysis.	Disaccharides	were	labeled	with	BODIPY	hydrazide	and	run	
over	 a	 strong	 anion	 exchange	 (SAX)	 Propac	 PA-1	 column.	 This	 method	 allowed	 compositional	
analysis	of	the	structure	of	the	HS	within	the	samples	with	reference	to	chromatogram	of	authentic	
standards	(Figure	2.5).		
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
Figure	2.5:	Fluorescence	strong	anion	exchange	(SAX)	HPLC	of	the	8	most	common	Δ-disaccharides	within	HS	
and	 heparin	 after	 heparinase	 digestion	 and	 labeling	 with	 BODIPY	 hydrazide.	 Commercially	 available	 Δ-
disaccharide	HS	standards	(80ng)	were	labeled	with	the	BODIPY	fluorescent	tag	and	run	over	TLC	plates	before	
undergoing	ethanol	precipitation.	Labeled	standards	were	then	injected	over	a	Propac	PA1	column	and	eluted	
with	a	 linear	gradient	of	sodium	chloride	 (0-1M	over	30	min)	and	isocratic	sodium	hydroxide	(150mM).	Peaks	
were	 detected	 using	 an	 inline	 fluorimeter,	 λex	 =	 488nm	 and	 λem	 =	 520nm.	 From	 left	 to	 right	 disaccharides	
present	a	progressively	greater	level	of	sulfation.	
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These	standards	were	used	to	identify	changes	in	disaccharide	ratios	in	the	AD	and	healthy	
age-matched	control	groups.	Previous	studies	have	found	that	the	efficiency	with	which	sugars	are	
labeled	 via	 Schiff’s	 base	 formation	 is	 influenced	heavily	 by	 the	 structure	of	 the	 reducing	 end	unit	
(Drummond,	 et	 al.	 2001).	 The	 different	 disaccharide	 standards	 are	 not	 all	 labeled	 with	 identical	
efficiency	and	as	a	 result,	appropriate	correction	 factors	were	applied	 to	standardise	 the	disparity	
between	the	different	disaccharide	labeling	affinities	as	previously	published	(Skidmore,	et	al.	2006)	
(Table	2.6).			
	
Table	2.6:	Correction	 factors	 for	quantification	of	 the	Δ-disaccharides	observed	 in	human	brain	 tissue	with	
BODIPY	 labeling.	 	 	 Abbreviations:	 UA,	 uronic	 acid	 residue;	 Ac,	 acetyl;	 GlcNAc,	 N-acetyl	 glucosamine;	 GlcNS,	
glucosamine-N-sulfate;	 H,	 hydrogen;	 2S,	 2-O-sulfate;	 6S,	 6-O-sulfate;	 Sulf,	 Sulfate.	 *not	 detected.	 The	 Δ	
represents	the	presence	of	an	unsaturated	double	bond	(Skidmore,	et	al.	2006).	
Standard	
Relative	
efficiency	(%)	
Correction	factor	
Δ-UA-GlcNAc	 n.d*	 1.3	
Δ-UA-GlcNAc(6S)	 2.5	 1.2	
Δ-UA(2S)-GlcNAc	 n.d*	 1.7	
Δ-UA(2S)-GlcNAc(6S)	 0.9	 1.4	
Δ-UA-GlcNS	 12.6	 1.2	
Δ-UA-GlcNS(6S)	 28.4	 1.0	
Δ-UA(2S)-GlcNS	
Δ-UA(2S)-GlcNS(6S)	
11.6	
43.9	
1.1	
1.1	
	
	
For	each	of	the	samples	analysed,	a	chromatogram	was	generated	(Figure	2.6)	and	the	area	
of	 each	 disaccharide	 peak	 was	 calculated	 as	 a	 percentage	 of	 the	 total	 sample	 to	 more	 easily	
compare	 changes	 in	 the	 ratio	 of	 disaccharides	within	 HS.	 	 Extraction	 and	 purification	 of	 HS	 from	
human	middle	temporal	gyrus	(BA21)	samples	revealed	the	presence	of	7	of	the	8	most	commonly	
occurring	 disaccharides,	 with	 the	 exception	 of	 the	 Δ-UA(2S)-GlcNAc(6S)	 disaccharide,	 which	 was	
found	to	be	present	in	only	very	small	quantities	in	all	of	the	samples	observed,	1.74%	and	3.53%	on	
average	in	AD	and	control	groups	respectively.	Largely,	the	least	sulfated	disaccharides	were	found	
in	greatest	abundance	vs.	their	more	highly	sulfated	counterparts.	For	easier	comparative	analysis,	
the	 area	 of	 each	 peak	 was	 calculated	 as	 a	 percentage	 of	 the	 total	 sample	 to	 more	 efficiently	
compare	 changes	 in	 the	 ratio	 of	 disaccharides	 within	 HS	 (Figure	 2.7).	 Overlaying	 standard	
disaccharide	 chromatograms	 over	 sample	 chromatograms	made	 it	 possible	 to	 accurately	 identify	
those	disaccharides	present	within	tissue	samples.	This	was	done	for	each	individual	sample	and	the	
distribution	 of	 disaccharides	 noted.	 Figure	 2.6	 represents	 one	 AD	 sample	 chromatogram	 overlaid	
with	reference	standards.	
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Figure	2.7:	Chromatogram	peaks	from	one	AD	female	sample	presented	in	Figure	2.6	depicted	as	peak	areas	
as	 a	%	of	 total	HS.	Chromatogram	peaks	as	observed	 in	Figure	2.6	were	best	analysed	by	presentation	of	 the	
area	of	each	peak	as	a	%	peak	area	of	the	total	HS	sample.	Bar	graphs	for	each	sample	could	then	be	more	easily	
compared.	 This	 figure	 represents	 an	 example	 of	 just	 one	 human	 AD	 patient	 HS	 sample.	 Variability	 between	
constituent	 disaccharide	 ratios	 was	 reasonable	 within	 samples.	 Across	 all	 samples	 in	 both	 AD	 and	 control	
groups,	 the	 Δ-UA(2S)-GlcNAc(6S)	 disaccharide	 was	 present	 at	 very	 low	 quantities.	 In	 this	 sample,	 the	 least	
sulfated,	Δ-UA-GlcNAc	disaccharide	was	present	in	the	highest	abundance.	This	was	not	true	of	all	AD	samples.		
 
Figure	 2.6:	 SAX	 HPLC	 of	 one	 AD	 female	 sample	 (black)	 overlaid	 with	 commercially	 available	 disaccharide	
standards	after	exhaustive	heparinase	digestion	and	 labeling	with	BODIPY	hydrazide.	 	HS	was	isolated	from	
one	AD	female	middle	temporal	gyrus	(BA21)	brain	sample	(black	line)	and	digested	with	a	mixture	of	heparin	
lyases	(heparinase	I,	II,	and	III).	The	resultant	disaccharides	alongside	commercially	available	HS	standards	(grey	
line)	 were	 then	 labeled	 with	 BODIPY	 hydrazide.	 Samples	 were	 then	 subjected	 to	 strong	 anion	 exchange	
chromatography	on	a	Propac	PA-1	column	and	eluted	with	a	linear	gradient	of	sodium	chloride	(0-1M	over	30	
min)	and	 isocratic	sodium	hydroxide	 (150mM).	Peaks	were	detected	using	an	 inline	 fluorimeter,	λex	=	488nm	
and	λem	=	520nm.		
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2.7.1.2	Quantification	of	total	heparan	sulfate	levels	
	
2.7.1.2.1	There	are	significantly	higher	levels	of	total	HS	within	healthy	age-matched	control	samples	
vs.	their	AD	counterparts	
	
The	 HS	 extracted	 and	 purified	 from	 AD	 and	 age-matched	 control	 brain	 tissue	 for	
disaccharide	 composition	 analysis	 was	 quantified	 and	 normalised	 to	 μg/100mg	 of	 wet	 starting	
material	 to	 look	 for	 potential	 changes	 in	 overall	 levels	 of	 HS	 in	 AD	 and	 control	 brain	 samples.		
Quantification	was	achieved	by	measuring	UV	absorbance	at	232nm,	to	detect	the	presence	of	the	
glycosidic	double	bond	within	disaccharides.	Results	showed	that	healthy	control	HS	was	present	at	
significantly	 higher	 levels	 when	 compared	 to	 their	 AD	 counterparts.	 A	 mean	 (±S.E.M)	 of	 122.3	
(±12.40)	μg/100mg	of	HS	was	extracted	 from	Ctrl	 (n=15)	brain	 tissue	and	78.61	 (±9.81)	μg/100mg	
from	AD	(n=20)	brain	tissue.	This	increase	in	the	quantity	of	HS	extracted	and	purified	from	control	
tissue	 vs.	 AD	 samples	 was	 found	 to	 be	 significant	 (p=0.009,	 Student’s	 t-test)	 (Figure	 2.8).	
Quantification	of	this	type	did	not	discriminate	between	individual	disaccharides	present	within	each	
of	the	brain	samples	studied.	This	quantification	allowed	a	basic	evaluation	of	differences	in	total	HS	
GAGs	within	brain	samples	of	AD	and	age-matched	control	patients.	Despite	this,	the	trend	towards	
slightly	lower	average	sulfation	of	HS	from	AD	patients	(Figure	2.9)	would	in	any	case	suggest	slightly	
lower	average	disaccharide	weight	per	disaccharide.	
	
Figure	 2.8.	 Total	 HS	 levels	 in	 AD	 and	 healthy	age-matched	 control	middle	 temporal	 gyrus	 (BA21)	 human	
brain	samples	are	significantly	different.	HS	was	extracted	from	AD	(black)	and	healthy	age-matched	control	
(grey)	and	digested	with	a	mixture	of	heparin	 lyases	 (heparinase	 I,	 II	and	 III	mixture)	 followed	by	exhaustive	
clean	 up	 enzymatic	 digestion	 to	 remove	 other	 GAGs,	 DNA,	 RNA	 and	 protein.	 Resultant	 disaccharides	were	
finally	quantified	and	total	HS	levels	were	normalised	to	μg	/100mg	of	wet	tissue	starting	material.	Error	bars	
represent	mean	(±S.E.M).	p<0.05	*,	p<0.01	**,	Student’s	t-test.	
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2.7.1.3	Compositional	profiling	of	Alzheimer’s	disease	and	healthy	age-matched	control	samples		
2.7.1.3.1	The	number	of	sulfs/disaccharide	within	HS	from	Alzheimer’s	disease	and	healthy	age-
matched	control	samples	does	not	differ	between	study	groups		
Compositional	data	obtained	from	20	AD	HS	brain	samples	and	15	control	HS	brain	samples	
were	 combined	and	mean	 (±S.E.M)	abundance	of	differing	 sulfated	moieties	was	 calculated.	 First,	
the	 degree	 of	 sulfation	 of	 HS	 extracted	 and	 purified	 from	 AD	 and	 healthy	 age-matched	 control	
samples.	 This	 was	 studied	 by	 calculating	 the	 number	 of	 sulfate	 groups	 present	 per	 individual	
disaccharide	of	the	HS	chain.	No	significant	differences	in	the	number	of	sulfs/disaccharide	(±S.E.M)	
was	 observed	 between	 AD	 and	 age-matched	 control	 samples	 (0.87	 	 (±0.07)	 and	 0.91	 (±0.10)	
respectively)	(p=0.734	Student’s	t-test)	suggesting	that	overall	average	sulfation	levels	might	not	be	
changing	but	rather	altered	levels	of	individual	disaccharides	(Figure	2.9).	
	
	
	
	
	
	
	
	
	
	
	
	
2.7.1.3.2	There	are	no	significant	differences	 in	the	relative	abundance	of	N-,	6-O	and	2-O	sulfated	
moieties	in	HS	from	Alzheimer’s	disease	and	healthy	age-matched	control	samples		
	
Since	no	changes	in	the	level	of	sulfs/disaccharide	were	recorded	between	AD	and	control	
samples,	the	%	abundance	of	NS-,	6-OS	and	2-OS	groups	within	the	HS	samples	from	AD	and	healthy	
age-matched	 control	 patients	were	 also	 calculated	 to	 explore	 possible	 changes	 in	 the	 location	 of	
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Figure	2.9.	Total	 sulfs/disaccharide	 levels	 in	AD	and	age-matched	Ctrl	BA21	brain	samples	are	not	altered	
between	groups.	HS	was	extracted	from	both	AD	(n=20)	(black)	and	age-matched	controls	(n=15)	(grey)	and	
purified	 as	 previously	 described	 and	 the	 total	 number	 of	 sulfs/disaccharide	 calculated.	 No	 change	 in	 the	
number	of	sulfs/disaccharide	was	observed	between	Ctrl	and	AD	patient	samples	of	HS.	Error	bars	represent	
mean	(±S.E.M).	
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sulfate	 groups	 along	 the	 HS	 chain.	 This	 did	 not	 distinguish	 between	 composition	 of	 individual	
disaccharides	but	rather	the	overall	content	of	sulfates	of	specific	types	in	the	HS	chain.		
	
No	 significant	 changes	were	observed	 in	mean	%	abundance	 (±S.E.M)	of	N-,	6-O	and	2-O	
sulfated	 disaccharides	 in	 HS	 from	 AD	 and	 healthy	 age-matched	 control	 samples	 (Figure	 2.10).	
Distribution	of	disaccharides	exhibiting	sulfation	at	 the	N-,	6-O	and	2-O	position	was	 largely	equal	
across	 both	 groups.	 Mean	 %	 abundance	 (±S.E.M)	 of	 N-sulfated	 disaccharides	 for	 AD	 and	 control	
groups	 respectively	 were	 28.81%	 (±3.42)	 and	 35.35%	 (±3.02)	 (p=0.177,	 Student’s	 t-test).	 Mean	
abundance	of	6-O	sulfated	disaccharides	 in	both	AD	and	control	groups	were	similar	 to	 that	of	N-	
sulfated	units	however	were	also	found	to	not	differ	between	AD	and	control	groups	(29.56	(±3.27)	
and	 33.21	 (±3.43)	 respectively)	 (p=0.453).	 Finally,	 abundance	 of	 2-O	 sulfated	 disaccharides	within	
both	 AD	 and	 control	 HS	 brain	 samples	 (19.70%	 (±2.53)	 and	 22.29	 (±3.77)	 respectively)	 (p=0.558)	
indicated	no	significant	change	in	sulfation	at	this	position	in	the	AD	phenotype.	HS	from	AD	patient	
samples	 did	 reveal	 a	 trend	 for	 decreased	 levels	 of	 N-,	 6-O	 and	 2-O	 sulfated	 disaccharides	 vs.	
controls,	perhaps	indicative	of	a	less	sulfated	HS.	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
Figure	2.10:	Average	 levels	of	specific	sulfation	types	do	not	change	with	AD.	HS	isolated	from	AD	(black)	
and	 age-matched	 control	 (grey)	 middle	 temporal	 gyrus	 (BA21)	 samples	 were	 digested	 with	 a	 mixture	 of	
heparin	 lyases	 (heparinase	 I,	 II	 and	 III	 mixture)	 and	 resultant	 disaccharides	 were	 labeled	 with	 BODIPY	
hydrazide	and	subjected	to	strong	anion	exchange	chromatography	on	a	Propac	PA-1	column	and	eluted	with	
a	linear	gradient	of	sodium	chloride	(0-1M	over	30	min)	and	isocratic	sodium	hydroxide	(150mM).	Peaks	were	
detected	using	an	inline	fluorimeter,	λex	=	488nm	and	λem	=	520nm.	Peak	areas	for	each	disaccharide	were	
measured	 and	 disaccharide	 analysis	 is	 expressed	 as	 a	 %	 of	 N-	 6-O	 and	 2-O	 sulfated	motifs	 within	 the	 HS	
analysed.	Data	shown	are	from	AD	(n=20)	and	control	(n=15)	patient	samples	and	error	bars	represent	mean	
(±SEM).		
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2.7.1.3.3	HS	from	Alzheimer’s	disease	brain	samples	displays	significantly	altered	levels	of	di-sulfated	
disaccharides	vs.	their	healthy	age-matched	control	counterparts		
	
Compositional	 data	obtained	 from	20	AD	HS	brain	 samples	 and	15	Ctrl	HS	brain	 samples	
were	combined	and	also	grouped	based	on	sulfation	levels		(unsulfated,	mono-,	di-	and	tri-sulfated	
patterns)	 within	 HS	 samples	 of	 AD	 and	 age-matched	 control	 patients.	 Structural	 motifs	 were	
grouped	 in	 this	 manner	 to	 assess	 gross	 potential	 changes	 across	 samples.	 Unsulfated	 (36.40%	
(±5.08)	and	38.26%	(±5.79)	in	AD	and	age-matched	control	samples	respectively)	and	mono-sulfated	
(46.02%	(±3.73)	and	36.24%	(±3.62)	respectively)	disaccharides	were	found	to	represent	the	largest	
proportion	 of	 all	 disaccharides	 analysed.	 Mean	 abundance	 (±S.E.M)	 of	 the	 di-	 sulfated	 (14.71%	
(±1.74)	and	21.9%	(±3.21)	for	AD	and	control	samples	respectively)	and	tri-	sulfated	(2.87%	(±0.77)	
and	 3.61%	 (±1.14)	 for	 AD	 and	 control	 samples	 respectively)	 units	 was	 found	 to	 be	 considerably	
lower.	 No	 significant	 differences	 in	 the	 abundance	 of	 unsulfated	 disaccharides,	 between	 AD	 and	
healthy	control	samples	were	observed.	However,	AD	HS	samples	displayed	a	strong	trend	towards	
greater	 levels	 of	 mono-sulfated	 disaccharides	 vs.	 their	 control	 counterparts,	 though	 this	 was	
observed	to	be	just	below	statistical	significance	(Student’s	t-test	p=0.074)	(Figure	2.11).	
	
In	 contrast,	 the	 difference	 in	 abundance	 of	 di-sulfated	 disaccharides	 between	 AD	 HS	
samples	 and	 healthy	 age-matched	 control	 samples	 was	 found	 to	 be	 statistically	 significant.	 AD	
samples	were	found	to	display	significantly	less	of	the	di-sulfated	disaccharides	vs.	controls	(14.71%	
(±1.74)	 and	 21.9%	 (±3.21)	 for	 AD	 and	 control	 samples	 respectively;	 p=0.045,	 Student’s	 t-test).	
Increased	 levels	 of	mono-sulfated	 disaccharides	 and	 decreased	 levels	 of	 di-sulfated	 disaccharides	
may	 be	 indicative	 of	 an	 overall	 lesser-sulfated	 HS	 displayed	 in	 AD	 patients	 vs.	 their	 healthy	 age-
matched	 counterparts.	 No	 significant	 differences	 in	 mean	 abundance	 (±S.E.M)	 of	 tri-sulfated	
disaccharides	 were	 recorded	 (2.87%	 (±0.77)	 and	 3.61%	 (±1.14)	 for	 AD	 and	 control	 samples	
respectively)	(p=0.585)	(Figure	2.11).		
	
2.7.1.3.4	 Alzheimer’s	 disease	 patient	 HS	 samples	 display	 altered	 levels	 of	 some	 HS	 disaccharides	
when	compared	to	their	healthy	age-matched	control	counterparts	
	
Compositional	analysis	data	from	AD	and	age-matched	control	samples	revealed	significant	
differences	 in	 levels	 of	 some	 individual	 disaccharides	 in	AD	 vs.	 age-matched	 control	 samples.	 The	
least	 sulfated	 disaccharide,	 Δ-UA-GlcNAc,	 was	 present	 in	 highest	 abundance	 in	 both	 groups	 with	
mean	(±S.E.M)	peak	areas	across	the	group	of	34.64%	(±5.04)	and	38.26%	(±5.79)	 for	AD	and	age-
matched	 control	 groups	 respectively	 (Figure	 2.12).	 Conversely,	 the	 more	 highly	 sulfated	
disaccharides	were	present	in	much	lower	quantities.		Most	noticeably,	the	di-sulfated	disaccharide	
Δ-UA(2S)-GlcNAc(6S)	was	observed	in	the	lowest	abundance	of	all	the	disaccharides	in	both	AD	and	
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age-matched	control	samples	with	observed	mean	(±S.E.M)	peak	areas	of	1.74%	(±0.36)	and	3.53%	
(±1.36)	for	the	AD	and	age-matched	control	groups	respectively	–	perhaps	indicative	of	a	structural	
characteristic	 of	 human	 brain	 HS.	 The	 analysis	 also	 revealed	 that	 AD	 and	 age-matched	 control	
samples	display	significantly	altered	HS	compositional	profiles,	suggestive	of	HS	structural	changes	in	
the	 presence	 of	 AD	 pathogenesis.	 AD	 samples	 (n=20)	 displayed	 significantly	 more	 of	 the	 mono-
sulfated	Δ-UAGlcNAc(6S)	disaccharide	vs.	healthy	age-matched	control	samples	with	recorded	mean	
(±S.E.M)	 peak	 %	 abundances	 of	 20.94%	 (±2.30)	 and	 12.83%	 (±1.83)	 respectively	 (Student’s	 t-test	
p=0.012).	 Conversely,	 HS	 from	 AD	 patients	 displayed	 significantly	 less	 of	 the	 Δ-UA-GlcNS(6S)	
disaccharide,	a	di-sulfated	disaccharide	common	in	HS	chain	structure.	Mean	(±S.E.M)	%	abundances	
of	7.18%	(±0.86)	and	13.25%	(±1.75)	in	AD	and	age-matched	control	samples	respectively	(Student’s	
t-test	p=0.003)	were	recorded	in	this	instance.		
	
Of	 the	other	HS	disaccharide	 standards	analysed,	 less	 significant	differences	 in	profiles	of	
AD	 and	 control	 patients	 samples	 were	 recorded.	 A	 trend	 for	 a	 decreased	 abundance	 of	 the	 di-
sulfated	Δ	-UA(2S)-GlcNAc(6S)	disaccharide	in	AD	patients	vs.	healthy	controls	was	observed	with	
Figure	 2.11:	Composition	 of	HS	 disaccharides	 displaying	 different	 numbers	 of	 sulfate	 groups	 change	with	
AD.	HS	isolated	from	AD	(black)	and	age-matched	control	(grey)	middle	temporal	gyrus	(BA21)	samples	were	
digested	with	a	mixture	of	heparin	 lyases	 (heparinase	 I,	 II	 and	 III	mixture)	and	 resultant	disaccharides	were	
labeled	 with	 BODIPY	 fluorescent	 hydrazide	 and	 subjected	 to	 strong	 anion	 exchange	 chromatography	 on	 a	
Propac	PA-1	 column	and	eluted	with	 a	 linear	 gradient	of	 sodium	chloride	 (0-1M	over	30	min)	 and	 isocratic	
sodium	 hydroxide	 (150mM).	 Peaks	 were	 detected	 using	 an	 inline	 fluorimeter,	 λexc	 =	 488nm	 and	 λemm	 =	
520nm.	 Peak	 areas	 for	 each	 disaccharide	were	measured	 and	 disaccharide	 analysis	 is	 expressed	 as	 a	 %	 of	
mono-	di	and	tri-	sulfated	motifs	within	the	HS	analysed.	Data	shown	are	from	AD	(n=20)	and	Ctrl	(n=15).	Error	
bars	represent	mean	(±S.E.M).	p<0.05	*,	Student’s	t-test.	
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mean	(±S.E.M)	%	abundances	of	1.74%	(±0.36)	and	3.53%	(±1.36)	observed	in	samples	respectively	
(p=0.177)	(Figure	2.12).	
	
Due	 to	 technical	 issues	over	 variability	 in	 the	 recovery	of	 the	unsulfated,	N-acetylated	Δ-
UA-GlcNAc	disaccharide	 (note	 the	 larger	error	bars	 for	 this	disaccharide),	data	analysis	of	HS	 from	
the	 AD	 and	 control	 samples	 was	 also	 conducted	 with	 exclusion	 of	 the	 non-sulfated	 disaccharide	
(calculated	 based	 on	 relative	 abundance	 of	 the	 sulfated	 units	 only).	 This	 was	 done	 to	 remove	
potential	 bias	 in	 the	 calculated	 proportions	 of	 disaccharides	 of	 interest.	 Overall	 ratios	 were	 very	
similar	to	those	observed	above.	The	same	significant	alterations	in	compositional	profiles	across	AD	
and	control	 groups	were	observed.	The	Δ-UA-GlcNS(6S)	disaccharide	was	 consistently	observed	at	
significantly	 lower	abundance	in	the	AD	groups	vs.	their	healthy	age-matched	control	counterparts	
(p=0.002	Student’s	t-test)	whilst	the	UA-GlcNAc(6S)	disaccharide	was	significantly	more	abundant	in	
AD	patient	HS	samples	vs.	healthy	controls	and	reached	a	greater	degree	of	statistical	significance	in	
the	absence	of	the	UA-GlcNAc	disaccharide	(p=0.003	Student’s	t-test)		(Figure	2.13).	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
Figure	2.12:	Brain	HS	 composition	 changes	with	AD.	HS	 isolated	from	AD	(black)	and	age-matched	control	
(grey)	middle	temporal	gyrus	(BA21)	samples	were	digested	with	a	mixture	of	heparin	lyases	(heparinase	I,	II	
and	 III	 mixture)	 and	 resultant	 disaccharides	 were	 labeled	 with	 BODIPY	 hydrazide	 and	 subjected	 to	 strong	
anion	 exchange	 chromatography	 on	 a	 Propac	 PA-1	 column	 and	 eluted	 with	 a	 linear	 gradient	 of	 sodium	
chloride	(0-1M	over	30	min)	and	 isocratic	sodium	hydroxide	(150mM).	Peaks	were	detected	using	an	 inline	
fluorimeter,	 λex	 =	 488nm	 and	 λem	 =	 520nm.	 Peak	 areas	 for	 each	 disaccharide	 were	 measured	 and	
disaccharide	analysis	 is	expressed	as	a	%	of	total	HS	analysed.	Data	shown	are	from	35	patients;	AD	(n=20)	
and	Ctrl	(n=15)	Error	bars	represent	mean	(±S.E.M).	p<0.05	*,	p<0.01	**,	Student’s	t-test.	
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2.7.1.3.5	There	are	no	gender	differences	in	the	structure	of	HS	in	either	AD	or	healthy	age-matched	
control	patients	
	
	 Analysis	 as	 described	 previously	 but	 with	 respect	 to	 gender	 revealed	 no	 significant	
differences	between	male	and	female	AD	patients.	Despite	a	slight	trend	for	reduced	N-	6-O	and	2-O	
sulfation	in	males	vs.	their	female	counterparts,	no	significant	gender	factor	was	observed	in	these	
samples	(Figure	2.14).		Likewise	distribution	of	unsulfated,	mono-,	di-	and	tri-sulfated	motifs	within	
HS	samples	from	male	and	female	AD	patients	were	not	significantly	different.	These	results	indicate	
that	structural	changes	 in	HS	as	observed	 in	AD	patient	brain	samples	were	not	driven	by	gender-
specific	 factors	 (data	 not	 shown).	 Gender	 differences	 were	 also	 not	 apparent	 within	 the	 age-
matched	control	set	of	samples	analysed	in	this	study	(data	not	shown).	
	
Figure	2.13:	Brain	HS	composition	of	sulfated	disaccharides	changes	with	AD.	HS	isolated	from	AD	(black)	and	
age-matched	control	 (grey)	middle	 temporal	gyrus	 (BA21)	 samples	were	digested	with	a	mixture	of	heparin	
lyases	 (heparinase	 I,	 II	and	 III	mixture)	and	 resultant	disaccharides	were	 labeled	with	BODIPY	hydrazide	and	
subjected	 to	 strong	 anion	 exchange	 chromatography	 on	 a	 Propac	 PA-1	 column	 and	 eluted	 with	 a	 linear	
gradient	 of	 sodium	 chloride	 (0-1M	 over	 30	 min)	 and	 isocratic	 sodium	 hydroxide	 (150mM).	 Peaks	 were	
detected	using	an	inline	fluorimeter,	λex	=	488nm	and	λem	=	520nm.	Peak	areas	for	each	sulfated	disaccharide	
were	 measured	 and	 disaccharide	 analysis	 is	 expressed	 as	 a	 %	 of	 total	 HS	 analysed.	 Peak	 areas	 for	 each	
disaccharide	were	measured	and	disaccharide	analysis	 is	expressed	as	a	%	of	total	HS	analysed.	Data	shown	
are	 from	 35	 patients;	 AD	 (n=20)	 and	 Ctrl	 (n=15)	 Error	 bars	 represent	mean	 (±S.E.M).	 p<0.05	 *,	 p<0.01	 **,	
Student’s	t-test.	
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2.7.2	Mouse	samples	(old	vs.	young)	
	
	 Compositional	 profiling	 of	 disaccharides	 within	 HS	 extracted	 from	 old	 (18	 month)	 and	
young	 (3	 month)	 mice	 was	 carried	 out	 in	 an	 identical	 manner	 to	 those	 methods	 employed	 for	
analysis	of	AD	human	patient	samples.	All	disaccharide	peak	analysis	was	carried	out	as	previously	
described	 in	 section	 2.7.1.1.	 Overall	 levels	 of	 sulfation	 were	 analysed,	 including	 total	 HS	
quantification	and	individual	disaccharide	composition	within	HS	samples.	
	
2.7.2.1	Quantification	of	total	HS	levels	in	aged	and	young	mouse	brain		
2.7.2.1.1	 Aged	 mice	 display	 significantly	 increased	 levels	 of	 total	 HS	 (μg/100mg	 tissue)	 vs.	 their	
younger	counterparts	
	
Figure	2.14:	Composition	of	human	AD	brain	HS	disaccharides	sulfated	at	different	positions	do	not	display	
gender	differences.	HS	isolated	from	AD	middle	temporal	gyrus	(BA21)	samples	were	digested	with	a	mixture	of	
heparin	lyases	(heparinase	I,	II	and	III	mixture)	and	resultant	disaccharides	were	labeled	with	BODIPY	hydrazide	
and	subjected	to	strong	anion	exchange	chromatography	on	a	Propac	PA-1	column.	Peaks	were	eluted	with	a	
linear	 gradient	of	 sodium	chloride	 (0-1M	over	 30	min)	 and	 isocratic	 sodium	hydroxide	 (150mM).	 Peaks	were	
detected	using	an	 inline	 fluorimeter,	λex	=	488nm	and	λem	=	520nm.	 	Peak	areas	 for	each	disaccharide	were	
measured	 and	 disaccharide	 analysis	 is	 expressed	 as	 a	%NS-,	%6-OS	 and	%2-OS	within	 the	HS	 analysed.	 Data	
shown	are	from	10	female	(n=10)	and	10	male	samples	(n=10)	Error	bars	represent	mean	(±S.E.M).		
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The	HS	extracted	and	purified	from	aged	and	young	brain	tissue	samples	for	compositional	
analysis	was	also	quantified	and	normalized	 to	μg/100mg	of	wet	 starting	material	 to	 look	 for	 any	
potential	changes	in	the	overall	levels	of	HS	that	may	occur	in	the	ageing	phenotype.	Quantification	
of	total	HS	levels	from	mouse	brain	samples	revealed	significantly	higher	 levels	of	HS	in	aged	mice	
vs.	 their	younger	counterparts	with	mean	(±S.E.M)	total	 levels	of	67.39	(±10.16)	and	29.33	(±9.81)	
μg/100mg	respectively	(Student’s	t-test	p=0.027)	(Figure	2.15).	
	
2.7.2.2	Compositional	profiling	of	old	and	young	mouse	brain	samples		
2.7.2.2.1	There	is	no	significant	difference	in	the	number	of	sulfs/disaccharide	in	HS	extracted	from	
the	brains	of	old	and	young	mice			 Next	the	average	degree	of	sulfation	of	disaccharides	within	the	HS	purified	from	aged	and	
young	mice	brain	samples	were	studied	to	explore	potential	global	changes	in	overall	sulfation	with	
age.	 The	 average	number	of	 sulfate	 groups	present	per	 individual	 disaccharide	was	 calculated	 for	
each	sample.	On	this	occasion,	aged	mice	displayed	a	strong	trend	for	an	increase	in	the	number	of	
sulfs	 per	 disaccharide	 vs.	 their	 younger	 control	 counterparts	 with	 mean	 (±S.E.M)	 values	 of	 0.58	
(±0.14)	 and	 0.23	 (±0.08)	 respectively;	 however,	 this	 difference	 was	 not	 statistically	 significant	
(p=0.084).	 This	 trend	would	 suggest	 that	 overall	 sulfation	might	 be	 changing	 in	 addition	 to	more	
subtle	changes	at	the	individual	disaccharide	level	(Figure	2.16).		
	
	
Figure	2.15:	Aged	(18	month)	mouse	brain	samples	display	significantly	greater	levels	of	total	HS	vs.	their	
younger	(3	month)	counterparts.	HS	was	extracted	from	young	(3	month)	(black)	and	aged	(18	month)	(grey)	
and	digested	with	a	mixture	of	heparin	lyases	(heparinase	I,	II	and	III	mixture)	followed	by	exhaustive	clean	up	
by	enzymatic	digestion	to	remove	other	glycosaminoglycans,	DNA,	RNA	and	protein.	Resultant	disaccharides	
were	finally	quantified	and	total	HS	levels	were	normalized	to	μg	/100mg	of	wet	tissue	starting	material.		Data	
is	 representative	 of	 10	mouse	 brain	 HS	 samples,	 young	 (n=5)	 and	 aged	 (n=5).	 Error	 bars	 represent	mean	
(±S.E.M).	p<0.05	*,	Student’s	t-test.		
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2.7.2.2.2	Aged	mice	display	significantly	higher	levels	of	2-O	sulfated	disaccharides	vs.	their	younger	
counterparts	
	
Total	%	abundance	of	N-,	6-O	and	2-O	groups	within	HS	samples	from	aged	and	young	mice	
brain	samples	was	also	calculated	to	explore	possible	changes	in	the	levels	of	specific	sulfate	groups	
in	the	HS	chain.	In	this	instance,	aged	mice	were	found	to	display	significantly	higher	mean	(±	S.E.M)	
abundance	of	2-O	sulfated	moieties	vs.	their	younger	counterparts	with	mean	(±S.E.M)	%	abundance	
levels	of	11.37%	(±2.61)	and	2.77%	(±0.44)	respectively	(Student’s	t-test;	p=0.012).	Aged	mice	brain	
HS	 samples	 were	 also	 found	 to	 contain	 more	 of	 the	 N-	 sulfated	 disaccharides	 vs.	 their	 younger	
control	 counterparts	 with	 mean	 (±S.E.M)	 recorded	 %	 abundance	 levels	 of	 27.05%	 (±6.57)	 and	
13.62%	(±4.22)	 respectively.	Furthermore,	aged	mice	also	displayed	 increased	abundance	of	 levels	
of	 6-O	 sulfation	 with	 recorded	 mean	 (±S.E.M)	 %	 levels	 of	 19.54	 (±5.27)	 and	 10.41%	 (±3.89)	
respectively.	 However,	 these	 differences	 were	 not	 found	 to	 be	 statistically	 significant	 on	 this	
occasion	 (p=0.124	 and	 p=0.200	 respectively,	 Student’s	 t-test)	 with	 significantly	 large	 error	 bars	
noted	for	these	measurements	(Figure	2.17).			
	
2.7.2.2.3	There	are	no	significant	differences	between	the	%	abundance	of	mono-,	di-	or	tri-sulfated	
disaccharides	in	HS	extracted	from	old	and	young	mouse	brain	samples	
	
Compositional	data	obtained	from	5	aged	(18months)	and	5	young	(3	months)	HS	mouse	
brain	samples	were	combined	and	the	mean	(±S.E.M)	%	abundance	of	differing	sulfated	moieties		
Figure	 2.16.	 Total	 sulfs/disaccharide	 levels	 in	 aged	 (18	 month)	 and	 young	 (3	 month)	 mouse	 brain	 HS	
samples	 are	not	 altered	between	groups.	HS	was	extracted	from	both	young	(black)	and	aged	(grey)	mice	
and	purified	as	previously	described	and	the	total	number	of	sulfs/disaccharide	calculated.	No	change	in	the	
number	of	sulfs/disaccharide	was	observed	between	aged	and	young	samples	of	HS.	Data	is	representative	of	
10	mouse	brain	HS	samples,	young	(n=5)	and	aged	(n=5).	Error	bars	represent	mean	(±S.E.M).	
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was	calculated.	Samples	were	first	analysed	based	on	total	%	abundance	of	unsulfated,	mono-,	di-	
and	 tri-	 sulfated	 disaccharides	 within	 HS	 samples	 of	 young	 and	 old	 mice.	 Structural	 motifs	 were	
grouped	in	this	manner	to	assess	gross	potential	changes	that	may	occur	with	age.	Analysis	revealed	
no	significant	changes	in	the	patterning	of	sulfation	between	old	and	young	mice	groups.	Overall	%	
abundance	 of	 unsulfated	 and	 mono-sulfated	 disaccharides	 were	 found	 to	 represent	 the	 largest	
proportion	of	all	disaccharides	across	both	the	aged	and	young	mice	groups	with	mean	(±S.E.M)	%	
abundance	 of	 unsulfated	 disaccharides	 recorded	 of	 75.74%	 (±8.70)	 and	 50.71%	 (±11.6)	 for	 young	
and	aged	groups	respectively.	Presence	of	tri-sulfated	disaccharides	within	mouse	HS	brain	samples,	
in	 both	 groups,	 was	 virtually	 absent.	 Indeed,	 overall	 compositional	 profiles	 were	 considerably	
different	to	that	observed	in	human	tissue.	Aged	mice	did	display	a	trend	for	increased	levels	of	di-
sulfated	 disaccharides	 vs.	 their	 younger	 control	 counterparts	 with	 respective	 mean	 (±S.E.M)	 %	
abundance	levels	of	7.87%	(±3.14)	and	1.14%	(±0.35)	that	was	close	to	reaching	significance	in	this	
instance	(p=0.065).		
	
	 In	addition,	levels	of	the	mono-sulfated	disaccharides	were	also	found	to	be	higher	in	aged	
mice	vs.	younger	counterparts	with	respective	mean	(±S.E.M)	%	abundance	levels	of	41.02%	
Figure	 2.17:	 Composition	 of	 mouse	 brain	 HS	 disaccharides	 sulfated	 in	 different	 positions	 change	 with	
ageing.	HS	isolated	from	young	(3	month)	(black)	and	aged	(18	month)	(grey)	total	mouse	brain	samples	were	
digested	with	a	mixture	of	heparin	 lyases	 (heparinase	 I,	 II	 and	 III	mixture)	and	 resultant	disaccharides	were	
labeled	with	 BODIPY	 hydrazide	 and	 subjected	 to	 strong	 anion	 exchange	 chromatography	 on	 a	 Propac	 PA-1	
column	 and	 eluted	 with	 a	 linear	 gradient	 of	 sodium	 chloride	 (0-1M	 over	 30	 min)	 and	 isocratic	 sodium	
hydroxide	(150mM).	Peaks	were	detected	using	an	 inline	fluorimeter,	λex	=	488nm	and	λem	=	520nm.	Peak	
areas	for	each	disaccharide	were	measured	and	disaccharide	analysis	is	expressed	as	a	%	of	NS-	6-OS	and	2-OS	
disaccharides	within	the	HS	analysed.	Data	shown	are	from	aged	(n=5)	and	young	(n=5)	in	each	group.	Error	
bars	represent	mean	(±S.E.M).	p<0.05	*,	Student’s	t-test.		
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	(±10.12)	 and	 22.42%	 (±9.17).	 Again,	 this	 did	 not	 reach	 significance	 in	 this	 instance	 (p=0.212).	
Conversely,	unsulfated	and	tri-sulfated	disaccharides	were	present	at	lower	levels	in	younger	mice		
vs.	 aged	mice,	 though	 these	 changes	only	displayed	a	 trend	and	did	not	 reach	 significance	 in	 this	
instance	(p=0.123	and	0.458	respectively)	(Figure	2.18).			
2.7.2.2.4	Aged	mouse	brain	 samples	display	 significantly	altered	 levels	of	 specific	HS	disaccharides	
when	compared	to	their	younger	counterparts		
	 Analysis	of	HS	disaccharide	 composition	data	 from	aged	and	young	mouse	brain	 samples	
revealed	 significant	 differences	 in	 the	 relative	 abundance	 of	 disaccharides.	 The	 least	 sulfated	
disaccharide	Δ-UA-GlcNAc,	was	present	in	highest	abundance	in	both	groups	with	mean	(±S.E.M)	%	
abundances	of	75.74%	(±8.70)	and	50.73%	(±11.61)	 in	young	and	aged	groups	respectively	 (Figure	
2.19).	 Conversely,	 the	 more	 highly	 sulfated	 Δ-UA(2S)-GlcNS,	 Δ-UA(2S)-GlcNAc(6S)	 and	 Δ-UA(2S)-
GlcNS(6S)	disaccharides	represented	a	much	smaller	proportion	in	both	groups.	Indeed,	these	three	
disaccharides	were	 found	 to	 represent	 less	 than	 1%	 total	HS	 in	 both	 the	 aged	 and	 young	 control	
mice	groups.			
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Figure	2.18:	Composition	of	mouse	HS	disaccharides	displaying	different	numbers	of	sulfate	groups	does	not	
change	 with	 age.	 HS	 isolated	 from	 young	 (3	 month)	 (black)	 and	 aged	 (18	 month)	 (grey)	 total	 mouse	 brain	
samples	 were	 digested	 with	 a	 mixture	 of	 heparin	 lyases	 (heparinase	 I,	 II	 and	 III	 mixture)	 and	 resultant	
disaccharides	were	labeled	with	BODIPY	hydrazide	and	subjected	to	strong	anion	exchange	chromatography	on	
a	Propac	PA-1	 column	and	eluted	with	a	 linear	gradient	of	sodium	chloride	 (0-1M	over	 30	min)	and	 isocratic	
sodium	hydroxide	(150mM).	Peaks	were	detected	using	an	inline	fluorimeter,	λex	=	488nm	and	λem	=	520nm..	
Peak	areas	for	each	disaccharide	were	measured	and	disaccharide	analysis	is	expressed	as	a	%	of	mono-	di	and	
tri-	sulfated	motifs	within	the	HS	analysed.	Error	bars	represent	mean	(±S.E.M)	in	aged	(n=5)	and	young	(n=5).	
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	 	Compositional	analysis	also	revealed	that	aged	and	young	mouse	brain	HS	samples	display	
significantly	 altered	profiles	 suggestive	of	HS	 structural	 changes	with	 the	 ageing	phenotype.	Aged	
samples	displayed	significantly	higher	 levels	of	 the	Δ-UA(2S)-GlcNAc	disaccharide	vs.	 their	younger	
counterparts	 with	 mean	 (±S.E.M)	 recorded	 %	 abundances	 of	 9.56%	 (±2.29)	 and	 1.97%	 (±0.30)	
respectively	(Student’s	t-test	p=0.011).	Likewise,	aged	mice	also	display	significantly	higher	levels	of	
the	 Δ-UA(2S)-GlcNS	 disaccharide	 with	 mean	 (±S.E.M)	 %	 abundance	 levels	 of	 0.70%	 (±0.19)	 and	
0.08%	(±0.04)	respectively	(Student’s	t-test	p=0.014).	There	was	also	a	strong	trend	to	suggest	that	
aged	 mice	 display	 increased	 abundance	 of	 the	 Δ-UA-GlcNS(6S)	 disaccharide	 (6.45%	 (±2.58)	 and	
1.04%	 (±0.36)	 for	 aged	 and	 young	 respectively),	 though	 this	 was	 just	 short	 of	 reaching	 statistical	
significance	 (Student’s	 t-test	 p=0.071)	 (Figure	 2.19).	 The	 Δ-UA-GlcNAc	 and	 Δ-UA(2S)-GlcNS(6S)	
disaccharides	 were	 found	 to	 be	 present	 in	 increased	 abundance	 in	 younger	 mice	 vs.	 their	 aged	
counterparts.	This	data	suggests	considerable	alterations	in	specific	sulfation	of	mouse	brain	HS	with	
ageing.		
	
2.8	Discussion		
2.8.1	Human	samples	-	Alzheimer’s	disease	vs.	healthy	age-matched	controls		
2.8.1.1	Disaccharide	peak	analysis	and	total	HS	quantification		
2.8.1.1.1	AD	HS	samples	contain	altered	HS	disaccharide	sulfated	moieties	when	compared	to	their	
age-matched	counterparts	
	
	
Analysis	 of	 the	 composition	 of	 HS	 from	 samples	 with	 respect	 to	 sulfation	 level	 within	
constituent	disaccharides	revealed	significant	changes	in	the	patterning	of	sulfation	between	AD	and	
control	 groups.	Overall	 abundance	 across	 both	 study	 groups	 of	 the	 less	modified,	 unsulfated	 and	
mono-sulfated	disaccharides	was	found	to	be	greater	than	the	di-	and	tri-sulfated	units	as	is	typical	
for	 tissue	HS.	No	significant	differences	 in	 the	abundance	of	unsulfated	disaccharides	between	AD	
and	healthy	control	samples	were	recorded.	AD	HS	samples	were	found	to	display	greater	levels	of	
mono-sulfated	disaccharides	vs.	 their	control	counterparts,	 though	this	 trend	was	not	 found	to	be	
statistically	 significant.	However,	AD	HS	 samples	 also	displayed	 significantly	 less	 of	 the	di-sulfated	
disaccharides	 vs.	 controls	 respectively.	 Increased	 levels	 of	 mono-sulfated	 disaccharides	 and	
decreased	 levels	 of	 di-sulfated	 disaccharides	 may	 be	 indicative	 of	 an	 overall	 lesser-sulfated	 HS	
displayed	in	AD	patients	vs.	their	healthy	age-matched	counterparts	(Figure	2.11).			
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	 This	 is	 consistent	with	 the	hypothesis	 that	a	 less	 sulfated	HS	 is	present	 in	 those	suffering	
with	AD	 could	 lead	 to	 less	 efficient	 inhibition	 of	 the	 BACE-1	 enzyme,	 and	 ultimately	 the	 elevated	
production	of	the	toxic	Aβ	peptide.	As	Patey	and	colleagues	observed,	efficacy	of	BACE-1	inhibition	
is	 largely	 determined	 by	 degree	 of	 sulfation	 (Patey,	 et	 al.	 2006),	 and	 hence	 we	might	 expect	 to	
observe	differences	in	sulfation	pattern	between	AD	and	control	groups.	Changes	observed	here	in	
the	number	of	 sulfate	 groups	present	on	 specific	 disaccharides	would	 suggest	 that	 sulfate	moiety	
patterning	could	be	key	 in	determining	BACE-1	 inhibition	efficacy,	though	this	data	alone	does	not	
allow	 a	 conclusion	 on	 whether	 the	 average	 number	 of	 sulfate	 groups	 is	 key	 or	 whether	 sulfate	
location	plays	a	role	in	determining	HS	mediated	BACE-1	inhibition.		
	
Following	recorded	changes	of	reduced	%	abundance	of	di-sulfated	disaccharides	in	AD	HS	
brain	samples,	total	%	abundance	of	N-	6-OS	and	2-OS	groups	within	the	HS	samples	from	AD	and	
healthy	age-matched	control	patients	was	also	calculated	to	explore	possible	changes	in	the	location	
Figure	2.19:	Mouse	brain	HS	composition	changes	with	ageing.	HS	isolated	from	young	(3	month)	(black)	and	
aged	(18	month)	(grey)	total	mouse	brain	samples	were	digested	with	a	mixture	of	heparin	lyases	(heparinase	
I,	II	and	III	mixture)	and	resultant	disaccharides	were	labeled	with	BODIPY	hydrazide	and	subjected	to	strong	
anion	exchange	chromatography	on	a	Propac	PA-1	and	eluted	with	a	linear	gradient	of	sodium	chloride	(0-1M	
over	30	min)	and	isocratic	sodium	hydroxide	(150mM).	Peaks	were	detected	using	an	inline	fluorimeter,	λexc	=	
488nm	 and	 λemm	 =	 520nm.	 Peak	 areas	 for	 each	 disaccharide	were	measured	 and	 disaccharide	 analysis	 is	
expressed	as	a	%	of	 total	HS	analysed.	Data	shown	are	from	10	mouse	brain	samples;	young	(n=5)	and	aged	
(n=5)	Error	bars	represent	mean	(±S.E.M).	p<0.05	*,	Student’s	t-test.		
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of	sulfate	groups	along	the	HS	chain.	Relative	abundance	of	the	2-O	sulfated	moiety	was	lower	than	
that	of	N-	and	6-O	sulfation	in	both	the	AD	and	healthy	age-matched	control	samples,	suggestive	of	
differential	 functional	 roles	 of	 sulfation	 at	 each	position	of	 the	disaccharide.	 The	presence	of	 just	
one	 2-O	 sulfotransferase	 enzyme	 may	 go	 some	 way	 to	 explain	 this	 reduced	 abundance	 of	 2-O	
sulfated	disaccharides	relative	to	those	patterned	with	sulfate	groups	at	the	6-O	and	3-O	positions	
(Esko	and	Selleck	2002).		
	
Analysis	of	HS	 from	AD	patient	samples	did	reveal	a	 trend	for	decreased	 levels	of	N-,	6-O	
and	2-O	sulfated	disaccharides	vs.	their	healthy	age-matched	control	counterparts;	however	this	did	
not	reach	statistical	significance,	perhaps	due	to	patient-patient	variability	(Figure	2.10).	Lindahl	and	
colleagues	have	also	previously	reported	a	differential	distribution	of	NS-	groups	within	HS	extracted	
from	AD	and	control	human	cerebral	cortex	brain	samples	(Lindahl,	et	al.	1995),	although	they	did	
not	 report	 any	 significant	 differences	 between	overall	 HS	 composition	 from	AD	 and	 control	 brain	
tissue.	 As	 such,	 the	 trends	 observed	 here,	 in	 the	 absence	 of	 statistically	 significant	 changes,	may	
support	 a	 notion	 of	 high	 variability	 between	 samples	 that	 make	 it	 challenging	 to	 determine	
significant	average	changes	across	a	population.	That	being	said,	this	work	by	Lindahl	and	colleagues	
also	 sampled	 only	 relatively	 small	 sample	 groups.	Moreover,	 the	work	 by	 Lindahl	 and	 colleagues	
analysed	 the	 disaccharide	 composition	 of	 HS	 samples	 digested	 with	 nitrous	 acid.	 The	 digestion	
products	 of	 this	 method	 are	 somewhat	 more	 limited	 to	 that	 afforded	 by	 heparinase	 digestion	
(nitrous	acid	cleaves	at	 the	site	of	 free	amino	groups	only)	as	carried	out	 in	 this	project	hence	we	
might	 expect	 differences	 in	 the	 final	 analysis	 of	 HS	 structural	 changes	 with	 AD.	 6-O	 sulfation	 is	
already	known	to	be	key	for	the	efficacy	of	BACE-1	inhibition	such	that	removal	of	6-O	sulfate	groups	
greatly	reduces	potency	of	inhibition	(Scholefield,	et	al.	2003).	A	trend	for	reduced	abundance	of	6-O	
sulfated	disaccharides	observed	here	in	AD	patient	brain	samples	would	thus	be	consistent	with	our	
hypothesis	 that	 HS	 from	 these	 patients	 in	 less	 able	 to	 inhibit	 the	 BACE-1	 enzyme	 and	 ultimately	
result	 in	elevated	generation	of	 the	Aβ	peptide.	Reduction	 in	2-O	sulfation	however	has	not	been	
shown	to	impact	BACE-1	inhibition	significantly	relative	to	heparin,	indicating	changes	in	this	region	
would	not	be	particularly	rate-limiting	in	the	context	of	BACE-1	inhibition	(Scholefield,	et	al.	2003).		
	
Changes	 in	 sulfation	 patterning	 as	 observed	 here,	 may	 be	 accounted	 for	 by	 changes	 in	
expression	of	HS-related	genes	that	modulate	sulfation	of	HS	chains.	Indeed,	HS	in	different	tissues	
has	 been	 shown	 to	 present	 variable	 sulfation	 patterns	 suggesting	 regulation	 of	 HS	 biosynthetic	
enzymes	varies	between	tissue	type	(Guimond,	et	al.	2009).	With	this	 in	mind,	variability	between	
tissue	types	and	indeed	regional	differences	in	the	brain	specifically	may	be	something	to	investigate	
in	the	future.	The	hippocampus	is	the	first	area	of	the	brain	to	be	affected	by	Alzheimer’s	pathology	
and	extraction	and	analysis	of	the	HS	from	this	region	may	reveal	different	changes	in	the	structure	
of	HS	to	those	already	studied.	Anti-HS	phage-display	antibodies	(Smits,	et	al.	2006,	van	Kuppevelt,	
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et	al.	1998)	could	also	be	used	to	identify	region	variability	in	the	degree	and/or	pattern	of	sulfation	
of	the	HS	present	in	different	brain	regions.		
	
No	significant	difference	in	the	number	of	sulfs/disaccharide	was	observed	between	AD	and	
age-matched	 control	 samples	 (Figure	 2.9).	 The	 lack	 of	 difference	 between	 the	 two	 groups	 in	 this	
instance	 would	 suggest	 that	 sulfation	 patterning	 in	 HS	 is	 not	 inherently	 changing	 in	 terms	 of	
abundance	 (as	 indicated	 by	 sulfs/disaccharide)	 but	 rather	 that	 the	 configuration	 of	 sulfation	 is	
altered	 in	 the	 presence	 of	 AD.	 Position	 of	 sulfation	 of	 disaccharides	 exhibiting	 specific	 sulfated	
features	may	 be	 the	 key	 driver	 in	 downstream	 BACE-1	 inhibition	 efficacy.	 Promisingly,	 Toida	 and	
colleagues	 in	 1997	 confirmed	 that	 the	 average	 HS	 chain	 sulfation	 isolated	 from	 porcine	 brain	
samples	 is	 1.01sulfate	 group	 per	 disaccharide	 (Toida,	 et	 al.	 1997).	 The	 HS	 extracted	 and	 purified	
from	 AD	 and	 healthy	 age-matched	 control	 brain	 samples	 in	 this	 instance	 was	 found	 to	 contain	
disaccharides	 with	 0.87	 (±0.07)	 and	 0.91	 (±0.10)	 sulfs/disaccharide	 for	 AD	 and	 control	 groups	
respectively.	 This	 data	 is	 therefore	 consistent	 with	 previous	 findings	 and	 indicates	 that	 the	
extraction	process	used	for	this	analysis	has	not	resulted	in	loss	of	any	sulfate	groups.		
	
2.8.1.1.2	AD	HS	samples	present	altered	levels	of	specific	HS	disaccharides	when	compared	to	their	
age-matched	control	counterparts	
	
	 Extraction	and	purification	of	HS	from	human	cortex	samples	revealed	the	presence	of	7	of	
the	 8	 most	 commonly	 occurring	 disaccharides	 in	 AD	 and	 age-matched	 control	 groups.	 Most	
noticeably,	the	di-sulfated	disaccharide,	Δ-UA(2S)-GlcNAc(6S)	was	observed	in	the	lowest	abundance	
of	all	 the	disaccharides	 in	both	AD	and	age-matched	control	 samples.	This	 finding	 is	 supported	by	
that	 of	 Huynh	 and	 colleagues	 who	 did	 not	 observe	 this	 disaccharide	 in	 rat	 myocardial	 muscle	
samples,	 perhaps	 indicative	 of	 this	 HS	 disaccharide	 being	 very	 rare	 in	 occurrence	 (Huynh,	 et	 al.	
2012).	 The	 Δ-UA-GlcNAc	 disaccharide	was	 found	 in	 highest	 abundance	 in	 both	 treatment	 groups.	
This	 standard	 is	 the	 non-sulfated	 disaccharide	 constituent	 of	 the	 HS	 chain	 and	 hence	 we	 would	
expect	 it	 to	be	present	within	all	of	our	samples	 in	significant	quantities	as	 it	 is	 the	common	non-
modified	unit	in	all	HS	species.	This	finding	is	also	consistent	with	the	work	of	Huynh	and	colleagues	
who	investigated	changes	 in	HS	disaccharide	composition	with	ageing.	They	also	found	that	the	Δ-
UA-GlcNAc	 disaccharide	 unit	was	 present	 in	 highest	 abundance	within	 their	 HS	 samples	 analysed	
(Huynh,	et	al.	2012).	Conversely,	abundance	of	the	most	highly	sulfated	disaccharide,	the	Δ-UA(2S)-
GlcNS(6S)	 unit,	 was	 considerably	 lower	 in	 both	 groups	 of	 samples	 observed.	 This	 disaccharide	 is	
sulfated	at	the	2-O,	N-	and	6-O	position	and	hence	has	undergone	the	most	extensive	modification	
of	the	whole	HS	chain	(excluding	consideration	of	the	rare	3-O	sulfation	modification).		
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Compositional	 profiling	 found	 significantly	 greater	 quantities	 of	 the	 UA-GlcNAc(6S)	
disaccharides	 in	 AD	 brain	 samples	 compared	 to	 their	 control	 counterparts.	 These	 mono-sulfated	
disaccharides	 have	 undergone	 only	 moderate	 modification	 and	 carry	 only	 one	 sulfate	 group.	 In	
contrast,	data	analysis	revealed	significantly	decreased	levels	of	the	UA-GlcNS(6S)	disaccharide	in	AD	
samples	 vs.	 controls.	 This	 disaccharide	 is	 sulfated	 in	 2	 locations	 and	 is	 therefore	 modified	 to	 a	
greater	 degree	 than	 the	 mono-sulfated	 units	 found	 to	 be	 in	 higher	 abundance	 in	 this	 group.	 In	
keeping	with	our	hypothesis,	lower	levels	of	this	disaccharide	in	AD	patients	would	be	indicative	of	
HS	composed	of	disaccharides	containing	fewer	sulfated	disaccharides	(Figure	2.12).		
	
It	is	clear	that	we	can	conclude	that	changes	do	occur	in	the	overall	composition	of	HS	with	
the	 AD	 phenotype	 vs.	 healthy	 age-matched	 controls.	 Somewhat	 surprisingly,	 these	 structural	
changes	are	occurring	at	an	individual	disaccharide	level	rather	than	just	a	global	one.	In	light	of	this,	
the	argument	for	consideration	of	the	overall	configuration	of	sulfate	patterning	along	the	HS	chain	
when	 elucidating	 ligand-binding	 functionality	 may	 be	 stronger	 than	 ever.	 Patient	 variability	 is	
naturally	a	likely	contributor	to	variation	and	increasing	the	number	of	patient	samples	analysed	in	
future	 studies	 may	 help	 smooth	 out	 the	 observed	 variability	 in	 HS	 composition	 and	 aid	 a	 more	
conclusive	 picture	 of	 the	 changes	 that	 are	 occurring.	 Furthermore,	 the	 variability	 observed	 here	
might	 be	 due	 to	 upstream	 changes	 that	 contribute	 to	 a	 change	 in	 the	 order	 in	 which	 these	
disaccharides	 appear	 rather	 than	 their	 relative	 amounts,	 something	 that	 SAX	 chromatography	
cannot	distinguish.	Similarly,	whilst	we	can	conclude	 that	 there	are	 significant	 if	 subtle	changes	 in	
the	 structure	 of	 HS	with	 AD,	 overall	 population	 differences	may	 be	 harder	 to	 observe.	Matching	
altered	expression	levels	of	enzymes	in	specific	samples	to	their	individual	disaccharide	profile	may	
therefore	prove	more	beneficial	in	understanding	how	very	subtle	changes	are	occurring.		
	
Finally,	 quantification	 of	 the	 total	 HS	 found	 within	 brain	 AD	 and	 age-matched	 control	
samples	 revealed	 significantly	 greater	 quantities	 of	 HS	 within	 control	 samples	 v.	 their	 AD	
counterparts.	Interestingly,	this	finding	is	not	in	agreement	with	previous	work	that	found	that	levels	
of	HS	were	increased	in	ageing	individuals	(Huynh,	et	al.	2012).	Despite	ageing	and	dementia	being	
different	conditions,	dementia	is	commonly	associated	with	ageing	and	we	would	have	thus	perhaps	
expected	to	observe	a	similar	trend	in	the	amount	of	HS	found	within	AD	samples.	Having	said	that,	
we	cannot	at	this	point	rule	out	that	altered	expression	of	those	genes	responsible	for	synthesising	
HS	are	 responsible	 for	 this	 change	with	 the	AD	phenotype	and	 that	 these	expression	patterns	are	
distinct	 from	these	 in	general	ageing.	Finally,	 this	 finding	that	HS	 is	present	 in	 lower	abundance	 in	
AD	patients	compared	to	healthy	age-matched	controls	is	consistent	with	our	hypothesis	of	reduced	
BACE-1	inhibition	efficacy	in	AD	patients.	Less	total	HS	will	naturally	be	less	able	to	block	the	activity	
of	 BACE-1	 effectively.	 Indeed,	 reduced	 BACE-1	 inhibition	 may	 not	 only	 be	 a	 result	 of	 altered	 HS	
structure	but	also	simply	reduced	levels	of	total	HS	present.		
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	 No	significant	variation	in	disaccharide	profiles	between	male	and	female	AD	patients	were	
observed	(Figure	2.14),	and	likewise	for	the	age-matched	control	study	group.	Previously,	research	
has	 found	 Alzheimer’s	 pathology	 to	 be	 accelerated	 in	 females	 vs.	 their	 male	 counterparts	 and	
studies	in	transgenic	murine	models	over	expressing	the	APP	and	PS1	genes	have	recorded	a	heavier	
amyloid	burden	and	increased	plaque	number	within	the	brain	of	female	compared	to	male	mice	of	
the	same	age.	Likewise,	increased	levels	of	the	plaque	precursor	peptides,	Aβ40	and	Aβ42	were	also	
observed	at	greater	 levels	 in	 female	mice	 (Wang,	et	al.	2003).	Furthermore,	more	complex	mouse	
models	 expressing	 both	 TAU	 and	 APP	 genes	 have	 been	 shown	 to	 have	 greater	 spatial	 learning	
deficits	in	females	over	their	male	littermates	(Ribe,	et	al.	2005).	Likewise,	differences	in	the	severity	
of	neuropathology	in	the	limbic	system	and	olfactory	cortex	has	been	reported	in	a	second	APP/tau	
model	whereby	 females	appear	more	severely	affected	than	their	male	counterparts	 (Lewis,	et	al.	
2001).	In	the	human	condition,	females	have	also	been	shown	to	be	more	susceptible	to	Alzheimer’s	
diseases	 than	 males.	 It	 is	 still	 unknown	 why	 females	 present	 an	 accelerated	 form	 of	 pathology;	
however	it	has	been	speculated	that	estrogenic	action	in	younger	females	might	have	a	protective	
role	against	mitochondrial	 toxicity	caused	by	amyloid-beta	that	 is	 lost	after	menopause.	 Indeed,	 it	
has	been	reported	that	mitochondria,	when	in	the	presence	of	amyloid	beta	increase	the	production	
of	 reactive	 oxygen	 species	 that	 lead	 to	 a	 series	 of	 reactions	 that	 ultimately	 induce	 neuronal	
apoptosis	by	increasing	intracellular	toxicity	(Vina	and	Lloret	2010).	Whether	hormonal	interactions	
with	 mitochondria	 are	 important	 with	 regards	 to	 Alzheimer’s	 pathology	 still	 remains	 to	 be	
elucidated	however	it	is	something	to	consider	when	studying	Alzheimer	study	groups	composed	of	
both	female	and	male	donors.		
	
In	 light	of	 this	 research,	we	might	have	expected	 to	observe	variation	 in	 the	disaccharide	
composition	of	HS	in	female	and	male	AD	patients,	such	that,	in	line	with	our	hypothesis,	a	greater	
proportion	of	Aβ	peptides	were	generated	as	a	result	of	altered	BACE-1	activity	and	APP	processing.	
As	we	did	not	observe	gender	differences	in	either	of	our	study	groups,	we	can	infer	that	structural	
alterations	 to	HS	chains	are	not	vulnerable	 to	gender	determined	risk	 factors.	Furthermore,	 larger	
samples	 sizes	 may	 reveal	 these	 seemingly	 subtle	 differences	 between	 males	 and	 females.	 The	
inherent	 variability	 between	 patient	 samples	 as	 discussed	 previously	may	make	 these	 differences	
less	 transparent	 than	 one	 might	 expect	 to	 observe	 in	 murine	 models.	 Likewise	 of	 course,	 the	
mechanisms	 for	 gender	 differences	 in	 observed	 Alzheimer’s	 pathology	 may	 simply	 not	 be	
intrinsically	linked	with	the	BACE-1	processing	pathway	as	focused	on	in	this	project.		
	
2.8.2	Mouse	samples	(Aged	vs.	Young)		
2.8.2.1	Disaccharide	peak	analysis	and	total	HS	quantification		
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2.8.2.1.1	 Aged	 (18	 month)	 HS	 samples	 display	 altered	 HS	 disaccharide	 sulfated	 moieties	 when	
compared	to	their	young	(3	months)	counterparts	
	
	 Analysis	of	 the	composition	of	HS	 from	mouse	brain	 samples	with	 respect	 to	 the	 level	of	
sulfation	 within	 constituent	 disaccharides	 revealed	 no	 significant	 changes	 in	 the	 patterning	 of	
sulfation	 between	 young	 and	 aged	 mice.	 As	 with	 the	 human	 samples,	 the	 observed	 large	
representation	of	the	unsulfated,	or	mono-sulfated	disaccharides	vs.	the	more	modified,	di-	and	tri-
sulfated	 disaccharides	 would	 be	 expected	 across	 both	 groups	 as	 a	 product	 of	 the	 typical	
modification	process	that	occurs	during	the	biosynthesis	of	HS.			
	
	 Analysis	was	undertaken	to	explore	whether	 the	 location	of	sulfate	groups	within	HS	was	
vulnerable	to	change	with	ageing.	Aged	mice	were	found	to	display	significantly	elevated	levels	of	2-
O	 sulfated	disaccharides	 vs.	 their	 younger	 control	 counterparts.	 Furthermore	a	 trend	 for	 elevated	
levels	 of	 N-	 and	 6-O	 sulfated	 disaccharides	 was	 also	 observed	 in	 aged	 mice	 vs.	 young	 controls,	
suggestive	of	an	overall,	globally	more	sulfated	HS	with	the	ageing	phenotype	(Figure	2.17).	
	
	 The	 connection	 between	 ageing	 and	 AD	 is	 well	 established;	 however	 the	 effect	 normal	
physiology	may	have	on	BACE-1	 inhibition	 is	unknown	and	has	not	been	fully	elucidated.	Likewise,	
the	 interaction	between	age	as	a	 risk	 factor	and	the	onset	and	development	of	AD	 is	 likely	a	very	
complex	one	and	thus	we	might	not	expect	to	observe	identical	changes	in	the	structure	of	HS	due	
simply	 to	 ageing	 and	 compared	with	 AD.	 Here,	 our	 ageing	 variable	 has	 only	 been	 investigated	 in	
mice.	 Similarities	 between	 mice	 and	 humans,	 whilst	 they	 do	 exist,	 cannot	 be	 assumed	 in	 every	
instance.	Hence	we	must	not	be	surprised	to	see	different	changes	in	the	structure	of	HS	with	ageing	
in	our	mouse	system	vs.	those	changes	observed	in	human	AD	patients.		
	
	 Interestingly,	changes	in	levels	of	sulfation	have	been	observed	in	HS	with	ageing	in	other	
tissues.	Muscle	from	mice	has	been	reported	to	display	an	age	dependent	increase	in	levels	of	6-O	
sulfation	(Ghadiali,	et	al.	2016),	indicating	that	dynamic	changes	in	the	structure	of	HS	do	occur	with	
ageing.	Whilst	this	study	did	not	report	changes	 in	the	 level	of	2-O	sulfation	as	observed	here,	we	
may	attribute	this	difference	to	the	fact	that	we	have	studied	HS	from	a	different	tissue	and	HS	 is	
known	 to	 present	 organ/tissue	 specific	 differences	 (Kreuger	 and	 Kjellen	 2012).	 In	 addition,	 the	
known	efficacy	of	BACE-1	inhibition	as	afforded	by	sulfated	HS	might	suggest	aged	mice	might	thus	
be	 better	 able	 to	 block	 the	 action	 of	 BACE-1	 due	 to	 their	 enhanced	 sulfation.	 Conversely,	 the	
increased	2-O	sulfation	observed	alongside	an	increase	in	6-O	sulfation	with	age	may	also	enhance	
BACE-1	 inhibition	as	2-O	sulfation	has	been	shown	to	 impact	BACE-1	 inhibition,	 though	to	a	 lesser	
degree	than	6-O	sulfation	(Scholefield,	et	al.	2003,	Schworer,	et	al.	2013).	However;	the	HS-BACE-1	
interaction	is	complex	and	currently	poorly	understood.	The	consequences	of	HS	structural	changes,	
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and	 the	 compensation	 mechanisms	 these	 may	 induce,	 will	 surely	 further	 complicate	 what	
determines	efficacious	BACE-1	inhibition/regulation.	
	
	 Moreover,	 as	 discussed	 previously,	 regional	 variability	 in	 HS	 structure	 across	 the	 brain	
cannot	be	distinguished	on	 this	 occasion	due	 to	 total	mouse	brain	HS	 sampling.	Only	 those	more	
gross	 changes	 in	 brain	 HS	 may	 be	 detected	 at	 this	 level	 of	 analysis.	 In	 the	 future,	 anatomical	
dissection	of	 specific	 regions	of	 the	brain	 should	be	explored	 to	allow	more	 subtle	 region-specific	
differences	in	HS	structure	to	be	determined.		
	
No	significant	changes	in	the	number	of	sulfs/disaccharide	were	observed	between	young	
and	aged	mice	(Figure	2.16).	There	was	however	a	strong	trend	to	indicate	that	aged	mice	do	display	
elevated	levels	of	sulfs/disaccharide	vs.	their	younger	control	counterparts.	This	lack	of	change	with	
ageing	may	 also	 be	 due	 to	 combinations	 of	 disaccharides	 being	 observed	 resulting	 in	masking	 of	
specific	 or	 average	 changes.	 This	 idea	 may	 be	 supported	 by	 the	 observation	 that	 there	 was	 no	
change	 in	 the	abundance	of	 sulfs/disaccharide	 in	 the	human	brain	 samples	also.	 	Configuration	of	
sulfated	disaccharides	in	combinations	(sequences)	may	be	more	important	in	determining	BACE-1	
inhibition	efficacy	over	changes	in	the	level	of	specific	disaccharides	themselves.		
	
2.8.2.1.2	 Aged	 mouse	 samples	 display	 significantly	 altered	 levels	 of	 some	 HS	 disaccharides	 when	
compared	to	their	younger	control	counterparts	
	
	 Purification	of	HS	from	aged	and	young	control	mouse	brain	tissue	revealed	changes	to	the	
compositional	profile	of	the	8	most	common	disaccharides	one	would	expect	to	see	within	HS.	Most	
noticeably,	 the	 three	 sulfated	 disaccharides,	 Δ-UA(2S)-GlcNS,	 Δ-UA(2S)-GlcNAc(6S)	 and	 Δ-
UAGlcNAc(6S),	 were	 found	 to	 be	 under	 represented	 with	 respect	 to	 the	 other	 disaccharides.	
Whether	this	is	a	feature	of	mouse	HS	or	whether	more	samples	are	needed	to	confirm	this	result	
remains	to	be	determined.	Should	the	very	 low	abundance	of	di-	and	tri-	sulfated	disaccharides	 in	
mouse	 brain	 HS	 be	 a	 characteristic	 of	 this	 species	 and	 organ,	 one	might	 question	whether	much	
more	subtle	changes	in	disaccharide	composition	are	occurring	to	drive	potential	changes	in	ligand	
binding	interactions.		
	
	 Furthermore,	 aged	 mice	 were	 found	 to	 display	 significantly	 increased	 levels	 of	 the	 Δ-
UA(2S)-GlcNAc	 disaccharide,	 a	mono-sulfated	 unit	with	 a	 sulfate	 group	 at	 the	 2-O	 position,	when	
compared	to	their	younger	control	counterparts.	 Increased	levels	of	this	sulfated	disaccharide	may	
be	indicative	of	changes	that	occur	with	ageing	that	may	go	some	way	to	alter	HS’	ability	to	interact	
with	its	ligands.		Similarly,	aged	mice	also	were	found	to	display	significantly	higher	levels	of	the	Δ-
UA(2S)-GlcNS	 disaccharide,	 a	 di-sulfated	 disaccharide,	 sulfated	 at	 both	 the	 2-O	 and	 N-	 positions.	
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Observed	abundance	of	 this	disaccharide,	 in	combination	of	 the	Δ-UA(2S)-GlcNAc	disaccharide	not	
only	indicates	that	2-O	sulfation	is	altered	in	the	presence	of	ageing	but	also	that	HS	from	aged	mice	
may	 be	 becoming	 overall,	 more	 sulfated.	 The	 consequence	 of	 enhanced	 2-O	 sulfation	 may	 be	
unknown;	 however	we	might	 hypothesise	 that	 this	 could	 have	 implications	 on	 efficacy	 of	 BACE-1	
inhibition	(Figure	2.19).		
	
These	 observed	 changes	 in	 the	 abundance	 of	 a	 disaccharide	 sulfated	 at	 the	 2-O	 position	
also	 strengthen	 the	 finding	 that	 2-O	 sulfation	 is	 significantly	 enhanced	 in	 aged	mice	 compared	 to	
other	 sulfate	 positions.	 One	 might	 expect	 to	 observe	 global	 changes	 in	 patterning	 of	 sulfation,	
whereas	differences	at	the	individual	disaccharide	level	as	reported	here	also	might	be	suggestive	of	
very	 subtle	 changes	 that	 could	 have	 big	 implications	 on	 ligand	 binding	 affinity	 and	 HS	 functions.	
Interestingly,	abundance	of	disaccharide	units	sulfated	at	the	2-O	position	was	not	found	to	change	
at	all	in	the	human	patient	brain	samples	discussed	previously.	In	light	of	this,	it	might	be	postulated	
that	ligand	binding	is	mediated	via	different	pathways/mechanisms	in	mice	vs.	humans.	More	work	
is	needed	to	confirm/deny	this	hypothesis.		
	
As	was	the	case	with	the	human	tissue,	the	Δ-UA-GlcNAc	disaccharide	was	found	in	highest	
abundance	in	both	treatment	groups.	This	standard	is	the	least	sulfated	disaccharide	constituent	of	
the	 HS	 chain.	 This	 finding	 is	 consistent	with	 the	work	 of	 Huynh	 and	 colleagues	who	 investigated	
changes	 in	 HS	 disaccharide	 composition	 with	 ageing	 in	 humans.	 They	 also	 found	 that	 the	 Δ-UA-
GlcNAc	 disaccharide	 unit	 was	 present	 in	 highest	 abundance	 within	 their	 HS	 samples	 analysed	
(Huynh,	et	al.	2012).		
	
From	this	data,	we	can	conclude	that	changes	occur	in	the	overall	composition	of	HS	with	
ageing	vs.	young	controls.	The	observation	that	these	changes	do	not	only	occur	globally	but	also	at	
the	 individual	 disaccharide	 level,	 would	 suggest	 that	 the	 overall	 configuration	 of	 sulfate	moieties	
within	HS	maybe	 key	 in	 determining	 ligand	binding	 efficiency.	 Changes	 in	 the	 structure	 of	HS	 are	
known	 to	 occur	 with	 ageing	 and	 understanding	 these	 changes	 may	 prove	 useful	 in	 further	
elucidating	the	role	that	ageing	may	play	as	a	risk	factor	of	AD.	Linking	ageing	and	AD	together	may	
shed	light	on	processes	that	may	be	initiated	very	early	before	full	onset	of	brain	pathology	and	as	
such	may	offer	new	potential	drug	discovery	targets.		
	
As	with	human	tissue,	variability	between	individuals	is	naturally	a	likely	contributor	to	the	
variation	 observed	 between	 samples	 observed	 here,	 and	 increasing	 sample	 size	 may	 not	 only	
smooth	out	the	observed	variability	but	also	offer	a	more	conclusive	picture	of	structural	changes	of	
HS	 that	 may	 be	 occurring.	 Similarly,	 and	 as	 highlighted	 previously,	 changes	 with	 ageing	 may	
contribute	 to	 changes	 in	 the	 specific	 order	 of	 disaccharides	 rather	 than	 just	 their	 relative	 ratios;	
disaccharide	 compositional	 analysis	 by	 SAX	 chromatography	 cannot	 determine	 this.	 In	 future	
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studies,	sequence	determination	may	prove	 invaluable	 in	 identifying	HS	saccharide	sequences	that	
underpin	 its	 interaction	with	protein	 ligands,	 and	 the	 changes	 in	 those	 sequences	 that	may	occur	
with	ageing.	
	
	 Extraction,	 purification	 and	 quantification	 of	 the	 total	 HS	 found	 within	 aged	 and	 young	
control	mouse	brain	samples	revealed	a	significantly	increased	level	of	total	HS	within	aged	samples	
compare	 to	 their	 younger	 control	 counterparts	 (Figure	 2.15).	 This	 observation	 may	 suggest	 that	
either	some	kind	of	upstream	mechanism	is	altering	the	total	level	of	HS	being	synthesised,	or,	that	
the	 turnover	and	degradation	of	HS	 is	altered	such	 that	 levels	are	accumulating	within	 the	 tissue.	
The	synthetic	enzymes	responsible	for	the	polymerisation	of	the	HS	chain,	or	the	core	proteins	onto	
which	HS	may	be	attached,	may	be	a	pathway	by	which	total	levels	of	HS	are	controlled.	This	finding	
sits	 well	 with	 previous	 studies	 that	 found	 that	 levels	 of	 HS	 were	 increased	 in	 ageing	 individuals	
(albeit	humans)	(Huynh,	et	al.	2012).			
	
2.9	General	conclusions	
	
Overall,	compositional	analysis	of	the	constituent	disaccharides	from	AD	and	age-matched	
control	 samples	 revealed	 that	 changes	 in	 the	 structure	 of	HS	do	occur	 in	 the	 presence	of	 the	AD	
phenotype.	AD	samples	display	significantly	 less	di-sulfated	disaccharides	and	more	mono-sulfated	
disaccharides.	 This	data	 is	 consistent	with	our	hypothesis	 that	HS	 from	AD	patient	 samples	 is	 less	
sulfated,	 and	may	 be	 less	 able	 to	 inhibit	 the	 BACE-1	 enzyme	 and	 thus	 implicated	 in	 the	 elevated	
generation	of	the	Aβ	peptide.	These	changes	are	not	seemingly	occurring	at	a	global	level	but	rather	
at	a	much	more	subtle,	individual	disaccharide	level.		Absolute	abundance	of	sulfation	along	the	full	
HS	 chain	 is	 not	 altered	with	 AD	 but	 rather	 perhaps	 the	 specific	 configuration	 of	 aforementioned	
sulfate	groups	in	combination	along	the	HS	chain.		
	
Furthermore,	we	observed	a	significant	decrease	in	the	total	amount	of	HS	in	AD	vs.	their	
age-matched	 control	 counterparts,	 indicative	 of	 an	 upstream	 change	 in	 the	 expression	 of	 those	
enzymes	 that	 generate	 the	 HS	 chain	 (Figure	 2.8).	 	 Further	 analysis	 of	 potential	 changes	 in	 the	
expression	 of	 these	 enzymes	may	 help	 to	 elucidate	 the	 upstream	 causes	 of	 these	 changes	 in	 the	
structure	 of	 HS	 and	 begin	 to	 further	 elucidate	 the	 consequences	 of	 these	 changes	 on	 BACE-1	
inhibition	and	generation	of	the	toxic	Aβ	peptide	as	observed	in	AD	patients.		
	
As	 with	 any	 study	 of	 this	 nature,	 larger	 sample	 group	 sizes	 in	 the	 future	 may	 more	
effectively	 reveal	 global	 changes	 between	 groups.	 Variability	 between	 individuals	 is	 naturally	
impossible	 to	 control	 for	 and	 ultimately	 will	 make	 detection	 of	 seemingly	 very	 subtle	 changes	
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difficult.	 	 Gender	 differences	may	 too	 be	 too	 subtle	 to	 pick	 out	 easily	 and	 accurately	 with	 these	
sample	group	sizes.	
	
With	respect	to	the	ageing	variable	of	this	study,	as	explored	with	mouse	brain	HS	samples,	
ageing	alone	appears	to	induce	an	increase	in	overall	sulfation	to	the	HS	chain,	alongside	an	increase	
in	total	HS	levels.	This	is	contrary	to	that	observed	in	the	AD	samples	and	might	suggest	that	perhaps	
ageing	and	AD	pathogenesis	 in	the	context	of	HS	may	be	mediated	by	separate	mutually	exclusive	
mechanisms.	Naturally	of	course	we	cannot	make	conclusions	based	on	data	from	human	and	mice	
as	the	two	species	may	behave	differently;	however	this	data	certainly	hints	at	separate	means	by	
which	HS	may	be	involved	in	normal	ageing	and	in	disease	development.	Further	studies	on	changes	
in	HS	with	ageing	of	healthy	brains	is	warranted.	
	
Ultimately,	 full	 sequencing	of	 full-length	HS	chains	would	allow	elucidation	of	 the	specific	
patterning	of	sulfate	groups.	However	despite	recent	advances	in	NMR	analysis	and	MS	to	study	the	
fine	 structure	 of	 HS	 oligosaccharides,	 information	 of	 full-length	 intact	 HS	 chains	 is	 still	 elusive.	
Composition	analysis	of	digested	chains	as	employed	in	this	project	has	proved	to	be	successful,	and	
are	most	suitable	for	determining	changes	in	the	relative	ratios	of	individual	disaccharides	as	well	as	
global	 changes	 in	 sulfated	moieties	 along	 the	 chain.	 They	 are	 thus	 highly	 useful	 in	 understanding	
structural	 changes	 to	HS	with	AD	or	ageing	 (and	 indeed	 in	other	diseases).	One	must	however	be	
aware	 of	 the	 limitations	 of	 this	 technique	 and	 the	 need	 to	 understand	 more	 detailed	 structural	
information	on	HS	in	the	future,	perhaps	initially	by	using	MS	profiling	methods	(Shao,	et	al.	2013,	
Shi	and	Zaia	2009).	
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3.	Chapter	3		
3.1	Introduction		
3.1.1	Gene	expression	of	HS	biosynthetic	genes	
	
	 Exploring	 the	 gene	 expression	 of	 the	 biosynthetic	 enzymes	 that	 produce	 HS	 has	 proved	
particularly	useful	in	further	elucidating	the	upstream	events	that	may	account	for	the	changes	in	its	
structure	of	this	GAG	as	observed	in	conditions	like	ageing	and	dementia.	There	are	several	different	
strategies	that	may	be	employed	to	study	the	function	of	HS	and	in	particular	specific	biosynthetic	
genes	 have	 been	 targeted	 and	 can	 be	 knocked	 down	 and	 the	 consequences	 observed.	
Understanding	the	wider	function	of	these	enzymes	and	their	baseline	expression	patterns	will	aid	
the	study	of	their	expression	in	the	context	of	disease	and	help	us	in	understanding	the	implications	
of	 altered	 expression	 patterns.	 Having	 shown	 changes	 in	 the	 overall	 disaccharide	 compositional	
profiles	of	brain	HS	in	AD	patients,	this	project	aimed	to	investigate	the	potential	upstream	causes	
for	 these	 structural	 differences.	 As	 described	 previously,	 there	 are	 three	 main	 phases	 of	 HS	
biosynthesis;	 chain	 initiation,	 chain	 polymerisation	 and	 chain	 modification.	 Different	 biosynthetic	
enzymes	 are	 involved	 in	 each	 of	 these	 phases	 and	 their	 knockdown	 will	 lead	 to	 very	 different	
alterations	 in	 the	 final	 structure	of	HS.	Knock	down	 for	example	of	 those	enzymes	 responsible	 for	
the	 elongation	 of	 the	 HS	 chain	 will	 result	 in	 truncated	 and/or	 lower	 levels	 of	 HS	 chain,	 whilst	
alteration	in	the	expression	of	modification	enzymes	may	have	a	more	subtle	outcome	on	the	level	
and	positions	of	sulfation	along	the	HS	chain.	All	of	 these	could	have	downstream	implications	for	
the	 HS	 chain’s	 ligand	 binding	 capacity.	 In	 addition,	 interruption	 in	 the	 expression	 of	 those	 core	
proteins	onto	which	HS	chains	may	be	attached,	will	have	considerable	effects	on	the	location	of	HS	
on	the	cell	surface	and	in	the	ECM,	and	may	prove	useful	in	understanding	function	and	roles	within	
the	 cell	 (Forsberg	 and	 Kjellen	 2001).	 	 There	 is	 added	 complexity	 when	 we	 consider	 the	 various	
isoforms	of	each	biosynthetic	gene	that	exist.	For	example,	there	are	4	NDST	genes	that	have	been	
identified	and	knock	down	of	 individual	members	have	different	consequences.	With	that	 in	mind,	
the	detailed	outcome	of	gene	knockdown	is	somewhat	complex.		
	
3.1.1.1	Knockdown	mouse	models	to	study	function	of	HS	biosynthetic	genes		
3.1.1.1.1	Knockdown	of	Ext	genes	
	
	 Knockout	mouse	modes	are	perhaps	the	clearest	way	to	study	the	roles	of	specific	genes	in	
physiological	pathways	and	 to	 that	effect,	 there	are	 several	 knock	out	models	 that	 currently	exist	
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that	have	explored	the	consequences	of	knocking	out	some	key	HS	biosynthetic	enzymes.		The	EXT1	
and	EXT2	proteins	both	share	glucuronyl-	and	N-acetylglucosaminyl-transferase	activity	(McCormick,	
et	al.	2000).	In	vivo,	these	two	proteins	form	a	heterodimer	to	achieve	efficient	transferase	activity	
to	 initiate	the	polymerisation	of	the	HS	chain.	Patients	who	inherit	a	single	mutation	 in	one	of	the	
EXT	genes	develop	several	benign	bone	tumours.	Furthermore,	homozygous	mutant	mouse	models	
for	this	gene	do	not	reach	full	term	due	to	death	at	gastrulation,	presumably	as	a	result	of	an	absent	
organised	mesoderm.	Similarly,	human	homozygous	mutants	have	not	been	identified	for	(assumed)	
similar	 reasons	 of	 early	 developmental	 abnormality	 (Lin,	 et	 al.	 2000).	 These	 studies	 combined	
highlight	the	key	role	of	EXTs	 in	the	synthesis	of	HS	and	importantly,	the	vast	consequences	 it	can	
have	on	the	GAG’s	formation	and	function.	
	
3.1.1.1.2	Knockdown	of	Ndst	genes	
	
Modification	 of	 the	 HS	 chain	 follows	 polymerisation.	 The	 NDSTs	 are	 the	 first	 group	 of	
enzymes	 to	 initiate	 this	modification	and	are	ultimately	 the	gateway	 to	addition	of	 sulfate	groups	
along	the	HS	chain.	With	this	in	mind,	the	Ndst	genes	in	mice	are	a	strong	candidate	for	knock	down.	
Knockout	of	the	Ndst1	gene	in	previous	studies	revealed	dramatic	loss	of	N-sulfation	of	the	HS	chain	
in	 most	 parts	 of	 the	 body,	 as	 well	 as	 considerable	 reduction	 in	 the	 levels	 of	 O-sulfation	 and	
epimerisation	of	GlcA	to	IdoA	residues	in	organs	such	as	the	liver,	suggesting	that	alterations	in	the	
expression	of	 this	enzyme	has	significant	 implications	 in	the	degree	of	sulfation	at	not	only	the	N-
position.	Lung	abnormality	proved	to	be	the	most	significant	phenotype	in	this	model	and	ultimately	
resulted	in	neonatal	lethality	(Ringvall,	et	al.	2000).	
	
In	contrast,	Humphries	and	colleagues	observed	that	knockdown	of	the	Ndst2	gene	in	mice,	
was	not	as	catastrophic	as	predicted	but	rather	only	manifested	as	a	deficit	in	the	connective	tissue	
type	mast	cells	–	those	cells	that	release	heparin	upon	inflammatory	stimulation	(Humphries,	et	al.	
1999).		Indeed,	the	little	heparin	that	was	observed	in	those	few	remaining	mast	cells	was	found	to	
be	largely	un-sulfated.	Most	notably,	the	lack	of	phenotype	in	the	Ndst2	 -/-	model	in	other	parts	of	
the	body,	would	suggest	that	other	NDST	enzymes	are	able	to	compensate	for	the	loss	of	NDST2	and	
may	also	hint	at	a	flexible	model	of	enzyme	activity	whereby	other	isoforms	of	this	family	are	in	fact	
more	important	functionally	in	the	synthesis	of	HS	(Grobe,	et	al.	2002).	This	idea	is	strengthened	in	
view	 of	Ndst1	 and	Ndst2	 gene	 double	 knockouts.	 The	 absence	 of	 both	 of	 these	 enzymes	 causes	
embryonic	lethality	in	mice	(Holmborn	et	al;	unpublished	results)	suggesting	the	role	of	NDST3	and	
NDST4	enzymes	is	not	sufficient	to	compensate	for	the	lack	of	NDST1	and	2.		
	
Ndst3	 gene	knockout	mice	have	been	 shown	 to	display	normal	development	and	 fertility	
and	might	 suggest	 some	 kind	 of	 redundancy	 in	 its	 function	 relative	 to	 its	 other	 family	 members	
(Pallerla,	 et	 al.	 2008).	 The	 action	 of	 the	 NDST	 enzymes	 is	 arguably	 the	 driver	 of	 all	 further	 HS	
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modification	as	it	determines	the	location	of	the	NA-	and	NS-	domains	(Lindahl,	et	al.	1998).	Indeed	
the	formation	of	these	NS-	domains	suggest	a	substrate	specificity	for	the	NDST	enzymes	and	may	
hint	at	a	self-fulfilling	influence	over	its	own	substrate.		
	
3.1.1.1.3	Knockdown	of	the	Glce	and	Hs2st1	genes	
	
Final	 steps	 in	 the	modification	of	 the	HS	 chain	 include	 the	 epimerisation	of	GlcA	 to	 IdoA	
residues	 by	 C5-epimerase,	 followed	by	 sulfation	 at	 the	 2-O	 position.	 Previous	work	 has	 identified	
that	 the	 epimerisation	 reaction	 is	 totally	 reversible	 however	 the	 action	 of	 the	 HS2ST1	 enzyme	 is	
intrinsically	linked	in	light	of	the	fact	it	is	able	to	lock	the	GlcA	or	IdoA	epimerized	configuration.	Lack	
of	 2-O	 sulfation	 therefore	 will	 drive	 the	 epimerisation	 reaction	 back	 to	 the	 GlcA	 configuration	
(Feyerabend,	et	al.	2006).	Furthermore,	loss	of	the	C5	epimerase	(GLCE)	in	mast	cells	lead	them	to	
display	distorted	heparin	O-sulfation	patterning	as	a	result	of	inhibited	epimerisation	of	GlcA	to	IdoA	
residues.		
	
Total	knockout	of	the	Glce	gene	in	mice	has	been	found	to	result	in	death	immediately	after	
birth	and	also	display	agenesis	of	the	kidney	alongside	stunted	body	growth	and	defects	within	the	
lungs	(Jia,	et	al.	2009,	Li,	et	al.	2003).	Mice	lacking	IdoA	decorated	HS	chains	(as	a	result	of	knockout	
of	the	Glce	gene)	also	display	attenuated	morphogenesis	of	the	thymus	via	binding	with	FGF2	and	10	
(Reijmers,	 et	 al.	 2010),	 suggesting	 this	moiety	within	HS	 is	 responsible	 for	 some	key	physiological	
events.		
	
	 HS2ST1	has	also	previously	been	shown	to	play	a	key	role	in	binding	ligand	specificity,	such	
as	FGF-2	(Maccarana,	et	al.	1993).	Mutations	in	the	Hs2st1	gene	in	mice	result	in	death	at	birth	on	
account	of	significant	renal	agenesis	and	abnormalities	of	the	CNS	(Bullock,	et	al.	1998).	It	should	be	
noted	that	loss	of	HS2ST1	activity	in	this	way	is	compensated	for	with	a	concomitant	increase	in	the	
abundance	 of	 N-	 and	 6-O	 sulfation.	 In	 addition,	 FGF-2	 signaling	 is	 not	 attenuated	 in	mice	 lacking	
Hs2st1	 gene	 expression,	 further	 strengthening	 an	 idea	 of	 a	 degree	 of	 flexibility	 for	 other	 sulfate	
positions	to	maintain	a	similar	ligand-binding	efficacy	(Merry,	et	al.	2001)	whether	that	be	replaced	
with	6-O	sulfation	rather	than	2-O	(Kamimura,	et	al.	2006).	As	with	Ndst	gene	expression,	knockout	
of	 both	 the	 Hs2st1	 and	 Hs6st	 genes	 results	 in	 HS	 that	 cannot	 play	 a	 role	 in	 FGF-2	 signaling,	
suggesting	 the	 level	 of	 sulfation	 along	 the	 HS	 chain	 is	 of	 greater	 importance	 to	 its	 positioning	
(Kreuger,	et	al.	2006).	Loss	of	sulfation	may	result	in	a	significantly	altered	final	confirmation	of	the	
resultant	HS	chain	and	 in	doing	 so	drastically	alter	 the	 ligand	binging	motif	necessary	 for	efficient	
ligand	binding	(Powell,	et	al.	2004).		
	
3.1.1.1.4	Knockdown	of	the	Hs6st	genes	
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	 The	 3	 members	 of	 the	 HS6ST	 enzyme	 family	 share	 50%	 homology	 however	 show	 very	
similar	 patterns	 of	 substrate	 specificity	 suggesting	 they	 can	 “share”	 each	 other’s	 roles	 of	 adding	
sulfate	groups	at	the	6-O	position	along	the	HS	chain.	HS6ST1	has	been	previously	shown	to	display	
minimal	preference	for	binding	sites	lacking	2-O	sulfation	suggesting	the	presence	of	absence	of	this	
modification	may	regulate	in	some	way	the	addition	of	sulfation	at	the	6-O	position	(Habuchi,	et	al.	
2003).		
	
Hs6st1	null	mice	do	not	survive	past	 late	embryonic	stage	(Pratt,	et	al.	2006).	These	mice	
are	 also	 smaller	 in	 size	 vs.	 their	 wild	 type	 counterparts	 and	 also	 display	 deficits	 in	 retinal	 axon	
guidance	due	to	perturbed	Slit-Robo	signaling	 (Conway,	et	al.	2011,	Pratt,	et	al.	2006).	 In	contrast	
however,	Hs6st2	null	mice	survive	normally,	despite	exacerbated	thyroid	hormone	levels	(Nagai,	et	
al.	 2013)	and	abnormal	muscle	 formation	 (Bink,	 et	al.	 2003).	 Fatality	with	knockout	of	 the	Hs6st1	
gene	but	not	the	Hs6st2	gene	may	suggest	functional	preference	of	these	isoforms	and	hint	at	the	
“key	players”	in	HS	modification.	Despite	this,	the	specific	role	of	the	HS6ST	isoforms	is	still	yet	to	be	
fully	determined.	Furthermore,	differential	expression	of	the	Hs6st	genes	during	different	stages	of	
development	and	 in	 specific	 tissue	 regions	would	 suggest	 tight	 regulation	of	6-O	sulfation	–	a	key	
feature	 of	 several	 ligand-binding	 partnerships	 (Habuchi,	 et	 al.	 2000).	 Double	 knockout	 of	 both	
Hs6st1	and	the	Hs6st2	genes	resulted	in	defected	storage	of	mast	cell	proteases	as	well	as	hindered	
FGF	signaling	in	embryonic	fibroblasts	(Sugaya,	et	al.	2008).	
	
3.1.1.1.5	Knockdown	of	the	Hs3st	genes	
	
	 The	3-O	sulfotransferase	enzymes	are	a	group	of	enzymes	 that	 catalyse	 the	addition	of	a	
sulfate	 group	 in	 the	 3-O	 position.	 The	 presence	 of	 the	 3-O	 sulfate	 group	 has	 been	 shown	 to	 be	
instrumental	 in	 the	 interaction	 between	 the	 unique	 pentasaccharide	 sequences	 of	 HS	 and	
antithrombin	 (Lindahl,	 et	 al.	 1980).	 Mouse	 models	 lacking	 the	 Hs3st1	 gene	 however	 have	 been	
found	 to	display	normal	development	and	anticoagulant	activity	 (HajMohammadi,	 et	al.	 2003).	As	
such,	it	cannot	be	ruled	out	that	other	members	of	the	HS3ST	family	are	able	to	compensate	for	the	
loss	of	the	Hs3st1	gene	(HajMohammadi,	et	al.	2003).	Indeed	this	may	go	some	way	to	explain	the	
large	number	of	HS3ST	enzyme	isoforms	that	exist	despite	relatively	low	abundance	of	3-O	sulfated	
moieties	within	HS.		
	
	 The	 seven	 isoforms	of	HS3ST	are	known	 to	have	 selective	 substrate	 specificities	 and	as	a	
result,	HS	may	be	endowed	with	a	number	of	distinct	biological	 functions	by	different	3-O	sulfate	
substitutions.	HS3ST5	 is	also	 implicated	 in	 the	key	3-O	sulfation	required	 for	anticoagulant	activity	
(Liu	and	Pedersen	2007).	The	activity	of	other	isoforms	including	HS3ST2,	3,4,5	and	6	are	believed	to	
promote	 the	 infection	 of	 the	 herpes	 simplex	 virus	 type	 1	 (HSV-1)	 (Shukla,	 et	 al.	 1999,	 Xu,	 et	 al.	
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2005).	 As	 such,	 knockdown	 of	 the	 genes	 that	 encode	 these	 enzymes	 may	 have	 considerable	
consequences	on	physiological	function.		
	
3.1.1.1.6	Knockdown	of	the	Sulf	genes		
The	 action	 of	 the	 SULFs,	 HS	 sulfatase	 enzymes	 that	 remove	 sulfate	 groups	 at	 the	 6-O	
position	 have	 been	 shown	 previously	 to	 fine	 tune	 final	 HS	 structure	 and	 in	 doing	 so	 play	 an	
important	 role	 in	 determining	 ligand	 binging	 configurations	 of	 HS.	 Both	 the	 SULF1	 and	 SULF2	
enzymes	have	shown	preference	for	binding	to	tri-sulfated	disaccharide	units	(Hossain,	et	al.	2010)	
however	 their	 activity	might	not	be	only	 restricted	 to	 these	 sites	 giving	 the	 SULFs	 a	 great	deal	 of	
functionality	in	the	modification	of	HS.	Indeed,	analysis	of	in	vivo	cerebellum	HS	from	knockout	mice	
has	 demonstrated	 that	 there	 are	 non-redundant	 actions	 of	 the	 2	 forms	 although	 they	 do	 display	
some	overlap	in	substrate	preferences	(Kalus,	et	al.	2015).	
	
	 Previous	work	on	Sulf	gene	knockout	mouse	models	found	the	mice	deficient	in	the	SULF1	
enzyme	(Sulf1	-/-)	are	seemingly	unaffected	(Lamanna,	et	al.	2006)	whilst	knockout	of	the	Sulf2	gene	
results	 in	a	 smaller	body	 size	and	mass	and	would	 suggest	 stunted	growth	 (Lamanna,	 et	al.	 2006,	
Lum,	 et	 al.	 2007).	 Furthermore,	 mice	 lacking	 both	 the	 Sulf1	 and	 Sulf2	 gene	 display	 considerable	
malformations	of	both	the	skeleton	and	renal	function	and	as	a	result,	die	before	birth	(Holst,	et	al.	
2007).	 6-O	 sulfation	 is	 known	 to	be	a	 key	modulator	of	 several	 ligand-binding	 interactions	 and	as	
such	 knockout	 of	 the	 Sulf	 genes	may	 go	 some	way	 to	 interfere	 with	 this	 functionality.	 The	 SULF	
enzymes	have	 long	been	 shown	 to	be	 important	 in	maintenance	of	 cartilage	 (Otsuki,	 et	al.	 2010),	
dentinogensis	via	Wnt	signaling	(Hayano,	et	al.	2012),	muscle	regeneration	(Langsdorf,	et	al.	2007),	
brain	 development	 (Kalus,	 et	 al.	 2009)	 and	 neurite	 outgrowth	 (Ai,	 et	 al.	 2007).	 Furthermore,	 the	
SULFs	 have	 also	 been	 shown	 to	 promote	 the	 migration	 of	 corneal	 epithelial	 cells	 during	 wound	
repair	 (Maltseva,	 et	 al.	 2013).	 Key	 roles	 such	 as	 this	 during	 morphogenesis	 implicate	 the	 SULF	
enzymes	heavily	in	modulating	HS	function.		
	
Knockdown	 of	 genes	 in	 this	 manner	 offers	 a	 great	 deal	 of	 insight	 into	 the	 pathways	 by	
which	important	physiological	mechanisms	may	be	regulated.	Seemingly	very	subtle	changes	in	HS	
structure	could	have	very	significant	down	stream	functional	consequences.		
	
3.1.1.2	Complexities	of	HS	chain	synthesis	and	modification	
	
The	roles	these	enzymes	play	is	seemingly	not	independent	of	one	another.	Studies	suggest	
that	 action	 of	 the	NDST	 enzymes	 is	 a	 determinant	 for	 the	 actions	 of	 other	modification	 enzymes	
downstream.	C5	epimerase	has	been	shown	to	occur	after	N-sulfation	(Esko	and	Selleck	2002)	and	2-
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O	sulfated	moieties	are	more	abundant	within	the	NS-	domains	of	HS,	indicative	of	a	functional	tie	
between	 the	 NDSTs	 and	 HS2ST1	 (Rong,	 et	 al.	 2001).	 Conversely,	 knockdown	 of	Hs2st1	 and	Glce	
genes	 in	mouse	models	 display	 increased	N-	 and	 6-O	 sulfation	 further	 interlinking	 the	 role	 of	 HS	
biosynthetic	enzymes	and	presenting	a	rather	more	complex	mechanism	to	elucidate.		
	
It	is	also	important	to	note	that	there	is	evidence	that	suggests	that	the	baseline	expression	
of	 HS	 biosynthetic	 genes,	 particularly	 between	 members	 of	 the	 individual	 gene	 families	 is	
particularly	 varied.	 Differential	 baseline	 expression	 of	 these	 key	 enzymes	 suggests	 some	 kind	 of	
regulation;	 however	 exactly	 how	 this	 occurs	 is	 still	 largely	 unknown.	 It	 is	 already	well	 established	
that	HS	from	different	tissues	differs	in	composition	significantly	(Lindahl,	et	al.	1995).	Furthermore,	
immunohistochemistry	has	demonstrated	that	antibodies	for	different	HS	epitopes	reveal	markedly	
different	 staining	 patterns	 when	 applied	 to	 different	 tissue	 sections,	 even	 sections	 of	 the	 same	
tissue,	perhaps	as	a	result	of	altered	cell	types	(Kapp,	et	al.	1995).	Changes	of	this	kind	are	indicative	
of	 altered	 enzyme	 expression	 and	 previous	 work	 has	 proved	 that	 heparin-producing	 mast	 cells	
express	the	NDST2	enzyme	in	preference	to	other	members	of	the	NDST	family	(consistent	with	the	
Ndst2	gene	mouse	knockout	phenotype	described	above),	despite	a	trend	for	the	opposite	in	other	
tissue	 types	 (Hansebo,	 et	 al.	 1998).	 The	 amounts	 and	 proportions	 of	 different	 HS	 biosynthetic	
enzyme	isoforms	are	seemingly	therefore	largely	regulated	to	some	extent	and	may	be	controlled	by	
gene	expression	predominantly	but	also	post	 translational	degradation.	 Indeed	 further	elucidation	
of	the	ways	in	which	this	may	occur	and	the	ways	in	which	these	enzymes	interact	with	each	other	in	
the	context	of	their	cellular	 localisation	is	also	of	key	importance	(Lindahl,	et	al.	1998).	Patterns	of	
action	of	 these	enzymes	and	 substrate	 interaction	 is	 largely	dependent	on	previous	 reactions	and	
modification	steps	and	these	factors	may	all	play	a	role	in	determining	baseline	expression	of	these	
genes	 (Lindahl,	et	al.	1998).	Furthermore,	observed	changes	 in	baseline	expression	of	 these	genes	
encoding	 HS	 biosynthetic	 enzymes	 may	 hint	 at	 explanations	 for	 differential	 vulnerability	 to	 AD	
pathogenesis	as	exhibited	by	different	regions	of	the	brain.	Spatial	accumulation	of	AD	pathology	in	
distinct	regions	of	the	brain	may	result	in	part	from	variable	expression	of	HS	biosynthetic	genes	and	
may	 offer	 insights	 into	 disease	 spread.	 Altered	 baseline	 expression	 of	 these	 enzymes	 may	 make	
identifying	changes	with	AD	in	the	context	of	this	project,	trickier	to	identify	as	a	result.		
	
Taken	together,	the	work	with	knock	out	models	of	HS	biosynthetic	genes,	and	studies	to	
investigate	 substrate	 specificities	 highlight	 the	 importance	 of	 these	 enzymes	 and	 their	 role	 in	 the	
synthesis	and	modification	of	the	HS	chain.	Importantly,	whilst	knockdown	of	these	genes	of	interest	
is	 expected	 to	 produce	 a	 somewhat	 exaggerated	 phenotype,	 in	 doing	 so,	 this	 highlights	 the	
significance	that	altered	expression	of	these	genes	may	play.	Changes	in	expression	of	these	genes	
may	go	some	way	to	explain	changes	in	the	structure	of	HS	and	potential	compensatory	mechanisms	
employed	 by	 cells	 to	 re-equilibrate	 to	 the	 norm.	 Furthermore,	 understanding	 these	 potential	
changes	in	the	context	of	disease,	such	as	AD	in	this	instance,	will	prove	invaluable	in	understanding	
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what	it	causing	the	downstream	changes	in	the	structure	of	HS	and	ultimately,	its	efficacy	as	a	ligand	
binding	GAG.	
	
3.1.2	Methods	available	to	explore	gene	expression	
	
There	 are	 a	 number	 of	methods	 available	 for	 the	 analysis	 of	 global	 gene	 expression	 in	 a	
particular	 sample	 of	 interest.	 As	with	 all	 techniques,	 there	 are	merits	 and	 disadvantages	 of	 each	
method	and	each	one	may	prove	the	“best’	depending	on	the	samples	to	be	analysed,	the	number	
of	genes	and	 the	 resources	available.	 Investigating	 the	 levels	of	 relative	mRNA	expression	may	be	
achieved	 via	 northern	 blots,	 Real	 Time-Polymerase	 Chain	 Reaction	 (RT-PCR),	 macroarrays,	
microarrays,	 differential	 display	 RT-PCR,	 Serial	 Analysis	 of	 Gene	 Expression	 (SAGE),	 comparative	
Expressed	 Sequence	 Tag	 (EST)	 analysis,	 and	 Massively	 Parallel	 Signature	 Sequence	 tag	 (MPSS)	
analysis	(Fryer,	et	al.	2002).		
	
In	general,	those	methods	that	work	via	sequence	analysis	to	identify	the	transcript	of	the	
gene	 of	 interest,	 like	 SAGE,	 EST	 analysis	 and	 MPSS	 analysis	 often	 prove	 expensive	 and	 require	
specialised	equipment	 that	may	not	be	available.	Other	methods,	 such	as	RT-PCR	often	prove	 the	
most	popular	and	allow	analysis	of	more	than	one	gene	at	a	time	at	a	relative	 low	cost.	The	most	
traditional	method	of	gene	expression	analysis	 is	the	Northern	blot	(Sabelli	and	Shewry	1995).	The	
northern	blot	 technique	 can	be	used	 to	 analyse	 the	expression	of	 one	 gene	at	 a	 time.	 It	 uses	 gel	
electrophoresis	 to	 separate	 samples	of	RNA	based	on	 their	 size,	which	can	 then	be	detected	with	
various	hybridised	probes.	 This	 technique	 is	 largely	 criticised	 for	 being	only	 a	 single	 gene	 analysis	
method	and	blot-to-blot	variation	may	introduce	error	in	large-scale	gene	level	comparisons.	By	the	
same	 token,	 scaling	 this	method	 up	 for	 large	 numbers	 of	 genes	makes	 this	 technique	 costly	 and	
time-consuming.		
	
Development	 in	 the	1980s	went	on	to	create	 the	use	of	microarrays	via	dot-blots	 initially	
that	aided	analysis	of	multiple	RNA	samples	that	could	be	detected	and	quantified	with	radioactivity	
(Fryer,	et	al.	2002).	This	technique	was	and	still	is	largely	a	popular	method	as	it	can	be	carried	out	
easily	and	the	arrays	can	be	manufactured	by	individual	research	groups	to	suit	their	specific	needs	
very	 easily.	 Despite	 this	 there	 are	 issues	with	 comparisons	 between	multiple	 dot-blot	 arrays	 and	
they	are	reportedly	tricky	to	use	for	analysis	of	very	low-abundance	transcripts	(Fryer,	et	al.	2002).		
	
Following	 this,	 in	 the	 1990s,	 the	 process	 of	 RT-PCR	 was	 developed	 and	 has	 become	
arguably	the	most	prominent	gene	analysis	technique	(Cale,	et	al.	1998,	Freeman,	et	al.	1999).	This	
technique	allows	the	researcher	to	use	a	96-well	plate	format	to	design	an	experiment	in	which	to	
analyse	the	relative	expression	of	several	genes	at	one	time,	and	allows	detection	with	even	only	a	
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very	 small	 amount	 of	 the	 target	 template.	More	 recent	 development	of	 this	method	has	 allowed	
relatively	affordable	techniques	for	the	real-time	quantification	of	genes	of	interest	within	multiple	
samples	 in	 a	 timely	 and	 non-labour	 intensive	 manner.	 Naturally,	 each	 reaction	 volume	 (well)	 is	
restricted	to	a	single	gene	so	generating	data	for	hundreds	of	thousands	of	genes	would	prove	very	
expensive	(Freeman,	et	al.	1999).	As	such,	RT-PCR	is	largely	regarded	as	a	reliable	validation	method	
for	confirming	the	expression	levels	of	target	genes	of	interest.	More	sophisticated	PCR	techniques	
have	been	developed	to	assess	expression	differences	by	using	primers	to	amplify	arbitrary	subsets	
of	 genes	 that	be	quantified	and	 then	 sequenced	 to	 identify	 specific	 genes	 (Shimkets,	 et	al.	 1999).	
This	method	is	beneficial	in	that	it	requires	no	earlier	knowledge	of	specific	genes	or	their	sequence;	
however	this	 is	 largely	a	much	more	technical	procedure	and	requires	expertise	so	as	to	avoid	the	
wrong	identification	of	target	sequences	(Adams,	et	al.	1993).			
	
	 Other	newer	methodologies	have	since	been	able	to	generate	high	throughput	expression	
data,	based	on	large	libraries	of	cDNA	that	may	represent	all	of	the	expressed	mRNA	within	a	tissue	
or	 cell	 type.	 From	 this	 a	 database	 can	 be	 generated	 that	 quantifies	 all	 of	 the	 genes	 that	 are	
expressed	within	 that	 sample	 and	are	 referred	 to	 as	 expressed	 sequence	 tags	 (ESTs)	 (Fryer,	 et	 al.	
2002).	SAGE	 is	a	similar	method	that	creates	a	 library	of	short	DNA	fragments	derived	 from	single	
mRNA	molecule	in	a	sample	of	interest.	These	shorter	fragments,	or	SAGE	tags,	can	then	be	linked	
together	linearly	to	form	larger	fragments	for	sequencing,	as	like	EST	analysis.	Whilst	both	of	these	
methods	 are	 highly	 specific	 and	 accurate	 in	 the	 identification	 of	 gene	 transcript	 levels,	 they	 both	
require	 expertise	 and	 are	 fairly	 technically	 challenging	 and	 can	 be	 both	 highly	 costly	 and	 time-
consuming	(Fryer,	et	al.	2002).	MPSS	is	similar	in	that	it	is	able	to	deduce	the	identity	of	thousands	
of	 transcripts	 at	 any	one	 time	 and	 is	most	 often	 employed	 in	 conjunction	with	 a	 pre-existing	 EST	
database	or	existing	mapped	genome	(Brenner,	et	al.	2000,	Tyagi	2000).	
	
	 For	larger	projects	to	explore	global	gene	expression	changes,	microarrays	or	“gene	chips”	
have	become	the	most	popular	choice	for	research	scientists.	Microarrays	have	become	a	great	deal	
more	cost	effective	in	recent	years	and	have	proved	relatively	simple	and	reproducible	to	carry	out	
and	can	be	used	to	investigate	the	expression	levels	of	thousands	of	genes	at	any	one	time	(Hsiao,	et	
al.	2000,	Kurella,	et	al.	2001).	Greater	fluorescence	intensity	will	be	recorded	with	those	probes	that	
bind	more	abundantly	to	a	specific	spot	on	the	microarray	and	hence	indicate	a	greater	abundance	
of	 a	 specific	 gene.	 Whilst	 microarrays	 are	 now	 widely	 available	 from	 a	 number	 of	 different	
manufacturers	and	can	be	engineered	in	house	by	researchers,	they	still	remain	relatively	expensive.	
Similarly,	disadvantages	with	this	method	include	varying	degrees	of	unspecific	binding	that	must	be	
corrected	for.	
	
	 Meta-analysis	of	large	expression	profiling	data	is	also	a	useful	tool	in	this	field	of	research	
as	 it	 allows	 investigation	 of	 large	 numbers	 of	 genes	 in	 the	 context	 of	 different	 phenotype	
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perturbations.	 Software	 is	 now	 readily	 available	 with	 large	 datasets	 to	 make	 these	 comparisons,	
making	these	resources	a	useful	tool	for	target	finding	strategies.	
	
	 For	 the	purposes	of	 this	project,	 it	was	most	appropriate	to	use	a	combination	of	RT-PCR	
and	meta-analysis	 of	microarray	 expression	data,	 to	 investigate	 the	 expression	of	HS	biosynthetic	
enzymes	in	the	brains	of	AD	and	age-matched	control	patients.	This	method	allowed	high	sensitivity	
detection	 of	 the	 gene	 transcripts	 of	 interest,	 from	 relatively	 very	 small	 quantities	 of	wet	 starting	
material.	 Indeed,	this	method	is	relatively	cheap	and	does	not	require	hugely	challenging	technical	
informatics	processing.	As	a	 target	 finding	endeavor,	RT-PCR	was	by	 far	 the	most	appropriate	and	
practical	method	to	employ.		
	
3.1.3	Changes	in	HS	biosynthetic	enzyme	expression	observed	in	disease	
	
	 The	extensive	variability	in	structure	afforded	by	HS	alongside	its	ubiquity	all	over	the	body,	
makes	it	a	prominent	member	of	several	key	signaling	pathways	and	cellular	functionalities,	that	if	
disturbed	 could	 prove	 detrimental	 in	 the	 context	 of	 several	 diseases.	 In	 particular,	 the	 EXT1	 and	
EXT2	enzymes	are	central	in	initiating	the	polymerisation	of	the	HS	chain.	Should	the	expression	of	
these	genes	be	altered	in	any	way,	the	resulting	HS	chains	will	absent	or	truncated	and	consequently	
prove	 unable	 to	 function	 effectively	 (Sugahara	 and	 Kitagawa	 2000).	 Likewise,	 the	 variety	 of	
biosynthetic	enzymes	involved	in	the	synthesis	and	modification	of	the	HS	chain	make	it	vulnerable	
to	 potentially	 significant	 alteration	 should	 these	 enzymatic	 pathways	 be	 disrupted.	 Altering	 the	
structure	of	HS,	as	described	previously	will	have	dramatic	effects	on	the	ligand	binding	affinities	the	
HS	 chain	 can	 participate	 in.	 	 As	 such,	 HS	 is	 implicated	 in	 a	 number	 of	 diseases	 including	 bone	
disorders	 (Shimo,	 et	 al.	 2004)	 and	 tumor	 growth;	 EXT1	 has	 been	 shown	 to	 present	 tumor	
suppressing	activity	(Ropero,	et	al.	2004).	Analysis	of	the	causes	of	these	disorders	and	the	role	of	HS	
and	its	biosynthetic	enzymes	may	play	offer	an	obvious	drug	discovery	target	for	modification	and	
treatment	of	these	diseases	(Nadanaka	and	Kitagawa	2008).		
	
	 More	 recently,	 the	 HS6ST1	 gene	 has	 been	 identified	 as	 a	 new	 genomic	 locus	 associated	
with	albuminuria	in	diabetes.	Genome	Wide	Association	Studies	(GWAS)	revealed	single	nucleotide	
polymorphisms	 (SNPs)	 at	 this	 gene	 locus	 that	 was	 associated	 with	 those	 with	 but	 not	 without	
diabetes.	Not	only	could	variants	of	the	HS6ST1	gene	thus	provide	potential	as	a	novel	biomarker	for	
susceptibility	to	albuminuria	 in	diabetes	but	offers	 insight	 into	ways	 in	which	HS	biosynthetic	gene	
expression	may	have	significant	implications	for	normal	physiology	and	the	development	of	disease	
(Teumer,	et	al.	2016).		
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	 In	addition,	as	described	previously,	HS	is	implicated	in	the	pathogenesis	of	AD	in	a	number	
of	ways.	 Its	role	 in	BACE-1	 inhibition	(Scholefield,	et	al.	2003),	alongside	 its	ability	to	sequester	Aβ	
peptides	and	 induce	fibrilisation	 into	fibrils	and	eventually	mature	plaques	(McLaurin,	et	al.	1999),	
make	it	a	key	target	for	further	investigation	and	drug	discovery.	Importantly,	the	structure	of	HS	is	
key	 in	 these	 interactions	 and	 as	 such,	 understanding	 the	 upstream	 causes	 of	 these	 structural	
changes	will	prove	invaluable	in	further	elucidating	the	in	vivo	role	of	HS.	The	relative	expression	of	
the	 various	 HS	 biosynthetic	 enzymes	 is	 an	 obvious	 upstream	 cause	 of	 the	 structural	 changes	
observed	in	HS.	The	structural	differences	as	observed	in	the	previous	chapter	would	 indicate	that	
those	biosynthetic	enzymes	responsible	 for	sulfation	modification	events	are	expressed	differently	
in	those	patients	suffering	from	AD	vs.	their	age-matched	counterparts	and	may	offer	a	mechanism	
by	which	HS	is	altered	between	these	two	study	groups.		
	
3.2	Aims	of	this	chapter	
	
1. Determine	 whether	 there	 is	 altered	 expression	 of	 HS-related	 genes	 in	 middle	 temporal	
gyrus	tissue	from	AD	patients	vs.	age-matched	controls.	
2. Determine	whether	there	is	any	correlation	between	expressions	of	HS	metabolic	enzymes	
and	prevalence	of	specific	HS	disaccharides.	
	
3.3	Methods		
3.3.1	Quantitative	real	time	polymerase	chain	reaction		
	
Due	to	limited	supplies	of	each	of	the	AD	and	age-matched	control	samples,	optimisation	of	
qRT-PCR	 protocol	 was	 carried	 out	 with	 RNA	 from	 HEK293T	 cells	 (ATCC).	 Optimisation	 of	 primer	
concentrations,	protocol	measures	and	analyses	were	practiced	with	this	cell	line	before	carried	out	
on	the	tissue	samples	to	assess	potential	changes	in	the	expression	of	key	genes.	HEK293T	cells	were	
grown	in	DMEM	media	(Gibco,	UK)	supplemented	with	foetal	bovine	serum	(FBS),	1mM	L-glutamine	
(Gibco,	UK)	and	1%	of	penicillin/streptomycin	(Gibco,	UK).	Cells	were	grown	to	~90%	confluence	and	
harvested	 ready	 for	 RNA	 extraction.	 Following	 optimisation,	 RNA	 extraction	 and	 qRT-PCR	 was	
carried	out	on	human	AD	and	age-matched	control	sample	brain	tissue.		
	
3.3.1.1	Manual	real	time	polymerase	chain	reaction		
3.3.1.1.1	RNA	extraction	
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To	minimise	the	risk	of	RNase	contamination,	vessels	and	pipette	tips	used	in	the	reaction	
were	 autoclaved	 and	 RNase	 Zap	 (Thermo	 Fisher	 Scientific,	 UK)	 was	 used	 to	 clean	 experimental	
workspace.	For	the	brain	samples	to	be	analysed,	an	RNeasy®	(Qiagen	Cat	no:	74134)	RNA	extraction	
kit	 was	 used	 according	 to	 manufacturer’s	 instructions.	 Briefly,	 20mg	 of	 brain	 tissue	 from	 each	
patient	 was	 homogenised	 in	 350μl	 of	 lysis	 buffer	 RLT	 Plus.	 Homogenisation	was	 achieved	with	 a	
hand-held	automatic	homogeniser	(VWR,	UK)	in	a	sterile	RNase-free	ependorf	tube.	The	lysate	was	
then	centrifuged	for	3min	at	13,000	x	g	before	removing	the	supernatant	and	transferring	to	a	gDNA	
Eliminator	 spin	 column	and	 collection	 tube.	 The	 spin	 column	was	 centrifuged	 for	 a	 further	 30s	 at	
8,000	x	g	and	the	flow	through	kept	for	the	next	step.	350μl	of	70%	ethanol	was	then	added	to	the	
flow-through	and	mixed	well	by	pipetting.	Samples	were	next	transferred	to	an	RNeasy	spin	column	
and	centrifuged	for	15s	at	8,000	x	g	and	the	flow-through	discarded.	700μl	of	buffer	RW1	was	added	
and	 centrifuged	 for	 15s	 at	 8,000	 x	 g	 and	 the	 flow-through	 discarded	 again.	 This	was	 followed	 by	
500μl	of	 buffer	RPE	and	a	 further	 spin	 for	 15s	 at	 8,000	 x	 g.	A	 second	500μl	 aliquot	of	buffer	RPE	
ensured	 complete	 washing	 of	 the	 column	 before	 adding	 30μl	 of	 RNase-free	 water	 to	 the	 spin	
column	membrane.	 Samples	were	 spun	 for	 a	 further	min	 at	 8,000	 x	 g	 to	 elute	 the	 purified	 RNA.	
Extracted	 RNA	 was	 immediately	 used	 to	 synthesise	 cDNA	 in	 preparation	 for	 qRT-PCR	 steps.	 A	
NanoDropTM	 2000	 spectrophotometer	 (Thermo	 Fisher	 Scientific,	 UK)	 was	 used	 to	 assess	 the	
concentration	 and	 purity	 of	 the	 RNA	 extracted	 from	 samples.	 A	 A260/A230	 ratio	 of	 ≥1.8	 and	 a	
A260/A280	ratio	between	1.8	and	2.1	was	used	as	a	threshold	for	RNA	to	be	taken	forward	for	use	in	
qRT-PCR	reactions.		
	
3.3.1.1.2	cDNA	synthesis	
	
cDNA	synthesis	was	carried	out	using	Reverse	Transcriptase	Transcriptor™	(Roche,	UK	Cat	
no:	 03531317001)	 according	 to	 manufacturer’s	 instructions.	 This	 step	 allowed	 synthesis	 of	 first	
strand	 cDNA	 for	 qRT-PCR	 steps	 to	 follow.	 Into	 a	 0.2ml	 microfuge	 PCR	 tube,	 according	 to	
manufacturer’s	protocol,	11μl	of	the	newly	synthesised	template	RNA	was	added,	followed	by	6μl	of	
random	p(dN)6	*50	A260	units	(Roche,	UK	Cat	no:	11034731001)	to	a	final	concentration	of	0.08	A260	
units	(3.2μg).	This	mixture	was	then	incubated	at	65°C	for	10min	before	being	 immediately	placed	
on	ice.	This	incubation	step	ensured	the	denaturation	of	RNA	secondary	structures.		
	
Following	 this,	 4μl	 of	 Transcriptor	 RT	 reaction	 buffer	 5x	 (Roche,	 UK)	 was	 added	 to	 the	
microfuge	tube,	followed	by	0.5μl	(20U)	of	Protector	RNase	inhibitor	(Roche,	UK).	Next,	2μl	of	10mM	
dNTP-Mix	was	 added	 followed	 by	 0.5μl	 (10U)	 of	 the	 Transcriptor	 Reverse	 Transcriptase™	 (Roche,	
UK).	The	microfuge	tube	was	mixed	and	centrifuged	briefly	before	being	put	in	a	Thermo	Scientific	
Hybrid	PX2	 thermal	 cycler	 (Thermo	Fisher	 Scientific,	UK)	 and	a	 two-step	 incubation	 carried	out	 to	
allow	efficient	annealing.	Samples	were	first	incubated	for	10min	at	25°C	followed	by	30min	at	55°C.	
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The	 reverse	 transcriptase	 was	 then	 inactivated	 by	 heating	 to	 85°C	 for	 5min.	 The	 tube	 was	
immediately	placed	on	ice	and	stored	at	-25°C	ready	for	the	qRT-PCR	reaction.		
	
3.3.1.1.3	Design	of	PCR	primers	and	probes		
Primers	 were	 purchased,	 pre-validated	 from	 GeneCopoeia	 in	 Maryland,	 USA.	 All	 in	 one	
mixes	were	purchased	containing	a	mixture	of	the	upstream	and	downstream	detection	primers	for	
qRT-PCR.	 All	 primers	 were	 dissolved	 in	 TE	 (10mM	 Tris-Cl,	 1mM	 EDTA)	 and	 used	 at	 a	 final	
concentration	of	 0.2	μM	per	well.	 Full	 sequences	were	undisclosed	however	 primer	 identification	
and	IDs	are	included	in	Table	3.1.	
	
Table	 3.1:	Primers	 used	 for	 qRT-PCR	 study	of	 gene	 expression	of	HS-related	metabolic	 enzymes	
and	core	proteins.	Primers	were	purchased	pre-validated	from	GeneCopoeia	in	Maryland	USA.	*	The	
GAPDH	 reference	 gene	 was	 selected	 as	 a	 control.	 Specific	 sequences	 are	 undisclosed	 however	
Primer	ID’s	are	listed	above.	
	
Gene	name	 Primer	ID	
Final	conc.	
per	well	
HS6ST1		-	Heparan	sulfate	6-O	sulfotransferase	1	 HQP022653	 0.2μM	
HS6ST2	–	Heparan	sulfate	6-O	sulfotransferase	2	 HQP021871	 0.2	μM	
HS6ST3	–	Heparan	sulfate	6-O	sulfotransferase	3	 HQP007336	 0.2	μM	
HS2ST1	–	Heparan	sulfate	2-O	sulfotransferase	1	 HQP064242	 0.2	μM	
HS3ST1	–	Heparan	sulfate	3-O	sulfotransferase	1	 HQP023407	 0.2	μM	
HS3ST2	–	Heparan	sulfate	3-O	sulfotransferase	2	 HQP023406	 0.2	μM	
HS3ST4	–	Heparan	sulfate	3-O	sulfotransferase	4	 HQP023403	 0.2	μM	
HS3ST5	-	Heparan	sulfate	3-O	sulfotransferase	5	 HQP005363	 0.2μM	
NDST1	–	N-deacetylase/N-sulfotransferase	1	 HQP071495	 0.2μM	
NDST2	–	N-deacetylase/N-sulfotransferase	2	 HQP021133	 0.2μM	
NDST3	–	N-deacetylase/N-sulfotransferase	3	 HQP022574	 0.2μM	
NDST4	–	N-deacetylase/N-sulfotransferase	4	 HQP017045	 0.2μM	
SULF1	–	Sulfatase	1	 HQP058565	 0.2μM	
SULF2	–	Sulfatase	2	 HQP064803	 0.2μM	
GLCE	–	C5	epimerase	 HQP006988	 0.2μM	
AGRN	–	Agrin	 HQP067787	 0.2μM	
GAPDH*	-	Glyceraldehyde-3-Phosphate	Dehydrogenase	 HQP064347	 0.2μM	
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3.3.1.1.4	Protocol	design		
qRT-PCR	 reactions	 were	 carried	 out	 in	 a	 final	 volume	 of	 20μl	 per	 well,	 according	 to	 the	
manufacturer’s	specifications,	using	20ng	(in	5μl)	of	the	cDNA	template,	with	2μl	of	primer	(0.2μM	
final	 concentration),	 10μl	 of	 LightCycler®	 480	 SYBR	 Green	 I	 Master	 mix	 (Roche,	 UK	 Cat	 no:	
04707516001)	 and	 3μl	 of	 PCR-grade	 water	 (Roche,	 UK).	 Reaction	 volumes	 were	 assembled	 into	
white,	96	well	plates	(Roche,	UK)	with	triplicate	wells	for	each	primer	and	each	sample.	The	plates	
were	 sealed	 with	 optical	 film	 and	 centrifuged	 at	 2,000	 x	 g	 for	 5min	 before	 being	 placed	 in	 a	
LightCycler	480®	system	(Roche,	UK).	The	following	cycling	conditions	were	maintained	as	described	
in	Table	3.2a	and	b.	qRT-PCR	was	performed	using	the	LightCycler®	480	Roche	machine	(Roche,	UK).	
		
3.3.1.1.5	Statistical	analysis	
	
Expression	levels	were	normalised	to	Glyceraldehyde	3-Phosphate	Dehydrogenase	(GAPDH)	
levels	and	the	delta-delta	Ct	method	was	used	to	calculate	the	relative	change	in	expression	of	the	
HS-related	 genes	 of	 interest	 from	 AD	 and	 age-matched	 control	 brain	 samples,	 assuming	 primer	
efficiency.	 In	 this	 instance,	 the	 relative	change	 in	gene	expression	compared	 to	normal	 conditions	
was	calculated	as:	
	
Table	 3.2a:	 List	 of	 programs	 used	 for	 qRT-PCR	 on	 the	 LightCycler	 480	 machine.	 Each	 sample	
underwent	45	amplification	cycles.	
Program	name	 Cycles	 Analysis	mode	
Pre-incubation	 1	 None	
Amplification	 45	 Quantification	
Melting	Curve	 1	 Melting	Curve	
Cooling	 1	 None	
	
Table	3.2b:	Breakdown	of	incubation	steps	used	for	qRT-PCR.	
Step	 Target	°C	 Acquisition	 Hold	hh:mm:ss	 Ramp	°C	
Pre-Incubation	 95	 None	 00:05:00	 4.4	
Amplification	
95	
60	
72	
None	
None	
Single	
00:00:10	
00:00:10	
00:00:10	
4.4	
2.2	
4.4	
Melting	Curve	
95	
70	
95	
None	
None	
Continuous	
00:00:10	
00:01:00	
-	
4.4	
2.2	
Cooling	 40	 None	 00:00:30	 1.5	
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Fold	change	=	2-ΔΔCt	=	[(Ct	gene	of	interest	–	Ct	internal	control)	sample	A	–	(Ct	gene	of	interest	–	Ct	
internal	control)	sample	B)]	
	
• Internal	control	=	GAPDH	(reference	housekeeping	genes)	
• Sample	A	=	Alzheimer’s	patients	(diseased	state)	
• Sample	B	=	Age-matched	controls	(“normal”	state)	
	
All	analyses	were	expressed	as	the	fold	change	of	expression	of	the	gene	of	interest	relative	to	
the	internal	control	in	the	diseased	samples	as	compared	with	the	age-matched	controls.	Using	the	
Ct	method	of	analysis	allowed	fold	changes	of	expression	to	be	calculated	for	each	gene	of	interest	
with	respect	to	the	disease	state	(AD	samples).		
	
All	PCR	reactions	were	carried	out	in	triplicate.	Experimental	triplicates	were	combined	and	
the	mean	calculated	and	data	for	individual	sample	groups	were	also	averaged	(4	AD	patients	and	8	
age-matched	control	patients).	Values	of	2-ΔΔCt	were	logged	to	generate	positive	and	negative	values	
indicative	of	up	and	down	regulated	expression	of	target	genes.		
	
3.3.1.2	TaqMan®	low	density	array	microfluidic	cards		
**All	 TaqMan®	 array	 analysis	 was	 carried	 out	 at	 the	 Kennedy	 Institute	 of	 Rheumatology	 at	 the	
University	of	Oxford	 in	 the	Troeberg	 Lab,	with	 the	help	of	Dr.	Anastasios	Chanalaris	and	Dr.	 Linda	
Troeberg.	**	
	
The	TaqMan®	array	cards	are	384-well	microfluidic	cards	that	allow	384	simultaneous	real	
time	 PCR	 reactions	 in	 a	 high	 throughput	 manner	 that	 utilise	 a	 small	 volume	 design	 to	 minimise	
sample	 and	 reagent	 consumption	 and	 to	 avoid	 labour	 intensive	 steps.	 These	 array	 cards	 were	
custom	designed	to	probe	for	selected	HS	biosynthetic	target	genes.	A	total	of	8	samples	could	be	
run	per	card	allowing	the	analysis	of	48	genes	(36	of	which	were	HS-related	gene	specific)	including	
endogenous	 housekeeping	 controls.	 This	 technique	was	 done	 to	 both	 validate	 the	 findings	 of	 the	
manual	qRT-PCR	and	to	also	screen	a	larger	number	of	gene	targets	with	much	smaller	quantities	of	
cDNA,	something	of	a	premium	in	the	small	sample	sizes	obtained	from	the	Oxford	Brain	Bank.		
	
3.3.1.2.1	RNA	extraction	
	
RNA	from	AD	and	age-matched	control	brain	samples	was	extracted	in	the	same	manner	(at	
the	University	of	Liverpool	before	transport	to	Oxford)	as	described	previously	in	section	3.3.1.1.1.	
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3.3.1.2.2	cDNA	synthesis	
	
	 For	the	conversion	of	RNA	to	cDNA	for	TaqMan®	array	expression	profiling,	a	High	Capacity	
cDNA	Reverse	Transcription	Kit	 (cat	no:	4368814)	 (Thermo	Fisher,	UK)	was	used,	according	 to	 the	
manufacturer’s	 instructions	 to	 convert	 extracted	 RNA	 to	 cDNA.	 Briefly,	 using	 the	 kit	 component	
reagents,	a	2x	reverse	transcription	master	mix	was	prepared	(10μl	per	reaction	volume)	with	2μl	of	
10x	 RT	 buffer,	 0.8μl	 of	 25	 x	 dNTP	 mix	 (100mM),	 2.0μl	 of	 10x	 RT	 random	 primers,	 1.0μl	 of	
MultiScribe™	Reverse	Transcriptase,	1.0μl	of	RNase	Inhibitor	and	3.2μl	of	nuclease	free	H2O.	
	
	 Following	preparation	of	the	master	mix,	10μl	was	transferred	to	thin	walled	PCR	tubes	and	
10μl	 of	 sample	 RNA	 (prepared	 to	 500ng	 and	 the	 total	 volume	made	 up	 with	 nuclease	 free	 H2O)	
added	before	mixing	gently	and	centrifuging	briefly.	 Samples	were	 then	placed	 in	a	 thermo	cycler	
and	heated	to	25°C	for	10min,	37°C	for	120min	and	finally	85°C	for	5min	before	cooling	at	4°C.	Once	
complete,	the	newly	synthesised	cDNA	was	stored	at	-20°C	until	ready	for	use	in	the	TaqMan®	array.	
	
3.3.1.2.3	PCR	primers	and	probes	
	
	 The	TaqMan®	array	card	was	custom	made	by	Applied	Biosystems	for	the	Troeberg	 lab	 in	
Oxford	 and	 contained	 48	 genes	 of	 interest	 including	 36	 of	 the	 HS	metabolic	 genes	 and	 the	 core	
proteins	onto	which	they	are	able	to	bind.	Details	of	these	gene	probes	and	their	IDs	are	outlined	in	
Table	3.3.	
	
3.3.1.2.4	TaqMan®	Array-card	protocol	
	
	 The	 TaqMan®	 Array	Micro	 Fluidic	 Card	 (Applied	 Biosystems,	 USA)	was	 prepared	 and	 run	
according	to	manufacturer’s	instructions.	Briefly,	following	RNA	extraction	and	cDNA	synthesis,	in	a	
1.5ml	 ependorf	 tube,	 per	 sample,	 100μl	 of	 total	 reaction	 mixture	 was	 made,	 containing	 50μl	 of	
cDNA	 template	 (200ng	 starting	 RNA)	 in	 nuclease	 free	 water	 and	 50μl	 of	 2X	 Universal	 PCR	 mix	
(Applied	Biosystems,	USA).	 Each	 sample	was	 then	vortexed	and	briefly	 centrifuged	before	 loading	
onto	 the	 card.	 Following	 loading,	 the	 card	 was	 centrifuged	 twice	 (1	 minute	 at	 12,000	 rpm	 and	
repeated,	 Sorvall	 centrifuge	 with	 custom	 buckets)	 before	 being	 sealed	 with	 the	microfluidic	 card	
sealer.	 Each	 TaqMan®	 card	 was	 run	 on	 the	 ViiA7	 thermocycler	 (Applied	 Biosystems,	 USA).	 The	
conditions	 for	 the	 reaction	was	 as	 follows;	 held	 for	 2	min	 at	 50°C,	 denatured	at	 10min	at	 94.5°C,	
followed	by	40	cycles	of	denaturing	at	97°C	for	30	sec	and	finally	annealing/extending	for	1	min	at	
60°C.	
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Table	3.3:	Details	of	gene	probes	printed	on	custom	TaqMan®	array	card.	
Gene	name	on	TaqMan®	array	
card	
Gene	ID	 Gene	Function	
18S	 Hs99999901_s1	 Housekeeping/Reference	gene*	
AGRN	 Hs00394748_m1	 HS	core	protein	
EXT1	 Hs00609162_m1	 HS	biosynthetic	enzyme	
EXT2	 Hs00181158_m1	 HS	biosynthetic	enzyme	
EXTL1	 Hs00184929_m1	 HS	biosynthetic	enzyme	
EXTL2	 Hs01018237_m1	 HS	biosynthetic	enzyme	
EXTL3	 Hs00918601_m1	 HS	biosynthetic	enzyme	
GLCE	 Hs00392011_m1	 HS	biosynthetic	enzyme	
GPC1	 Hs00892476_m1	 HS	core	protein	
GPC2	 Hs00415099_m1	 HS	core	protein	
GPC3	 Hs01018936_m1	 HS	core	protein	
GPC4	 Hs00155059_m1	 HS	core	protein	
GPC5	 Hs00270114_m1	 HS	core	protein	
GPC6	 Hs00170677_m1	 HS	core	protein	
HPSE2	 Hs00222435_m1	 HS	biosynthetic	enzyme	
HPSE	 Hs00935036_m1	 HS	biosynthetic	enzyme	
HS2ST1	 Hs00202138_m1	 HS	biosynthetic	enzyme	
HS3ST1	 Hs00245421_s1	 HS	biosynthetic	enzyme	
HS3ST2	 Hs00428644_m1	 HS	biosynthetic	enzyme	
HS3ST3A1	 Hs00925624_s1	 HS	biosynthetic	enzyme	
HS3ST3B1	 Hs00797512_s1	 HS	biosynthetic	enzyme	
HS3ST4	 Hs00901124_s1	 HS	biosynthetic	enzyme	
HS3ST5	 Hs00999394_m1	 HS	biosynthetic	enzyme	
HS3ST6	 Hs03007244_m1	 HS	biosynthetic	enzyme	
HS6ST1	 Hs00757137_m1	 HS	biosynthetic	enzyme	
HS6ST2	 Hs02925656_m1	 HS	biosynthetic	enzyme	
HS6ST3	 Hs00542178_m1	 HS	biosynthetic	enzyme	
HSPG2	 Hs00194179_m1	 HS	core	protein	
NDST1	 Hs00925442_m1	 HS	biosynthetic	enzyme	
NDST2	 Hs00234335_m1	 HS	biosynthetic	enzyme	
NDST3	 Hs01128584_m1	 HS	biosynthetic	enzyme	
NDST4	 Hs00224024_m1	 HS	biosynthetic	enzyme	
RPLP0	 Hs99999902_m1	 Housekeeping/Reference	gene*	
SDC1	 Hs00896423_m1	 HS	core	protein	
SDC2	 Hs00299807_m1	 HS	core	protein	
SDC3	 Hs01568665_m1	 HS	core	protein	
SULF1	 Hs00290918_m1	 HS	remodelling	enzyme	
SULF2	 Hs01016476_m1	 HS	remodelling	enzyme	
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3.3.1.2.5	Statistical	analysis	
	
Expression	 levels	were	normalised	to	 the	housekeeping	60S	ribosomal	protein	P0	 (RPLP0)	
and	 ribosomal	 RNA	 (18S)	 levels	 and	 the	 delta	 delta	 Ct	method	was	 used	 to	 calculate	 the	 relative	
change	 in	 expression	 of	 the	 HS	 biosynthetic	 genes	 of	 interest	 from	 AD	 and	 age-matched	 control	
brain	samples,	assuming	primer	efficiency.	In	this	instance,	the	relative	change	in	gene	expression	of	
HS	biosynthetic	enzymes	compared	to	normal	conditions	was	calculated	as:	
	
Fold	change	=	2-ΔΔCt	=	[(Ct	gene	of	interest	–	Ct	internal	control)	sample	A	–	(Ct	gene	of	interest	–	Ct	
internal	control)	sample	B)]	
	
• Internal	control	=	RPLP0	and	18S	(reference	housekeeping	genes)	
• Sample	A	=	Alzheimer’s	patients	(diseased	state)	
• Sample	B	=	Age-matched	controls	(“normal”	state)	
	
All	analyses	were	expressed	as	the	fold	change	of	expression	of	the	gene	of	interest	relative	to	
the	internal	control	in	the	diseased	samples	as	compared	with	the	age-matched	controls.	
	
The	 Ct	method	 of	 analysis	 allowed	 fold	 changes	 of	 expression	 to	 be	 calculated	 for	 each	
target	gene	with	respect	to	the	diseased	state.	All	reactions	were	carried	out	in	triplicate.	The	mean	
of	experimental	triplicates	was	calculated	and	data	for	individual	samples	were	also	averaged	(11	AD	
patients	and	11	healthy	controls	in	each	group).	Values	of	2-ΔΔCt	were	logged	to	generate	positive	and	
negative	values	indicative	of	up	and	down	regulated	expression	of	target	genes.		
	
3.4	Results		
3.4.1	Quantitative	real	time	PCR	of	HS-related	genes		
3.4.1.1	Manual	real	time	polymerase	chain	reaction	
	
Analysis	of	 the	expression	of	HS-related	genes	by	manual	qRT-PCR	was	carried	out	on	AD	
(n=4)	and	healthy	age-matched	controls	(n=8).	Expression	of	HS-related	genes	were	calculated	with	
manual	qRT-PCR	and	normalised	with	respect	to	GAPDH	gene	levels	and	the	delta	delta	Ct	method	
use	 to	 calculate	 the	 relative	 change	 in	 expression	 of	 these	 genes,	 assuming	 pre-optimised	 primer	
efficiency	 (data	not	 shown).	Mean	 (±S.E.M)	 fold	 changes	of	 the	expression	of	HS-related	genes	as	
recorded	in	AD	and	healthy	age-matched	control	patients	are	displayed	in	Table	3.4.	No	statistically		
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Table	 3.4:	 Data	 collected	 from	manual	 qRT-PCR	 studies.	 HS	 biosynthetic	 and	 core	 protein	 genes	
were	profiled	in	AD	(n=4)	and	healthy	age-matched	control	patients	(n=8)	brain	samples	using	qRT-
PCR.	 RNA	 was	 purified	 from	 samples	 and	 converted	 to	 cDNA	 followed	 by	 qRT-PCR.	 All	 changes	
presented	 are	 relative	 to	healthy	 controls	 and	normalised	 to	 the	GAPDH	 housekeeping	 gene.	 The	
delta	delta	CT	method	was	used	for	analysis	and	are	the	log2	fold	changes	presented	below.		
Gene	
Name	
Gene	ID	
(GeneCopoeia	
ref)	
Mean	log	(fold	
change)	in	AD	
±S.E.M	(n=4)	
Mean	log	(fold	
change)	in	Ctrl	
±S.E.M	(n=8)	
Up/Down	
reg.	in	AD	
vs.	Ctrl	
T-test	p-
value	
p<0.05*	
NDST1	 HQP071495	 1.304	±	1.62	 1.25e-010	±	0.45	 UP	 0.3265	
NDST2	 HQP021133	 0.4501	±	1.88	 1.25e-010	±	0.76	 UP	 0.7927	
NDST3	 HQP022574	 11.21	±	8.45	 -1.25e-010	±	0.756	 UP	 0.0809	
NDST4	 HQP017045	 -2.249	±	9.64	 -1.875e-009	±	5.94	 DOWN	 0.8388	
HS6ST1	 HQP022653	 1.07	±	1.64	 1.25e-010	±	0.72	 UP	 0.4972	
HS6ST2	 HQP021871	 -2.142	±	9.52	 -1e-009	±	5.70	 DOWN	 0.8416	
HS6ST3	 HQP007336	 4.794	±	5.12	 1.25e-010	±	0.82	 UP	 0.2165	
HS2ST1	 HQP064242	 9.898	±	7.68	 0.00	±	0.63	 UP	 0.0878	
GLCE	 HQP006988	 10.26	±	8.49	 1.25e-010	±	1.30	 UP	 0.1181	
AGRN	 HQP067787	 9.966	±	8.55	 -1.25e-010	±	0.58	 UP	 0.1161	
SULF1	 HQP058565	 1.89	±	3.18	 2.5e-010	±	0.45	 UP	 0.4165	
SULF2	 HQP064803	 2.022	±	2.23	 0.00	±	0.57	 UP	 0.2640	
HS3ST1	 HQP023407	 -5e-010	±	4.32	 -5.081	±	8.52	 UP	 0.5642	
HS3ST2	 HQP023406	 6.341	±	8.49	 0	±	4.44	 UP	 0.4774	
HS3ST4	 HQP023403	 8.405	±	8.14	 -6.25e-010	±	4.10	 UP	 0.3224	
HS3ST5	 HQP005363	 1.152	±	9.19	 -2.5e-010	±	5.82	 UP	 0.9144	
	
significant	 changes	 were	 detected	 by	 manual	 qRT-PCR,	 though	 some	 strong	 trends	 for	 altered	
expression	were	noted	for	NDST3,	HS2ST1,	SULF2,	HS6ST2,	AGRN	and	GLCE	genes.	This	absence	of	
statistical	significance	may	be	due	to	a	combination	of	patient	variability	and	small	sample	size.	
	
Analysis	of	expression	of	the	NDST	genes	(which	code	for	NDST	enzymes	that	catalyse	the	
removal	of	an	acetyl	group	and	the	addition	of	a	sulfate	group	along	the	HS	chain)	revealed	variable	
changes	 in	expression	 in	 the	presence	of	 the	AD	phenotype.	The	NDST1,	NDST2	and	NDST3	genes	
were	 found	 to	be	up-regulated	with	AD	 relative	 to	age-matched	controls	with	mean	 (±S.E.M)	 fold	
changes	 of	 1.30	 (±1.62),	 0.45	 (±1.88)	 and	 11.21	 (±8.45)	 recorded	 respectively.	NDST3	 expression	
exhibited	 the	 strongest	 trend	 of	 this	 family	 however	 fell	 just	 short	 of	 statistical	 significance	
(p=0.081).	Conversely,	the	NDST4	gene	was	down	regulated	with	a	mean	(±S.E.M)	fold	change	of	-
2.25	(±9.64).	
	
Expression	 of	 the	 HS2ST1	 gene	 (which	 codes	 for	 the	 HS2ST	 enzyme	 that	 catalyses	 the	
addition	of	a	sulfate	group	to	the	2-O	position	of	the	HS	chain)	exhibited	the	next	strongest	trend	
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with	a	recorded	increase	in	expression	with	AD	with	respect	to	the	GAPDH	housekeeping	gene	and	
healthy	age-matched	control	samples.	A	mean	(±S.E.M)	fold	change	of	9.90	(±7.68)	was	observed	in	
this	instance	and	may	be	indicative	of	an	increase	in	the	sulfation	at	the	2-O	position	of	the	HS	chain.	
Despite	a	strong	trend,	this	did	not	quite	reach	statistical	significance	(p=0.088).	
	
Quantitative	 analysis	 of	 the	 expression	of	 the	HS6ST	 family	 of	 genes	 (which	 code	 for	 the	
HS6ST	 enzymes	 that	 catalyse	 the	 addition	of	 a	 sulfate	 group	 to	 the	 6-O	position	of	 the	HS	 chain)	
revealed	variable	regulation	with	the	AD	phenotype.	The	HS6ST1	gene	displayed	a	trend	towards	up-
regulation	 with	 a	 mean	 (±S.E.M)	 fold	 change	 of	 1.07	 (±1.64)	 in	 AD	 patients	 relative	 to	 healthy	
controls	alongside	the	HS6ST3	gene	that	also	displayed	increased	expression	with	a	mean	(±	S.E.M)	
fold	change	of	4.79	 (±5.12).	Despite	 the	strong	 trend	 for	 increased	expression	of	HS6ST3	with	AD,	
larger	error	bars	meant	 this	 change	 fell	 short	of	 statistical	 significance	 (p=0.217).	 	 In	 contrast,	 the	
HS6ST2	 gene	displayed	decreased	expression	 in	 those	patients	with	AD	with	a	mean	 (±S.E.M)	 fold	
change	in	expression	of	-2.14	(±9.52).		
	
Expression	of	the	SULF2	gene	(that	codes	for	the	SULF2	enzyme	that	catalyse	the	removal	
of	 a	 sulfate	 group	 at	 the	 6-O	 position	 along	 the	HS	 chain)	 displayed	 the	 next	 strongest	 trend	 for	
change	 in	 expression	with	 the	AD	 phenotype	with	 a	 recorded	mean	 (±S.E.M)	 fold	 change	 of	 2.02	
(±2.23)	(p=0.264).	Expression	of	the	SULF1	gene	followed	a	similar,	however	less	strong	trend	for	up	
regulation	with	the	AD	phenotype	with	mean	(±S.E.M)	fold	change	of	1.89	(±3.18)	(p=0.417).	
	
Finally,	strong	trends	for	changes	in	expression	with	the	AD	phenotype	were	recorded	for	
the	GLCE	gene	(responsible	for	the	epimerisation	of	GlcA	to	IdoA)	with	a	mean	(±S.E.M)	fold	change	
in	 expression	 of	 10.26	 (±8.49)	 relative	 to	 healthy	 age-matched	 controls.	 This	 change	 fell	 short	 of	
statistical	significance	despite	a	strong	trend	for	up-regulation	(p=0.118).	In	addition,	expression	of	
the	core	protein	gene	AGRN,	displayed	a	strong	trend	for	up-regulation	with	the	AD	phenotype	with	
a	recorded	mean	(±S.E.M)	fold	change	of	9.97	(±8.55)	(p=0.116).	
	
Changes	 in	 the	 expression	of	 the	HS3ST	 gene	 family	 did	 not	 reveal	 any	 strong	 trends	 for	
changes	 in	 expression	 with	 the	 AD	 phenotype.	 The	 HS3ST4	 gene	 presented	 the	 biggest	 mean	
(±S.E.M)	 fold	 change	 in	 expression	of	 8.41	 (±8.14)	whilst	 the	HS3ST2	 and	HS3ST1	 genes	displayed	
mean	(±S.E.M)	fold	changes	of	6.34	(±8.49)	and	5.08	(±8.62)	respectively.	The	HS3ST5	gene	displayed	
the	most	modest	increase	in	expression	with	a	mean	(±S.E.M)	fold	change	of	1.15	(±9.19)	observed.		
The	 large	 variation	 between	 samples	 is	 likely	 the	 reason	 why	 these	 fold	 changes	 did	 not	 reach	
statistical	significance	on	this	occasion.		
	
Overall,	 manual	 qRT-PCR	 as	 carried	 out	 here,	 suggested	 the	 possibility	 of	 significant	
alterations	in	HS	related-gene	expression	profiles	in	AD,	but	was	not	conclusive.	It	was	hypothesised	
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that	 larger	numbers	of	 samples	would	need	 to	be	analysed	 to	observe	 significant	 changes.	 Strong	
trends	to	indicate	changes	in	the	expression	of	the	SULF2,	NDST3,	HS6ST3,	HS2ST1,	GLCE	and	AGRN	
genes	may	go	some	way	to	account	 for	the	structural	changes	 in	HS	as	observed	 in	chapter	2	and	
may	offer	an	upstream	mechanism	by	which	some	of	these	changes	may	be	mediated.		
	
3.4.1.2	TaqMan®	low	density	array	microfluidic	cards	 	
	
Analysis	 of	 gene	 expression	 using	 TaqMan®	 array	 fluidic	 cards	 revealed	 changes	 in	 the	
expression	 of	 HS	 biosynthetic	 enzyme	 genes	 and	 core	 protein	 genes.	 	 AD	 (n=11)	 and	 Ctrl	 (n=11)	
patient	 HS	 samples	 were	 screened	 for	 the	 expression	 of	 36	 HS-related	 genes.	 Results	 were	
compared	to	the	relative	expression	of	the	RPLP0	and	18S	housekeeper	genes	whilst	also	relative	to	
the	expression	of	the	healthy	controls.	The	delta	delta	CT	method	was	used	for	analysis	as	described	
previously.	Results,	for	the	most	part,	matched	those	found	with	manual	qRT-PCR,	but	also	allowed	
for	 a	much	more	 extensive	 profiling	 of	 HS-related	 genes.	 Details	 of	 log2	 fold	 changes	 (±S.E.M)	 in	
expression	are	detailed	in	Table	3.5.	
	
	 	 Significant	changes	in	expression	were	observed	in	AD	(relative	to	housekeeper	genes	and	
healthy	 controls)	 in	 the	AGRN,	 HS3ST2,	HS6ST1,	HSPG2	 and	NDST1	 genes.	 The	AGRN	 and	HSPG2	
genes	 code	 for	 core	 proteins	 onto	which	HS	may	be	 covalently	 bound.	 Both	of	 these	 genes	were	
found	to	be	up-regulated	in	the	presence	of	the	AD	phenotype	with	mean	(±S.E.M)	fold	changes	of	
1.19	 (±0.28)	 (p=0.003,	 Student’s	 t-test)	 and	 1.40	 (±0.51)	 (p=0.041,	 Student’s	 t-test)	 recorded	
respectively	(Figure	3.1A-B).	Up-regulation	of	these	core	proteins	may	be	indicative	of	mechanisms	
to	regulate	quantity	of	total	HS	within	cells	and	its	location.	The	observed	increase	in	expression	of	
the	 AGRN	 gene	 here	 also	 matched	 that	 found	 with	 manual	 qRT-PCR	 as	 described	 previously	 in	
section	3.4.1.1.	
	 	
	 Furthermore,	 the	HS6ST1	 gene,	 coding	 for	 a	 6-O	 sulfotransferase	1	was	 also	 found	 to	be	
significantly	 up-regulated	with	 a	mean	 (±S.E.M)	 fold	 change	of	 1.30	 (±0.34)	 (p=0.012,	 Student’s	 t-
test),	 also	matching	 the	 results	 generated	with	manual	 qRT-PCR.	 This	 was	 in	 contrast	 to	 the	 3-O	
sulfotransferase	 2,	HS3ST2	 gene	 that	was	 significantly	 down	 regulated	with	 a	mean	 (±S.E.M)	 fold	
change	 of	 -1.10	 (±0.35)	 (p=0.029,	 Student’s	 t-test)	 (Figure	 3.2A-B).	 Here,	 TaqMan®	 analysis	
contradicted	 that	 of	manual	 qRT-PCR	 that	 had	 reported	 a	 trend	 for	 up-regulation	 of	 the	HS3ST2	
gene	(but	was	not	statistically	significant).	
	
	 	 A	 significant	 up-regulation	 was	 also	 observed	 for	 the	 NDST1	 gene,	 coding	 for	 the	 N-
deacetylase/N-sulfotransferase	 1	 enzyme.	 A	mean	 (±S.E.M)	 fold	 change	 of	 1.23	 (±0.40)	 (p=0.011,	
Student’s	 t-test)	 was	 recorded	 (Figure	 3.3).	 Again,	 this	 change	matched	 the	 trend	 reported	 with
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Table	3.5:	Data	from	TaqMan	array	card.	HS-related	genes	were	profiled	in	AD	(n=11)	and	healthy	
age-matched	 control	 patients	 (n=11)	 brain	 samples	 using	 a	 custom	made	 TaqMan	 array	 card.	 All	
changes	presented	below	are	relative	to	healthy	age-matched	controls	and	normalized	to	the	Rplp0	
and	18s	 housekeeping	 genes.	 The	 delta	 delta	 CT	method	was	 used	 for	 analysis	 and	 the	 log2	 fold	
changes	 presented	 below.	 Those	 genes	 found	 to	 be	 expressed	 significantly	 altered	 in	 AD	 are	
displayed	in	bold.		
Gene	
Name	 Gene	ID	
Mean	log	(fold	
change)	in	Ctrl	±	
S.E.M	(n=11)	
Mean	log	(fold	
change)	in	AD	±	
S.E.M	(n=11)	
Up/Do
wn	reg.	
in	AD	
vs.	Ctrl	
t-test	p-
value	
P<0.05*	
AGRN	 Hs00394748_m1	 -1.45E-15	±	0.24	 1.19	±	0.29	 UP	 0.003**	
EXT1	 Hs00609162_m1	 2.67E-16	±	0.29	 0.51	±	0.43	 UP	 0.313	
EXT2	 Hs00181158_m1	 4.74E-16	±	0.29	 0.50	±	0.48	 UP	 0.359	
EXTL1	 Hs00184929_m1	 1.07E-15	±	0.21	 -0.15	±	0.40	 UP	 0.726	
EXTL2	 Hs01018237_m1	 9.84E-16	±	0.42	 0.10	±	0.67	 UP	 0.900	
EXTL3	 Hs00918601_m1	 -5.12E-16	±	0.22	 0.87	±	0.40	 UP	 0.062	
GLCE	 Hs00392011_m1	 -7.78E-16	±	0.28	 1.43	±	0.81	 UP	 0.093	
GPC1	 Hs00892476_m1	 3.13E-16	±	0.14	 0.53	±	0.33	 UP	 0.140	
GPC2	 Hs00415099_m1	 -7.11E-16	±	0.27	 0.81	±	0.33	 UP	 0.069	
GPC3	 Hs01018936_m1	 9.69E-16	±	1.39	 1.49	±	2.08	 UP	 0.538	
GPC4	 Hs00155059_m1	 1.61E-16	±	0.23	 0.70	±	0.51	 UP	 0.203	
GPC5	 Hs00270114_m1	 1.08E-15	±	0.40	 0.97	±	0.49	 UP	 0.125	
GPC6	 Hs00170677_m1	 -3.53E-16	±	0.41	 1.47	±	0.72	 UP	 0.086	
HPSE	 Hs00935036_m1	 1.49E-15	±	0.34	 0.99	±	0.39	 UP	 0.059	
HPSE2	 Hs00222435_m1	 -4.64E-16	±	0.37	 1.11	±	0.45	 UP	 0.056	
HS2ST1	 Hs00202138_m1	 1.91E-15	±	0.25	 0.61	±	0.25	 UP	 0.243	
HS3ST1	 Hs00245421_s1	 3.40E-15	±	0.37	 1.15	±	0.77	 UP	 0.175	
HS3ST2	 Hs00428644_m1	 9.49E-16	±	0.32	 -1.10	±	0.35	 DOWN	 0.029*	
HS3ST3A1	 Hs00925624_s1	 -1.33E-15	±	0.72	 2.00	±	0.70	 UP	 0.091	
HS3ST3B1	 Hs00797512_s1	 0.00	±	0.34	 1.28	±	0.66	 UP	 0.085	
HS3ST4	 Hs00901124_s1	 -1.01E-15	±	0.25	 0.82	±	0.47	 UP	 0.122	
HS3ST5	 Hs00999394_m1	 5.15E-16	±	0.32	 0.47	±	0.48	 UP	 0.405	
HS6ST1	 Hs00757137_m1	 -6.66E-16	±	0.34	 1.30	±	0.36	 UP	 0.012*	
HS6ST2	 Hs02925656_m1	 -3.57E-15	±	0.76	 -0.13	±	0.65	 DOWN	 0.899	
HS6ST3	 Hs00542178_m1	 1.81E-16	±	0.29	 -0.53	±	0.39	 DOWN	 0.261	
HSPG2	 Hs00194179_m1	 -9.69E-16	±	0.41	 1.40	±	0.54	 UP	 0.041*	
NDST1	 Hs00925442_m1	 0.00	±	0.18	 1.23	±	0.42	 UP	 0.011*	
NDST2	 Hs00234335_m1	 -7.87E-16	±	0.31	 1.20	±	0.62	 UP	 0.085	
NDST3	 Hs01128584_m1	 -2.93E-16	±	0.29	 -0.10	±	0.51	 UP	 0.854	
NDST4	 Hs00224024_m1	 3.55E-16	±	0.87	 1.05	±	0.85	 UP	 0.467	
Chapter	3																																																																																										Analysis	of	the	expression	of	HS-related	genes	in	AD		
2017	 114	
SDC1	 Hs00896423_m1	 -1.08E-15	±	0.26	 0.59	±	0.83	 UP	 0.507	
SDC2	 Hs00299807_m1	 8.07E-16	±	0.28	 0.30	±	0.49	 UP	 0.589	
SDC3	 Hs01568665_m1	 -2.52E-17	±	0.20	 0.16	±	0.26	 UP	 0.617	
SDC4	 Hs00161617_m1	 1.76E-15	±	0.39	 -0.17	±	0.29	 DOWN	 0.712	
SULF1	 Hs00290918_m1	 -1.44E-15	±	0.27	 0.99	±	0.52	 UP	 0.097	
SULF2	 Hs01016476_m1	 -6.46E-16	±	0.34	 0.02	±	0.39	 UP	 0.966	
	
	
	
Figure	3.1A	–	B.	TaqMan®	array	profiling	of	AGRN	and	HSPG2	core	protein	gene	expression	is	altered	in	AD.	
Expression	of	HS	genes	from	AD	(n=11)	and	healthy	age-matched	controls	(n=11)	brain	samples	were	analysed	
on	a	custom	made	TaqMan®	array	card	and	the	delta	delta	CT	method	used	for	analysis.	All	expression	changes	
were	normalised	 to	healthy	controls	 and	the	RPLP0	 and	18S	housekeeper	 genes.	Of	 the	core	proteins,	Agrin	
(AGRN)	 (A)	and	Perlecan	(HSPG2)	 (B)	were	 found	to	be	up-regulated	with	significant	mean	(±S.E.M)	 log2	 fold	
changes	of	1.19	(±0.29)	and	1.40	(±0.54)	respectively.	p<0.05*;		p<0.01	**,	Student’s	t-test.	
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with	manual	 qRT-PCR,	however,	 perhaps	due	 to	 larger	 sample	 sizes;	 this	 result	 reached	 statistical	
significance	here.		
	
Other	genes	 studied	were	not	 found	 to	be	altered	significantly	 in	AD;	 this	was	consistent	
with	 findings	 from	 the	 manual	 qRT-PCR	 despite	 smaller	 sample	 sizes	 in	 the	 manual	 method.	
Likewise,	trends	in	expression	levels	suggested	that	other	key	sulfotransferases	such	as	the	genes	for	
the	HS6ST2	and	HS6ST3	enzymes	were	down	regulated	in	the	presence	of	the	AD	phenotype	with	
	
Figure	3.2A	–	B.	TaqMan®	array	profiling	of	HS6ST1	and	HS3ST2	sulfotransferase	gene	expression	is	altered	in	
AD.	 Expression	 of	 HS	 genes	 from	 AD	 (n=11)	 and	 healthy	 age-matched	 controls	 (n=11)	 brain	 samples	 were	
analysed	on	a	custom	made	TaqMan®	array	card	and	the	delta	delta	CT	method	used	for	analysis.	All	expression	
changes	 were	 normalized	 to	 healthy	 controls	 and	 the	 RPLP0	 and	 18S	 housekeeper	 genes.	 Of	 the	
sulfotransferases,	 heparan-sulfate	 6-O-sulfotransferase	 1	 (HS6ST1)	 (A)	 and	 heparan-sulfate	 3-O-
sulfotrasnferase	2	 (HS3ST2)	 (B)	were	 found	to	be	up-	and	down-regulated	respectively	with	significant	mean	
(±S.E.M)	log2	fold	changes	of	1.30	(±	0.36)	and	-1.10	(±	0.35)	respectively.	p<0.05	*	Student’s	t-test.	
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mean	(±S.E.M)	fold	changes	of	-0.13	(±0.65)	(p=0.899,	Student’s	t-test)	and	-0.54	(±0.37)	(p=0.261,	
Student’s	t-test)	respectively,	implicating	these	too	as	being	altered	and	potentially	affecting	sulfate	
patterning	 along	 HS	 chains	 found	 in	 the	 brains	 of	 these	 patients.	 In	 addition,	 trends	 for	 the	 up-
regulation	of	the	SULF1	gene,	coding	for	the	HS	6-O	sulfatase	1	enzyme,	was	found	to	show	a	strong	
trend	to	be	increased	with	AD,	with	a	recorded	mean	(±S.E.M)	fold	change	of	0.99	(±0.52)	(p=0.097,	
Student’s	t-test).		This	data	also	corroborated	data	collected	from	manual	qRT-PCR	work.	TaqMan®	
did	 however	 report	 an	 absence	 of	 any	 change	 in	 the	 expression	 of	 the	 SULF2	 gene	 with	 mean	
(±S.E.M)	fold	change	of	0.02	(±0.39)	(p=0.966,	Student’s	t-test).		Furthermore,	the	HPSE	and	HPSE2	
genes	that	encode	the	heparanase	enzymes	that	digest	the	HS	chain,	displayed	strong	trends	for	up-
regulation	with	AD	with	recorded	mean	(±S.E.M)	fold	changes	of	0.99	(±0.37)	(p=0.059,	Student’s	t-
test)	and	1.12	(±0.43)	(p=0.056,	Student’s	t-test)	respectively.		
	
In	addition,	 trends	 for	an	 increase	 in	other	HS	core	proteins	such	as	 the	GPC1-6	 family	of	
genes	 were	 observed	 in	 AD	 patient	 brain	 samples	 vs.	 their	 healthy	 age-matched	 control	
counterparts.	This	was	also	true	of	the	SDC1-4	family,	with	the	exception	of	SDC4	that	displayed	a	
trend	for	a	decrease	in	expression	with	AD.	Furthermore,	the	EXT	and	EXTL	genes,	that	encode	the	
EXT	and	EXTL	enzymes	required	for	HS	chain	polymerisation	and	extension,	also	displayed	elevated	
expression	 relative	 to	 healthy	 age-matched	 controls.	 All	 details	 of	 recorded	 mean	 (±S.E.M)	 fold	
changes	in	expression	of	HS-related	genes	are	detailed	in	Table	3.5.	
Figure	3.3.	TaqMan	array	profiling	of	NDST1	N-deacetylase/N-sulfotransferase	gene	expression	 is	 altered	 in	
AD.	 Expression	 of	 HS	 genes	 from	 AD	 (n=11)	 and	 healthy	 age-matched	 controls	 (n=11)	 brain	 samples	 were	
analysed	on	a	custom	made	TaqMan®	array	card	and	the	delta	delta	CT	method	used	for	analysis.	All	expression	
changes	 were	 normalized	 to	 healthy	 controls	 and	 the	 RPLP0	 and	 18S	 housekeeper	 genes.	 N-deacetylase/N-
sulfotransferase	1	(NDST1)	was	up	regulated	with	a	significant	mean	(±S.E.M)	log2	fold	change	of	1.23	 (±0.42).	
p<0.05	*,	Student’s	t-test.	
CT
RL AD
-3
-2
-1
0
1
2
3
lo
g 2
(F
ol
d 
C
ha
ng
e 
of
 N
D
ST
1 
Ex
pr
es
si
on
)
*
*
Chapter	3																																																																																										Analysis	of	the	expression	of	HS-related	genes	in	AD		
2017	 117	
3.5	Discussion		
3.5.1	Relative	expression	of	the	HS-related	genes	are	altered	in	Alzheimer’s	disease	compared	to	
their	healthy	age-matched	counterparts	
	
Having	 established	 some	 strong	 trends	 for	 changes	 in	 expression	 of	 these	 genes	 in	 the	
presence	of	the	AD	phenotype	with	manual	qRT-PCR,	the	use	of	the	TaqMan®	technology	to	explore	
this	further	could	be	justified,	with	both	a	larger	number	of	samples,	and	across	a	broader	spectrum	
of	HS-related	genes.	TaqMan®	microfluidic	arrays	were	thus	carried	out	to	confirm	the	findings	and	
also	 to	overcome	some	of	 the	shortcomings	experienced	with	 this	earlier	 technique.	As	described	
previously,	post-mortem	delay	proved	 to	be	a	 significant	 limiting	 factor	with	human	 tissue	as	 this	
unavoidable	feature	dramatically	affects	RNA	quality.	TaqMan®	array	analysis,	as	employed	on	this	
occasion,	 overcame	 some	of	 these	difficulties	 in	 that	 it	 conferred	 a	much	broader	 analysis	 of	HS-
related	genes,	but	also,	with	significantly	less	RNA	material	than	required	for	manual	qRT-PCR.		
	
	 Promisingly,	 in	the	majority	of	cases,	 the	data	reported	with	TaqMan®	analysis	supported	
that	found	using	manual	qRT-PCR.	In	addition,	perhaps	due	to	the	larger	sample	numbers	that	could	
be	 analysed	with	 this	 technique,	 some	 of	 these	 changes	were	 found	 to	 be	 significant.	 This	 study	
revealed	a	significant	up-regulation	of	the	HS6ST1	gene	in	the	presence	of	the	AD	phenotype	relative	
to	 healthy	 controls.	 This	 was	 coupled	 with	 a	 trend	 for	 decreased	 expression	 of	 the	HS6ST2	 and	
HS6ST3	genes.	Furthermore,	whilst	a	decrease	in	the	expression	of	the	HS6ST2	and	HS6ST3	genes	is	
consistent	with	the	notion	that	HS	from	AD	patients	is	less	sulfated	and	less	able	to	block	the	activity	
of	BACE-1	(Scholefield,	et	al.	2003),	the	significant	increase	in	HS6ST1	expression	reported	here	may	
represent	compensation	to	counter	the	loss	of	sulfotransferase	activity	induced	by	other	isoforms.		
	
There	 seems	 to	 be	 a	 strong	 argument	 for	 distinct	 substrate	 specificities	 of	 the	 HS6ST	
enzymes	whose	 activities	may	 be	 somewhat	 distinct	 from	 their	 isoforms	 (Esko	 and	 Selleck	 2002).	
Previous	 research	 has	 indeed	 indicated	 that	 each	 HS6ST	 isoform	 does	 appear	 to	 display	 varied	
substrate	specificity	whereby,	HS6ST1	shows	preferences	for	IdoA-GlcNS	units,	HS6ST2	acts	on	both	
GlcA-GlcNS	and	IdoA-GlcNS	units	and	HS6ST3	displays	preferences	for	any	substrate	independently	
of	substrate	concentration.	In	light	of	this,	it	may	be	plausible	that	HS6ST	isoforms	are	able	to	target	
enzymatic	 reactions	 in	 regions	of	HS	different	 to	 their	usual	preferences	 in	 their	absence	of	other	
family	members	 (Habuchi,	et	al.	2000).	Understanding	the	mechanisms	by	which	enzyme	 isoforms	
are	 able	 to	 re-establish	 equilibrium	 via	 compensatory	 mechanisms	 may	 prove	 invaluable	 in	
deciphering	the	upstream	causes	for	the	observed	structural	changes	of	HS	with	AD.	Regulation	of	
HS	biosynthesis	is	known	to	be	complex	and	as	such	it	is	highly	unlikely	that	there	are	not	regulatory	
pathways	 in	 place	 to	 counteract	 disturbances	 that	may	be	 induced	by	 disease	 conditions	 like	AD.	
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Manual	qRT-PCR	also	reported	a	trend	for	up-regulation	of	the	HS6ST1	gene	and	a	down	regulation	
of	 HS6ST2	 to	 support	 this	 finding.	 In	 contrast,	 manual	 qRT-PCR	 did	 report	 a	 trend	 for	 an	 up-
regulation	 of	 the	HS6ST3	 gene,	 however	 large	 error	 bars	would	 suggest	 great	 variability	 and	 this	
result	 was	 not	 statistically	 significant.	 This	 coupled	 with	 a	 small	 sample	 group	 may	 explain	 this	
alternate	observation.	
	
A	 significant	 decrease	 in	 the	 expression	 of	 the	 HS3ST2	 gene	 was	 observed	 following	
TaqMan®	 array	 analysis.	 Previous	 research	 did	 not	 explore	 whether	 BACE-1	 inhibition	 efficacy	 is	
directly	affected	by	3-O	sulfation	(Patey,	et	al.	2006),	so	we	cannot	know	how	decreased	expression	
of	the	HS3ST2	gene	as	noted	here	may	have	implications	for	HS	structure	and	its	ability	to	interact	
with,	 and	 potentially	 modulate	 BACE-1.	 There	 is	 some	 evidence	 to	 suggest	 that	 HS	 modification	
enzymes	 exhibit	 preferences	 with	 regard	 to	 location	 of	 action	 dependent	 upon	 the	 motifs	 that	
surround	 their	 active	 site.	 Specifically,	 6-O	 sulfation	 is	 reported	 to	be	 favoured	on	GlcNS	 residues	
flanked	by	2-O	sulfated	IdoA	units	(Liu,	et	al.	2014).	As	such,	we	cannot	rule	out	the	possibility	that	
changes	in	3-O	sulfation	may	impact	the	activity	of	other	biosynthetic	enzymes	such	as	the	binding	
preferences	of	other	sulfotransferases.	In	reference	to	2-O	sulfation	in	this	context,	a	reported	up-
regulation	of	expression	of	the	HS2ST1	gene	in	this	study,	as	well	as	the	GLCE	gene	(encoding	the	C5-
epimerase	 responsible	 for	epimerisation	of	 the	GlcA	unit	 to	 IdoA	units)	 (Hagner-McWhirter,	 et	al.	
2004)	may	again	prove	to	act	as	compensation	mechanisms	to	indirectly	enhance	6-OS	sulfation	in	
response	to	its	decline	in	AD	patients.		
	
Elevated	 expression	 of	 the	 GLCE	 gene	 observed	 here	 would	 suggest	 the	 potential	 for	
increased	levels	of	the	GLCE	enzyme	and	ultimately,	an	enhanced	turnover	of	GlcA	residues	to	IdoA	
residues	along	the	HS	chain.	As	discussed	previously,	SAX	chromatography	as	employed	in	chapter	2	
to	 investigate	 structural	 changes	 in	HS	with	AD,	was	unable	 to	distinguish	 the	original	uronic	acid	
identities.	As	such,	changes	in	the	expression	of	this	gene	as	noted	here	cannot	be	attributed	to	any	
structural	 changes	 that	may	 or	may	 not	 be	 occurring	with	 respect	 to	 uronic	 acid	 unit	 abundance	
within	the	AD	and	control	samples	under	investigation.	The	increase	in	the	expression	of	this	gene	
however	 may	 indicate	 some	 gross	 structural	 changes	 that	 may	 be	 occurring	 that	 could	 have	
implications	on	the	activity	of	HS	and	its	ability	to	interact	with	and	inhibit	BACE-1.			Up-regulation	of	
the	HS3ST2	gene	with	TaqMan®	array	analysis	was	not	supported	by	findings	with	manual	qRT-PCR,	
however	 this	 disparity	may	 be	 explained	 by	 the	 lack	 of	 a	 large	 enough	 sample	 population	 in	 the	
manual	qRT-PCR	experiments.	Trends	for	an	up-regulation	of	the	HS2ST1	and	GLCE	genes	however	
were	consistent	across	both	sets	of	PCR	data.	In	addition	structural	analysis	as	described	in	chapter	
2,	 did	not	 reveal	 any	 significant	 changes	 in	 levels	 of	 2-O	 sulfation;	 however	 there	was	 a	 reported	
trend	for	AD	patient	brain	HS	to	display	elevated	abundance	of	 the	UA(2S)-GlcNS	disaccharide,	vs.	
healthy	controls.	This	might	be	consistent	with	the	increased	levels	of	HS2ST1	gene	expression		
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	 The	reported	significant	increase	in	NDST1	gene	expression	noted	here	with	TaqMan®	array	
analysis	 could	 be	 indicative	 of	 enhanced	 N-deacetylase/N-sulfotransferase	 activity	 along	 the	 HS	
chain.	 It	has	already	been	established	that	NDST	enzymes	exhibit	variable	sulfotransferase	activity	
and	NDST1	 is	known	to	display	a	much-reduced	N-acetylase/N-sulfotransferase	activity	vs.	NDST2,	
and	even	less	activity	vs.	the	NDST4	enzyme	(Aikawa,	et	al.	2001).	Assuming	the	NDST1	enzyme	does	
indeed	display	the	 lowest	degree	of	sulfotransferase	activity,	the	observed	increased	in	expression	
of	 the	NDST1	 gene	 in	 this	manner	may	 indicate	 an	 enhanced	 NDST	 activity	 that	 actually	 confers	
reduced	NS	sulfation	levels.	Indeed,	Patey	and	colleagues	found	that,	after	unmodified	PIMH,	de-N-
sulfated	 and	 re-N-acetylated	 heparin	 was	 the	 best	 inhibitor	 of	 BACE-1	 (Patey,	 et	 al.	 2006).	 This	
indicated	that	when	coupled	with	6-O	sulfation,	N-	sulfation	 is	not	essential	 for	efficacious	BACE-1	
inhibition,	but	can	modulate	activity.	As	such,	enhanced	NDST1	gene	expression	as	noted	here	may	
serve	 to	 attempt	 to	 restore	 BACE-1	 inhibition	 efficacy,	 assuming	 there	 is	 a	 combinatorial	 effect	
between	6-O	sulfation	and	N-	sulfation	patterns.	It	should	also	be	noted	that	loss	of	N-	sulfation	only	
has	minor	effects	on	BACE-1	 inhibitory	activity	compared	to	 the	 loss	of	6-O	sulfation	 (Patey,	et	al.	
2006,	 Scholefield,	 et	 al.	 2003).	We	might	 therefore	 expect	 that	 changes	 in	NDST	 gene	 expression	
might	 act	 in	 combination	 with	 other	 modification	 enzymes,	 rather	 than	 in	 isolation	 to	 modulate	
efficacy	of	BACE-1	inhibition.		Indeed,	changes	in	the	expression	of	all	of	the	NDST	genes	was	largely	
consistent	 with	 the	 findings	 of	 manual	 qRT-PCR,	 with	 the	 exception	 of	 the	 NDST4	 gene,	 which	
reported	both	up	and	down	regulatory	trends	with	manual	and	TaqMan®	analysis	respectively.			
	 The	HSPG2	and	AGRN	core	protein	genes	were	also	significantly	regulated	in	AD.	AD	patient	
brain	samples	displayed	significantly	increased	expression	of	both	the	HSPG2	(encoding	the	perlecan	
core	 protein)	 and	 AGRN	 (encoding	 the	 agrin	 core	 protein)	 genes,	 suggesting	 enhanced	 levels	 of	
these	core	proteins	as	a	result.	This	data	is	somewhat	contradictory	to	compositional	analysis	data	
(chapter	 2)	 that	 revealed	 significantly	 decreased	 levels	 of	 HS	 within	 AD	 patient	 brain	 samples	
relative	to	their	age-matched	healthy	controls.	Enhanced	levels	of	core	proteins	might	be	indicative	
of	 elevated	 levels	 of	 HS,	 rather	 than	 decreased	 levels,	 as	 we	 reported.	 This	 discrepancy	 may	
however	be	reconciled	with	the	notion	that	these	core	proteins,	whilst	expressed	at	greater	levels,	
may	 not	 actually	 carry	 more	 HS	 chains	 thus	 explaining	 the	 reduced	 levels	 in	 AD	 as	 reported	 in	
chapter	2.	Indeed,	a	trend	for	increased	levels	of	HPSE	and	HPSE2	genes	in	AD	vs.	healthy	controls	as	
reported	here	following	TaqMan®	array	analysis	supports	the	finding	of	decreased	levels	of	total	HS	
as	these	genes	encode	the	HPSE	enzymes,	 responsible	 for	degradation	of	 the	HS	chain	 (Tao,	et	al.	
2013).		
	
There	may	 also	 be	 a	 shift	 in	 the	 balance	 of	 HS	modification	 of	 different	 alternative	 core	
proteins.	 Interestingly,	 HSPG2	 and	 AGRN	 are	 both	 extracellular	 HSPGs,	 and	 these	 may	 be	 less	
efficient	 at	 regulating	 BACE-1	 at	 the	 cell	 surface	 compared	 to	 the	 SDCs	 and	 GPCs	 for	 example.	
Furthermore,	 the	HSPG2	and	AGRN	proteins	are	both	known	to	associate	with	 the	 features	of	AD	
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including	NFTs	and	amyloid	plaques	(Snow,	et	al.	1994,	Verbeek,	et	al.	1999)	and	as	such,	we	might	
expect	their	gene	transcript	levels	to	be	elevated.	It	is	therefore	encouraging	that	we	observed	a	an	
increase	 in	 the	 expression	 of	AGRN	 and	HSPG2	 genes	 in	 this	 instance	 as	we	might	 expect	 this	 to	
translate	 to	enhanced	 levels	of	 the	core	proteins	 that	co-localise	with	 the	pathological	 features	of	
AD.	 It	 has	 been	 hypothesised	 that	 the	 presence	 of	 nine	 follistatin-like	 protease	 inhibitor	 domains	
(Groffen,	et	al.	1998)	in	AGRN	may	drive	the	persistence	of	the	plaque	and	tangle	features	of	AD	by	
protecting	 them	 from	 degradation.	 This	 interaction	 between	 AGRN	 and	 AD	 pathology	 may	 thus	
explain	 the	 disparity	 between	enhanced	 levels	 of	 the	AGRN	 gene	 expression	 vs.	 lowered	 total	HS	
levels	 within	 the	 cell,	 as	 their	 abundance	may	 be	 driven	 by	 separate	 pathways.	Moreover,	 if	 we	
accept	 the	 hypothesis	 that	 these	 core	 proteins	might	 drive	 the	 pathogenesis	 of	 AD,	 the	 elevated	
expression	of	 these	proteins	may	not	be	attributed	to	changes	 in	HS	 levels	at	all,	but	 rather,	 their	
context	in	AD	pathology	interactions.	This	hypothesis	may	also	go	some	way	to	explain	the	observed	
trend	 for	 increase	 in	expression	of	other	HS	core	protein	genes,	 including	the	GPC	and	SDC	 family	
(with	the	exception	of	the	SDC4	gene).	
	
	 Reasonably	little	work	has	been	done	to	assess	the	potential	changes	in	the	expression	of	
HS-related	genes	 that	may	occur	with	disease	despite	 the	known	 importance	of	 these	enzymes	as	
established	 by	 knockout	 models	 as	 described	 previously.	 That	 being	 said,	 there	 is	 increasing	
evidence	 to	 suggest	 that	 changes	 in	 the	expression	of	 specific	HS-related	genes	may	be	occurring	
alongside	a	variety	of	different	pathologies.	Of	note,	up-regulation	of	HPSE,	particularly	in	a	number	
of	cancers	has	been	reported	recently	(Vlodavsky,	et	al.	2012).	Indeed,	this	post	synthetic	modulator	
of	 HS	 has	 also	 been	 associated	 with	 the	 pathogenesis	 of	 a	 number	 of	 inflammatory	 disorders	
including	 inflammatory	 lung	 injury,	 rheumatoid	 arthritis	 and	 chronic	 colitis	 (Goldberg,	 et	 al.	 2013,	
Meirovitz,	et	al.	2013).	 A	great	deal	of	work	has	now	been	done	to	further	elucidate	the	role	of	
heparanase	in	a	number	of	neuroinflammatory	disorders	(Massena,	et	al.	2010,	Wang,	et	al.	2005).	
Furthermore,	extensive	work	in	a	transgenic	murine	model	for	the	over	expression	of	the	HPSE	gene	
(Hpa-tg),	has	reported	enhanced	sulfation	and	fragmentation	of	the	HS	chain	(Zcharia,	et	al.	2004)	
and	 has	 also	 been	 utilised	 as	 a	 model	 by	 which	 to	 explore	 the	 role	 of	 HS	 and	 heparanases	 in	
amyloidosis.	 In	 2005,	 Li	 and	 colleagues	 reported	 direct	 in	 vivo	 evidence	 that	 over-expression	 of	
human	 heparanase	 in	 the	 Hpa-tg	 mouse	 model	 resulted	 in	 dramatic	 fragmentation	 of	 HS	 and	
consequentially	attenuated	amyloidosis	(Li,	et	al.	2005).	This	work	naturally	confirmed	the	key	role	
of	HS	in	amyloid	disorders	such	as	AD,	but	also	raises	the	question	as	to	whether	the	observed	trend	
for	 up-regulation	 of	HPSE	 and	HPSE2	 genes	 as	 reported	 here,	 is	 a	 compensatory	 mechanism	 by	
which	to	protect	cells	from	the	accumulation	of	amyloid.		
	
	 In	addition,	work	by	Huynh	and	colleagues	in	2012,	reported	changes	in	the	expression	of	
some	 HS-related	 genes	 in	 the	 context	 of	 an	 ageing	 phenotype.	 Expression	 analysis	 of	 HS-related	
genes	from	aged	and	adult	hippocampus	samples	revealed	a	decreased	expression	of	GLCE,	HS2ST1	
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and	HS3ST5	 genes	and	an	 increase	 in	 the	expression	of	NDST2	 and	HS3ST4	 in	aged	 individuals	 vs.	
their	 younger	 counterparts	 (Huynh,	 et	 al.	 2012).	 	 Interestingly,	 some	 of	 the	 genes	 found	 to	 be	
significantly	 down-regulated	 in	 this	 study	 displayed	 a	 trend	 for	 an	 increase	 in	 expression	 in	 the	
TaqMan®	array	profiling	carried	out	here.	In	contrast,	the	NDST2	and	HS3ST4	genes	reported	to	be	
up-regulated	with	 ageing,	were	 similarly	 observed	 to	be	up-regulated	 in	 the	work	 as	 described	 in	
this	 chapter.	 Naturally,	 this	 study	 looked	 at	 an	 ageing	 phenotype	 rather	 than	 AD	 and	 as	 such	
differential	 regulation	 of	 HS	 structure	 might	 not	 be	 surprising	 particularly	 in	 light	 of	 the	 altered	
structural	changes	described	with	ageing	and	with	AD	in	chapter	2.	Changes	in	the	expression	of	HS-
related	 genes	 as	 reported	 by	 Huynh	 and	 colleagues	 however,	 not	 only	 support	 the	 notion	 of	 an	
upstream	mechanism	by	which	HS	structure	may	be	modulated,	but	also	go	some	way	to	confirm	
the	hypothesis	of	separate	and	distinct	mechanisms	by	which	HS	may	mediate	normal	physiological	
ageing	and	dementia.		
	
	 Conditional	deletion	of	 the	Ext-1	 gene	 in	postnatal	neurons	of	 the	amyloid	mouse	model	
APP-PS1	has	also	been	reported	to	attenuate	both	the	oligomerisation	of	the	Aβ	peptide	as	well	as	
its	deposition	into	more	mature	plaques	(Liu,	et	al.	2016).	This	work	by	Liu	and	colleagues	 in	2016	
also	goes	some	way	to	support	the	notion	that	changes	in	the	expression	of	HS-related	genes	may	
be	 key	 in	 underpinning	 key	 functionality	 of	 HS	 both	 physiologically	 and	 in	 a	 disease	 context.	 The	
strong	 association	between	HS	 and	a	number	of	 features	of	AD,	 not	 least	 its	 interaction	with	 the	
BACE-1	 enzyme,	 immediately	 implicates	 the	 expression	 of	 those	 enzymes	 responsible	 for	 its	
modification	as	the	main	upstream	coordinators	of	the	functionality	of	HS	in	AD.		
	
	 Finally,	there	has	been	a	great	deal	of	research	to	investigate	the	ways	in	which	the	roles	of	
PGs	may	be	important	in	psychiatric	disorders	and	intellectual	disabilities	(Maeda	2015).	Functional	
mutations	 of	 the	 XYLT1	 gene	 has	 been	 shown	 to	 result	 in	 short	 stature	 syndrome	 linked	 with	
intellectual	 disability	 (Schreml,	 et	 al.	 2014).	 The	EXT1	 gene	has	 also	been	 shown	 to	be	associated	
with	autism	 (Li,	 et	al.	 2002).	 Finally,	mutations	within	 the	NDST1	 gene	have	been	shown	 to	cause	
intellectual	 disability,	 epilepsy	 and	 muscular	 hypotonia	 implicating	 in	 HS	 in	 key	 developmental	
functionality	of	neuronal	circuits	(Reuter,	et	al.	2014).	These	studies	together	all	strongly	 implicate	
not	 only	 HS	 in	 a	 number	 of	 pathological	 pathways	 but	 also	 the	 biosynthetic	 machinery	 that	
generates	heterogeneous	HS	species.	The	changes	observed	here	in	the	expression	of	a	number	of	
HS-related	genes	in	AD	confirm	the	notion	of	an	upstream	mechanism	by	which	the	final	structure	of	
HS	 is	 altered	 such	 that	 it	becomes	unable	 to	efficiently	deliver	 its	normal	 functionality.	 This	 could	
include	its	ability	to	modulate	BACE-1	activity.	 	
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3.6	General	conclusions		
It	 is	 important	 to	 note	here,	 that	 qRT-PCR,	whether	 via	manual	 qRT-PCR	methods	or	 the	
TaqMan®	microfluidic	card	arrays,	was	only	able	to	quantify	the	levels	of	RNA	transcripts	of	target	
biosynthetic	 genes	 and	 core	 proteins,	 and	 not	 the	 actual	 protein	 levels.	We	 cannot	 therefore	 be	
certain	that	altered	RNA	levels	as	detected	in	these	experiments	truly	represent	changes	in	inherent	
levels	and	activity	of	 the	HS	biosynthetic	enzymes.	This	may	be	due	to	regulation	of	 translation	of	
the	mRNA,	or	a	low	turnover	rate	(half	life)	of	the	proteins	themselves.	As	such,	we	must	be	careful	
in	 making	 conclusions	 about	 protein	 activity	 based	 on	 RNA	 levels	 alone.	 Antibodies	 for	 these	
enzymes	 may	 prove	 useful	 in	 western	 blot	 studies	 to	 more	 conclusively	 determine	 the	 levels	 of	
these	 proteins	 within	 brain	 samples.	 Availability	 of	 specific	 antibodies	 however	 is	 limited;	
furthermore	 determining	 the	 specific	 activity	 of	 these	 enzymes	 (in	 addition	 to	 their	 abundance	
within	brain	 tissue	 samples)	 is	 another	 challenge	 in	 itself	 and	 is	 not	 currently	 technically	 feasible.	
qRT-PCR	was	the	best	methodology	to	employ	at	this	time	for	identifying	possible	up	stream	causes	
of	the	observed	structural	alterations	to	HS.	It	is,	however	important	to	recognise	the	limitations	of	
this	approach	and	the	conclusions	from	the	data	collected	here.	
	
	 The	 changes	 in	 expression	 of	 the	 genes	 encoding	 some	 of	 the	 HS-related	 enzymes	 as	
observed	here	may	go	some	way	to	explain	the	observed	changes	in	the	structure	of	HS	as	described	
in	chapter	2.	Expression	of	the	enzymes	responsible	for	the	elongation	and	modification	of	the	HS	
chain	is	an	obvious	upstream	target	for	understanding	how	structural	changes	are	occurring	and	this	
data	 supports	 our	 hypothesis	 of	 altered	 HS	 structure	 in	 AD.	 Whilst	 we	 cannot	 attribute	 enzyme	
expression	directly	 to	enzyme	activity,	 changes	 in	 the	expression	of	 the	HS6ST	 and	SULF	 genes	as	
described	in	this	chapter	are	consistent	with	our	findings	of	altered	sulfation	patterns	as	determined	
directly	by	compositional	analysis.	The	mechanisms	by	which	HS	structure	is	modulated	and	refined	
is	 still	 largely	undiscovered	and	 there	are	undoubtedly	 compensation	mechanisms	 that	occur	 that	
may	counter	loss	of	gene	expression	of	specific	HS	biosynthetic	machinery.	More	work	is	needed	to	
fully	understand	changes	 in	HS	biosynthesis	that	may	occur	in	disease	conditions.	 Indeed,	a	recent	
GWAS	 study	 has	 identified	 a	 SNP	 of	 the	 HS6ST1	 gene	 that	 may	 cause	 genetic	 predisposition	 to	
albuminuria	associated	with	diabetes	 (Teumer,	et	al.	2016).	This	work	strengthens	the	notion	that	
changes	in	HS	biosynthetic	machinery	gene	expression	could	have	significant	affects	on	downstream	
functionality	 of	 HS	 and	 may	 even	 prove	 useful	 as	 diagnostic	 biomarkers	 should	 these	 genes	 be	
altered	 in	early	disease	pathogenesis.	This	work,	albeit	preliminary,	offers	a	pathway	by	which	HS	
structure,	and	ultimately	its	effect	on	BACE-1	activity,	may	be	determined	within	the	AD	phenotype.	
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4.	Chapter	4		
4.1	Introduction		
4.1.1	More	about	BACE-1	
	
	 The	BACE-1	enzyme	is	a	key	transmembrane	aspartic	protease	with	important	roles	in	the	
processing	of	APP	and	ultimately,	the	onset	and	development	of	AD.		BACE-1	is	related	to	the	pepsin	
family	of	aspartyle	proteases	and	works	best	at	low	pH.	As	a	result,	BACE-1	is	predominantly	found	
in	more	acidic	regions	of	the	cell,	in	particular	the	endosomes	and	trans-golgi	regions.	With	respect	
to	locality	of	action,	the	highest	expression	of	BACE-1	has	been	reported	in	the	neurons	of	the	brain	
(most	likely	explaining	its	large	contribution	to	AD	pathogenesis,	a	disorder	of	the	brain).	BACE-2,	a	
homolog	 of	 BACE-1	 was	 discovered	 shortly	 after	 and	 the	 two	 isoforms	 share	 64%	 structural	
homology.	 It	 has	however	 since	been	 ruled	out	 that	BACE-2	 shares	 functionality	 as	 a	β-secretase.	
BACE-2	 is	 expressed	 only	 at	 very	 low	 levels	within	 neurons	 and	 does	 not	 process	 APP	 as	 BACE-1	
does,	suggesting	it	is	not	a	strong	candidate	as	a	β-secretase	(Vassar,	et	al.	2009).			
	
4.1.2	Pro-BACE-1	and	mature	BACE-1	
	
Upon	 synthesis,	 BACE-1	 is	 initially	 formed	 as	 an	 immature,	 pro-peptide	 (pro-BACE-1)	
(Benjannet,	 et	 al.	 2001),	 where	 it	 is	 then	 cleaved	 into	mature	 BACE-1	 in	 the	 Golgi	 (Haniu,	 et	 al.	
2000).	 Pro-BACE-1	 may	 exist	 in	 two	 different	 conformations,	 open	 and	 closed.	 The	 open	
conformation	 of	 BACE-1	 displays	 a	 small	 degree	 of	 enzymatic	 activity	 however,	 in	 the	 closed	
conformation,	the	pro-domain	of	BACE-1	physically	blocks	the	active	site	of	BACE-1	thus	precluding	
any	enzymatic	activity	(Shi,	et	al.	2001).	Naturally	therefore,	cleavage	of	the	pro-domain	of	BACE-1	
removes	inhibition	of	the	active	site	and	results	 in	full	enzymatic	potential	of	BACE-1	(Ermolieff,	et	
al.	 2000).	 	 There	exist	N-glycosylation	 sites	 at	 four	potential	 locations	within	BACE-1	alongside	 six	
cysteine	residues	that	are	able	to	form	three	disulfide	bonds	(Huse,	et	al.	2000).	The	folding	and	final	
confirmation	 of	 mature	 BACE-1	 is	 dependent	 upon	 these	 disulfide	 bonds,	 specifically	 Cys	
330/Cys380	is	located	within	the	active	site	of	BACE-1	and	as	such,	is	responsible	for	maintenance	of	
the	 stability	 of	 the	 active	 site	 of	 this	 enzyme	 (Fischer,	 et	 al.	 2002).	 In	 addition,	 a	 dileucine	motif	
within	 the	 cytoplasmic	domain	of	 BACE-1	 is	 responsible	 for	 the	 localisation	of	 this	 enzyme	 to	 the	
endosomes	(Huse,	et	al.	2000).		
	
	 Variations	 in	 conformation	 are	 not	 limited	 to	 just	 pro-BACE-1,	 mature	 BACE-1	 may	 also	
exist	in	either	a	flap	open	or	flap	closed	confirmation.		BACE-1	not	bound	to	its	substrates	exists	in	a	
flap	 open	 confirmation,	 an	 energetically	 stable	 confirmation	 secured	 via	 hydrogen	bonding	 (Hong	
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and	Tang	2004).	If	bound	to	its	substrate	however,	BACE-1	displays	a	flap-closed	confirmation.	The	
hydrogen	bonds	that	once	stabilised	the	 flap	open	confirmation	are	broken	and	a	new	 interaction	
established	 to	 allow	 substrates	 of	 BACE-1	 to	 interact	 via	 a	 cleft	 in	 BACE-1	 (Hong	 and	 Tang	2004).		
There	 is	evidence	that	a	small	degree	of	substrate	flexibility	 is	 required	for	effective	 interaction	of	
substrate	 and	 BACE-1	 via	 this	 cleft	 and	 it	 has	 been	 hypothesised	 that	 this	 apparent	 selectivity	 of	
BACE-1	may	confer	a	substrate	specificity	mechanism	(Hong	and	Tang	2004).			
	
4.1.3	Physiological	roles	of	BACE-1	
	
	 Whilst	BACE-1	may	be	most	commonly	known	for	 its	 role	 in	 the	processing	of	APP	 in	AD,	
there	 are	 several	 other	 substrates	 that	 BACE-1	 may	 also	 act	 upon.	 Understanding	 these	 binding	
partners	is	particularly	important	when	we	consider	side	effects	to	new	therapeutic	strategies	that	
may	block	 the	action	of	BACE-1.	 Furthermore,	understanding	 the	ways	 in	which	BACE-1	 is	 able	 to	
interact	with	these	binding	ligands	may	also	shed	light	into	the	ways	in	which	novel	therapeutics	can	
be	 designed	 to	 effectively	 interact	 whilst	 sparing	 these	 alternative	 targets	 (Vassar,	 et	 al.	 2009).	
Previous	work	 to	 confirm	 that	 soluble	 BACE-1	 is	 unable	 to	 process	 APP	 led	 to	 the	 notion	 that	 all	
BACE-1	substrates	must	be	membrane	bound	proteins.	There	are	a	number	of	substrates	that	have	
been	confirmed	in	recent	years,	all	of	which	are	indeed	transmembrane	proteins.	BACE-1	substrates	
include;	APP	homolog	proteins	APLP1	and	APLP2	(Eggert,	et	al.	2004),	voltage	gated	sodium	channel	
(Nav1)	 β2	 subunit	 (Navβ2)	 (Kim,	 et	 al.	 2005),	 neuregulin-1	 (NRG1)	 (Hu,	 et	 al.	 2006),	 neuregulin-3	
(NRG3)	(Hu,	et	al.	2008),	P-selectin	glycoprotein	 ligand-1	(PSLG-1)	 (Lichtenthaler,	et	al.	2003),	 low-
density	 lipoprotein	 receptor	 related	 protein	 (LRP)	 (von	 Arnim,	 et	 al.	 2005)	 and	 Golgi-localised	
membrane	 bound	 α2,	 6-sialytransferase	 (Kitazume,	 et	 al.	 2001).	 Total	 inhibition	 of	 BACE-1	 may	
therefore	have	the	potential	 to	also	block	several	critical	physiological	processes.	NRG1	and	NRG3	
for	example	 is	key	 in	synaptic	plasticity	and	have	been	shown	to	balance	excitatory	and	 inhibitory	
connections	 within	 the	 brain.	 In	 essence,	 NRG	 isoforms	 are	 essential	 for	 the	 development	 and	
maintenance	of	 the	CNS	 (Talmage	2008).	Attenuation	 therefore	of	NRG1	binding	 for	example	and	
NRG3	 may	 result	 in	 reduced	 myelin	 sheath	 thickness	 of	 axons,	 and	 could	 have	 significant	
consequences	on	synaptic	plasticity	and	cognitive	 function	 in	patients.	Finally,	BACE-1	 is	known	to	
regulate	 voltage-gated	 sodium	 channels.	 Strong	 inhibition	 of	 BACE-1	 therefore	 may	 well	 lead	 to	
substantial	 behavioral	 phenotypes	 as	 a	 result	 of	 altered	 neuronal	 excitability	 and	 must	 be	
considered	when	 considering	 the	effects	of	BACE-1	 inhibition	 (Vassar,	 et	 al.	 2009).	Understanding	
the	 implications	of	 these	physiological	binding	partners	of	BACE-1	 is	 key	 if	 successful	 therapeutics	
against	BACE-1	are	to	be	generated.		
	
4.1.4	Inhibitors	of	BACE-1	
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	 Extensive	 research	has	been	 carried	out	 to	 further	understand	 the	mechanisms	by	which	
the	 activity	 of	 BACE-1	 can	 be	 inhibited	 effectively	 and	 use	 of	 3D	 crystallography	 and	 X-ray	 has	
offered	a	great	deal	of	insight	into	the	ways	in	which	substrates	are	able	to	bind	to	BACE-1	and	the	
ways	to	best	design	potent	inhibitors.	The	creation	of	substrate-based	pseudo	peptide	inhibitors	and	
elucidation	of	BACE-1	structure	upon	substrate	binding	provided	substantial	aid	in	the	design	of	drug	
inhibitor	 templates.	Despite	 this	advance	 in	our	understanding	of	BACE-1	 inhibition,	 there	are	still	
several	 complexities	 to	 overcome	 with	 regard	 to	 successful	 design	 of	 therapeutics	 to	 block	 the	
activity	 of	 this	 enzyme.	 Not	 least	 of	 all,	 is	 molecular	 size;	 drugs	 to	 target	 BACE-1,	 an	 enzyme	
predominantly	expressed	within	the	brain,	will	need	to	be	small	enough	to	efficiently	cross	the	BBB.	
Likewise,	the	expression	of	several	other	aspartic	acid	proteases	such	as	pepsin,	renin,	cathepsin	E	
and	D	alongside	BACE-1	all	over	 the	body	may	 result	 in	 significant	off	 target	effects	unless	a	high	
degree	 of	 BACE-1	 specificity	 is	 achieved.	 Aspartic	 acid	 residues	 are	 conserved	 across	 the	 whole	
family	of	proteases,	hence	much	more	subtle	specificity,	perhaps	via	exploitation	of	the	non-native	
side	chains	(Turner,	et	al.	2002),	needs	to	be	achieved	in	any	successful	BACE-1	inhibitor	(Ghosh	and	
Osswald	 2014).	 Targeting	 other	 substrates	 such	 as	 cathepsin	 D	 (CatD)	 may	 prove	 particularly	
detrimental	in	terms	of	toxic	adverse	effects	in	light	of	CatD’s	role	in	protein	degradation,	apoptosis	
and	hydrolysis	of	cholesterol	(Benes,	et	al.	2008).	In	addition,	P-glycoprotein	(Pgp)	efflux	is	another	
key	hurdle	to	be	overcome	in	effective	drug	design	of	BACE-1	inhibitors.	The	P-gp	protein	is	an	ATP-
dependent	efflux	pump	that	coordinates	the	removal	of	xenobiotics	such	as	toxins	or	drugs	out	of	
the	brain	and	back	into	the	capillaries.	This	efflux	is	essentially	a	defense	mechanism	to	protect	the	
brain	 against	 harmful,	 unknown	 substances	 and	 as	 such,	 offers	 a	 significant	 barrier	 against	 the	
administrations	of	BACE-1	inhibitors	into	the	brain	(Ghosh,	et	al.	2012).		
	
	 Despite	 the	 potential	 benefits	 of	 inhibition	 of	 BACE-1	 in	 the	 treatment	 of	 AD,	 currently	
there	 exists	 no	 FDA	 approved	 inhibitors	 on	 the	 market	 despite	 some	 candidates	 showing	 some	
potential	within	the	clinic.	Currently,	efforts	to	design	BACE-1	inhibitors	may	be	classified	under	two	
categories,	 peptidomimetic	 and	 nonpeptidic.	 Some	 natural	 products	 including	 epigallacatechin	
gallate	from	green	tea	have	also	shown	efficacy	as	a	non-competitive	inhibitor	of	BACE-1	(Jeon,	et	al.	
2003).	 Combination	 of	 understanding	 the	 interaction	 between	 substrate	 and	 BACE-1,	 alongside	
recognition	of	the	hurdles	associated	with	designing	new	therapeutics	has	led	to	a	high	throughput	
screening	 effort	 to	 generate	 lead	 molecules	 as	 BACE-1	 inhibitors.	 Inhibitors	 developed	 by	
AstraZeneca	 and	 Eli	 Lilly	 have	 reached	 phase	 II	 clinical	 trials	 and	 have	 suggested	 preliminary	
evidence	 for	efficacy	as	drugs	 to	 reduce	Aβ	burden	within	 the	brain.	Merck	also	has	a	 compound	
currently	 in	phase	 III	clinical	 trials	 that	 is	showing	promise	 (Kennedy,	et	al.	2016).	These	drugs	are	
yet	to	reach	FDA	approval	and	a	great	deal	more	work	is	necessary	to	generate	suitable	treatment	of	
AD	 via	 BACE-1	 inhibition	 (Ghosh	 and	 Osswald	 2014).	 There	 are	 number	 of	 ways	 to	 regulate	 the	
activity	of	BACE-1,	as	described	in	the	following	sections.	
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4.2	BACE-1	and	the	treatment	of	AD:	how	can	it	be	targeted?	
	
	 As	previously	discussed	in	chapter	1,	the	role	of	BACE-1	is	fundamental	in	the	generation	of	
the	 toxic	 Aβ	 species	 associated	 with	 the	 onset	 and	 development	 of	 AD	 pathogenesis.	 As	 such,	
finding	ways	to	target	BACE-1	may	be	crucial	 in	successfully	generating	an	appropriate	therapeutic	
strategy	to	this	disease.		Indeed,	a	great	deal	of	research	effort	has	been	focused	on	finding	ways	to	
most	 effectively	 inhibit	 the	 action	 of	 BACE-1.	 Early	work	 has	 concluded	 that	 inhibition	 of	 BACE-1	
should	directly	reduce	accumulation	of	the	toxic	Aβ	amyloid	species;	siRNA	to	disrupt	the	expression	
of	 the	 Bace-1	 gene	 resulted	 in	 the	 decreased	 build	 up	 of	 Aβ	 species	 and	 ultimately	 improved	
cognitive	deficits	in	APP	transgenic	mice	(Laird,	et	al.	2005,	Singer,	et	al.	2005).	Furthermore,	rescue	
of	 memory	 deficits	 in	 mice	 totally	 void	 of	 BACE-1	 (Bace-1-/-)	 confirm	 the	 notion	 that	 BACE-1	
inhibitors	could	be	very	effective	as	treatment	for	AD	(Ghosh	and	Osswald	2014).	
	
BACE-1	 is	 known	 to	 play	 several	 key	 roles	 in	 normal	 physiological	 function	 (as	 described	
above)	 and	 as	 such	 robust	 inhibition	 of	 BACE-1	 with	 AD	 therapeutics	 may	 have	major	 toxic	 side	
effects	within	the	brain.	Research	has	gone	on	to	assess	the	effects	of	only	a	moderate	reduction	in	
the	activity	of	BACE-1.	12-month-old	transgenic	APPswe;	Ps1de9;	Bace-1+/-	mice	display	a	significant	
reduction	in	Aβ	deposition	within	the	brain	vs.	BACE-1	double	knockout	counterparts.	Interestingly,	
this	improvement	was	not	observed	in	20-month-old	mice,	perhaps	indicative	of	an	effect	of	age	on	
the	 efficacy	 of	 BACE-1	 knockdown	 (Laird,	 et	 al.	 2005).	 Partial	 reduction	 in	 BACE-1	 activity	 in	 this	
manner	may	prove	more	beneficial	overall	vs.	total	block.	In	the	same	vein,	γ-secretase	is	a	cleavage	
event	that	follows	that	of	BACE-1.	Indeed,	reduction	of	γ	-secretase	has	not	displayed	adverse	side	
effects	(Li,	et	al.	2007)	and	as	such	may	implicate	a	combination	of	BACE-1	and	γ-secretase	reduction	
as	a	worthy	therapeutic	strategy	against	AD	to	preclude	the	formation	of	the	Aβ	peptide.	
	
4.2.1	Regulation	of	trafficking	of	BACE-1	
	
	 BACE-1	 is	 synthesised	 as	 a	 zymogen	 that	 contains	 a	 pro-domain,	within	 the	 endoplasmic	
reticulum	 (ER)	 before	 transport	 to	 the	 Golgi	 complex	 and	 early	 endosomes	where	 it	 can	 process	
APP.	The	 low	pH	 found	within	 the	Golgi	and	early	endosomes	 is	 strongly	 favoured	by	BACE-1	and	
greatly	enhances	its	activity.	Phosphorylation	of	BACE-1	at	the	Ser498	residue	alongside	a	C-terminal	
dileucine	motif	are	 together	 responsible	 for	 regulating	 the	movement	of	BACE-1	between	 the	cell	
surface	 and	 endosomes	 (Huse,	 et	 al.	 2000,	 Walter,	 et	 al.	 2001).	 Additionally,	 BACE-1	 is	 S-
palmitoylated	 on	 4	 Cys	 residues	 found	 between	 the	 cytosolic	 and	 transmembrane	 domains	
(Benjannet,	 et	 al.	 2001).	 It	 is	 this	post-translational	modification	 that	 sequesters	BACE-1	 into	 lipid	
rafts.	Research	has	 indicated	 that	 targeting	of	BACE-1	 to	 the	 lipid	 raft	 increases	 the	processing	of	
APP	and	as	such,	the	turnover	of	Aβ	is	increased	(Tun,	et	al.	2002).	With	this	in	mind,	regulation	of	
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the	specific	 localisation	of	BACE-1	within	the	cell	may	prove	a	useful	target	for	AD	therapeutics.	 In	
particular,	various	regulatory	factors	may	play	a	role	in	this	such,	 increased	expression	of	reticulon	
(RTN)	proteins	(found	predominantly	within	the	ER),	for	example,	known	BACE-1	binders	(He,	et	al.	
2004,	Murayama,	et	al.	2006),	have	been	shown	to	increase	the	retention	of	BACE-1	within	the	ER,	
and	 in	 doing	 so	 reduce	 its	 activity	 due	 to	 the	 sub	optimal	 pH	 in	 this	 region	of	 the	 cell	 (Shi,	 et	 al.	
2009).	 Transgenic	mice	 expressing	 RTN3	 display	 reduced	 levels	 of	 C99	 fragments	 (the	 product	 of	
BACE-1	 cleavage).	 Therapeutic	 targets	 to	 enhance	 levels	 of	 these	 proteins	 may	 go	 some	 way	
therefore	 to	 regulate	 the	 production	 of	 Aβ	within	 cells.	 In	 addition,	 physical	 interaction	 between	
BACE-1	and	RTN	proteins	obstructs	the	ability	of	BACE-1	to	interact	with,	and	process	APP	to	further	
reduce	 the	 formation	 of	 the	 Aβ	 peptide	 (Vassar,	 et	 al.	 2009).	 Finally,	 expression	 of	 neuronal	
reticulon	 protein	 is	 significantly	 reduced	 in	 the	 brains	 of	 those	 with	 AD,	 implicating	 this	 protein	
perhaps	in	an	abnormal	increase	of	BACE-1	activity	(Hu,	et	al.	2007).	
	
	 Conversely,	targeted	trafficking	of	BACE-1	to	sites	of	optimal	pH	such	as	the	endosomes	will	
enhance	the	processing	of	APP	(He,	et	al.	2005).	Studies	have	shown	that	depletion	of	specific	GGA	
proteins	 (Golgi-localised	 γ-ear–containing	 ARF-binding	 proteins)	 with	 RNAi	 modulates	 BACE-1	 in	
such	 a	 way	 that	 it	 is	 targeted	 to	 early	 endosomes	 (He,	 et	 al.	 2002),	 an	 acidic	 environment	 that	
promotes	processing	of	APP.		AD	patients	have	been	shown	to	display	significantly	decreased	levels	
of	GGA3	 (Tesco,	et	al.	2007)	such	that	 finding	ways	 to	enhance	the	brain	 levels	of	both	RTN3	and	
GGA3	may	also	be	effective	therapeutics	against	AD.		
	
4.2.2	Enhancing	shedding	of	BACE-1	
	
	 An	alternative	method	by	which	BACE-1	may	be	targeted	as	a	potential	therapeutic	in	AD	is	
to	enhance	the	 level	 it	 is	shed.	A	fragment	of	BACE-1	found	within	cells	 is	 regularly	shed	between	
Ala429	and	Val430	via	 the	action	of	an	ADAM-like	sheddase	 (Hussain,	et	al.	2003).	 Interestingly,	 this	
fragment	 is	 able	 to	 act	 like	 other	 proteases	 to	 process	 their	 substrate	 (β-secretase	 cleavage	 site	
containing)	 peptides.	 However,	 the	 effects	 of	 these	 fragments	 have	 only	 been	 shown	 in	 vitro.	 As	
such,	finding	ways	to	enhance	the	shedding	of	BACE-1	may	be	successful	in	reducing	the	generation	
of	 the	Aβ	peptide.	 Indeed,	 soluble	BACE-1	 is	unable	 to	 successfully	 interact	with	APP	 in	 cells	 thus	
precluding	 its	 processing	 (Yan,	 et	 al.	 2001).	 It	 is	 also	 noteworthy	 that,	 ADAM	activity,	 if	 elevated,	
may	 drive	 the	 processing	 of	 BACE-1	 towards	 the	 non-amyloidogenic	 pathway	 such	 that	 APP	 is	
processed	by	α-secretases	instead	thus	precluding	formation	of	the	Aβ	peptide	(Vassar,	et	al.	2009).	
	
4.2.3	Targeting	BACE-1	indirectly	
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	 Expression	 levels	of	BACE-1	are	 significantly	 increased	 in	 those	with	AD	 (Fukumoto,	 et	al.	
2002).	 In	 light	 of	 this,	 one	 might	 postulate	 that	 BACE-1	 in	 some	 way	 is	 the	 main	 driver	 of	 AD	
development	within	the	brain.	Furthermore,	reports	have	suggested	that	oxidative	stress,	a	known	
associate	of	AD	pathology,	may	enhance	the	levels	of	BACE-1	found	within	the	brain	(Tamagno,	et	al.	
2002).	 Indeed,	 other	 factors	 including,	 ischemia	 (Wen,	 et	 al.	 2004),	 apoptosis	 (Tesco	 et	 al	 2007),	
hypoxia	 (Zhang,	 et	 al.	 2007)	 and	 traumatic	 brain	 injury	 (Blasko,	 et	 al.	 2004)	may	 also	 elevate	 the	
levels	of	BACE-1	detected	in	the	brain.	Finding	ways	to	treat	and/or	prevent	these	risk	factors	may	
thus	prove	effective	as	 indirect	strategies	 to	 target	BACE-1.	Combination	of	 this	method	alongside	
direct	 targets	 of	 BACE-1	 may	 prove	 particularly	 useful	 in	 combating	 the	 processing	 of	 APP	 and	
ultimately	the	generation	of	the	Aβ	peptide.	Glucose	metabolism	is	another	inducer	of	cellular	stress	
that	may	also	elevate	BACE-1	levels	in	the	brain.	Indeed,	work	in	APP	mouse	models	of	AD	treated	to	
disrupt	energy	metabolisms	pathways	were	found	to	display	increased	levels	of	BACE-1	and	also	Aβ	
(Velliquette,	 et	 al.	 2005).	 In	 addition,	 mRNA	 expression	 levels	 of	 BACE-1	 remained	 unaltered	
indicating	enhanced	 levels	as	observed	here	were	not	a	 result	of	elevated	gene	expression	per	 se	
(Velliquette,	et	al.	2005).	Further	research	went	on	to	confirm	that	energy	deprivation	may	induce	
phosphorylation	 events	 that	 result	 in	 elevation	 of	 mRNA	 translation	 (O'Connor,	 et	 al.	 2008)	
(Lammich,	 et	 al.	 2004).	 These	 findings	 would	 suggest	 that	 appropriate	 management	 of	 cellular	
homoeostasis	may	be	a	key	regulator	in	BACE-1	levels	and	therapeutics	to	maintain	this	equilibrium	
may	prove	efficacious	in	AD	patients.		
	
4.3	HS	and	BACE-1	
	
The	 role	 of	 HS	 and	 its	 interaction	 and	 inhibition	 of	 BACE-1	 is	 naturally,	 a	 very	 attractive	
target	 for	 the	 design	 of	 AD	 therapies	 in	 light	 of	 the	 challenges	 discussed	 earlier.	 Following	 the	
discovery	 that	 HS	 was	 able	 to	 effectively	 inhibit	 BACE-1	 and	 ultimately	 the	 processing	 of	 APP	 to	
generate	Aβ,	work	was	done	to	investigate	how	chemically	modified	analogues	of	HS	might	vary	in	
their	 ability	 to	 block	 BACE-1,	 as	 a	 potential	 template	 for	 therapeutics	 in	 the	 future	 (Patey,	 et	 al.	
2006).	 As	 discussed	 previously,	 administration	 of	 unmodified	 heparins	 would	 have	 serious	 side	
affects,	most	specifically	in	the	context	of	their	anticoagulant	activities.	Unmodified	derivatives	may	
therefore	increase	the	risk	of	internal	bleeding	and	disrupt	blood-clotting	mechanisms	all	around	the	
body.	On	the	other	side	of	the	coin,	utilising	a	naturally	occurring	structure	like	HS	may	also	be	key	
in	avoiding	rejection	via	Pgp	efflux	 (HS	 is	 largely	expressed	within	 the	brain)	and	toxic	side	effects	
that	may	 result	 from	 unnatural	 type	 structures	 as	 represented	 by	 typical	 small	 molecule	 organic	
drugs.	 To	 compromise,	 finding	ways	 to	 subtly	alter	 the	 structure	of	HS	 so	as	 to	 create	derivatives	
that	 still	 exert	 BACE-1	 inhibitory	 activity	 whilst	 negating	 their	 anti-coagulant	 effects	 may	 prove	
effective	as	AD	therapeutics,	without	adverse	effects	that	would	otherwise	make	them	unsuitable	in	
the	 clinic.	Work	 by	 Patey	 and	 colleagues	 investigated	 the	 activities	 of	 several	 HS	 analogues	 with	
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respect	 to	 their	 BACE-1	 activity	 and	 anti-coagulant	 activity.	 Results	 suggested	 that	 strong	 BACE-1	
inhibition	efficacy	 could	 still	be	maintained	alongside	 reduced	anti-coagulant	activity	 (Patey,	 et	al.	
2006).	The	most	simple	and	effective	 inhibitor	of	BACE-1	was	achieved	with	a	de-N-sulfated,	re-N-
acetylated	 porcine	 intestinal	 mucosal	 heparin	 (PIMH).	 2-O	 de-sulfated	 and	 2-O	 de-sulfated/N-
acetylated	PIMH	also	exhibited	good	BACE-1	inhibitory	action	suggesting	that	neither	2-O	sulfation	
nor	 N-sulfation	 is	 the	 key	motif	 in	 effective	 inhibition	 of	 BACE-1,	 particularly	 when	 levels	 of	 6-O	
sulfation	 is	 maintained.	 Removal	 of	 2-O	 and	 6-O	 sulfate	 groups	 dramatically	 reduced	 BACE-1	
inhibitory	activity	whilst	total	de-sulfation	totally	abolished	activity	altogether,	thus	implicating	6-O	
sulfation	as	key	determinants	in	BACE-1	inhibition	efficacy	(Patey,	et	al.	2006).		
	
The	presence	of	some	correlations	between	sulfation	pattern	(especially	6-O	sulfation)	and	
BACE-1	 inhibition	 would	 indicate	 that	 the	 interaction	 between	 HS	 and	 BACE-1	 is	 not	 simply	
dependent	upon	charge	density.	Understanding	the	ways	in	which	HS	is	able	to	block	the	activity	of	
BACE-1	is	key	to	further	“fine	tune”	HS	derivatives.		
	
Most	interestingly,	the	use	of	HS	analogues	as	inhibitors	of	BACE-1	may	also	avoid	adverse	
affects	as	early	work	indicates	they	do	not	interact	significantly	with	other	protease	family	members,	
a	significant	downfall	of	other	similar	compounds	that	have	been	identified	in	the	past.	Activities	of	
a	number	of	the	HS	analogues	tested	by	Patey	and	colleagues	revealed	that	modified	HS	derivatives	
exhibiting	substantial	BACE-1	inhibitory	activity	were	not	able	to	significantly	inhibit	renin,	pepsin	or	
cathepsin	D	(Patey,	et	al.	2006).	Overcoming	adverse	 interactions	and	potential	side	effects	 in	this	
manner,	 makes	 the	 interaction	 of	 HS	 and	 BACE-1	 even	 more	 attractive	 as	 a	 target	 to	 design	
templates	for	AD	therapeutics	in	the	future.		
	
4.3.1	How	does	HS	inhibit	BACE-1?	
	
	 The	 exact	mechanism	 by	which	HS	 is	 able	 to	 inhibit	 the	 activity	 of	 BACE-1	 has	 not	 been	
widely	 studied	as	 yet.	However	 initial	 research	upon	 the	discovery	of	 the	 interaction	between	HS	
and	 BACE-1	 went	 some	way	 to	 elucidate	 this	mechanism.	 Fluorescence	 polarisation	 was	 used	 to	
examine	 the	effects	of	binding	of	a	 rhomadime-labeled	non-cleavable	peptide	 substrate	 (R110)	 to	
BACE-1.	Research	found	that	R110	ligand	is	able	to	bind	to	free	BACE-1	at	the	substrate-binding	site.	
In	 doing	 so,	 the	 polarisation	 of	 light	 relative	 to	 an	 unbound	 ligand	 was	 increased.	 In	 addition,	 a	
known	 competitive	 ligand	 of	 the	 binding	 site	 of	 the	 BACE-1	 (GW642976A)	 produced	 a	 detected	
decrease	 in	 the	 polarisation	 of	 light,	 due	 to	 dose-dependent	 displacement	 of	 the	 R110	 ligand	 as	
would	be	expected	for	a	competitive	inhibitor.	This	effect	was	observed	independently	of	whether	
the	 antagonist	was	 added	before,	 or	 after	 the	 pre-equilibrium	of	 BACE-1	 and	R110.	 Furthermore,	
incubation	 of	 R110	 and	 BACE-1	 before	 addition	 of	 N-acetylated	 heparin	 negated	 its	 inhibitory	
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effects.	From	this	data,	it	was	concluded	that	HS	is	able	to	prevent	the	entry	of	the	substrate	to	the	
active	site	but	is	not	a	competitive	inhibitor.	In	addition,	this	research	suggested	that	if	the	ligand	is	
pre-bound	to	BACE-1,	HS	is	able	to	lock	the	ligand	into	the	active	site	(Scholefield,	et	al.	2003).		
	
	 This	study,	coupled	with	the	research	to	determine	how	differing	structures	of	HS	are	able	
to	 inhibit	 BACE-1,	 led	 to	 conclusions	 that	 the	 principal	means	 by	 which	 HS	 in	 able	 to	 inhibit	 the	
activity	of	BACE-1	is	via	binding	to	the	secretase	enzyme	at,	or	near	to	the	active	site	and	in	doing	so	
either	physically	blocks	the	binding	of	the	substrate	to	BACE-1,	or	possibly	exerts	a	conformational	
change	in	BACE-1	that	precludes	substrate	access.	Previous	research	into	the	co-crystal	structure	of	
BACE-1	with	a	peptide	isoster	analogue	(OM99-2)	has	previously	revealed	the	presence	of	a	hairpin	
loop	that	covers	the	active	site	of	BACE-1	when	not	actively	bound	to	its	ligand	(Hong,	et	al.	2000).	
The	data	collected	in	this	study	sits	well	with	the	notion	of	the	binding	of	HS	when	BACE-1	is	in	its	
closed	 conformation.	NMR	 and	 X-ray	 crystallography	 however	would	 be	 required	 to	 fully	 confirm	
this	notion	(Scholefield,	et	al.	2003),	though	preliminary	evidence	from	small	angle	X-ray	scattering	
(SAXS)	 has	 identified	 a	 change	 in	 BACE-1	 conformation	 that	 would	 be	 consistent	 with	 a	
conformational	effect	model	(Turnbull,	personal	communication).		
	
Alongside	the	observed	interaction	of	HS	and	BACE-1,	it	has	also	been	established	that	HS	
can	 interact	 with	 its	 substrate,	 APP.	 As	 such,	 the	 role	 of	 HS	 in	 BACE-1	 cleavage	 pathways	 is	
somewhat	of	a	complex	one	and	suggests	a	further	potential	mechanism	of	inhibition	of	BACE-1	in	
that	HS	may	be	able	to	bind	to	APP	and	sequester	it	away	from	the	BACE-1	active	site,	thus	blocking	
its	processing.	Indeed,	in	light	of	the	many	interactions	HS	is	able	to	make	with	the	components	of	
the	amyloid	processing	pathway,	it	has	been	suggested	that	perhaps	binding	of	HS	to	BACE-1	alone	
is	 not	 enough	 to	 achieve	 maximum	 inhibition	 but	 rather	 interaction	 with	 the	 native	 protein	
substrate	is	also	an	important	factor	to	consider	in	this	pathway	(Scholefield,	et	al.	2003).		
	
Now	that	 research	has	 identified	 the	potential	mechanisms	by	which	HS	 is	able	 to	 inhibit	
BACE-1	specifically,	further	work	is	needed	to	clarify	the	HS	binding	site	in	the	BACE-1	enzyme.	The	
structural	characterisation	of	HS	from	AD	and	healthy	age-matched	control	patients	as	described	in	
chapter	 2	 may	 go	 some	 way	 to	 elucidate	 some	 of	 the	 structures	 that	 are	 responsible	 for	 this	
interaction	between	HS	and	BACE-1.	Changes	in	the	structure	of	HS	as	we	have	observed	here	may	
account	for	possible	changes	 in	the	way	 in	which	HS	 is	able	to	 interact	with	BACE-1.	Furthermore,	
previous	research	into	the	surface	charge	modeling	of	the	known	crystal	structure	of	BACE-1	(Hong,	
et	 al.	 2000)	 identified	 strongly	 basic	 regions	 that	 may	 serve	 as	 binding	 sites	 with	 which	 HS	 can	
interact.	Changes	in	charge	density	of	the	HS	chain	as	a	result	of	changes	in	the	pattern	of	sulfation	
along	the	chain	for	example	may	also	go	some	way	to	provide	a	mechanism	by	which	elevated	BACE-
1	 activity	 is	 observed	 in	 AD	 patients.	 Finally,	 the	 conformational	 shape	 that	 HS	may	 exhibit	 as	 a	
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result	of	specific	structural	features	along	its	chain	may	too	provide	a	physical	mechanism	by	which	
it	is	able	to	interact	with	BACE-1	in	an	allosteric	fashion.		
	
4.4	Conclusions	
	
In	light	of	the	advances	made	in	this	manner	towards	understanding	the	interaction	of	HS	
and	BACE-1,	as	well	as	ways	in	which	inhibitors	may	be	used	to	target	processing	of	APP,	this	project	
aimed	to	determine	whether	HS	purified	from	AD	patient	brain	samples	was	able	to	inhibit	BACE-1	
compared	to	the	HS	purified	from	age-matched	control	healthy	counterparts.	Now	that	it	has	been	
established	that	structural	alterations	in	HS	do	occur	with	AD,	we	might	hypothesise	that	this	could	
have	downstream	consequences	on	 the	ability	of	HS	 to	 interact	with	and	regulate	BACE-1.	Should	
the	 reported	 structural	 changes	 in	HS	 in	AD	patient	brain	 samples	have	 consequences	 for	BACE-1	
inhibition	efficacy,	the	notion	of	appropriately	designed	inhibitors	of	BACE-1	based	on	these	changes	
will	be	strengthened.	This	chapter	aimed	to	determine	the	BACE-1	inhibitory	activity	of	HS	from	AD	
and	healthy-age-matched	control	patients.	In	addition,	the	purified	HS	from	aged	and	young	mouse	
brain	samples	as	analysed	in	chapter	2	were	also	assayed	for	BACE-1	inhibitory	activity	to	determine	
whether	the	structural	changes	that	occur	with	age	have	implications	for	BACE-1	activity.		
	
4.5	Chapter	Aims	
	
• Investigate	 the	BACE-1	 inhibitory	activity	of	HS	purified	 from	AD	patient	and	healthy	age-
matched	control	human	brain	samples.	
• Explore	how	manipulation	of	HS	structure	via	knockdown	of	HS6ST	and	SULF	enzymes	in	a	
cell-based	system	in	vitro	can	regulate	the	activity	of	BACE-1	and	ultimately	the	generation	
of	Aβ	by	cells.		
• Investigate	how	age	may	be	implicated	in	BACE-1	inhibition	efficacy	by	testing	the	BACE-1	
inhibitory	activity	of	HS	purified	from	old	and	young	mouse	brains.		
• Determine	 whether	 total	 knockdown	 of	 Sulf	 gene	 expression	 in	 a	 mouse	 model	 has	
consequences	for	BACE-1	inhibition	efficacy.		
	
4.6	Methods		
4.6.1	 Exploring	 the	 relationship	 between	 changes	 in	 endogenous	 HS	 structure	 and	 BACE-1	
inhibition	efficacy		
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4.6.1.1	Sample	selection		
The	ability	of	HS	to	inhibit	BACE-1	at	differing	concentrations	was	assessed	from	human	AD	
(n=20)	and	healthy	age-matched	control	(n=15)	samples	as	described	previously	in	chapter	2,	as	well	
as	HS	purified	from	old	(n=5)	and	young	(n=5)	mice	as	detailed	in	chapter	2.	In	addition,	mouse	brain	
samples	 from	Sulf	KO	mouse	models	 (n=3)	 for	each	of	Sulf1	KO,	Sulf2	KO,	Double	KO	and	controls	
were	analysed	 for	 their	 ability	 to	block	 the	activity	of	 the	BACE-1	enzyme.	Having	highlighted	 the	
importance	of	sulfation,	in	particular	6-O	sulfation	in	BACE-1	inhibition,	a	mouse	model	that	ablated	
all	 SULF	 activity	 was	 utilised	 to	 capitulate	 a	 scenario	 whereby	 HS	 is	 “highly”	 sulfated	 due	 to	 the	
absence	 of	 sulfatase	 activity	 at	 the	 6-O	 position.	 Sulf	 KO	 mice	 were	 donated	 from	 Bielefeld	
University,	Germany	and	were	 raised	on	a	C57BL6/JRccHsd	background.	Mice	were	 fed	ad	 libitum	
and	sacrificed	at	embryonic	stage	18.5	(E18.5).	Brains	were	removed	immediately	and	snap	frozen	
before	being	sent	to	the	University	of	Liverpool.		
	
4.6.1.2	FRET	BACE-1	activity	assay	
	
FRET	is	a	method	employed	to	measure	the	transfer	of	energy	from	a	donor	fluorophore	in	
an	 excited	 state	 to	 an	 appropriate	 acceptor	 fluorophore.	 The	 donor	 fluorophore,	 in	 an	 excited	
electronic	 state	 is	 able	 to	 transfer	 its	 energy	 to	 a	 nearby	 (this	 technique	 is	 distance	 dependent)	
acceptor	chromophore	and	in	doing	so	significantly	reduces	the	fluorescence	intensity.	Disturbances	
in	 this	 intramolecular	 resonance	 energy	 transfer	 to	 the	 acceptor	 chromophore	 will	 disrupt	
fluorescence	intensity	and	enhance	the	fluorescent	signal	emitted	by	the	donor.	The	BACE-1	activity	
assay	exploits	 the	 features	of	FRET	by	 incubating	 the	BACE-1	enzyme	with	 its	 substrate,	a	peptide	
with	a	fluorescent	tag	linked	to	one	end	and	a	second,	quencher	tag	on	the	other.	When	in	its	full-
length	form,	the	distance	between	the	donor	chromophore	and	quencher	is	small	enough	for	energy	
transfer	 to	 occur,	 thus	 quenching	 the	 fluorescence	 intensity	 of	 the	 donor	 tag.	 Cleavage	 of	 the	
peptide	 by	 the	 BACE-1	 enzyme	 however,	 separates	 the	 tag	 and	 quencher	 thus	 disrupting	 the	
resonance	energy	transfer	and	consequently	enhances	the	fluorescent	signal	that	can	be	measured.	
As	such,	Fluorescence	intensity	is	a	signal	for	the	efficacy	of	BACE-1	cleavage	activity.	Addition	of	the	
heparan	sulfate	inhibitors	will	modulate	this	activity	and	alter	these	intensities	accordingly.		
	
This	assay	was	carried	out	in	a	96	well	format	and	measured	the	fluorescence	intensity	of	
the	cleaved	BACE-1	substrate	peptide	after	 incubation	 in	 the	presence	of	a	 selected	HS	 (inhibitor)	
sample.	 10μl	 of	 the	 substrate	 peptide	 (N-terminus:	 5-FAM,	 C-terminus:	 Amide	 and	 Sequence:	
EVNLDAEFK)	 (Pepceuticals	 Limited,	 Leicestershire,	 UK)	 was	 added	 to	 265μl	 assay	 buffer	 (20mM	
sodium	acetate	with	0.1%	Triton	X-100	pH	4.5.	0.2μm	filtered).	Followed	by	a	further	1:8	dilution	in	
assay	buffer	 for	addition	of	10μl	of	peptide	 to	each	well	 to	be	assayed.	The	BACE-1	enzyme	 (R+D	
systems	931-AS	50mg	–	reconstituted	to	500μg/ml	 in	sterile	deionised	water)	was	diluted	1:500	 in	
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assay	 buffer	 for	 addition	 of	 25μl	 per	 test	 well	 and	 kept	 on	 ice	 until	 needed.	 	 For	 the	 heparin	
inhibition	 curve,	 samples	 were	 prepared	 at	 5.0μg/ml	 and	 diluted	 1:2	 sequentially	 to	 a	 final	
concentration	of	0.16μg/ml.	To	note,	addition	of	20μl	of	heparin	samples	 in	a	final	well	volume	of	
100μl,	 resulted	 in	a	1:5	dilution	of	all	 samples	 so	 final	working	concentrations	of	heparin	 samples	
ranged	from	1.0μg/ml	to	0.03μg/ml.	Finally,	HS	samples	purified	from	mouse	samples	was	prepared	
at	either	10.0,	5.0,	2.5	or	1.25	μg/ml	with	a	final	working	concentration	of	2.0,	1.0,	0.5	or	0.25	μg/ml	
and	human	samples	to	a	final	working	concentrations	of	2.0,	1.0,	0.2	or	0.02	μg/ml.	
	
To	 each	 well,	 45μl	 of	 assay	 buffer	 was	 added,	 followed	 by	 20μl	 of	 inhibitor	 (heparin	
standards	or	HS	purified	from	tissue),	25μl	of	enzyme,	and	10μl	of	peptide.	All	samples	were	assayed	
in	 triplicate.	A	no	 inhibitor	control	 (65μl	of	assay	buffer,	25μl	of	enzyme	and	10μl	of	peptide)	and	
substrate	control	 (90μl	assay	buffer	and	10μl	of	substrate)	were	also	set	up	 in	triplicate.	The	plate	
was	 sealed	 with	 a	 cover,	 protected	 from	 the	 dark	 and	 incubated	 for	 2hr	 at	 37°C.	 Following	
incubation,	100μl	of	stop	solution	(2.5M	sodium	acetate,	0.2μm	filtered)	was	added	to	each	well	to	
stop	the	reaction.	The	plate	was	then	read	using	a	FRET	endpoint	488/520nm	protocol	(Figure	4.1).		
	
4.6.1.3	Statistical	Analysis	
	
	 BACE-1	activity	was	calculated	as	a	percentage	relative	to	a	no-inhibitor	control	(100%).	All	
test	 cases	 were	 carried	 out	 in	 triplicate.	 For	 human	 AD	 (n=10)	 and	 healthy	 age-matched	 control	
samples	(n=10),	mean	(±S.E.M)	%	BACE-1	activity	was	plotted	as	a	bar	graph	and	Two-Way	ANOVA	
with	 multiple	 comparisons	 used	 to	 calculate	 the	 statistical	 difference	 between	 mean	 BACE-1	 %	
activity	of	AD	and	control	samples	at	each	concentration	of	HS.	This	was	true	also	 for	 the	old	and	
young	mice	derived	HS	studied.	For	the	Sulf	KO	mice,	Sulf1	KO	(n=3),	Sulf2	KO	(n=3),	Double	KO	(n=3)	
and	control	mice	(n=3)	were	tested	for	mean	(±S.E.M)	%	BACE-1	activity	in	the	presence	of	purified	
HS	in	the	same	manner,	however	a	One-Way	ANOVA	with	multiple	comparisons	was	used	to	assess	
changes	in	BACE-1	activity	between	control	mice	and	knockout	models	at	each	concentration	of	HS	
assayed.		
	
4.6.2	Exploring	whether	modulation	of	HS	structure	in	cellulo	is	able	to	regulate	generation	of	the	
toxic	Aβ	peptide		
4.6.2.1	Transfection	
	
All	transfection	experiments	were	carried	out	using	human	embryonic	kidney	cells	modified	
to	 expression	 the	 Swedish	 APP	 mutation	 (overexpression	 of	 APP).	 HEKSweAPP	 cells	 were	 kindly	
donated	by	 the	Hooper	 Lab	at	 the	University	of	Manchester.	Cells	were	maintained	 in	Dulbecco’s	
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Modified	 Eagled	 Medium	 (DMEM)	 (Gibco,	 Thermo	 Fisher,	 UK)	 supplemented	 with	 fetal	 bovine	
serum	(FBS),	1mM	L-glutamine	(Gibco,	UK)	and	1%	penicillin	G/streptomycin	(Gibco,	UK).		
	
	
	
	
	
	
	
	
	
	
	
Figure	4.1:	FRET	based	assay	to	assess	BACE-1	inhibition	efficacy	by	HS	samples.	The	BACE-1	substrate	peptide	
is	 tagged	 at	 both	 ends.	 On	 one,	 a	 fluorescent	 tag	 and	 at	 the	 other,	 a	 quencher.	 Due	 to	 a	 intramolecular	
resonance	energy	transfer	phenomenon,	so	long	as	the	quencher	is	in	close	proximity	(i.e.	the	peptide	remains	
intact),	the	intensity	of	the	fluorescent	tag	is	significantly	reduced.	Upon	cleavage,	the	spatial	proximity	of	the	
quencher	and	fluorescent	tag	is	disrupted	and	the	fluorescence	intensity	of	the	tag	is	enhanced	for	detection.	
Incubation	of	the	BACE-1	enzyme	and	peptide	substrate	with	HS	inhibitors	will	attenuate	this	fluorescent	signal.	
	
	
24hr	before	 transfection,	6x104	HEKSweAPP	cells	were	plated	 in	400μl	of	 (DMEM)	 (Gibco,	Thermo	
Fisher,	UK)	growth	medium	and	FBS	without	antibiotics	per	well	(all	experiments	were	carried	out	in	
24	well	plates).	Cells	were	~90%	confluent	at	the	time	of	transfection.	For	each	of	the	sample	wells	
to	undergo	transfection	RNAi-Lipofectamine™	2000	(Thermo	Fisher,	UK)	complexes	were	prepared	
as	follows.	Per	well,	100pmol	of	RNAi	(Silencer	Select	RNAi,	Ambion,	Thermo	Fisher,	UK)	(Table	4.1)	
was	 diluted	 in	 50μl	 of	Opti-MEM®	 reduced	 serum	medium	 (Gibco,	 Thermo	 Fisher,	UK)	 and	mixed	
gently.	Additionally,	per	well,	1μl	of	Lipofectamine™	2000	was	diluted	in	50μl	of	Opti-MEM®	reduced	
serum	 medium,	 mixed	 gently	 and	 incubated	 at	 room	 temperature	 for	 15min.	 “Scrambled”	 RNAi	
(Stealth™	RNAi	Negative	Control	Duplexes,	 Invitrogen,	Cat	no:	12935-100)	was	used	as	an	 internal	
control	 for	 the	transfection	and	was	selected	based	on	the	GC	content	of	 the	gene	to	be	knocked	
down	(Table	4.2).		
	
Following	 incubation,	 the	diluted	RNAi	 (or	 scrambled	RNAi	 for	 the	 control	wells)	 and	 the	
diluted	Lipofectamine™	2000	were	combined	and	mixed	gently	before	a	further	15min	incubation	at	
room	temperature	to	allow	complexes	to	form.	After	incubation,	106μl	of	the	RNAi-Lipofectamine™	
2000	complexes	were	added	to	each	well	containing	cells	and	medium	and	the	plate	gently	mixed.	
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Plates	were	 incubated	at	37°C	 in	 a	humidified	CO2	 incubator	 for	6hr	 to	 allow	 transfection	 to	 take	
place.	 At	 this	 time,	medium	was	 removed	 and	 discarded	 and	 replaced	 with	 fresh	 DMEM	 (Gibco,	
Thermo	 Fisher,	 UK)	 growth	medium	 and	 antibiotics	 as	 described	 previously.	 Transfection	 studies	
were	carried	out	over	a	72hr	time	period	with	24hr	timepoints.	At	designated	timepoints	(24,	48	and	
72hr),	cells	and	media	were	collected,	as	described	below	and	prepared	in	preparation	for	qRT-PCR	
to	confirm	knock	down	and	ELISA	to	quantify	the	concentration	of	Aβ	present	within	the	media.	
	
4.6.2.2	Extraction	of	cells	and	RNA	
	
	 Cells	at	appropriate	timepoints	were	collected	according	to	manufacturer’s	 instruction	for	
Roche	High	 Pure	RNA	 Isolation	 kit	 (Roche,	UK	Cat	 no:	 11	 828	 665	 001).	 Briefly,	 200μl	 of	 PBS	was	
added	to	each	well	to	be	collected	followed	by	400μl	of	lysis-binding	buffer.	A	cell	scraper	was	used	
to	remove	cells	from	the	well	and	collected	in	an	Eppendorf	before	vortexing	for	15s.	Samples	were	
then	transferred	to	a	high	pure	filter	tube	and	centrifuge	for	15s	at	8,000	x	g.	After	centrifugation,	
the	 flow-through	 liquid	 was	 discarded	 and	 the	 filter	 tube	 and	 collection	 tube	 re-assembled.	
Following	this,	10μl	of	DNase	I	was	added	to	90μl	of	DNase	incubation	buffer	and	added	to	the	glass	
filter	fleece	in	the	upper	reservoir	of	the	filter	tube	and	incubated	for	15min	at	room	temperature.	
Following	incubation,	500μl	of	washer	buffer	I	was	added	and	centrifuged	for	15s	at	8,000	x	g.	The	
flow	through	was	discarded	and	500μl	of	wash	buffer	II	added	and	centrifuged	again	for	15s	at	8,000	
x	 g.	 The	 flow	 through	 was	 discarded	 again	 and	 was	 followed	 by	 200μl	 of	 washer	 buffer	 II	 and	
centrifuged	 at	 maximum	 speed	 for	 2min.	 Finally,	 the	 RNA	 was	 eluted	 by	 adding	 50μl	 of	 elution	
buffer	 to	 the	 upper	 reservoir	 and	 the	 assembly	 centrifuged	 for	 1min	 at	 8,000	 x	 g.	 The	 RNA	was	
quantified	 using	 the	 Nano	 Drop™	 2000c	 (Thermo	 Fisher	 Scientific,	 UK)	 and	 stored	 at	 -80°C	 until	
needed	for	qRT-PCR.		
	
Table	 4.1:	 Details	 of	 silencer	 RNAi	 used	 for	 transfection	 experiments.	 5	 genes	 were	 studied	
individually,	HS6ST1,	HS6ST2,	HS6ST3,	SULF1	and	SULF2.	All	RNAi	was	purchased	from	Ambion,	Life	
Technologies;	product	codes	are	outlined	below.	
Gene	
Type	of	
RNAi	
Ambion	Cat	no:	
Concentration	per	well	in	
50μl	media	
GC	content	
HS6ST1	 Silencer		 AM51331	 100pmol		 48%	
HS6ST2	 Silencer		 AM16708	 100pmol		 14%	
HS6ST3	 Silencer	 AM16708	 100pmol	 9%	
SULF1	 Silencer		 AM16708	 100pmol		 43%	
SULF2	 Silencer		 AM16708	 100pmol		 43%	
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Table	 4.2:	 Details	 of	 “scrambled”	 RNAi	 duplexes	 used	 as	 internal	 controls	 for	 each	 transfection	
experiment.	 Appropriate	 control	 RNAi	 was	 selected	 based	 on	 the	 GC	 content	 of	 the	 target	 gene	
RNAi	used	in	each	instance.	RNAi	duplexes	were	purchased	from	Invitrogen.	
RNAi	Negative	
Control	Duplex	
%GC	 Suitable	for	use	with	RNAi	
duplexes	containing	%GC	
Suitable	as	control	for	target	
genes	
Low	GC	 36	 35-45%	 SULF1,	SULF2,	HS6ST2,	HS6ST3	
Medium	GC	 48	 45-55%	 HS6ST1	
High	GC	 68	 55-70%	 n/a	
	
4.6.2.3	Extraction	of	media	
	
Total	 media	 was	 collected	 at	 time	 points	 as	 outlined	 above	 and	 frozen	 at	 -80°C	 until	
required	for	analysis	by	ELISA.	All	media	samples	were	diluted	1:10	for	all	ELISA	protocol	steps.		
	
4.6.2.4	Manual	quantitative	real	time	polymerase	chain	reaction	(qRT-PCR)	
	
	 All	qRT-PCR	steps	were	carried	out	as	described	earlier	 in	chapter	3,	section	3.3.1.1.	Only	
expression	analysis	of	 the	gene	knocked	down	 in	each	experiment	 (Table	 4.1)	was	carried	out.	All	
primers	used	and	protocol	design	was	identical	to	that	used	in	chapter	3,	section	3.3.1.1	also.	
	
	 qRT-PCR	was	performed	using	the	LightCycler®	480	Roche	machine	(Roche,	UK).	Expression	
levels	were	normalised	to	Glyceraldehyde	3-Phosphate	Dehydrogenase	(GAPDH)	levels	and	the	delta	
delta	Ct	method	was	used	to	calculate	the	relative	change	in	expression	of	the	HS	biosynthetic	genes	
of	interest	from	samples,	assuming	primer	efficiency.	All	analyses	were	expressed	as	the	fold	change	
of	 expression	 of	 the	 gene	 of	 interest	 relative	 to	 the	 internal	 control	 in	 the	 treated	 samples	 as	
compared	with	the	controls.	Using	the	Ct	method	of	analysis	allowed	fold	changes	of	expression	to	
be	 calculated	 for	 each	 gene	 of	 interest	 at	 each	 time	 point	 with	 respect	 to	 the	 treated	 state	
normalised	 to	 internal	 controls.	 All	 qRT-PCR	 reactions	were	 carried	 out	 in	 triplicate.	 Experimental	
triplicates	were	combined	and	 the	mean	 (±S.E.M)	calculated	and	data	 for	 individual	 samples	were	
also	averaged.	Values	of	2-ΔΔCt	were	logged	to	generate	positive	and	negative	values	indicative	of	up-	
and	down-regulated	expression	of	target	genes.		
	
4.6.2.5	ELISA	protocol	
	
Aβ1-42	 peptide	 was	 quantified	 from	 media	 following	 transfection	 to	 identify	 possible	
regulation	of	the	generation	of	this	toxic	species.	An	amyloid	beta	42	ELISA	kit	for	Human	samples	
(Cat	no:	KHB3441,	Thermo	Fisher,	UK)	was	used	to	quantify	levels	of	this	peptide	in	media	samples	
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collected	 during	 transfection	 experiments.	 The	 kit	 was	 used	 according	 to	 manufacturer’s	
instructions.		
	
Briefly,	 human	 beta-amyloid	 standards	 1-42	 were	 reconstituted	 with	 1ml	 of	 peptide	
standard	reconstitution	buffer	to	1000mg/ml	final	concentration	and	hydrated	for	10min.	Standards	
were	then	aliquoted	in	100μl	per	vial	and	stored	at	-80°C	until	needed.	The	mouse	monoclonal	anti-
beta-amyloid	 1-42	 coated	plate	was	 then	 assembled	 according	 to	 sample	number	 and	 a	 standard	
curve	 of	 9	 serial	 dilutions	 of	 the	 amyloid	 beta	 standards	 set	 up	 from	 1000pg/ml	 to	 15.63pg/ml.	
Dilutions	were	prepared	with	standard	dilution	buffer	as	provided	by	the	ELISA	kit.	Media	samples	
collected	from	each	timepoint	were	diluted	1:10	in	standard	dilution	buffer	also.	50μl	of	either	Aβ1-42	
standards	 (as	part	of	 the	concentration	curve)	or	media	 samples	were	pipetted	 (in	duplicate)	 into	
test	wells	of	the	plate.		
	
Following	preparation	of	 the	standard	curve	and	test	samples,	50μl	of	detection	antibody	
solution	was	then	added	to	all	wells	to	be	assayed	and	the	plate	tapped	gently	to	mix.	The	plate	was	
then	covered	with	an	adhesive	plate	cover,	and	incubated	for	3hr	at	room	temp	with	gentle	shaking	
throughout.	
	
	 Following	incubation,	assay	wells	were	aspirated	and	washed	4x	with	a	1x	wash	buffer	(as	
diluted	from	the	25x	stock	included	in	kit).	Next,	an	anti-rabbit	IgG	HRP	solution	was	prepared.	Per	8	
well	strip	of	the	assay	plate	used,	10μl	of	the	100X	Anti-Rabbit	IgG	HRP	solution	was	added	to	1ml	of	
HRP	diluent.	 100μl	of	 the	diluted	anti-rabbit	 IgG	HRP	 solution	was	 then	added	 to	each	assay	well	
before	recovering	the	plate	with	a	plate	cover	and	incubating	for	30min	at	room	temp.	After	30min,	
wells	 were	 aspirated	 and	 washed	 again	 4x	 as	 previously	 before	 addition	 of	 100μl	 of	 stabilized	
chromagen	to	each	well,	causing	a	colour	changes	 from	clear	to	blue.	The	plate	was	then	covered	
with	a	plate	cover	and	incubated	in	the	dark	for	30	min	at	room	temp.		Following	incubation,	100μl	
of	 stop	 solution	was	added	 to	each	well	 and	 the	plate	 tapped	gently	 to	mix.	This	mixing	causes	a	
colour	change	from	blue	to	yellow.	The	absorbance	(OD)	of	the	plate	was	then	measured	at	450nm	
using	a	microplate	absorbance	reader	(Multiskan	EX,	Thermo	Fisher	Scientific,	UK)	within	30	min	of	
adding	the	stop	solution.	
	
4.6.2.5.1	Analysis	of	ELISA	data	
	
Mean	 absorbance	 values	 for	 the	 Aβ	 peptide	 standard	 curve	 were	 calculated	 and	 a	
calibration	curve	plotted	using	linear	regression	curve	fit	and	a	threshold	value	for	R2	of	0.98	used	
for	 accuracy.	 The	 straight-line	 equation	 was	 determined	 and	 used	 to	 calculate	 average	
concentrations	of	each	of	the	test	media	samples	and	multiplied	by	10	to	account	for	dilution	factor.	
Concentrations	 of	 Aβ	 standards	 from	 the	 media	 were	 then	 plotted	 as	 bar	 graphs	 over	 the	 time	
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course	of	 the	transfection	experiment	to	observe	changes	 in	 its	 regulation	over	time.	Transfection	
experiments	 were	 carried	 out	 in	 triplicate	 and	 assayed	 with	 ELISA	 as	 duplicates.	 Mean	 (±S.E.M)	
differences	between	timepoints	were	determined	using	a	Student’s	t-test.	
	
4.7	Results		
4.7.1	 Exploring	 the	 relationship	 between	 changes	 in	 endogenous	 HS	 structure	 and	 BACE-1	
inhibition	efficacy		
	 Varying	concentrations	of	purified	HS	from	AD	and	age-matched	control	samples,	aged	and	
young	mouse	brain	samples	and	mouse	Sulf	KO	brain	samples,	were	incubated	in	the	presence	of	a	
fluorescently	labeled	peptide	to	assess	inhibition	of	the	BACE-1	enzyme.	Previous	work	has	already	
established	that	HS	is	able	to	interact	with	and	inhibit	BACE-1,	and	so	this	part	of	the	project	aimed	
to	determine	how	known	changes	in	the	structure	of	HS	(as	already	identified	in	chapter	2),	may	be	
implicated	in	the	ability	of	HS	to	regulate	BACE-1.		
	
4.7.1.1	AD	and	age-matched	control	healthy	human	brain	sample	HS	
	
	 HS	extracted	and	purified	from	human	AD	(n=10)	and	age-matched	control	samples	(n=10)	
was	 incubated	at	varying	concentrations,	0.02,	0.2,	1.0	and	2.0μg/ml	with	the	BACE-1	enzyme	and	
fluorescently	tagged	peptide.	Each	HS	sample	was	assayed	in	triplicate	and	mean	(±S.E.M)	%	BACE-1	
activity	 was	 calculated	 relative	 to	 a	 no	 inhibitor	 control	 (100%).	 Potent	 inhibitory	 activity	 of	 a	
positive	control,	heparin,	was	noted	at	1.0μg/ml	(~35%	of	no	 inhibitor	control;	Figure	4.2).	A	dose	
dependent	decrease	 in	%	BACE-1	 activity	 in	 the	presence	of	 healthy	 age-matched	 control	HS	was	
observed	(Figure	4.2).		
	
In	contrast,	HS	purified	from	human	AD	(n=10)	samples	displayed	a	reduced	ability	to	block	
the	activity	of	the	BACE-1	enzyme	particularly	at	higher	concentrations.	No	significant	 inhibition	of	
BACE-1	by	HS	from	AD	patient	brain	samples	was	observed	at	any	dose	(Figure	4.2).	At	the	highest	
dose	 tested,	 2.0μg/ml,	 HS	 from	 AD	 patient	 brain	 samples	 incubated	 with	 BACE-1	 and	 substrate	
peptide	displayed	mean	(±S.E.M)	%	BACE-1	activity	of	90.02%	(±7.81).	This	differed	significantly	 to	
that	of	age-matched	control	HS	samples	at	this	concentration	(55.30%	(±4.00))		(p=0.004,	Two-Way	
ANOVA	with	multiple	comparisons),	 indicating	reduced	inhibitory	activity	of	BACE-1	of	HS	from	AD	
patients.	At	all	concentrations	assayed,	inhibition	of	BACE-1	by	HS	was	found	to	be	less	than	in	the	
presence	of	heparin	(data	not	shown).		
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4.7.1.2	Aged	vs.	young	mouse	brain	samples	
	
	 HS	extracted	from	aged	(18	month)	(n=5)	and	young	(3	month)	(n=5)	mouse	brain	samples	
was	incubated	with	the	BACE-1	enzyme	and	fluorescently	tagged	peptide	at	varying	concentrations,	
identical	 to	 that	of	 the	AD	and	 control	HS	 samples.	 Each	HS	 sample	was	 assayed	 in	 triplicate	 and	
mean	 (±S.E.M)	%	BACE-1	activity	was	calculated	 relative	 to	a	no	 inhibitor	control	 (100%).	HS	 from	
aged	and	young	brain	samples	was	compared	at	each	concentration	for	its	ability	to	block	the	action	
of	the	BACE-1	enzyme.	Unexpectedly,	the	lowest	concentration	of	HS	tested,	0.25μg/ml,	elicited	the	
most	potent	inhibition	of	BACE-1	with	recorded	mean	(±S.E.M)	%	BACE-1	activity	for	young	and	aged	
HS	of	 57.20%	 (±4.39)	 and	18.04%	 (±2.28)	 respectively.	Aged	HS	at	 this	 concentration	was	notably	
more	 able	 to	 inhibit	 BACE-1	 as	 highlighted	 by	 the	 considerably	 reduced	 BACE-1	 %	 activity.	 This	
change	 was	 found	 to	 be	 statistically	 significant	 (p=0.0004,	 Two-Way	 ANOVA	 with	 multiple	
comparisons).	At	0.5μg/ml,	HS	from	young	mouse	brain	samples	(n=5)	reduced	%	BACE-1	activity	to	
74.48%	 (±4.86)	 and	 to,	 72.68%	 (±5.58)	 from	 aged	 samples;	 this	 difference	 was	 not	 found	 to	 be	
statistically	 significant	 (p=0.999).	 No	 significant	 inhibition	 of	 BACE-1	 was	 observed	 at	 higher	
No
 in
hib
ito
r 
1u
g/m
l H
ep
ari
n
0.0
2u
g/m
l C
trl
 H
S
0.0
2u
g/m
l  A
D 
HS
0.2
ug
/m
l C
trl
 H
S
0.2
ug
/m
l A
D 
HS
1.0
ug
/m
l C
trl
 H
S
1.0
ug
/m
l  A
D 
HS
2.0
ug
/m
l C
trl
 H
S
2.0
ug
/m
l A
D 
HS
0
50
100
150
%
 A
ct
iv
ity
 o
f B
A
C
E-
1 
En
zy
m
e
**
Figure	4.2:	BACE-1	inhibition	efficacy	by	HS	 is	reduced	in	AD.	HS	extracted	and	purified	from	AD	(n=10)	and	
age-matched	healthy	controls	 (n=10)	was	 incubated	at	varying	 concentrations	with	 the	BACE-1	enzyme	and	
the	 fluorescently	 tagged	substrate	peptide.	At	higher	concentrations	of	1.0μg/ml	and	2.0μg/ml,	HS	 from	AD	
patient	brain	samples	was	less	able	to	inhibit	the	BACE-1	enzyme,	as	evidenced	by	elevated	mean	(±S.E.M)	%	
BACE-1	activity.	At	2.0μg/ml,	 the	difference	 in	BACE-1	 inhibition	efficacy	was	significantly	different	between	
AD	and	healthy	 age-matched	 control	 samples.	 All	 samples	were	 assayed	 in	 triplicate	 and	mean	 (±S.E.M)	%	
BACE-1	activity	calculated	relative	to	 an	 internal	no	 inhibitor	control	 (100%).	p<0.05	*,	p<0.01	**,	Two-Way	
ANOVA	with	multiple	comparisons.	
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concentrations.	Overall	lower	concentrations	of	HS	in	this	instance	were	found	to	be	most	effective	
at	inhibiting	BACE-1	activity.	Indeed,	aged	mouse	brain	HS	samples	at	these	concentrations	proved	
more	efficacious	as	a	BACE-1	inhibitor	compared	to	younger	mouse	brain	HS	samples	(Figure	4.3).		
	
4.7.1.3	Sulf	KO	mouse	model	brain	samples	
	
	 Following	the	finding	that	AD	patient	HS	was	functionally	 less	able	to	 inhibit	the	action	of	
the	BACE-1	enzyme	and	aged	mouse	HS	was	more	able	to	block	BACE-1	activity	it	was	hypothesised	
that	alterations	in	6-O	sulfation	may	be	implicated	in	these	effects.	Studies	were	thus	carried	out	to	
evaluate	 how	 mouse	 models	 exhibiting	 knockout	 of	 either	 (or	 both)	 Sulf1	 or	 Sulf2	 genes	
(compositional	profiling	detailed	 in	Appendix	B)	were	able	to	regulate	BACE-1	activity	(since	these	
mice	do	not	express	 the	SULF	enzymes,	 they	express	HS	that	 is	more	highly	6-O	sulfated).	HS	was	
purified	 from	 d18.5	 embryonic	 mice	 (as	 described	 in	 methods)	 and	 tested	 in	 BACE-1	 inhibitory	
assays.	In	control	mice	and	all	of	the	Sulf	KO	groups	(Sulf1	KO,	Sulf2	KO	and	Double	KO	mice),	a	dose	
dependent	 increase	 in	 mean	 (±S.E.M)	 %	 BACE-1	 activity	 was	 recorded	 indicating	 a	 reduction	 in	
inhibition	efficacy	by	these	embryonic	HS	samples	with	increasing	concentration.	In	addition,	at	the		
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
Figure	4.3:	BACE-1	 inhibition	efficacy	by	HS	 is	 increased	with	age	at	 low	concentrations.	HS	extracted	and	
purified	 from	aged	 (n=5)	and	young	 (n=5)	mice	brain	samples	was	 incubated	at	varying	concentrations	with	
the	BACE-1	enzyme	and	the	fluorescently	tagged	substrate	peptide.	At	0.25μg/ml,	HS	from	aged	mouse	brain	
samples	 was	more	 able	 to	 inhibit	 the	 BACE-1	 enzyme,	 as	 evidenced	 by	 reduced	mean	 (±S.E.M)	 %	 BACE-1	
activity.	 These	 differences	 were	 less	 apparent	 at	 higher	 concentrations,	 whereby	 BACE-1	 activity	 was	 not	
reduced	in	the	presence	of	HS	from	either	aged	or	young	mouse	brain	samples.	All	samples	were	assayed	in	
triplicate	and	mean	(±S.E.M)	%	BACE-1	activity	calculated	relative	to	an	 internal	no	 inhibitor	control	 (100%).	
p<0.05	*,	p<0.01	**,	p<0.001	***	,	Two-Way	ANOVA	with	multiple	comparisons.	
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highest	concentrations,	1.0	and	2.0μg/ml,	HS	extracted	from	the	Sulf	KO	mouse	model	brain	samples	
appeared	 to	 activate	 the	 BACE-1	 enzyme	 by	 ~20%	 with	 mean	 (±S.E.M)	 %	 BACE-1	 activity	 values	
greater	than	100%.	At	all	concentrations	assayed	(apart	from	0.25	μg/ml),	HS	from	Sulf1	KO	mice	did	
not	reveal	any	inhibitory	activity	but	rather	activation.		
	
In	 contrast,	 the	 Sulf2	 KO	 mice,	 at	 lower	 concentrations	 of	 0.25μg/ml	 and	 0.5μg/ml,	
displayed	 strong	 inhibition	of	 the	BACE-1	enzyme	with	 recorded	mean	 (±S.E.M)	%	BACE-1	 activity	
values	 of	 54.66%	 (±3.46)	 and	 68.62%	 (±8.34)	 at	 each	 respective	 concentration.	 Indeed,	 at	 this	
concentration,	 the	 HS	 from	 Sulf2	 KO	 mouse	 model	 brain	 samples	 exhibited	 the	 highest	 BACE-1	
inhibition	 efficacy	 with	 the	 lowest	 mean	 (±S.E.M)	 %	 BACE-1	 activity	 values	 recorded.	 When	
compared	to	HS	from	control	mouse	brain	samples	at	0.5μg/ml,	%	BACE-1	activity	in	the	presence	of	
0.5μg/ml	HS	from	Sulf2	KO	mouse	samples	were	significantly	decreased	(p=0.035	One-Way	ANOVA	
with	multiple	 comparisons).	 This	 difference	was	 not	 found	 to	 be	 significant	 between	 control	 and	
Sulf2	KO	mice	at	0.25μg/ml.	
	
Double	KO	mouse	model	HS	at	0.25μg/ml	also	displayed	strong	inhibitory	action	against	the	
BACE-1	enzyme,	similar	 to	 that	of	heparin	 (a	known	potent	 inhibitor	of	HS)	with	mean	 (±S.E.M)	%	
BACE-1	 activity	 of	 40.84%	 (±3.44).	 This	 was	 greatly	 reduced	 vs.	 control	 mouse	 HS	 tested	 at	 this	
concentration	 (71.35%	 (±10.09)	 however	 did	 not	 reach	 statistical	 significance	 on	 this	 occasion	
(p=0.763).	 HS	 extracted	 from	 Double	 KO	 mice	 brain	 samples	 exhibited	 the	 greatest	 degree	 of	
sulfation	 as	 a	 consequence	 of	 knockout	 of	 both	 the	 Sulf1	 and	 Sulf2	 genes,	 indicative	 of	 a	 highly	
sulfated	HS	with	greater	ability	to	inhibit	BACE-1.	The	Sulf2	KO	mice	displayed	a	similar	profile	of	HS	
inhibition	suggesting	HS	from	these	mice	is,	at	the	right	concentration,	an	effective	BACE-1	inhibitor.		
	 		
The	Sulf1	KO	mouse	model	derived	HS	samples	did	not	display	BACE-1	inhibition	efficacy.	At	
all	concentrations	of	HS	from	these	mice	assayed,	mean	(±	S.E.M)	%	BACE-1	activity	was	greater	than	
100%,	 indicating	 possible	 activation	 of	 the	 BACE-1	 enzyme	 in	 the	 presence	 of	 HS	 extracted	 and	
purified	from	these	samples.	However,	none	of	these	differences	were	statistically	significant.	This	
data	indicates	that	SULF1	has	less	or	no	impact	on	the	BACE-1	inhibitory	activity	of	HS.	Similarly,	at	
0.5,	 1.0	 and	 2.0μg/ml	 concentrations,	 the	 activity	 of	 BACE-1	 in	 the	 presence	 of	 HS	 purified	 from	
control	mice	samples	was	potentially	slightly	raised	through	these	differences	were	not	statistically	
significant	(Figure	4.4).		
	
4.7.2	 Exploring	 whether	 modulation	 of	 heparan	 sulfate	 structure	 in	 cellulo	 is	 able	 to	 regulate	
generation	of	the	toxic	Aβ	peptide.	
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The	 above	 data	 provided	 evidence	 that	 endogenous	 in	 vivo	 HS	 from	 AD	 patient	 brain	
samples	 has	 altered	 structure	 and	 reduced	 ability	 to	 inhibit	 BACE-1	 in	 vitro.	 To	 explore	 this	
mechanism	 further	 cell	 culture	 models	 were	 employed,	 using	 human	 embryonic	 kidney	 cells	
expressing	 the	 Swedish	 mutant	 form	 of	 APP.	 The	 focus	 was	 knockdown	 of	 genes	 involved	 in	
controlling	6-O	sulfation	in	HS.	
	
4.7.2.1.	Aβ1-42	peptides	accumulate	in	a	time-dependent	manner	in	cultured	HEKSweAPP	cells.	
	 Before	knockdown	of	selected	genes,	a	time	course	of	the	Aβ1-42	peptide	accumulation	was	
recorded	to	assess	rising	 levels	of	 this	oligomer	within	the	media	of	culture	HEKSweAPP	cells	with	
time	 without	 any	 experimental	 knockdown	 of	 genes.	 Cultured	 cells	 displayed	 a	 time	 dependent	
accumulation	of	Aβ1-42	peptide	within	the	media	up	to	72hr	with	mean	(±S.E.M)	peptide	levels	rising	
from	496.50	(±9.92)	pg/ml	at	24hr	to	1141.00	(±65.63)	pg/ml	over	the	full	course	of	the	experiment.	
Accumulation	of	the	toxic	Aβ	species	in	this	manner	would	be	expected	over	time	and	set	a	baseline	
to	compare	the	effects	of	gene	knockdown	upon	these	levels	(Figure	4.5).			
Figure	4.4:	BACE-1	inhibition	efficacy	by	HS	is	increased	in	Sulf2	and	Double	Sulf	KO	mice	brain	samples	at	low	
concentrations.	HS	extracted	and	purified	from	Sulf1	KO	(n=3),	Sulf2	KO	(n=3),	Double	Sulf	KO	(n=3)	and	control	
(n=3)	mice	brain	samples	was	incubated	at	varying	concentrations	with	the	BACE-1	enzyme	and	the	fluorescently	
tagged	 substrate	 peptide.	 At	 lower	 concentrations	 of	 0.25	 and	 0.5ug/ml,	 HS	 from	 Sulf2	 and	 DOUBLE	 Sulf	 KO	
mouse	brain	samples	was	more	able	to	 inhibit	 the	BACE-1	enzyme,	as	evidence	by	decreased	mean	%	BACE-1	
activity.	All	 samples	were	assayed	 in	 triplicate	and	mean	 (±	 S.E.M)	%	BACE-1	activity	 calculated	 relative	 to	an	
internal	no	inhibitor	control	(100%).	p>0.05*,	One-Way	ANOVA	with	multiple	comparisons.	
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4.7.2.2	Knockdown	of	the	HS6ST1	gene	in	cultured	HEKSweAPP	cells	does	not	affect	generation	of	
the	toxic	Aβ1-42	peptide.	
	
Cultured	 HEKSweAPP	 cells	 were	 incubated	 with	 Lipofectamine	 2000	 and	 HS6ST1	 pre-	
validated	 RNAi	 complexes,	 and	 media	 and	 cells	 collected	 at	 specified	 time	 points.	 Cells	 were	
collected	and	the	RNA	extracted	for	qRT-PCR	analysis	to	assess	success	of	knockdown	of	the	HS6ST1	
gene	with	transfection.	Following	this,	media	samples	were	analysed	by	ELISA	to	quantify	total	levels	
of	 the	Aβ1-42	generated	by	 the	HEKSweAPP	cells.	Expression	of	 the	HS6ST1	 gene	was	calculated	by	
normalising	 the	 change	 in	 expression	 with	 both	 the	 housekeeping	 GAPDH	 gene	 and	 relative	 to	
untreated	controls	using	the	delta	delta	Ct	method.	
	
Analysis	 revealed	 a	 decreased	 expression	 of	 the	 HS6ST1	 gene	 across	 a	 72hr	 time	 period	
with	mean	(±S.E.M)	log2	fold	change	of	expression	of	-1.607	(±0.25),	-1.72	(±0.66)	and	-1.54	(±0.66)	
at	24,	48	and	72hr	respectively.	Decreased	expression	as	reported	here	was	indicative	of	successful	
transfection	 whereby	 the	 expression	 of	 the	 HS6ST1	 gene	 had	 been	 knocked	 down	 appropriately	
(Figure	 4.6A).	 ELISA	 analysis	 to	 quantify	 total	 levels	 of	 Aβ1-42	 within	 media	 collected	 at	 each	
timepoint	 revealed	no	statistically	 significant	changes	 in	 the	abundance	of	 the	Aβ1-42	peptide,	with	
similar	levels	of	Aβ	generated	at	each	timepoint	(Figure	4.6B).	These	results	indicate	that	decreased	
expression	of	the	HS6ST1	gene	does	not	result	in	elevated	levels	of	the	Aβ1-42	peptide.	At	48hr,	the		
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Figure	4.5:	Time	course	of	Aβ1-42	accumulation	in	HEKSweAPP	cells.	Before	knockdown	of	target	genes,	a	time	
course	 was	 carried	 out	 to	 investigate	 baseline	 accumulation	 of	 toxic	 Aβ1-42	 species	 within	 the	 media	 of	
cultured	HEKSweAPP	cells.	Cultured	cells	displayed	a	 time	dependent	 increase	 in	 the	accumulation	of	Aβ1-42	
with	significant	(One-way	ANOVA)	differences	in	the	quantity	(pg/ml)	of	Aβ	at	specified	time	points.	All	data	
points	are	representative	of	triplicate	experiments	tested	in	triplicate	with	ELISA.	Error	bars	represent	mean	±	
S.E.M.	
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opposite	 trend	 was	 recorded	 whereby	 treated	 wells	 displayed	 higher	 levels	 of	 Aβ1-42	 vs.	 their	
untreated	counterparts	(Figure	4.6B).		
	
4.7.2.3	Knockdown	of	the	HS6ST2	gene	in	cultured	HEKSweAPP	cells	results	in	significantly	reduced	
generation	of	the	toxic	Aβ1-42	peptide	
	
	 Cultured	 HEKSweAPP	 cells	 were	 incubated	 with	 Lipofectamine	 2000	 and	 HS6ST2	 pre-	
validated	RNAi	complexes,	and	media	and	cells	collected	at	specified	 time	points.	Analysis	of	qRT-
Figure	 4.6:	 	 Knockdown	 of	 the	 HS6ST1	 gene	 in	 cultured	 HEKSweAPP	 cells	 results	 in	 no	 effect	 on	 the	
generation	of	the	toxic	Aβ1-42	peptide.	6A:	Cultured	HEKSweAPP	cells	were	incubated	with	HS6ST1	RNAi	and	
Lipofectamine	2000	 complexes	 to	 knockdown	 the	 expression	of	 the	HS6ST1	 gene.	 Cells	 and	media	 samples	
were	collected	for	analysis	over	a	72hr	time	period	at	24hr	time	points.	qRT-PCR	was	used	to	confirm	success	
of	 transfection.	Fold	changes	 in	expression	of	 the	HS6ST1	gene	were	calculated	relative	 to	 the	housekeeper	
GAPDH	gene	and	relative	to	untreated	controls.	6B:	ELISA	was	used	to	quantify	total	levels	(pg/ml)	of	the	Aβ1-
42	peptide	within	the	media	samples	collected	at	each	timepoint.	Changes	in	relative	abundance	of	the	Aβ1-42	
peptide	were	 recorded	 between	 treated	 and	 untreated	 cells	 following	 knockdown	 of	 the	HS6ST1	 gene.	 All	
qRT-PCR	 data	 points	 are	 representative	 of	 n=3	 assayed	 in	 triplicated	 and	 all	 ELISA	 data	 points	 are	
representative	of	n=3	assayed	in	duplicate.	All	data	points	represent	mean	(±S.E.M).	
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PCR	data	to	assess	success	of	transfection	revealed	a	decrease	in	the	expression	of	the	HS6ST2	gene	
over	the	72hr	time	period	with	mean	(±S.E.M)	log2	fold	change	of	expression	of	-1.77	(±0.41),	-1.80	
(±0.35)	and	-0.87	(±0.98)	at	24,	48	and	72hr	respectively.	Decreased	expression	of	the	HS6ST2	gene	
as	 reported	 here	was	 indicative	 of	 successful	 transfection	whereby	 the	 expression	 of	 the	HS6ST2	
gene	had	been	knocked	down	appropriately	(Figure	4.7A).	
	
ELISA	 analysis	 to	 quantify	 total	 levels	 of	 Aβ1-42	within	media	 collected	 at	 each	 timepoint	
revealed	changes	in	the	abundance	of	the	Aβ1-42	peptide	following	knockdown	of	the	HS6ST2	gene.		
At	all	timepoints,	cells	treated	with	HS6ST2	gene	knockdown	were	found	to	produce	reduced	mean	
(±S.E.M)	 levels	 of	 the	 Aβ1-42	peptide	 vs.	 their	 untreated	 cell	 counterparts.	 At	 the	 24hr	 timepoint,	
treated	cells	had	generated	a	166.39	(±0.41)	pg/ml	Aβ1-42	whilst	untreated	cells	at	this	timepoint	had	
generated	 172.51	 (±2.16)	 pg/ml	 Aβ1-42.	 This	 difference	 was	 found	 to	 be	 statistically	 significant	
(p=0.050,	Student’s	t-test).		At	48hr,	this	difference	was	still	evident	whereby	treated	cells	displayed	
decreased	levels	of	the	Aβ1-42	peptide	vs.	their	untreated	counterparts	with	mean	(±S.E.M)	levels	of	
Aβ1-42	of	186.37	(±5.09)	pg/ml	and	227.56	(±15.64)	pg/ml	respectively;	however,	this	difference	was	
just	 short	 of	 statistical	 significance	 (p=0.066,	 Student’s	 t-test).	No	 difference	was	 observed	 at	 the	
72hr	timepoint	(Figure	4.7B).	
	
4.7.2.4	Knockdown	of	the	HS6ST3	gene	in	cultured	HEKSweAPP	cells	results	in	significantly	reduced	
generation	of	the	toxic	Aβ1-42	peptide		
Cultured	 HEKSweAPP	 cells	 were	 incubated	 with	 Lipofectamine	 2000	 and	 HS6ST3	 pre-	
validated	RNAi	complexes,	and	media	and	cells	collected	at	specified	 time	points.	Analysis	of	qRT-
PCR	data	to	assess	success	of	transfection	revealed	a	decrease	in	the	expression	of	the	HS6ST3	gene	
over	the	72hr	time	period	with	mean	(±S.E.M)	log2	fold	change	of	expression	of	-3.15	(±2.50),	-0.84	
(±0.39)	and	-0.55	(±0.89)	at	24,	48	and	72hr	respectively.	Decreased	expression	of	the	HS6ST3	gene	
as	 reported	 here	was	 indicative	 of	 successful	 transfection	whereby	 the	 expression	 of	 the	HS6ST3	
gene	has	been	knocked	down	appropriately	at	24	and	48hr	(Figure	4.8A).		
	
Using	 quantification	 by	 ELISA,	 all	 timepoints	 displayed	 a	 reduction	 in	 levels	 of	 the	 Aβ1-42	
peptide	 in	treated	cells	vs.	their	untreated	counterparts	at	respective	time	points	(Figure	4.8B).	At	
24hr,	treated	cells	had	generated	mean	(±S.E.M)	286.94	(±2.32)	pg/ml	of	the	Aβ1-42	whilst	untreated	
cells	recorded	303.50	(±5.38)	pg/ml.	This	difference	was	found	to	be	statistically	significant	(p=0.048	
Student’s	 t-test).	 At	 48hr,	 knockdown	 of	 the	HS6ST3	 gene	 generated	 reduced	 levels	 of	 the	 Aβ1-42	
peptide	in	treated	cells	vs.	untreated	controls	with	mean	(±S.E.M)	recorded	levels	of	Aβ1-42	of	379.00	
(±8.37)	 pg/ml	 and	 502.72	 (±27.07)	 pg/ml	 in	 treated	 and	 untreated	 control	 cells	 respectively	
(p=0.012,	 Student’s	 t-test).	 Finally,	 at	 72hrs,	 cells	 treated	with	HS6ST3	 RNAi	 complexes	 were	 still	
found	to	generate	reduced	levels	of	the		Aβ1-42	peptide	with	respective	mean	(±S.E.M)	levels	in		
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treated	 and	 untreated	 cells	 of	 559.35	 (±20.66)	 pg/ml	 and	 638.92	 (±82.89)	 pg/ml,	 though	 this	
difference	was	not	found	to	be	statistically	significant	(p=0.404,	Student’s	t-test)	(Figure	4.8B).	
	
4.7.2.5	Knockdown	of	the	SULF1	gene	in	cultured	HEKSweAPP	cells	results	in	significantly	reduced	
generation	of	the	Aβ1-42	peptide	
	
Analysis	of	qRT-PCR	confirmed	an	initial	decrease	in	the	expression	of	the	SULF1	gene	over	
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Figure	4.7:	 	Knockdown	of	the	HS6ST2	gene	 in	cultured	HEKSweAPP	cells	 results	 in	reduced	generation	of	
the	toxic	Aβ1-42	peptide.	7A:	Cultured	HEKSweAPP	cells	were	incubated	with	HS6ST2	RNAi	and	Lipofectamine	
2000	complexes	to	knockdown	the	expression	of	the	HS6ST2	gene.	Cells	and	media	samples	were	collected	for	
analysis	 over	 a	72hr	 time	period	at	24hr	 time	points.	qRT-PCR	was	used	 to	 confirm	 success	of	 transfection.	
Fold	changes	in	expression	of	the	HS6ST2	gene	were	calculated	relative	to	the	housekeeper	GAPDH	gene	and	
relative	to	untreated	controls.	7B:	ELISA	was	used	to	quantify	total	levels	(pg/ml)	of	the	Aβ1-42	peptide	within	
the	media	 samples	 collected	 at	 each	 timepoint.	 Changes	 in	 relative	 abundance	 of	 the	 Aβ1-42	peptide	were	
recorded	between	 treated	 and	 untreated	 cells	 following	 knockdown	 of	 the	HS6ST2	 gene.	 All	 qRT-PCR	data	
points	 are	 representative	 of	 n=3	 assayed	 in	 triplicate	 and	 all	 ELISA	 data	 points	 are	 representative	 of	 n=3	
assayed	in	duplicate.	All	data	points	represent	mean	(±S.E.M).	p<0.05	*,	Student’s	t-test.	
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a	48hr	time	period,	followed	by	an	 increase	by	72hr	(perhaps	 indicative	of	the	transfection	effects	
lessening)	with	mean	 (±	 S.E.M)	 log2	 fold	 change	of	expression	of	 -9.66	 (±5.61),	 -10.85	 (±9.09)	 and	
10.26	(±1.35)	at	24,	48	and	72hr	respectively	(Figure	4.9A). 
	
ELISA	 analysis	 to	 quantify	 total	 levels	 Aβ1-42	 within	 media	 collected	 at	 each	 timepoint	
revealed	changes	in	the	abundance	of	the	Aβ1-42	peptide	following	knockdown	of	the	SULF1	gene.	At	
24hr,	treated	cells	were	found	to	display	similar	levels	of	the	Aβ1-42	peptide	vs.	untreated	cells	at	
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Figure	4.8:		Knockdown	of	the	HS6ST3	gene	in	cultured	HEKSweAPP	cells	results	in	reduced	generation	of	the	
toxic	Aβ1-42	peptide.	8A:	Cultured	HEKSweAPP	cells	were	incubated	with	HS6ST3	RNAi	and	Lipofectamine	2000	
complexes	 to	 knockdown	 the	 expression	 of	 the	HS6ST3	 gene.	 Cells	 and	 media	 samples	 were	 collected	 for	
analysis	over	a	72hr	time	period	at	24hr	time	points.	qRT-PCR	was	used	to	confirm	success	of	transfection.	Fold	
changes	 in	 expression	 of	 the	 HS6ST3	 gene	 were	 calculated	 relative	 to	 the	 housekeeper	 GAPDH	 gene	 and	
relative	to	untreated	controls.	8B:	ELISA	was	used	to	quantify	total	 levels	(pg/ml)	of	the	Aβ1-42	peptide	within	
the	 media	 samples	 collected	 at	 each	 timepoint.	 Changes	 in	 relative	 abundance	 of	 the	 Aβ1-42	 peptide	 were	
recorded	 between	 treated	 and	 untreated	 cells	 following	 knockdown	 of	 the	 Hs6st3	 gene.	 All	 qRT-PCR	 data	
points	 are	 representative	 of	 n=3	 assayed	 in	 triplicate	 and	 all	 ELISA	 data	 points	 are	 representative	 of	 n=3	
assayed	in	duplicate.	All	data	points	represent	mean	(±S.E.M).	p<0.05	*,	Student’s	t-test.	
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this	 timepoint	with	mean	 (±S.E.M)	 abundance	 values	 of	 248.93	 pg/ml	 (±32.06)	 and	 234.96	 pg/ml	
(±12.10)	 in	 treated	 and	 untreated	 cells	 respectively.	 At	 48	 and	 72hr	 timepoints	 however,	 treated	
cells	 displayed	 reduced	 levels	 of	 the	Aβ1-42	peptide	 indicative	 of	 decreased	 processing	 of	 the	APP	
protein	as	a	consequence	of	knockdown	of	the	SULF1	gene.	At	48hr,	media	collected	from	treated	
and	 untreated	 cells	 displayed	mean	 (±S.E.M)	 levels	 of	 Aβ1-42	of	 267.55	 pg/ml	 (±13.11)	 and	 360.66	
pg/ml	 (±8.68)	 respectively,	 (p=0.011,	 Student’s	 t-test).	 At	 the	 72hr	 timepoint,	 there	 were	 no	
statistically	significant	difference	(mean	(±S.E.M)	levels	of	Aβ1-42	of	259.09	pg/ml	(±37.77)	and	293.79	
pg/ml	 (±59.75)	 in	 treated	 and	 untreated	 cells	 respectively,	 (p=0.649,	 Student’s	 t-test)	 perhaps	
reflecting	the	lack	of	knockdown	of	the	SULF1	gene	at	72hrs	(Figure	4.9B).		
	
4.7.2.6	Knockdown	of	the	SULF2	gene	in	cultured	HEKSweAPP	cells	results	in	reduced	generation	of	
the	Aβ1-42	peptide	
	
Finally,	cultured	HEKSweAPP	cells	were	treated	to	knockdown	the	expression	of	the	SULF2	
gene	over	a	72hr	time	period.	Cells	and	media	were	collected	as	with	other	gene	knockdown	studies	
at	24hr	timepoints	to	assess	transfection	success	and	the	consequences	of	gene	knockdown	on	the	
generation	of	the	Aβ1-42	peptide.	Analysis	by	qRT-PCR	confirmed	a	decreased	in	the	expression	of	the	
Sulf2	gene	over	a	72hr	time	period	with	mean	log2	fold	change	of	expression	of	-0.17	(±	0.83),	-2.01	
(±	 0.71)	 and	 -1.90	 (±	 0.26)	 at	 24,	 48	 and	 72hr	 respectively.	 Reported	 decrease	 in	 expression	 as	
reported	here	 confirmed	 that	 transfection	had	been	 successful	 and	expression	of	 the	SULF2	 gene	
had	been	knocked	down	appropriately	(Figure	4.10A).			
	
	 ELISA	analysis	 to	quantify	 total	 levels	of	 the	Aβ1-42	peptide	within	media	collected	at	each	
timepoints	 revealed	 changes	 in	 the	 abundance	 of	 the	 Aβ1-42	peptide	 following	 knockdown	 of	 the	
SULF2	gene.	At	24hr,	the	levels	of	Aβ1-42	recorded	in	treated	vs.	untreated	cells	were	not	statistically	
significant,	with	mean	(±S.E.M)	levels	of	205.99	(±1.70)	pg/ml	and	194.66	(±6.47)	pg/ml	respectively,	
(p=0.084,	 Student’s	 t-test).	 At	 48hr,	 media	 collected	 from	 treated	 and	 untreated	 cells	 displayed	
similar	 mean	 	 (±S.E.M)	 levels	 of	 Aβ1-42	 of	 243.74	 (±15.45)	 pg/ml	 and	 256.48	 (±4.93)	 pg/ml	
respectively,	(p=0.476,	Student’s	t-test).	Similarly,	at	72hr,	levels	of	the	Aβ1-42	peptide	vs.	untreated	
cells	had	similar	 recorded	 levels	of	276.77	pg/ml	 (±	3.	69)	and	294.70	pg/ml	 (±	7.59)	 respectively,	
(p=0.101,	Student’s	t-test)	(Figure	4.10B).		
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Figure	4.9.		Knockdown	of	the	SULF1	gene	in	cultured	HEKSweAPP	cells	results	in	reduced	generation	of	the	
toxic	 Aβ1-42	 peptide	 at	 48hrs.	 9A:	 Cultured	 HEKSweAPP	 cells	 were	 incubated	 with	 SULF1	 RNAi	 and	
Lipofectamine	 2000	 complexes	 to	 knockdown	 the	 expression	 of	 the	 SULF1	 gene.	 Cells	 and	media	 samples	
were	collected	for	analysis	over	a	72hr	time	period	at	24hr	time	points.	qRT-PCR	was	used	to	confirm	success	
of	 transfection.	 Fold	 changes	 in	 expression	 of	 the	 SULF1	 gene	were	 calculated	 relative	 to	 the	 housekeeper	
GAPDH	gene	and	relative	to	untreated	controls.	9B:	ELISA	was	used	to	quantify	total	levels	(pg/ml)	of	the	Aβ1-
42	peptide	within	the	media	samples	collected	at	each	timepoint.	Changes	in	relative	abundance	of	the	Aβ1-42	
peptide	were	recorded	between	treated	and	untreated	cells	following	knockdown	of	the	SULF1	gene.	All	qRT-
PCR	data	points	are	representative	of	n=3	assayed	in	triplicate	and	all	ELISA	data	points	are	representative	of	
n=3	assayed	in	duplicate.	All	data	points	represent	mean	(±	S.E.M).	p<0.05	*	,	P<0.01	**,	Student’s	t-test.	
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Figure	4.10:		Knockdown	of	the	SULF2	gene	in	cultured	HEKSweAPP	cells	results	in	reduced	generation	of	the	
toxic	Aβ1-42	peptide.	10A:	Cultured	HEKSweAPP	cells	were	incubated	with	SULF2	RNAi	and	Lipofectamine	2000	
complexes	 to	 knockdown	 the	 expression	 of	 the	 SULF2	 gene.	 Cells	 and	 media	 samples	 were	 collected	 for	
analysis	 over	 a	72hr	 time	period	at	24hr	 time	points.	qRT-PCR	was	used	 to	 confirm	 success	of	 transfection.	
Fold	changes	in	expression	of	the	SULF2	gene	were	calculated	relative	to	the	housekeeper	GAPDH	gene	and	
relative	to	untreated	controls.	10B:	ELISA	was	used	to	quantify	total	levels	(pg/ml)	of	the	Aβ1-42	peptide	within	
the	media	 samples	 collected	 at	 each	 timepoint.	 Changes	 in	 relative	 abundance	 of	 the	 Aβ1-42	peptide	were	
recorded	 between	 treated	 and	 untreated	 cells	 following	 knockdown	 of	 the	 SULF2	 gene.	 All	 qRT-PCR	 data	
points	 are	 representative	 of	 n=3	 assayed	 in	 triplicate	 and	 all	 ELISA	 data	 points	 are	 representative	 of	 n=3	
assayed	in	duplicate.	All	data	points	represent	mean	(±S.E.M).	
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4.8	Discussion		
4.8.1	 Exploring	 the	 relationship	 between	 changes	 in	 endogenous	 heparan	 sulfate	 structure	 and	
BACE-1	inhibition	efficacy			
4.8.1.1	AD	and	age-matched	control	healthy	human	samples	
	
	 HS	extracted	and	purified	from	human	AD	(n=10)	and	age-matched	control	samples	(n=10)	
was	incubated	with	the	BACE-1	enzyme	and	fluorescently	tagged	peptide	at	varying	concentrations.	
A	dose	dependent	decrease	in	%	BACE-1	activity	in	the	presence	of	healthy	age-matched	control	HS	
was	 observed.	 A	 dose	 dependent	 decrease	 in	 BACE-1	 activity	 is	 consistent	with	 previous	 findings	
that	HS	is	able	to	interact	with,	and	inhibit	BACE-1	(Scholefield,	2003).	In	contrast,	HS	purified	from	
human	 AD	 samples	 displayed	 a	 greatly	 reduced	 ability	 to	 block	 the	 activity	 of	 the	 BACE-1.	 In	
particular,	at	the	higher	concentrations	of	1.0	and	2.0μg/ml,	HS	from	AD	patient	brain	samples	did	
not	 inhibit	 the	 BACE-1	 enzyme	whereas	 control	HS	was	 strongly	 inhibitory	 at	 these	 doses	 (Figure	
4.2)	and	possibly	is	interesting	in	the	context	of	the	findings	of	chapter	2	that	found	that	changes	in	
the	 structure	 of	 HS	 with	 AD	 result	 in	 reduced	 sulfation	 vs.	 age-matched	 healthy	 counterparts.	
Reduced	 sulfation	 as	 observed	would	 be	 indicative	 of	 HS	 that	may	 be	 less	 able	 to	 inhibit	 BACE-1	
(Patey,	 et	 al.	 2006,	 Scholefield,	 et	 al.	 2003).	 This	 hypothesis	 was	 confirmed	 here	 supporting	 the	
notion	 that	 structural	 changes	 in	 HS	 associated	 with	 AD	 have	 downstream	 implications	 on	 the	
efficacy	of	BACE-1	inhibition,	and	thus	process	most	APP	to	form	the	toxic	Aβ	peptide.	Loss	of	sulfate	
groups	 at	 various	 positions	 along	 the	HS	 chain	may	 affect	 the	 final	 structure	 of	 the	HS	 chain	 and	
affect	the	way	it	is	able	to	interact	with	the	BACE-1	enzyme.		
	
	 Previous	 research	 by	 Cui	 and	 colleagues	 (Cui,	 et	 al.	 2016)	 found	 that	 AD	 SweAppTg2576	
mice,	treated	with	enoxaparin,	a	low	molecular	weight	heparin,	displayed	elevated	levels	of	amyloid	
plaques	 compared	 to	 untreated	 controls.	 This	 data	 contrasted	 previous	 work	 that	 found	 that	
enoxaparin	could	reduce	BACE-1	levels	and	Aβ	peptide	generation	(Bergamaschini,	et	al.	2004,	Cui,	
et	al.	2011).	The	increased	deposition	of	amyloid	plaques	in	Tg2576	mice	as	reported	here	was	not	
found	to	result	from	elevated	BACE-1	expression	or	APP	processing	as	one	might	expect.	It	may	be	
that	 the	heterogeneous	molecular	weights	of	 the	heparins	 that	make	up	enoxaparin	may	account	
for	 diminished	 concentrations	 within	 the	 brain	 (larger	 chains	 will	 not	 effectively	 cross	 the	 BBB	
(Leveugle,	 et	 al.	 1997))	 that	 were	 too	 low	 to	 regulate	 APP	 processing	 fully.	 It	 may	 be	 also,	 that	
increased	 amyloid	 plaque	 burden	 as	 noted,	may	 reflect	 decreased	 toxic	 Aβ	 species	 (arguably	 the	
most	potent	species	linked	to	AD-related	cognitive	decline)	and	a	shift	in	the	relative	ratios	of	Aβ42	
and	 Aβ40.	 The	 conflicting	 results	 reported	 in	 these	 studies	 confirm	 the	 complexities	 of	
understanding	AD	pathogenesis	and	the	mechanisms	that	underpin	it.	Creating	a	heparin	derivative	
Chapter	4																																							Changes	in	endogenous	HS	structure	are	implicated	in	BACE-1	inhibition	efficacy		
2017	 153	
that	 can	 be	 administered	 without	 anti-coagulant	 side	 effects,	 cross	 the	 BBB,	 inhibit	 BACE-1	 and	
preclude	fibrilisation	of	Aβ	species	is	undoubtedly	a	challenge	however	currently	unpublished	work	
by	Turnbull	and	colleagues	(personal	communication)	have	identified	promising	heparin	derivatives	
(particularly	 N-acetylated	 chains)	 that	 upon	 administration,	 can	 cross	 the	 BBB	 and	 reduce	 plaque	
burden	 within	 AD	 mouse	 brain	 tissue.	 The	 challenges	 associated	 with	 standard	 heparins	 may	
account	for	some	of	the	disparity	reported	here.		
	
Interestingly,	as	observed	in	chapter	2,	AD	patient	brain	samples	displayed	significantly	less	
total	HS	vs.	 their	healthy	age-matched	control	counterparts.	The	known	role	of	HS	 in	a	number	of	
different	 features	 of	 AD	 pathology,	 including	 its	 potential	 role	 in	 BACE-1	 regulation	 and	 also	
amyloidogenesis,	 may	 all	 be	 affected	 by	 these	 overall	 reduced	 total	 levels	 of	 HS	 as	 described	 in	
chapter	2.	As	such,	understanding	the	implications	of	changes	in	endogenous	levels	in	this	manner	
may	 help	 further	 elucidate	 the	 mechanisms	 by	 which	 HS	 is	 able	 to	 play	 important	 roles	 in	 AD	
pathogenesis.	
	
4.8.1.2	Aged	vs.	young	mouse	brain	samples	
	
	 In	 contrast	 to	 the	 lack	 of	 inhibition	 of	 BACE-1	 by	 HS	 from	 AD	 patient	 brain,	 low	
concentrations	 of	 HS	 from	 both	 aged	 and	 young	 mouse	 brain	 samples	 elicited	 the	 most	 potent	
inhibition	 of	 BACE-1.	 This	 result	 contrasts	 that	 observed	 with	 AD	 patient	 HS	 samples	 at	 low	
concentrations	whereby	 incubation	with	 HS	 at	 these	 concentrations	 did	 not	 result	 in	 any	 BACE-1	
inhibitory	action.	This	disparity	may	partly	reflect	the	variability	between	HS	from	human	and	from	
mouse	species	samples,	although	control	HS	samples	from	healthy	age-matched	patients	did	inhibit	
BACE-1	 (Figure	 4.3).	 To	 study	 the	effect	of	 age	on	HS	 structure	and	 its	 interaction	with	BACE-1,	 a	
young	control	was	necessary,	 something	difficult	 to	obtain	with	human	 tissue	 samples.	As	 such,	a	
mouse	model	was	most	 suitable	 to	 study	 this	 variable.	Of	 course,	 there	 are	 therefore	 drawbacks	
with	respect	to	alternate	tissue	sources.	It	has	not	previously	been	established	whether	HS	derived	
from	mouse	 brain	 is	 able	 to	 inhibit	 the	 BACE-1	 enzyme	 so	 the	 observation	 here	 that	 thy	 can	 be	
potent	inhibitors	of	the	enzyme	are	entirely	novel	and	warrant	further	studies.	HS	has	been	shown	
to	be	differentially	regulated	with	respect	to	structure	in	different	tissue	regions	(Warda,	et	al.	2006)	
hence	one	might	expect	HS	structure	to	vary	even	more	considerably	across	different	species.		
	
Having	previously	observed	that	AD	HS	(at	0.25μg/ml)	is	unable	to	block	the	action	of	BACE-
1,	one	might	have	expected	to	observe	a	similar	response	in	the	case	of	aged	HS	compared	to	young	
HS,	 in	 light	 of	 the	 fact	 that	 age	 remains	 the	 greatest	 risk	 factor	 for	 the	 development	 of	 AD.	 In	
contrast,	 aged	 HS	 was	 better	 able	 to	 inhibit	 BACE-1	 (Figure	 4.3)	 Recent	 research	 has	 reported	
decreased	levels	of	the	microRNA-186	gene,	miR-186,	in	ageing	mouse	cortices,	and	was	also	shown	
Chapter	4																																							Changes	in	endogenous	HS	structure	are	implicated	in	BACE-1	inhibition	efficacy		
2017	 154	
to	suppress	the	expression	of	BACE-1.	It	was	concluded	that	miR-186	is	a	potent	negative	regulator	
of	BACE-1	and	as	such,	decreased	expression	of	miR-186	with	ageing,	may	 induce	up-regulation	of	
BACE-1	 within	 the	 brain	 and	 provide	 a	 molecular	 link	 between	 ageing	 and	 the	 onset	 and	
development	of	AD	(Kim,	et	al.	2016).	Our	findings	suggest	the	possibility	that	aged	HS,	even	at	low	
concentrations,	is	able	to	decrease	BACE-1	activity.	The	role	of	HS	as	an	inhibitor	of	BACE-1	may	well	
sit	 entirely	 independently	 of	 changing	 BACE-1	 levels	with	 ageing	 and	 in	 AD;	 indeed	 the	 potential	
changes	in	HS	with	ageing	may	provide	a	protective	“balancing”	effect	to	control	excessive	BACE-1	
activity.	The	observed	 increase	 in	BACE-1	expression	with	ageing	however	 further	strengthens	 the	
notion	that	this	is	an	important	and	potentially	very	potent	target	to	block	in	efforts	to	treat	AD.		
	
In	addition,	a	previous	study	by	Fukumoto	et	al	in	2004,	reported	increased	activity	of	the	
BACE-1	 enzyme	 in	 humans,	 monkeys	 and	 mice	 brain	 samples	 with	 ageing	 that	 correlated	 with	
enhanced	levels	of	the	Aβ1-42	peptide	in	these	brain	samples	(Fukumoto,	et	al.	2004).	Based	on	our	
finding,	it	is	possible	that	aged	brain	HS	at	high	concentrations	could	enhance	the	activity	of	BACE-1	
leading	to	elevated	Aβ	levels.		The	overall	role	HS	may	play	in	regulating	activity	of	BACE-1	in	aged	
samples	has	not	yet	been	studied	and	as	such	our	study’s	 findings	are	novel;	more	studies	will	be	
necessary	to	full	understand	the	mechanisms	involved.		
	
4.8.1.3	SULF	KO	mouse	model	brain	samples			 Surprisingly	in	all	of	the	Sulf	KO	groups,	a	reciprocal	relationship	between	%	BACE-1	activity	
was	noted.	Indeed,	at	the	highest	concentrations,	(1.0	and	2.0μg/ml),	HS	extracted	from	the	Sulf	KO	
mouse	model	 brain	 samples	 appeared	 to	 activate	 the	 BACE-1	 enzyme	with	 activity	 values	 slightly	
greater	than	100%.	Furthermore,	HS	from	Sulf1	KO	mice	did	not	demonstrate	 inhibitory	activity	at	
any	 of	 the	 doses	 tested	 but	 rather	 activation.	 Activation	 of	 the	 BACE-1	 enzyme	 as	 recorded	 here	
indicates	 a	 potential	 balance	 between	 both	 inhibition	 and	 activation	 of	 BACE-1	 and	may	 suggest	
some	kind	of	biphasic	relationship	between	HS	and	BACE-1.	Research	 in	1997	reported	the	role	of	
heparin	as	a	promoter	of	BACE-1	activity	and	subsequently	 the	processing	of	APP	 (Leveugle,	et	al.	
1997).	Other	findings	indicated	that	heparin	at	similar	high	doses	can	activate	the	pro-enzyme	form	
of	BACE-1	(Beckman,	et	al.	2009).	These	findings	coupled	with	more	recent	work	that	reported	the	
role	of	HS	 in	 the	 inhibition	of	BACE-1	 (Scholefield,	 et	al.	2003)	may	suggest	 that	abundance	of	HS	
within	the	cells	 is	 important	 in	determining	the	effects	 it	has	on	the	BACE-1	activity	component	of	
AD	pathology.			
	 In	contrast,	the	Sulf2	KO	mice,	at	lower	concentrations	(0.25μg/ml	and	0.5μg/ml),	displayed	
strong	 inhibition	 of	 the	 BACE-1	 enzyme.	 Indeed,	 at	 these	 concentrations,	 the	 HS	 from	 Sulf2	 KO	
mouse	 model	 brain	 samples	 exhibited	 the	 highest	 BACE-1	 inhibition	 efficacy	 recorded	 in	 the	
experiments	here.	When	compared	to	HS	from	control	mouse	brain	samples	at	0.5μg/ml,	%	BACE-1	
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activity	in	the	presence	of	0.5μg/ml	HS	from	Sulf2	KO	mouse	samples	were	significantly	decreased.	
The	strong	inhibitory	effect	as	exhibited	by	Sulf2	KO	mice	in	this	manner	indicates	that	the	influence	
of	the	SULF2	enzyme	is	the	more	prominent	of	the	two	enzyme	isoforms.	Indeed,	Sulf1	KO	mice	do	
not	 display	 any	major	 abnormality	 whilst	mice	 deficient	 in	 both	 the	 Sulf1	 and	 Sulf2	 gene	 display	
significant	renal	and	skeletal	deficits	(Lamanna,	et	al.	2006)	suggesting	the	action	of	SULF2	is	key	in	
HS	modification	and	resultant	functionality.	Deficiencies	in	brain	HS	have	also	been	noted	as	being	
different	 between	 SULF1	 and	 SULF2	 indicating	 that	 these	 genes	 are	 not	 redundant	 and	may	 only	
partially	overlap	(Kalus,	et	al.	2015).	
	
	 Double	KO	mouse	model	HS	at	0.25μg/ml	also	displayed	strong	 inhibitory	activity	against	
the	BACE-1	enzyme,	similar	to	that	of	heparin	(a	known	potent	inhibitor	of	HS).	Consistent	with	this,	
HS	extracted	from	Double	KO	mice	brain	samples	exhibited	the	highest	degree	of	sulfation	as	was	
expected	due	to	knockout	of	both	the	Sulf1	and	Sulf2	genes.	Double	knockout	of	both	the	Sulf1	and	
Sulf2	genes	in	this	manner	would	totally	negate	post-biosynthetic	removal	of	sulfate	groups	at	the	6-
O	position	hence	we	would	expect	it	to	exhibit	strong	inhibitory	action	as	described	here.	However,	
at	 high	 concentrations	 activation	 of	 BACE-1	 activity	 was	 again	 observed	 and	 is	 suggestive	 of	 a	
biphasic	regulation	of	BACE-1	activity	(Leveugle,	et	al.	1997,	Scholefield,	et	al.	2003).	It	will	clearly	be	
important	 to	 undertake	 further	 studies	 on	 lower	 doses	 of	 these	 HS	 species	 to	 examine	 more	
complete	dose	response	relationships.	
	
4.8.2	 Exploring	 whether	 modulation	 of	 heparan	 sulfate	 structure	 in	 cellulo	 is	 able	 to	 regulate	
generation	of	the	toxic	Aβ	peptide	
	
	 ELISA	 revealed	 no	 statistically	 significant	 changes	 in	 the	 abundance	 of	 the	 Aβ1-42	peptide	
following	knockdown	of	the	HS6ST1	gene	however;	there	was	a	recorded	trend	at	the	24	and	72hr	
timepoints	 for	 an	 increase	 in	 the	 Aβ1-42	 peptide	 with	 respect	 to	 untreated	 controls.	 A	 trend	 for	
enhanced	levels	of	this	peptide	would	be	consistent	with	the	notion	that	knockdown	of	the	HS6ST1	
gene	may	result	in	reduced	inhibition	of	BACE-1	and	thus	elevated	processing	of	the	APP	precursor	
to	 generate	 the	 Aβ1-42	 peptide.	 Reduction	 of	 the	 expression	 of	 the	 HS6ST1	 gene	 as	 induced	 via	
knockdown	 in	this	 instance	may	result	 in	decreased	translation	of	 the	HS6ST1	enzyme	though	this	
was	not	confirmed	at	the	protein	level.	This	in	turn	may	have	implications	for	the	addition	of	sulfate	
groups	at	the	6-O	position	and	as	such,	generate	a	lesser	sulfated	HS	less	able	to	inhibit	the	BACE-1	
enzyme	(Patey,	et	al.	2006).	The	absence	of	statistically	significant	changes	in	the	BACE-1	inhibitory	
activity	 of	 this	 HS	 may	 however	 be	 confounded	 by	 altered	 expression	 of	 other	 HS6ST	 enzymes,	
compensating	for	decreased	expression	of	the	HS6ST1	gene.	The	HS6ST3	enzyme	is	known	to	display	
variable	 substrate	 specificity	 (Esko	 and	 Selleck	 2002)	 and	 this	 could	 go	 some	way	 to	 explain	why	
more	dramatic	effects	on	processing	of	APP	were	not	observed.	Further	studies	to	examine	whether	
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compensatory	 increases	 in	HS6ST2	or	HS6ST3,	or	other	sulfation	enzymes	are	occurring,	alongside	
changes	 in	 their	 protein	 levels,	 are	 clearly	 warranted,	 along	 with	 analysis	 of	 the	 HS	 structures	
produced	in	those	cells.	
	
	 Interestingly,	 TaqMan®	 analysis	 of	 the	 expression	 of	 genes	 that	 encode	 HS	 biosynthetic	
enzymes	 (as	 detailed	 in	 chapter	 3),	 revealed	 a	 significant	 up-regulation	 of	 the	 expression	 of	 the	
HS6ST1	 gene.	 Elevated	 expression	 of	 this	 gene,	 we	 would	 hypothesise,	 would	 elicit	 enhanced	
sulfation	 of	 HS	 causing	 increased	 inhibition	 efficacy	 for	 the	 BACE-1	 enzyme.	 Despite	 this,	 we	
observed	decreased	 sulfation	of	 actual	HS	 products	 (chapter	 2)	 and	 reduced	 ability	 for	 this	HS	 to	
inhibit	the	BACE-1	enzyme.	In	light	of	this,	one	might	question	how	much	of	a	role	HS6ST1	may	play	
in	the	changes	to	HS	observed	with	AD.	Perhaps	its	isoform,	HS6ST2	and	HS6ST3	play	more	central	
roles	in	the	changes	associated	with	this	disease.	Knockdown	of	this	gene	alone	therefore,	may	not	
be	 sufficient	 to	elicit	 significant	 effects	on	 the	processing	of	APP	and	 the	generation	of	 the	Aβ1-42	
peptide.	Furthermore,	 the	situation	may	be	more	complex	depending	on	 the	 interplay	of	multiple	
enzymes	to	alter	the	functional	capacity	of	HS.	
	
	 ELISA	 analysis	 to	 quantify	 total	 levels	 of	 Aβ1-42	within	media	 following	 knockdown	 of	 the	
HS6ST2	reduced	levels	of	the	Aβ1-42	peptide	vs.	their	untreated	controls	at	respective	timepoints.	At	
the	 24hr	 timepoint,	 this	 difference	 was	 found	 to	 be	 statistically	 significant,	 perhaps	 indicative	 of	
early,	 more	 pronounced	 effects	 of	 the	 transfection.	 Knockdown	 of	 the	 HS6ST2	 gene,	 we	
hypothesised,	would	 result	 in	 reduced	 6-O	 sulfation	 of	 the	HS	 chain	 that	would	 ultimately	 confer	
reduced	 inhibition	 of	 BACE-1	 and	 enhanced	 levels	 of	 the	 Aβ1-42	 peptide.	 This	 result	 therefore	
contradicted	our	hypothesis.	Again,	knockdown	of	this	gene	in	isolation	may	be	insufficient	to	elicit	a	
consistent	 or	 expected	 response.	 Total	 knockout	 of	 the	Hs6st2	 gene	 in	 mice	 in	 previous	 studies	
reported	 normal	 development	 with	 no	 significant	 abnormality	 and	 raises	 the	 question	 of	 the	
potency	this	enzyme	exhibits	with	respect	to	HS	modification	and	its	resultant	functionality	(Nagai,	
et	 al.	 2013).	 Again,	 there	 may	 well	 be	 compensatory	 changes	 in	 other	 HS6STs	 and	 the	 broader	
biosynthetic	machinery	that	confound	over-simplistic	interpretation	of	this	data.	
	
	 TaqMan®	array	analysis	as	detailed	 in	chapter	3,	reported	a	decrease	 in	expression	of	the	
HS6ST2	gene.	This	finding	partially	mimics	the	knockdown	as	established	in	this	experiment	and	so	
we	might	expect	the	results	observed	in	the	HEKSweAPP	cells	to	infer	what	might	occur	in	the	body.	
Our	 findings	 suggest	 that	 HS	 modification	 is	 more	 complex	 than	 originally	 thought	 and	 that	
knockdown	 of	 individual	 genes	 in	 isolation	 may	 not	 be	 suitable	 to	 test	 for	 modulation	 of	 the	
processing	of	APP	and	production	of	 the	Aβ1-42	peptide.	Naturally,	we	cannot	know	for	certain	 the	
enzyme	turnover	rates	with	respect	to	knockdown	of	gene	expression,	and	how	this	translates	into	
changes	in	protein	levels	and	ultimately	enzyme	activity.	It	is	possible	that	at	the	timepoints	studied,	
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knockdown	may	have	not	efficiently	negated	presence	of	 the	HS6ST2	enzyme	and	 its	activity	with	
respect	to	modification	of	the	HS	chain.		
Finally,	knockdown	of	expression	of	the	HS6ST3	gene	revealed	reduced	levels	of	the	Aβ1-42	
peptide	vs.	their	untreated	controls	at	respective	timepoints.	As	with	the	HS6ST2	gene,	knockdown	
of	the	HS6ST3	gene,	would,	we	hypothesised,	reduce	the	translation	of	the	HS6ST3	enzyme,	and	as	
such,	reduce	the	sulfation	of	the	HS	chain	at	the	6-O	position.	As	a	consequence,	we	hypothesised	
that	a	lesser-sulfated	HS	as	generated	in	this	scenario	would	be	less	able	to	block	the	action	of	BACE-
1,	 and	ultimately	 result	 in	 elevated	 levels	 of	 the	Aβ1-42	peptide.	Observation	 therefore	 of	 reduced	
levels	of	the	Aβ1-42	peptide,	suggests	that	knockdown	of	HS6ST3	alone	is	not	sufficient	to	modify	HS	
and	Aβ1-42	production.		
	
	 In	addition,	whilst	it	has	been	reported	previously	that	6-O	sulfation	is	necessary	for	potent	
BACE-1	 inhibition	 efficacy,	 it	 may	 be	 that	 the	 overall	 structure	 and	 conformation	 of	 HS,	 i.e.	 the	
combination	of	6-O	sulfated	motifs	and	other	features	of	the	HS	chain	together,	may	be	necessary	to	
elicit	the	appropriate	structures	to	regulate	BACE-1	activity.	Single	gene	knockdown	as	carried	out	in	
these	initial	studies	may	not	be	sufficient	to	mimic	the	changes	that	occur	with	AD	to	modulate	the	
production	of	the	Aβ1-42	peptide.	Detection	of	very	subtle	changes	as	induced	by	knockdown	of	only	
single	 genes	 may	 not	 be	 possible	 in	 this	 context.	 Knockdown	 for	 example	 of	 the	 HS6ST3	 gene	
alongside	full	expression	of	the	NDST	enzymes	may	negate	the	consequences	of	knockdown,	due	to	
currently	 unknown	 compensation	 mechanisms	 to	 re-establish	 a	 functional	 HS	 chain	 following	
disruption	in	expression	of	genes	encoding	HS	biosynthetic	machinery.			
	
Analysis	of	the	consequences	of	the	HS	modification	enzymes,	SULF1	and	SULF2	was	carried	
out	to	investigate	other	means	by	which	6-O	sulfation	of	HS	may	be	important	for	BACE-1	inhibition.	
Knockdown	 of	 both	 the	 SULF1	 and	 SULF2	 genes	 resulted	 in	 a	 reduction	 (or	 at	 least	 a	 trend	 for	
reduction)	 in	 levels	 of	 the	 Aβ1-42	peptide	 suggesting	 knockdown	 of	 these	 genes	 was	 sufficient	 to	
modulate	the	structure	of	HS	and	its	interaction	with	the	BACE-1	enzyme.	The	sulfatase	enzymes	are	
responsible	 for	 the	 removal	 of	 sulfate	 groups	 at	 the	 6-O	 position.	 Knockdown	 of	 the	 SULF1	 and	
SULF2	genes,	we	hypothesised,	would	enhance	the	overall	sulfation	of	the	HS	chain,	making	it	more	
able	 to	 inhibit	 BACE-1	 and	 thus	 reduce	 the	 formation	 of	 the	 toxic	 Aβ1-42	 peptide.	 Therefore	 the	
reduced	 levels	 of	 Aβ1-42	supported	 our	 hypothesis	 and	 are	 consistent	 with	 6-O	 sulfation	 as	 a	 key	
determinant	in	BACE-1	inhibition	efficacy.	The	action	of	SULF	enzymes	is	known	to	fine	tune	the	final	
structure	of	HS	after	all	biosynthetic	modification	events	are	complete;	as	such,	they	can	confer	very	
subtle	 changes	 in	 functionality	 with	 big	 consequences	 on	 HS	 ligand	 binding	 affinity	 (Morimoto-
Tomita,	et	al.	2002).	Knockdown	of	these	genes	therefore	may	elicit	more	substantial	effects	on	HS	
structure	compared	to	knockdown	of	other	genes.	Further	studies	to	confirm	expected	changes	 in	
HS	structure	in	the	SULF	knockdown	cells	are	clearly	warranted.	
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4.9	General	conclusions		
In	conclusion,	this	work	has	established	that	changes	in	the	structure	of	HS	(as	determined	
in	 chapter	 2),	 resulting	 from	 changes	 in	 expression	 of	 the	 genes	 encoding	 the	 HS	 biosynthetic	
machinery	(as	described	 in	chapter	3)	have	direct	 implications	on	the	ability	of	HS	to	 interact	with	
and	 inhibit	 the	activity	of	 the	BACE-1	enzyme.	AD	sample	HS	was	shown	to	be	 less	able	 to	 inhibit	
BACE-1,	confirming	the	notion	that	changes	in	the	structure	of	HS	are	implicated	in	APP	processing	
by	BACE-1	and	production	of	the	Aβ1-42	peptide	in	vivo.	Furthermore,	the	observation	that	changes	in	
the	structure	of	HS	with	ageing	linked	with	enhanced	BACE-1	inhibition	in	aged	mouse	brain	samples	
may	 also	 indicate	 separate	 pathways	 by	 which	 BACE-1	 activity	 is	 regulated	 in	 ageing	 and	 in	 AD.	
Understanding	the	mechanisms	by	which	HS	is	able	to	interact	with	BACE-1	and	the	implications	this	
has	 for	 development	 of	 AD	 pathogenesis	 and	 in	 ageing	 is	 undoubtedly	 complex,	 but	 this	 data	
strengthens	the	connection	between	HS	and	roles	in	AD	pathogenesis.		
	
Furthermore,	 this	 chapter	 has	 identified	 that	 controlled	 modulation	 of	 the	 endogenous	
structure	 of	 HS	 in	 cultured	 HEKSweAPP	 cells	 can	 regulate	 the	 production	 of	 the	 Aβ1-42	 peptide.	
Knockdown	of	 the	SULF	 genes	were	 found	 to	decrease	 levels	of	Aβ1-42	,	 supporting	our	hypothesis	
that	modulation	of	HS	can	alter	its	BACE-1	inhibitory	activity,	and	result	 in	altered	accumulation	of	
the	 toxic	 oligomers	 that	 pre-dispose	 the	 development	 of	 mature	 amyloid	 plaques	 in	 AD	 patient	
brains.	 Naturally,	 we	 cannot	 assume	 a	 direct	 correlation	 between	 gene	 expression	 and	 protein	
translation,	 or	 indeed	 enzyme	 activity	 of	 the	 final	 protein;	 however,	 changes	 in	 HS	 may	 have	
significant	 implications	 for	 its	 ability	 to	 interact	 with	 BACE-1.	 Moreover,	 knockdown	 of	 genes	 as	
described	 in	 this	 chapter	 may	 also	 have	 consequences	 for	 the	 functions	 of	 HS	 and	 in	 other	
pathogenic	 features	 of	 AD	 such	 as	 amyloid	 aggregation.	 Decreased	 sulfation	 of	 HS	 induced	 by	
knockdown	of	the	HS6ST	genes,	whilst	not	necessarily	directly	regulating	production	of	Aβ1-42,	may	
have	other	implications	on	how	HS	induces	fibrilisation	of	toxic	oligomers	into	mature	plaques	(van	
Horssen,	 et	 al.	 2003)	 for	 example.	 It	 is	 also	 important	 to	 note	 that	 these	 experiments	were	 only	
focused	on	determining	changes	 in	the	abundance	of	the	Aβ1-42	peptide.	 It	may	be	that	changes	 in	
endogenous	 HS	 structure	 as	 induced	 by	 gene	 knockdown	may	 not	 effect	 levels	 of	 the	 Aβ1-42	but	
rather	 Aβ1-40	peptides	that	 also	 result	 from	processing	 of	 the	 APP	 precursor	 (LaFerla,	 et	 al.	 2007).	
Future	 studies	 to	 assess	 changes	 in	 this	 peptide	may	 also	 help	 to	 elucidate	 the	 role	 of	HS	 in	APP	
processing.	Likewise,	the	sAPPβ	and	C99	fragment,	the	first	products	of	APP	processing	before	final	
cleavage	 by	 γ-secretase,	 may	 also	 change	 with	 alteration	 to	 endogenous	 HS	 structure.	 As	 such	
further	work	may	be	needed	 to	explore	 the	mechanisms	by	which	HS	 is	able	 to	modulate	BACE-1	
activity	and	how	structural	changes	may	affect	this	interaction.		
	
Finally,	 these	 preliminary	 experiments	 naturally	 did	 not	 look	 into	 the	 potentially	 very	
complex	interactions	between	specific	HS-related	gene	isoforms	and	the	ways	in	which	disturbances	
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to	one	gene	may	be	compensated	for	by	another.	Detecting	very	small	changes	may	be	made	even	
harder	 by	 the	 masking	 effects	 that	 compensation	 of	 this	 nature	 may	 have.	 Future	 studies	 to	
determine	 combinatorial	 roles	 of	 HS-related	 genes,	 especially	 the	 3	 HS6ST	 isoforms,	 will	 prove	
particularly	useful	in	further	understanding	the	ways	in	which	modulation	of	endogenous	HS	can	be	
exploited	to	regulate	production	of	amyloid	species.	Despite	these	added	complexities,	this	work	has	
confirmed	not	only	a	role	for	HS	 in	modulating	the	activity	of	BACE-1	and	the	formation	of	the	Aβ	
peptide	 in	 AD,	 but	 also	 establishes	 an	 argument	 for	 the	 fine	 tuning	 of	 HS	 structure	 that	 may	
significantly	modulate	the	APP	processing	pathways	and	amyloid	accumulation	within	the	brains	of	
AD	patients.	Finding	ways	to	exploit	these	structural	motifs	may	be	key	 in	developing	effective	AD	
therapies	in	the	future.			 			 			
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5.	Chapter	5		
5.1	Introduction		
5.1.1	The	use	of	bioinformatics	in	research	
	
	 With	 the	 huge	 growth	 and	 speed	 of	 technological	 advances	 in	 scientific	 research,	 the	
output	of	data	has	grown	also	with	large	throughput	data	sets	becoming	the	norm.	With	this	growth	
come	 new	 challenges	 in	 the	ways	 in	which	 this	 data	 can	 be	 stored	 and	 analysed.	 Bioinformatics,	
including	 large-scale	 data	 analysis,	 has	 now	 become	 common	 practice	 in	 all	 fields	 of	 scientific	
research	 from	 structural	 biology	 to	 gene	 expression	 studies.	 As	 early	 as	 2000,	 SWISS-PROT	
databases	 of	 protein	 sequences	 were	 reported	 to	 be	 doubling	 in	 size	 approximately	 every	 15	
months	(Benson,	et	al.	2000).	Furthermore,	as	of	2011,	The	Genomes	On	Line	Database	(GOLD)	has	
reported	 information	 for	 11,472	 sequencing	 projects,	 of	 which	 2,907	 have	 been	 completed	 and	
published	 for	 public	 consumption	 (Pagani,	 et	 al.	 2012).	 Similarly,	 genome-sequencing	projects	 are	
often	accompanied	by	studies	to	investigate	gene	expression,	elucidate	protein	structure	and	study	
protein	 network	 interactions	 and	 in	 combination,	 result	 in	 complex	 data	 sets	 that	 must	 be	
appropriately	digested	and	analysed.	Large	datasets	as	described	here	are	best	suited	to	computer	
based	 analytical	 techniques	 and	 software	 has	 been	 developed	 to	 aid	 the	 processing	 of	 large	
datasets.	Furthermore,	data	of	this	kind	is	largely	becoming	publically	available	allowing	a	number	of	
projects	 to	assess	gene	expression	changes	 in	multiple	diseases,	 sequencing	data	 for	a	number	of	
organisms	and	structural	information	for	a	variety	of	target	proteins.		
	
5.2	The	aims	of	bioinformatics	
	
	 Ultimately,	the	aim	of	bioinformatics	as	a	research	tool	is	to	allow	comparison,	classification	
and	systematic	storage	of	complex	and	often	 large	data	sets.	Types	of	data	may	 include	biological	
structures,	 functions	 and	 correlations	 discovered	 via	 experimental	 or	 computational	 studies.	 The	
Protein	 Data	 Bank	 (PDB)	 is	 an	 example	 of	 this,	 the	 database	 for	 the	 3D	 structures	 of	 selected	
proteins	(Bernstein,	et	al.	1977)	(Berman,	et	al.	2000).	Furthermore,	meta-analysis	of	existing	data	
can	 largely	 complement	 a	 focused	 experimental	 research	 project	 and	 the	 data	 that	 may	 be	
generated	from	this	work.	In	essence,	the	world	of	the	classified	and	stored	biological	meta-data	can	
be,	and	 is,	constantly	validated,	updated	and	refined.	Queries	that	may	originate	from	the	specific	
need	 of	 a	 research	 project	 may	 be	 able	 to	 utilise	 existing	 data	 in	 a	 novel	 way	 such	 that	 these	
datasets	may	help	answer	questions	which	they	were	not	previously	originally	intended	to	address.	
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	 There	 is	 a	 large	 variety	 of	 data	 that	may	be	mined	 and	 analysed	with	 the	 use	 of	 various	
tools	and	software.	These	include	raw	DNA	sequence	data	sets,	protein	sequences,	macromolecular	
structures,	genome	sequences	and	gene	expression	data.	The	ways	in	which	this	data	may	be	mined	
with	bioinformatics	is	many-fold	and	are	highlighted	in	Table	5.1.		
	
Table	5.1:	Bioinformatics	tools.	Table	to	highlight	the	variety	of	datasets	more	commonly	available	in	biological	
research	and	the	bioinformatics	projects	that	may	be	employed	to	utilise	these	datasets.	Information	taken	and	
adapted	from	table	in	(Luscombe,	et	al.	2001).	
Dataset	 Uses	for	dataset	with	bioinformatics	
Raw	DNA	sequence	 • Separation	of	coding	and	non-coding	regions	
• Identification	of	introns	and	exons	
• Gene	product	prediction	
• Forensic	analysis	
	
Protein	sequence	 • Sequence	comparison	algorithms	
• Multiple	sequence	alignment	algorithms	
• Identification	of	conserved	sequence	motifs	
	
Macromolecular	structure	 • Secondary	and	tertiary	structure	prediction	of	proteins	
• 3D	structural	alignment	algorithms	
• Protein	geometry	measurements	
• Surface	and	volume	shape	calculations	
• Intermolecular	interactions	
• Molecular	 simulations	 (force-field	 calculations,	
molecular	movements	and	docking	predictions)	
	
Genome	sequence	
	
	
	
• Characterisation	of	repeats	
• Structural	assignments	to	genes	
• Phylogenetic	analysis	
• Genomic-scale	 censuses	 (characterisation	 of	 protein	
content,	 metabolic	 pathways	 and	 prediction	 of	
functional	interactions)	
• Linkage	 analysis	 relating	 specific	 genes	 to	 diseases,	
anatomical	 and	 structural	 features	 and	 experimental	
conditions	
	
Gene	expression	 • Correlating	expression	patterns	 to	 validate	potential	of	
interactions	 between	 proteins	 and	 to	 suggest	 possible	
regulators	
• Mapping	 expression	 data	 to	 sequence	 structural	 and	
biochemical	data	
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5.3	Types	of	datasets	that	may	be	mined	with	bioinformatics		
5.3.1	Raw	DNA	and	genome	sequences			 The	 advent	of	 the	 availability	 of	 genome	 sequences	 has	proved	one	of	 the	most	 exciting	
advances	in	scientific	research.	Databases	such	as	GenBank	(Benson,	et	al.	2000),	EMBL	(Baker,	et	al.	
2000)	and	DDBJ	(Okayama,	et	al.	1998)	are	all	examples	of	databases	that	contain	DNA	sequences	
for	the	genes	that	encode	a	variety	of	proteins.	In	a	similar	fashion,	the	Entrez	database	(Tatusova,	
et	al.	1999)	 is	a	repository	for	all	of	 the	complete	and	partially	complete	genomes	that	have	been	
elucidated	so	far	and	allows	users	to	investigate	sequencing	at	a	number	of	different	levels	of	detail	
including,	 chromosomes,	 non-coding	 and	 coding	 regions	 all	 the	 way	 down	 to	 the	 sequences	 for	
single	 genes.	 Detailed	 annotations	 are	 also	 available	 within	 these	 datasets	 regarding	 sequence	
alignments	 between	 proteins	 and	 genes	 as	well	 as	 information	 regarding	 functionality	 of	 specific	
proteins,	 whether	 that	 be	 lab-validated	 or	 hypothesised.	 GeneCensus	 (Tatusova,	 et	 al.	 1999)	 is	 a	
resource	for	studies	at	a	higher	level	whereby	reference	between	individual	genomes	may	be	made	
in	order	to	gain	insight	from	an	evolutionary	standpoint	(Luscombe,	et	al.	2001).			
5.3.2	Protein	sequences			 Protein	 sequence	 databases	 may	 be	 used	 to	 study	 and	 compare	 the	 sequences	 of	 an	
individual,	 or	 group	 of	 proteins	 of	 interest.	 SWII-PROT	 (Bairoch	 and	 Apweiler	 2000)	 is	 a	 common	
repository	 for	 this	 information	and	may	be	used	 to	determine	 the	 function	of	 specific	proteins	as	
well	 as	 understand	 its	 domain	 structures	 and	any	post-translational	modifications	 it	may	undergo	
upon	 synthesis.	 These	databases	may	 also	be	used	 to	 determine	 sequence	 conservation	between	
groups	of	related	proteins.	The	program	PROSITE	(Hofmann,	et	al.	1999)	is	the	most	popular	for	this	
alongside	its	ability	to	identify	biologically	relevant	or	active	sites	within	the	protein	of	interest.	The	
PRINTs	 (Attwood,	 et	 al.	 2000)	 software	 catalogues	 regions	 of	 conservation	 within	 families	 of	
proteins	to	predict	confirmation	and	functions	of	newly	discovered	proteins.	Understanding	already	
established	protein	sequencing	 is	key	 in	underpinning	novel	protein	structure	and	 large	databases	
that	combine	all	current	knowledge	of	protein	sequencing	information	prove	invaluable	for	protein	
identification	projects.	The	PFAM	(protein	families)	database	(Finn,	et	al.	2016)	is	just	one	example	
of	a	large	dataset	of	protein	annotations	and	sequence	alignments.		
	
5.3.3	Macromolecular	structures		
	 The	PDB	 (Berman,	 et	al.	 2000,	Bernstein,	 et	al.	 1977)	 is	perhaps	 the	primary	archive	 that	
exists	 for	 the	 study	of	3D	 structures	of	proteins,	RNA,	DNA	and	a	variety	of	 complexes.	 In	August	
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2000,	there	were	approximately	13,000	structures	solved	by	x-ray	crystallography	and	NMR	and	in	
some	 cases,	 theoretical	modeling	 alone.	 Structural	 analyses,	 schematic	 diagrams	 and	 information	
regarding	 interactions	between	different	molecules	can	all	be	found	in	these	repositories	and	may	
be	 used	 to	 elucidate	 structural	 and	 evolutionary	 relationships	 between	 novel	 and	 pre-established	
protein	 structures.	 There	exist	 also	 specialised	databases,	 for	example	 the	Nucleic	Acids	Database	
(NDB)	 (Berman,	 et	 al.	 1992)	 for	 all	 nucleic	 acid	 structures.	 Additionally,	 ReLiBase	 (Hendlich	 1998)	
may	be	used	to	explore	receptor-ligand	complexes	structures	and	functions.			
5.3.4	Gene	expression	studies		
	 Experiments	 to	 evaluate	 the	 expression	 levels	 of	 individual	 genes	 has	 become	 an	
increasingly	popular	 tool	 for	assessing	changes	 in	 target	genes	 that	may	be	affected	by	disease	or	
injury.	Levels	of	RNA	can	be	quantified	relatively	quickly	and	easily	and	allow	conclusions	to	be	made	
about	translation	of	target	proteins	within	cells	of	interest.	Whilst	this	may	be	carried	out	on	a	very	
small	scale	using	qRT-PCR	methodology	(see	Chapter	3),	 larger	scale	applications	of	 this	 technique	
include	 cDNA	 microarray	 (Cheung,	 et	 al.	 1999,	 Eisen	 and	 Brown	 1999),	 Affymetrix	 Gene	 Chip	
(Lipshutz,	et	al.	1999)	and	SAGE	(Velculescu	1999)	technology.	Relative	levels	of	target	genes	may	be	
determined	 using	 cDNA	 microarray	 technologies	 whilst	 absolute	 expression	 levels	 may	 be	
established	with	Affymetrix	Gene	Chip	and	SAGE	methodologies.	For	humans,	established	examples	
of	gene	expression	databases	include	The	Molecular	Portraits	of	Breast	Tumours	(Perou,	et	al.	2000)	
and	Lymphoma	and	Leukemia	Molecular	Profiling	(Golub,	et	al.	1999)	and	offer	detailed	databases	
with	which	to	explore	gene	expression	experiments	in	human	cancer	cell	lines.	The	Cancer	Genome	
Atlas	 (TCGA)	 is	 one	 database	 most	 commonly	 used	 for	 human	 cancers	
(http://cancergenome.nih.gov/).	 Other	 pieces	 of	 software	 including	 Genevestigator	 (NEBION,	
Switzerland)	 (Hruz,	 et	 al.	 2008)	 and	 Braineac	 (www.braineac.org)	 are	 now	 other	 repositories	 for	
gene	expression	levels	that	allow	complex	query	searches	to	determine	changes	in	gene	expression	
in	 the	 context	 of	 specific	 diseases	 or	 in	 target	 tissues/organs.	 	 The	 use	 of	 bioinformatics	 in	 this	
context	may	also	serve	as	a	preliminary	target-finding	resource	as	a	way	of	determining	gene	targets	
of	 interest	that	may	change	in	disease	and	can	be	identified	for	further	validation	in	the	lab	in	the	
future.		
	
	 A	great	deal	of	work	has	been	undertaken	to	simplify	the	way	in	which	groups	of	genes	can	
be	 classified	 or	 grouped	 together	 based	 on	 shared	 similarities	 within	 their	 expression	 profiles.	
Clustering	 genes	 by	 their	 expression	profiles	may	 allow	 groups	 of	 proteins	 to	 be	determined	 that	
may	be	expressed	together	in	response	to	certain	cellular	perturbations	(Luscombe,	et	al.	2001),	for	
example	 in	 the	 presence	 of	 a	 specific	 disease	 phenotype.	 Other	 attributes	 including	 structure,	
function	 and	 cellular	 localization	 of	 each	 gene	 product	may	 also	 be	 considered.	 In	 this	 context,	 a	
“bigger	picture”	may	be	established	with	respect	to	the	roles	of	certain	gene	products	and	changes	
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in	 their	 functionality	 with	 different	 cellular	 conditions.	 In	 the	 medical	 sciences,	 gene	 expression	
analysis	may	 be	 used	 to	 provide	 insight	 into	 the	 gene	 expression	 biology	within	 cells	 affected	 by	
various	diseases	(Friend	1999).	Cancer	(Golub,	et	al.	1999)	and	arteriosclerosis	(Hiltunen,	et	al.	1999)	
are	 examples	 of	 this,	 whereby	 changes	 in	 expression	 in	 the	 context	 of	 these	 diseases	 may	 be	
compared	 to	 that	 of	 the	 healthy	 individual.	 Furthermore,	 identification	 of	 the	 genes	 that	 are	
expressed	 differentially	 in	 these	 conditions	 may	 prove	 useful	 in	 prediction	 of	 the	 causes	 that	
underlie	the	disease	of	interest,	as	well	as	potential	biomarkers	or	even	drug	targets	in	this	system	
(Luscombe,	et	al.	2001).	Elucidating	the	transcriptional	regulators	that	may	underpin	observed	gene	
expression	changes	might	also	prove	useful	 in	determining	disease	risk	 factors	or	areas	of	 interest	
for	investigation	of	disease	pathological	mechanisms	and	pathways.	Expression	analysis	of	this	kind	
may	 also	 prove	 beneficial	 in	 determining	 the	 response	 of	 trial	 pharmacological	 intervention	
(Colantuoni,	 et	 al.	 2000,	 Debouck	 and	Metcalf	 2000)	 and	 in	 doing	 so,	may	 also	 offer	 insight	 into	
potential	side	effects	or	toxicological	risk	that	may	arise	upon	administration.		
	
	 Ultimately,	 assuming	 persistence	 in	 the	 growth	 of	 technological	 expertise,	 the	 use	 of	
systems	 biology	 combined	 with	 bioinformatics	 methods	 and	 large	 scale	 sequencing	 data	 are	
predicted	to	become	a	tool	within	the	healthcare	system.	Post-natal	genotyping	for	example	may	be	
more	readily	carried	out	as	a	tool	to	determine	susceptibility	or	even	immunity	from	certain	diseases	
or	 pathogens.	 Indeed,	 a	 future	 of	 “personalised”	 medicine	 may	 become	 possible	 whereby	
vaccinations	 and	 treatment	 strategies	may	be	 prescribed	on	 an	 individual	 basis	 as	 determined	by	
genetic	history	and	predicted	predisposition	to	specific	conditions	(Sander	2000).	
	
	 Overall,	 bioinformatics	 essentially	 aims	 to	 understand,	 analyse	 and	 categorise	 complex	
datasets	of	 information	 so	as	 to	determine	a	greater	depth	of	biological	understanding	 in	a	 given	
research	field.	Databases	of	this	kind	dictate	a	need	for	proper	classification,	encoding	and	storage	
for	further	meta-analysis.	Meta-analysis	requires	sophisticated	methods	for	data	interrogation	so	as	
to	decipher	it	in	a	meaningful	functional	sense.	In	this	way,	existing	data	may	prove	beneficial	to	any	
particular	project	where	similar	genes	and	gene	sets	may	be	implicated.		
	
5.4	Bioinformatics	and	Alzheimer’s	disease		
5.4.1	Functional	protein	sequences		
AD	is	characterised	by	protein-based	pathologies	and	bioinformatics	tools	to	study	protein	
sequences	 and	 their	 functionality	 are	 becoming	 increasingly	 more	 popular	 more	 recently.	 One	
particular	study	for	example	in	2008	collected	74	already	established	proteins	known	to	be	involved	
in	 the	 pathogenesis	 of	 AD	 and	 studied	 their	 sequences	 with	 the	 help	 of	 databases	 that	 store	
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functional	protein	sequences	available	for	public	use.	Multiple	sequence	alignment	algorithms	could	
then	 be	 applied	 to	 this	 group	 of	 proteins	 to	 identify	 any	 similarities	 that	may	 exist	 between	 the	
proteins	 of	 interest.	 The	 phylogenetic	 tree	 of	 distance	 between	 these	 proteins	 was	 established	
based	 on	 sequence	 similarity	 and	 disparity.	 In	 this	 particular	 study,	 of	 the	 74	 protein	 sequences	
studied,	the	presenilin-1	(PS-1),	presenilin-2	(PS-2)	and	amyloid	precursor	protein	(APP)	were	found	
to	exhibit	the	minimum	distance	between	each	other.	This	data	implicated	these	3	proteins	as	key	in	
the	evolution	of	AD	and	suggested	significant	 roles	 in	 the	development	of	 this	disease	 (Rao,	et	al.	
2008).		
	
This	study	went	on	to	postulate	that,	owing	to	their	significance	in	the	pathogenesis	of	AD,	
missense	 mutation	 in	 the	 APP,	 PS-1	 or	 PS-2	 genes	 might	 have	 significant	 implications	 on	 the	
processing	 of	 the	 APP	 protein	 and	 ultimately	 the	 generation	 of	 the	 toxic	 Aβ	 peptide.	 Indeed,	
accumulation	of	the	Aβ	peptide	 into	mature	 insoluble	plaques	within	the	brain	 is	known	to	trigger	
inflammatory	responses	via	microglial	activation	and	the	release	of	pro-inflammatory	cytokines.	This	
work	has	been	supported	by	reports	of	increased	interleukin-1	(IL-1)	and	tumor-necrosis	factor	(TNF-
α)	 in	plasma	and	cerebrospinal	 fluid	 levels	of	patients	with	AD	 (Cacabelos,	 et	al.	1991,	Fillit,	 et	al.	
1991).	As	such,	informatics	may	be	used	in	this	manner	to	elucidate	target	proteins	to	uncover	new	
proteins	of	 interest	with	regard	a	wider	context	of	AD.	Piecing	together	findings	to	create	a	bigger	
picture	 may	 be	 achieved	 with	 informatics,	 which	 coupled	 with	 lab	 validation	 may	 result	 in	 new	
hypotheses	and	conclusions	regarding	the	mechanisms	of	this	disease.	
	
5.4.2	The	use	of	bioinformatics	as	a	tool	for	drug	repurposing	in	Alzheimer’s	disease		
	 The	 process	 by	 which	 drug	 therapies	 are	 designed	 and	 make	 their	 way	 from	 bench	 to	
bedside	 is	 an	 extremely	 long	 and	 costly	 one,	 not	 least	 because	 of	 the	 challenges	 associated	with	
identifying	 and	 isolating	 novel	 compounds.	 Natural	 products	 are	 particularly	 favorable;	 indeed	
approximately	75%	of	all	Food	and	Drug	Administration	(FDA)	approved	small	molecules	are	either	
natural	products	themselves	or	derivatives	of	natural	products	(Newman	and	Cragg	2012).	There	are	
many	attractions	of	natural	products	not	least	due	to	their	complexity	and	protein	binding	specificity	
(Newman	and	Cragg	2012).	There	is	however	limitations	in	that	they	take	a	great	of	time	to	identify	
and	require	time-consuming	purification	methodologies	to	isolate.		
	
	 Drug	 repurposing	 is	 a	 process	 by	 which	 new	 indications	 for	 pre-existing	 drugs	 can	 be	
identified	for	other	diseases.	This	method	is	often	safer,	cheaper	and	saves	a	great	deal	more	time	
(Siavelis,	 et	 al.	 2016).	 This	 method	 uses	 a	 number	 of	 bioinformatics	 tools	 to	 compare	 chemical	
structures	 of	 known	 drugs,	 molecular	 docking,	 gene	 analyses,	 network	 simulations	 and	 chemo	
genomics	data	processing	(Liu,	et	al.	2013).	Microarray	profiles	in	particular	are	used	routinely	in	this	
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process	 as	 they	 can	 generate	 lists	 of	 up	 and	 down	 regulated	 genes.	 These	 lists	 can	 then	 be	
formulated	into	drug-drug,	disease-disease	and	drug-disease	comparisons.	
	
If	 a	 compound	 is	 found	 to	 be	 consistently	 anti-correlated	 with	 AD,	 this	 reinforces	 its	
significance	 as	 a	 pharmacological	 target.	 Compounds	 may	 also	 be	 selected	 based	 on	 structural	
comparisons	 and	 similarities	 they	 may	 share	 with	 other	 identified	 compounds.	 Finally,	 pathway	
enrichment	analysis	may	be	used	alongside	network	analysis	methodologies	to	assess	the	efficacy	of	
a	 drug	 compound	 against	 AD.	 From	 this	 work,	 a	 more	 manageable	 list	 of	 compounds	 can	 be	
compiled,	based	on	mode	of	action	and	structural	data	that	can	then	go	on	to	be	further	validated	in	
a	lab	based	environment	(Siavelis,	et	al.	2016).		
	
	 One	 particular	 study,	 assessed	 gene	 signatures	 from	 five	 different	 gene	 expression	
experiments	derived	 from	AD	human	hippocampus	 samples.	 This	 study	by	 Siavelis	 and	 colleagues	
resulted	 in	a	 list	of	27	drugs	 that	were	structurally	different	 to	 those	drugs	 that	were	currently	 in	
clinical	 use	 against	 AD	 (in	 particular	 they	 differed	 from	 acetylcholinesterase	 inhibitors	 and	NMDA	
channel	 blockers,	 as	 discussed	 in	 chapter	 1).	 This	 research	 proposed	 that	 protein	 kinase	 C	 (PKC)	
(mediates	 several	 cellular	 functions)	 (Mellor	 and	 Parker	 1998),	 histone	 deacetylase	 (HDAC)	
(associated	 with	 epigenetic	 modification)	 (Smith	 2008),	 arginase	 (ARG)	 (converts	 arginine	 to	
ornithine	 and	urea)	 (Durante,	 et	 al.	 2007),	 and	 glycogen	 synthase	 kinase	 3	 (GSK3)	 (participates	 in	
Wnt	and	insulin	pathways)	(Forde	and	Dale	2007)	inhibitors	might	be	beneficial	in	the	reversal	of	the	
Alzheimer’s	 induced	 gene	 expression	 pattern	 and	 thus	 show	 the	 potential	 to	 tackle	 the	 disease	
phenotype.	 These	 inhibitors	 may	 work	 as	 anti-Alzheimer’s	 agents	 and	 this	 study	 indicated	 they	
might	elicit	their	action	via	an	epidermal	growth	factor	receptor	(EGFR)	mediated	pathway.	Having	
identified	target	compounds	in	this	manner,	further	work	can	be	carried	out	in	the	lab	to	assess	the	
efficacy	 of	 these	 lead	 compounds	 and	 their	 potential	 as	 AD	 therapeutics.	 Naturally,	 there	 are	 a	
number	 of	 challenges	 to	 overcome	 with	 this	 method	 of	 screening.	 Re-purposing	 of	 drugs	 in	 this	
manner	 will	 likely	 encounter	 complexities	 regarding	 dosage,	 toxicity	 and	 in	 the	 context	 of	 AD,	
whether	these	compounds	can	effectively	cross	the	BBB.	Despite	this,	more	thorough	research	into	
multi	modal	use	of	certain	compounds	may	prove	a	more	time	and	money-effective	strategy.	
	
	 Whilst	 the	 efforts	 to	 treat	 AD	 are	 naturally	 still	 very	 much	 challenging,	 the	 use	 of	
bioinformatics	 tools	on	this	occasion	highlights	 the	resources	 that	are	now	available	and	the	ways	
they	 can	 be	 exploited	 for	 scientific	 research.	 The	 advantages	 of	 such	 large	 repositories	 of	
information	 that	 are	now	publically	 available	 allow	 for	 a	much	more	 streamlined	method	of	 drug	
discovery.	Understanding	 new	uses	 for	 already	 established	 drug	 compounds	 in	 the	 context	 of	 AD	
may	prove	vital	in	treating	this	condition	(Siavelis,	et	al.	2016).		
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5.4.3	Identification	of	biomarkers	
	
	 Understanding	 ways	 in	 which	 AD	 can	 be	 treated	 relies	 heavily	 on	 confirming	 early	
diagnoses	 with	 which	 treatment	 strategies	 can	 be	 initiated.	 Diagnosis	 has	 proved	 particularly	
challenging	with	AD	and	often	treatment	 initiatives	begin	too	late	making	them	not	as	effective	as	
they	could	be.	Biomarkers	are	fast	becoming	a	focus	of	intensive	research;	finding	a	biomarker	that	
can	be	easily	and	relatively	cheaply	detected	in	patients,	as	part	of	a	screening	initiative	may	prove	
crucial	in	detecting	the	early	stages	of	AD.	With	application	of	computational	methods	large	datasets	
can	be	screened	for	specific	gene	expression	patterns	or	mutations	associated	with	disease	onset,	
early	 markers	 of	 change,	 or	 even	 identifier	 risk	 genes	 in	 individuals	 more	 predisposed	 to	 the	
condition.		
	
	 One	particular	study,	aimed	at	elucidating	the	mechanisms	that	underpin	AD	pathology	by	
investigating	microarray	 data	 of	mRNA	 in	 cortex	 samples	 from	 patients	 with	 AD	 as	 compared	 to	
healthy	 age-matched	 controls	 using	 the	 Gene	 Expression	 Omnibus	 (GEO)	 (Edgar,	 et	 al.	 2002)	
database	 (Zhao,	 et	 al.	 2016).	 This	 study	 aimed	 to	 identify	 potential	 changes	 in	 the	 expression	 of	
genes	in	AD	patents	that	could	then	be	integrated	into	wider	networks	to	identify	target	genes	that	
may	 help	 diagnose	 AD	 more	 efficiently.	 	 This	 study	 identified	 target	 genes	 SEC22B	 and	 SEC63	
regulated	by	miRNA-206;	RAB10	 regulated	by	miRNA-369-3p	and	FLT1	 regulated	by	miRNA-30e-3p	
that	may	play	important	roles	in	the	progression	and	development	of	AD.	Having	identified	miRNAs	
known	to	significantly	change	in	AD	patients,	this	data	may	also	offer	potential	targets	for	the	design	
of	novel	 therapeutic	 strategies.	 In	addition,	 interaction	analysis	and	network	 construction	analysis	
revealed	 that	 RBA	 proteins	 are	 important	 in	 the	 regulation	 of	 levels	 of	 Aβ	 (Udayar,	 et	 al.	 2013).	
Indeed	RAB10	(Ras-Related	GTP-Binding	Protein	10)	 is	able	to	decrease	 levels	of	Aβ	and	hints	at	a	
regulatory	 role	 of	 RAB10	 to	modulate	 the	 activity	 of	 the	 γ-secretase	 cleavage.	 	 Likewise	 elevated	
levels	 of	 FLT1	 (Vascular	 Endothelial	Growth	 Factor	Receptor	 1)	 in	AD	patients	 as	 identified	 in	 this	
study	 revealed	 that	 FLT1	 contributes	 to	 deposits	 of	 Aβ	 within	 the	 brain	 as	 well	 as	 microglial	
autocrine	processes	(Ryu,	et	al.	2009).	Chronic	inflammation	is	a	key	feature	in	AD	pathogenesis	and	
is	associated	with	the	deposition	of	Aβ	in	the	brain.	FLT	may	help	to	mobilise	microglia	and	regulate	
their	role	in	the	development	of	AD.	As	such	identification	of	this	component	may	be	an	important	
target	for	future	efforts	to	treat	AD	(Zhao,	et	al.	2016).		
	
	 Several	 other	 targets	 of	 interest	 have	 been	 identified	 in	 this	 way	 via	 meta-analysis	 of	
microarray	data	 from	AD	patients	can	reveal	changes	 in	 the	expression	of	specific	genes	 that	may	
prove	 fundamental	 in	 identifying	 the	 onset	 and	 development	 of	 AD	 pathology.	 For	 this	 reason,	
bioinformatics	offers	a	helpful	approach	at	 the	beginning	of	 research	projects	 to	 identify	genes	of	
interest	that	can	be	elucidated	further	within	the	laboratory	at	a	later	date.	High	level	screening	in	
this	 way	 serves	 as	 a	 top	 down	 approach	 to	 finding	 important	 pathological	 mechanisms	 and	
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pathways	that	can	be	targeted	with	therapeutics	 in	the	future	to	aid	the	treatment	and	ultimately	
cure	of	this	disease.		
	
5.4.4	GWAS	and	AD	
	
	 Genome-wide	 association	 studies	 (GWAS)	 have	 proven	 particularly	 beneficial	 in	 AD	
research.	GWAS	is	an	approach	by	which	genetic	variants	in	a	large	group	of	individuals	is	examined	
to	determine	whether	 specific	genetic	variants	are	associated	with	a	particular	 trait	of	 interest,	 in	
this	instance,	AD.	GWAS	investigations	usually	focus	on	the	association	between	SNPs	and	diseases.	
Understanding	 association	 between	 specific	 genetic	 variations	 and	 disease	 may	 prove	 useful	 in	
identifying	biomarkers	for	the	early	diagnosis	of	AD,	particularly	for	those	individuals	who	may	carry	
risk	 factor	 genes.	 	 The	 Human	Genome	 Project	 in	 2003	 and	 the	 international	 HapMap	 project	 in	
2005	 have	 made	 sequencing	 information	 more	 readily	 available	 to	 researchers.	 Harold	 and	
colleagues	in	2009	undertook	a	two-stage	GWAS	to	study	genomic	data	from	16,000	individuals,	the	
largest	AD	study	to	date.	This	study	confirmed	the	earlier	finding	that	APOE	(Avramopoulos	2009)	is	
still	 the	most	significant	SNP.	This	study	also	discovered	two	genetic	 loci	not	previously	associated	
with	 the	 development	 of	 AD;	 CLU	 and	 PICALM	 (Harold,	 et	 al.	 2009).	 The	 CLU	 gene	 encodes	 the	
clusterin	 protein	 that	 is	 up	 regulated	 in	 a	 number	 of	 conditions	 that	 involve	 chronic	 injury	 or	
inflammation	within	the	brain	(Calero,	et	al.	2000).	Moreover,	levels	of	clusterin	are	reported	to	be	
elevated	 in	AD	patients	within	 cortical	 areas	 directly	 affected	by	AD	pathology.	 Elevated	 levels	 of	
clusterin	are	also	reported	within	the	CSF	and	the	amyloid	plaques	themselves	(Giannakopoulos,	et	
al.	 1998,	 Liang,	 et	 al.	 2008,	 McGeer,	 et	 al.	 1992).	 The	 second	 identified	 locus	 was	 PICALM	
(phosphatidylinositol-binding	 clathrin	 assembly	 protein).	 Expression	 of	 this	 protein,	 although	
ubiquitous,	 is	predominantly	 found	within	neurons,	most	specifically	at	 the	pre-	and	post-synaptic	
structures	(Harold,	et	al.	2009).	The	PICALM	protein	has	been	shown	to	play	a	role	in	the	regulation	
of	trafficking	of	protein.	In	the	context	of	AD,	PICALM	is	reported	to	traffic	VAMP2,	a	SNARE	protein	
key	 in	 the	 fusion	 of	 synaptic	 vesicles	 to	 the	 presynaptic	 membrane	 for	 neurotransmitter	 release	
(Harel,	 et	 al.	 2008).	 AD	 patients	 are	 known	 to	 display	 reduced	 synaptic	 activity	 correlated	 with	
cognitive	decline	and	so	implicated	PICALM	heavily	in	the	progression	of	this	disease.	Identification	
of	 these	 two	genetic	 loci	 offer	 new	 targets	 to	 study	 in	 the	 search	 for	 biomarkers	 of	AD	and	drug	
discovery	targets.	Currently	there	are	very	few	known	genetic	risk	factors	for	AD.	Mutations	in	the	
genes	that	encode	APP,	PSN-1	and	PSN-2	are	known	to	cause	rare	early	onset	forms	of	the	disease.	
However,	the	more	common	sporadic	late	onset	form	of	the	disease	are	a	little	more	misunderstood	
with	APOE	as	the	only	unequivocally	established	susceptibility	gene	(Avramopoulos	2009).		
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5.5	Conclusions		
In	conclusion,	there	is	a	wealth	of	information	available	to	research	scientists	now	that	may	
serve	 to	aid	 in	 the	 identification	of	novel	protein	 targets,	 structural	analysis	of	novel	proteins	and	
potential	biomarkers	for	a	variety	of	diseases.	 In	the	context	of	AD,	there	is	still	a	huge	amount	of	
information	to	be	gained	with	regard	to	risk	factor	genes,	network	analysis	and	drug	discovery	target	
identification	 and	with	 the	 advent	 of	 several	 pieces	 of	 software	 to	 aid	 such	 research,	 the	 use	 of	
bioinformatics	 is	 more	 common	 than	 ever.	 In	 particular,	 integration	 of	 different	 data	 types	 via	
various	 bioinformatics	 approaches	 may	 serve	 to	 generate	 new	 networks	 and	 models	 why	 which	
pathogenesis	may	be	initiated.	This	project	aimed	to	employ	some	of	these	resources	to	investigate	
further	 the	 role	of	HS	 in	AD	and	set	 the	 functionality	of	HS	 in	a	wider	context	of	 the	disease,	not	
limited	only	to	its	interaction	and	regulation	of	BACE-1.			
5.6	Aims	of	chapter	
	
• Investigate	 changes	 in	 the	 expression	 of	 genes	 encoding	 HS	 biosynthetic	 genes	 as	
determined	with	microarray	analysis	and	curated	into	gene	expression	profiling	databases.	
• Determine	how	changes	to	HS	may	be	regulated	in	different	regions	of	the	brain.	
• Investigate	 the	 role	of	HS	 in	 the	wider	 context	of	AD	with	pathway	network	analysis	 and	
association	studies	to	explore	alternative	pathways	in	AD	that	may	be	regulated	by	HS.		
5.7	Methods			 For	 the	 bioinformatics	 work,	 three	 gene	 lists	 were	 compiled	 and	 used	 in	 data	 mining	
efforts.	The	first	contained	Gene	IDs	encoding	the	HS	biosynthetic	enzymes	and	their	core	proteins	
(Sarrazin,	 et	al.	2011)	 (Esko	and	Selleck	2002).	This	 list	was	also	established	with	 the	use	of	KEGG	
(Version	 80.1,	 Kaneshisa	 laboratories,	 Japan)	 (Kanehisa	 and	 Goto	 2000,	 Kanehisa,	 et	 al.	 2016)	 to	
determine	the	pathway	for	the	synthesis	of	HS.	The	 list	also	 included	the	HS	degradation	enzymes	
HPSE	and	HPSE2	and	SULF1	and	SULF2.	The	second	list,	all	previously	established	GWAS	significant	
AD	 risk	 factor	 genes	 and	 the	 third	 list,	 the	 heparin	 interactome	 	 (a	 list	 of	 over	 300	 proteins	 that	
heparin	is	known	to	interact	with)	(Ori,	et	al.	2011).	The	gene	lists	are	detailed	in	Appendix	C.		
	
5.7.1	STRING	
	
	 STRING	(Version	10.0)	(Jensen,	et	al.	2009)	 is	a	database	of	known	and	predicted	protein-
protein	 interactions.	 STRING	 software	 was	 used	 initially	 as	 a	 way	 of	 searching	 for	 interactions	
between	 the	 selected	 proteins	 of	 interest	 in	 this	 project.	 STRING	 software	 was	 used	 to	 assess	
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interactions	of	different	types,	whether	that	was	experimentally	validated	links,	co-expression,	gene	
fusion,	 data-mining	 etc.	 Each	 interaction	was	 given	 a	 score	 based	 on	 the	 confidence	 of	 a	 specific	
interaction.	All	scores	rank	from	0	to	1	where	1	indicated	the	highest	confidence	and	0,	the	lowest.	
On	 this	 occasion,	 all	 interactions	 were	 investigated	 based	 only	 on	 human	 data,	 not	 any	 other	
organism.	A	 confidence	 threshold	of	0.4	was	 set	 to	eliminate	any	 “weak”	 interaction	 information.		
STRING	software	was	used	to	investigate	any	potentially	unexpected	links	between	the	proteins	of	
interest	 and	 to	 explore	 possible	 relationships	 between	 specific	 groups/subgroups	 of	 proteins.	 No	
additional	 nodes	 (additional	 proteins	 separate	 to	 proteins	 of	 interest	 that	 may	 tie	 proteins	 of	
interest	 together)	 were	 added	 to	 networks	 for	 the	 sake	 of	 simplicity.	 This	 software	 was	 used	
primarily	 to	 assess	 connections	 between	 the	 HS	 biosynthetic	 enzymes	 and	 any	 previously	
unconsidered	interactions	that	may	exist.	
	
5.7.2	Genevestigator®			 Genevestigator®	 software	 (Genevestigator®	 Version	 47326744,	 NEBION)	 was	 used	 to	
review	expression	of	HS	biosynthetic	genes	and	the	genes	encoding	core	proteins	in	the	context	of	
both	AD	and	from	an	anatomical	standpoint.	The	Genevestigator®	software	allowed	a	quick	look	at	
curated	microarray	information	previously	collected	and	made	publically	available	for	meta-analysis.	
This	 software	 was	 therefore	 ideal	 as	 a	 means	 to	 assess	 whether	 changes	 in	 HS	 biosynthetic	
machinery	 gene	 expression	 occurs	with	AD	 and	 indeed	 how	expression	may	 vary	 across	 different	
regions	of	the	brain.	As	a	first	look,	this	database	mining	approach	was	used	to	identify	target	genes	
of	interest	for	future	lab	validation	studies.		
	
	 Gene	expression	data	for	the	HS	biosynthetic	enzymes	and	core	proteins	were	investigated	
in	the	context	of	AD	as	well	as	different	anatomical	locations	within	the	brain.	High	level	analysis	of	
gene	expression	changes	in	response	to	these	perturbations	(disease	or	anatomy)	could	be	explored	
with	heat	map	analysis	 to	determine	whether	 a	 gene	of	 interest	was	up-	or	down-	 regulated	and	
data	points	could	be	further	analysed	with	regard	to	experimental	detail,	sample	numbers,	p	value	
statistical	 significance	 etc.	 With	 respect	 to	 microarray	 analysis	 of	 HS	 biosynthetic	 genes	 in	 the	
context	 of	 AD,	 one	 particular	 study	 was	 found	 to	 be	 most	 relevant	 to	 this	 project	 within	 the	
database	 and	 was	 carried	 out	 by	 Liang	 and	 colleagues	 in	 2006	 to	 assess	 microarray	 expression	
profiling	of	genes	from	AD	brains	and	healthy	age-matched	controls.	The	experimental	details	of	this	
study	are	outlined	in	detail	in	Appendix	D.		
	
	 Expression	 of	 the	 HS	 biosynthetic	 genes	 and	 core	 proteins	 with	 respect	 to	 anatomical	
region	allowed	investigation	of	variation	in	expression	and	was	used	to	assess	potential	vulnerability	
to	certain	areas	with	respect	to	changes	in	the	structure	of	HS	and	the	implications	this	may	have	on	
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AD	 pathology.	 Anatomical	 analysis	 was	 carried	 out	 independently	 to	 the	 AD	 phenotype	 and	 was	
obtained	only	from	healthy	individuals.		
	
5.7.3	Ingenuity	Pathway	Analysis	(IPA®)		
The	“core	analysis”	function	was	used	in	the	IPA®	(Ingenuity	System	Inc.,	USA)	software	to	
interpret	 the	 genes	 of	 interest	 in	 the	 context	 of	 biological	 pathways	 and	 networks.	 Both	 up-	 and	
down-	 regulated	 identifiers	 were	 defined	 as	 value	 parameters	 for	 the	 analysis.	 The	 software	
generated	networks	that	were	ordered	according	to	a	score	of	significance.	The	Fisher	exact	test	p-
value	was	used	to	assess	significance	of	certain	connections	and	canonical	pathways.	This	pathway	
analysis	software	was	able	to	generate	networks	whereby	the	differently	regulated	genes	could	all	
be	placed	into	higher	network	systems	based	on	previously	known	association	and	interactions,	but	
independently	 of	 already	 established	 canonical	 pathways.	 Genes	 of	 interest	 explored	 with	 this	
system	 included	 the	 HS	 biosynthetic	 genes,	 their	 core	 proteins,	 the	 heparin	 interactome	 of	 300+	
proteins	and	AD	risk	genes	previously	identified	in	GWAS.	
	
This	 software	was	used	 to	display	 the	most	 significant	 canonical	pathways	 that	may	exist	
within	 a	 particular	 dataset	 uploaded	 into	 the	 software.	 The	 significance	 of	 interactions	 was	
determined	based	upon	the	probability	of	association	between	molecules	within	the	dataset	being	
studied.	 Furthermore,	 upstream	 regulator	 analysis	 was	 used	 to	 identify	 potential	 upstream	
regulators	that	may	be	responsible	for	the	gene	expression	changes	as	observed	in	other	work.		
	
This	work	hoped	to	establish	any	novel	associations	with	HS	and	other	proteins	implicated	
in	 AD,	 outside	 of	 the	 established	 BACE-1	 interaction	 pathway.	 	 Naturally,	 these	 associations	 are	
largely	 based	 on	 predictions	 and	 as	 such,	 further	 work	 would	 be	 needed	 to	 validate	 potential	
interactions/	 pathways	 within	 the	 lab.	 Hence,	 this	 work	 was	 largely	 preliminary	 and	 hoped	 to	
establish	connections	that	may	strengthen	the	view	that	HS	has	roles	in	AD	pathogenesis	in	a	wider	
context	to	that	already	known,	and	that	might	provide	new	directions	for	future	research.	
	
5.8	Results		
5.8.1.	STRING	
	
Analysis	 with	 STRING	 software	 revealed	 a	 strong	 interaction	 network	 between	 the	 HS	
biosynthetic	 enzymes	 and	 core	 proteins,	 consistent	with	 expectations	 for	 these	 related	 genes.	 All	
interactions	between	 the	proteins	of	 interest	were	assigned	a	 specific	 colour	depending	upon	 the	
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type	of	 interaction	(Figure	5.1).	For	the	majority	of	 interactions	observed	in	this	 instance,	the	lime	
green	line	represented	a	”text	mining”	interaction	whereby	interactions	were	based	on	two	proteins	
found	 to	 be	 mentioned	 within	 the	 literature	 together	 frequently.	 As	 expected,	 this	 type	 of	
interaction	was	 common	within	 this	 group	 of	 proteins	 and	 largely	 cross-linked	 between	 different	
families	 of	 enzymes	 within	 the	 HS	 biosynthetic	 pathway.	 The	 pink	 interaction	 lines	 represented	
interactions	that	had	been	experimentally	determined	and	were	discovered	between	EXT1	and	EXT2	
(protein-protein	 interaction	 in	 humans)	 and	 also	 between	 NDST1	 and	 EXT2	 (protein-protein	
interaction	 in	 mice).	 Experimentally	 determined	 interactions	 were	 also	 reported	 between	 all	
members	 of	 the	 SDC	 family	 (protein-protein	 interactions	 in	 humans)	 and	 also	 between	GPC4	 and	
GPC6.	 The	 turquoise	 line	 between	 proteins	 distinguished	 interactions	 based	 on	 previously	
established	 curated	database	data.	 These	 interactions	were	 largely	 known	pathways	 regarding	HS	
biosynthesis	including	N-deacetylation/N-sulfotransferase	activity	by	the	NDSTs,	sulfation	at	the	6-O,	
3-O	and	2-O	position	by	 the	HS6STs,	HS3STs	and	HS2ST	 respectively	and	polymerisation	of	 the	HS	
chain	 by	 the	 EXTs.	 The	 large	 nodes	 within	 the	 network	 represented	 those	 proteins	 where	 3D	
structure	was	either	confirmed	or	predicted	and	smaller	nodes	represented	those	proteins	with	no	
known	 3D	 structure.	On	 this	 occasion,	 all	 proteins	 studied	 displayed	 a	 large	 node,	 indicative	 of	 a	
known,	 or	 at	 least	 partly	 known	 3D	 structure	 with	 the	 exception	 of	 the	 HS6ST	 family	 and	 GLCE	
whose	nodes	were	small	indicative	of	unknown	3D	structures.	With	this	set	of	proteins,	the	EXTs	and	
XYLTs	 displayed	 fewer	 interactions	 vs.	 the	 modification	 enzymes	 within	 the	 HS	 biosynthetic	
machinery.	Coloured	nodes	represented	all	query	nodes	(Figure	5.1).			
	
Following	this,	GWAS	identified	risk	proteins	were	also	included	in	the	search	to	determine	
whether	 there	 were	 any	 interactions	 between	 known	 AD	 risk	 factor	 genes/proteins	 and	 the	 HS	
biosynthetic	 machinery	 proteins.	 With	 the	 two	 lists	 combined,	 the	 STRING	 generated	 network	
revealed	 a	 much	 less	 tightly	 connected	 network.	 	 Both	 protein	 list	 groups	 remained	 reasonably	
isolated	 from	 each	 other.	 Indeed,	 the	 only	 points	 of	 contact	 between	 the	 two	 groups	 were	
Interactions	found	between	the	SDC	family	and	APOE.	Any	other	connections	found	were	largely	co-
mentions	in	the	literature	between	known	HS	core	proteins.	With	regard	to	the	AD	risk	protein	list,	
little	 experimental	 evidence	 was	 determined	 with	 reported	 interactions	 mainly	 arising	 from	
literature	searches	(Figure	5.2).	
	
5.8.2	Genevestigator®	
	
Genevestigator®	 software	 was	 then	 used	 to	 determine	 how	 the	 presence	 of	 the	 AD	
phenotype	 might	 affect	 the	 expression	 of	 the	 genes	 that	 encode	 HS	 related	 enzymes	 and	 core	
proteins.	 	 Heat	maps	were	 generated	 to	 assess	whether	 expression	 of	 each	 gene	 of	 interest	was	
either	 up-	 or	 down-regulated	 in	 the	 presence	 of	 AD	 vs.	 healthy	 controls.	 Changes	 were	
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representative	of	 log2	 fold	 changes	of	 expression.	Green	 squares	within	 the	heat	map	 indicated	a	
down-regulation	and	red	indicated	an	up-regulation	of	expression	relative	to	healthy	controls.	Each	
gene	 is	 listed	 along	 the	 top	of	 the	heat	map	horizontally	whilst	 the	 region	of	 the	brain	 studied	 is	
listed	vertically	on	the	left	hand	side.	The	data	presented	in	the	heat	map	are	all	representative	of	a	
single	study	whereby	several	regions	of	the	brain	were	studied	in	a	number	of	individuals	with	AD.	
The	heat	map	generated	 for	HS	biosynthetic	genes	 in	 the	presence	of	 the	AD	phenotype	revealed	
strong	changes	in	expression	of	a	number	of	genes	in	a	number	of	different	regions	within	the	brain,	
several	of	which	were	significant	(Figure	5.3)(Table	5.2).	
Figure	5.1:	Output	 interaction	network	as	generated	by	STRING	software	to	display	 interactions	between	HS	
biosynthetic	enzymes	and	core	proteins.	STRING	software	was	used	to	assess	interactions	of	different	varieties.	
On	 this	 occasion,	 all	 interactions	 were	 investigated	 based	 only	 on	 human	 data,	 not	 any	 other	 organism.	 A	
confidence	threshold	of	0.4	was	set	 to	eliminate	any	“weak”	 interaction	 information.	 	All	 interactions	between	
the	proteins	of	interest	were	assigned	a	specific	colour	depending	upon	the	type	of	interaction.	Lime	green	lines	
represent	 ”text	mining”	 interaction,	 Pink	 interaction	 lines	 represent	 interactions	 that	 had	been	experimentally	
determined.		Turquoise	lines	between	proteins	distinguish	interactions	based	on	previously	established	curated	
database	 data.	 The	 large	 nodes	 within	 the	 network	 represent	 those	 proteins	 where	 3D	 structure	 was	 either	
confirmed	or	predicted	and	smaller	nodes	represented	those	proteins	with	no	known	3D	structure.		
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Investigation	of	the	raw	data	behind	the	heat	map	generated	revealed	significant	up-	and	
down-regulation	of	expression	of	the	genes	encoding	the	HS	biosynthetic	enzymes	and	core	proteins	
in	all	of	the	brain	regions	studied.	In	the	case	of	the	HS	biosynthetic	enzymes,	data	generated	from	
this	microarray	profiling	experiment	revealed	strong	down-regulation	of	the	EXT	and	EXTL	genes		
Figure	5.2:	Output	interaction	network	as	generated	by	STRING	software	to	display	interactions	between	HS	
biosynthetic	 enzymes,	 core	 proteins	 and	 GWAS	 identified	 AD	 risk	 proteins.	 STRING	 software	was	 used	 to	
assess	 interactions	 of	 different	 varieties.	 On	 this	 occasion,	 all	 interactions	 were	 investigated	 based	 only	 on	
human	data,	not	any	other	organism.	A	confidence	threshold	of	0.4	was	set	to	eliminate	any	“weak”	interaction	
information.		All	interactions	between	the	proteins	of	interest	were	assigned	a	specific	colour	depending	upon	
the	type	of	 interaction.	Lime	green	 lines	represent	a	”text	mining”	 interaction	Pink	 interaction	 lines	represent	
interactions	 that	 had	 been	 experimentally	 determined.	 	 Turquoise	 lines	 between	 proteins	 distinguish	
interactions	 based	 on	 previously	 established	 curated	 database	 data.	 The	 large	 nodes	 within	 the	 network	
represent	those	proteins	where	3D	structure	was	either	confirmed	or	predicted	and	smaller	nodes	represented	
those	proteins	with	no	known	3D	structure.		
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Figure	5.3:	Heat	map	displaying	fold	changes	 in	expression	of	the	genes	encoding	HS	biosynthetic	enzymes	and	core	proteins	 in	the	presence	of	the	AD	phenotype	 in	6	different	brain	
regions.	Individual	genes	are	listed	across	the	top	of	the	map	(genes	encoding	HS	biosynthetic	enzymes	and	core	proteins)	with	experiment	type/region	listed	vertically	along	the	left.	Logged	
normalised	fold	changes	in	expression	levels	were	used	to	generate	this	map;	colours	range	from	red	(high	expression)	to	green	(low	expression).	p	values	and	fold	changes	were	generated	
and	viewed	upon	selection	(see	table	5.2).	Regulation	of	expression	varied	significantly	across	the	different	brain	regions	studied	on	this	occasion.	HS	biosynthetic	machinery	displayed	robust	
down	regulation	vs.	the	core	proteins	that	was	more	prominently	up	regulated.	Heat	map	generated	with	Genevestigator®	software	and	is	based	upon	original	data	collected	by	Liang	et	al;	
2006.	
	
NEED	TO	FINSIH	
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across	 all	 of	 the	brain	 regions	 studies.	 Conversely,	 this	 experiment	 revealed	 strong	 trends	 for	 up-
regulation	of	expression	of	the	SULF	and	HPSE	genes	across	the	brain	regions	sampled	in	this	study.	
Furthermore,	 expression	 of	 the	 HS	 biosynthetic	 genes	 was	 differentially	 regulated	 across	 the	
different	 brain	 regions	with	 variable	 expression	 patterns	 displayed	 in	 each	 of	 the	 areas	 sampled.	
With	respect	to	the	core	proteins,	a	much	more	substantial	up-regulation	of	expression	of	the	genes	
encoding	 core	 proteins	 was	 observed	 in	 the	 presence	 of	 the	 AD	 phenotype	 relative	 to	 healthy	
controls	with	much	 fewer	 genes	displaying	decreased	expression.	 In	 particular,	 the	primary	 visual	
cortex	 (PVC)	 and	 superior	 frontal	 gyrus	 (SFG)	 brain	 regions	 displayed	 the	 most	 prominent	 up	
regulation	 in	expression	across	all	 genes	 studied.	Conversely	 the	hippocampus	displayed	 the	most	
prominent	down-regulation	of	gene	expression	on	 this	occasion.	The	SRGN	and	AGRN	 genes	were	
found	 to	 be	 strongly	 up-regulated	 across	 all	 brain	 regions	 studied,	 the	 only	 genes	 to	 display	 this	
consistent	expression	change.	Raw	data	values	for	these	fold	changes	are	detailed	in	Table	5.2.		
	
Following	 the	 finding	 that	 the	expression	of	 the	genes	encoding	HS	biosynthetic	enzymes	
and	 core	 proteins	 is	 altered	 in	 the	 presence	 of	 the	 AD	 phenotype.	 This	 software	 was	 used	 to	
determine	 how	 expression	 might	 be	 regulated	 across	 different	 regions	 of	 the	 brain	 in	 healthy	
individuals,	AD	is	known	to	spread	in	a	temporal	and	spatial	fashion	across	different	regions	of	the	
brain	 and	 the	 Genevestigator®	 software	 was	 used	 to	 determine	 whether	 regulation	 of	 the	
expression	of	HS	biosynthetic	machinery	and	core	proteins	in	specific	brain	regions	may	determine	
resulting	vulnerability	of	certain	regions	to	AD	pathology.			
	
	 The	 Genevestigator®	 software	 curated	 several	 absolute	 expression	 datasets	 for	 the	
expression	of	 the	 genes	encoding	HS	biosynthetic	 enzymes	and	 core	proteins	 relative	 to	different	
anatomical	regions.	This	study	was	limited	to	the	brain	only	and	a	heat	map	generated	to	determine	
how	 expression	 varies	 across	 different	 regions	 of	 the	 brain.	 The	 heat	 map	 generated	 from	 this	
search	 displayed	 strong	 expression	 differences	 across	 the	 different	 HS	 biosynthetic	 enzymes.	 Red	
coloured	squares	indicated	the	highest	expression	potential	whilst	those	paler	in	colour	represented	
lower	 expression	 potential.	 The	 hierarchal	 clustering	 tool	was	 used	 to	 group	 genes	 together	 that	
share	similar	expression	potential	profiles.	Grouping	genes	 in	this	way	highlighted	groups	of	genes	
that	 were	 switched	 on	 and	 off	 together	 in	 response	 to	 particular	 anatomical	 location	 or	 disease	
state.	The	Euclidian	distance	function	was	used	with	this	search	to	cluster	groups	of	genes.	
	
The	heat	map	generated	revealed	very	high	expression	of	some	genes	and	in	contrast,	very	
low	expression	potential	of	other	genes	(Figure	5.4).	On	several	occasions,	differences	 in	high	and	
low	expression	potentials	were	shared	between	enzyme	subfamilies,	perhaps	indicative	of	regional	
specificity	of	specific	isoforms.	The	HPSE2	gene	for	example	displayed	very	high	expression	potential	
across	nearly	all	brain	regions	studied	whilst	the	HPSE	gene	displayed	one	of	the	lowest	expression	
potential	profiles	of	all	the	genes	searched	for.	Furthermore,	the	HS3ST3A1	and	HS3ST3B1	genes		
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Table	5.2:	Raw	data	 (logged	normalised	 fold	 changes)	as	generated	by	Genevestigator®	 software	based	on	
expression	 profiling	 experiment	 by	 Liang	 et	 al	 (Liang,	 et	 al.	 2007).	 Genes	 are	 detailed	 vertically	with	 brain	
regions	of	AD	and	healthy	patients	 listed	vertically.	Abbreviations:	ECX:	entorhinal	 cortex;	HIP:	hippocampus;	
MTG:	middle	 temporal	 gyrus;	 PCX:	 prefrontal	 cortex;	 SFG:	 superior	 frontal	 gyrus;	 PVC:	 primary	 visual	 cortex.	
Green	represents	down	regulation	of	expression,	red	represents	up	regulation.	Data	shown	in	bold	represents	
fold	 changes	 in	 expression	 with	 AD	 (relative	 to	 healthy	 controls)	 that	 reached	 significant	 (p<0.05)	 table	 A	
displays	all	genes	encoding	HS	biosynthetic	enzymes,	table	B,	those	genes	encoding	HS	core	proteins.	
A	 ECX	 HIP	 MTG	 PCX	 SFG	 PVC	
EXT1	 -1.03	 1.28	 -1.33	 -1.10	 -1.15	 -1.07	
EXT2	 -1.42	 -2.00	 -1.23	 -2.20	 -2.11	 -1.39	
EXTL1	 -1.74	 -1.31	 -1.39	 1.05	 1.05	 1.23	
EXTL2	 -1.74	 -2.09	 -2.59	 -2.31	 -2.62	 -1.45	
EXTL3	 -1.21	 -1.25	 -1.69	 -1.38	 -1.23	 1.11	
XYLT1	 1.04	 1.23	 2.15	 -1.05	 -1.01	 1.10	
XYLT2	 -1.19	 -1.26	 1.01	 1.13	 1.19	 1.29	
NDST1	 1.05	 -1.24	 -1.38	 1.19	 1.27	 1.20	
NDST2	 -1.24	 1.03	 1.21	 1.32	 1.15	 1.02	
NDST3	 -1.95	 1.89	 -1.22	 -1.86	 -1.20	 -1.06	
NDST4	 1.15	 1.19	 -1.07	 1.16	 1.09	 1.14	
GLCE	 -1.33	 -3.00	 -1.39	 -2.36	 -1.94	 -1.67	
HS6ST1	 1.20	 -1.39	 -1.37	 -1.11	 1.10	 1.14	
HS6ST2	 -1.35	 1.47	 -1.43	 -1.96	 -1.98	 -1.90	
HS6ST3	 -2.87	 1.67	 -2.28	 -.1.24	 -1.18	 -1.20	
HS2ST1	 1.20	 -1.01	 3.70	 -1.26	 1.31	 1.12	
HS3ST1	 1.19	 2.21	 -1.10	 -1.49	 -1.36	 -1.28	
HS3ST2	 -1.68	 1.50	 -1.84	 -2.56	 -2.32	 -1.06	
HS3ST3A1	 -1.07	 1.31	 1.21	 1.13	 1.13	 -1.03	
HS3ST3B1	 1.02	 -1.20	 1.93	 -1.25	 1.06	 -1.70	
HS3ST4	 1.70	 -1.17	 -1.13	 -1.37	 -1.26	 1.05	
HS3ST5	 2.16	 1.56	 1.23	 1.61	 -1.15	 1.17	
SULF1	 1.16	 1.11	 1.63	 -1.56	 1.03	 -1.47	
SULF2	 -1.32	 -3.12	 1.18	 -1.28	 1.06	 -1.06	
HPSE	 1.12	 1.01	 -1.07	 1.01	 1.22	 1.03	
HPSE2	 1.03	 1.26	 1.08	 1.46	 1.14	 1.10			
B	 ECX	 HIP	 MTG	 PCX	 SFG	 PVC	
GPC1	 -2.04	 -1.16	 -1.09	 1.41	 1.14	 1.00	
GPC2	 1.07	 1.01	 -1.56	 1.23	 1.14	 1.04	
GPC3	 1.07	 1.15	 -1.29	 1.15	 1.03	 1.18	
GPC4	 -1.06	 -1.09	 1.83	 1.30	 1.65	 1.02	
GPC5	 -1.65	 -1.68	 3.32	 -1.43	 2.13	 1.24	
GPC6	 1.04	 -1.15	 -1.18	 -1.21	 1.10	 -1.17	
SDC1	 1.02	 1.01	 -1.56	 -1.08	 -1.10	 1.02	
SDC2	 1.38	 -1.12	 3.30	 -1.50	 2.52	 1.57	
SDC3	 -2.14	 1.08	 2.37	 2.14	 1.91	 1.38	
SDC4	 1.87	 -1.02	 6.86	 -1.43	 2.63	 1.31	
HSPG2	 -1.12	 -1.03	 -1.37	 1.29	 1.20	 1.19	
AGRN	 1.51	 1.10	 1.21	 1.51	 1.50	 1.27	
CD44	 9.90	 -1.09	 5.36	 1.86	 2.53	 -1.02	
COL18A1	 -2.28	 1.11	 1.35	 1.55	 1.68	 1.06	
SRGN	 1.17	 1.22	 2.01	 1.31	 1.34	 1.11		
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displayed	 very	 low	 expression	 potential	 in	 nearly	 all	 brain	 regions	 studied,	 indicative	 perhaps	 of	
redundancy	 of	 these	 isoforms	within	 the	 brain.	 Other	HS3ST	 genes	 including	HS3ST4	 and	HS3ST2	
displayed	much	higher	expression	potentials	and	were	clustered	with	other	genes	sharing	a	similar	
profile	 including	 NDST3,	 HS6ST1-3	 and	 EXTL2.	 Whilst	 this	 data	 did	 not	 distinguish	 between	
expression	changes	that	may	occur	in	the	presence	of	the	AD	phenotype,	as	investigated	above,	this	
search	 provided	 novel	 grouping	 of	 some	 of	 the	 HS	 biosynthetic	 genes	 that	 may	 be	 expressed	
together	in	select	regions	of	the	brain	and	highlighted	those	whose	low	expression	potential	may	be	
indicative	 of	 less	 downstream	 consequences	 on	 structure	 of	 HS	 and	 its	 ligand	 binding	 affinities	
(Figure	5.4).		
	
Finally,	 this	 search	 confirmed	 those	 regions	 of	 the	 brain	 implicated	 in	 AD	 such	 as	 the	
hippocampus	 and	middle	 temporal	 gyrus	 that	 share	 high	 expression	 potential	 of	 HS	 biosynthetic	
enzymes	 and	 thus	 may	 strengthen	 our	 notion	 of	 a	 regulatory	 role	 of	 HS	 in	 AD	 pathogenesis	 in	
patients.	 The	 anatomical	 clustering	 was	 also	 carried	 out	 as	 described	 above	 but	 to	 look	 for	
expression	potential	profiling	of	the	genes	that	encode	the	HS	core	proteins	(Figure	5.5).	Hierarchal	
clustering	of	the	genes	that	express	the	HS	core	proteins	revealed	very	high	expression	potential	of	
the	GPC5	and	SDC3	genes	and	very	low	expression	potential	of	the	SDC1	and	GPC3	genes.	Clustering	
in	 this	 manner	 would	 suggest	 very	 tightly	 regulated	 expression	 of	 specific	 enzyme	 isoforms	 in	
different	 regions	of	 the	brain.	 	GPC1,	SDC2,	SDC4	 and	AGRN	 genes	all	displayed	higher	expression	
potential	vs.	other	HS	core	protein	genes.	As	with	 the	HS	biosynthetic	genes,	expression	potential	
across	 the	 different	 brain	 regions	 was	 highly	 variable	 and	 indicated	 tight	 regulation	 in	 select	
locations	 of	 the	 brain	 that	 may	 predict	 vulnerability	 to	 different	 pathologies,	 not	 limited	 to	 AD	
(Figure	5.5).	 	 In	contrast	to	the	heat	map	generated	with	genes	encoding	HS	biosynthetic	enzymes	
(Figure	 5.4),	 those	 genes	 that	 encode	 HS	 core	 proteins	 appeared	 to	 display	 an	 overall	 lower	
expression	potential	across	the	brain	regions	studied.		
	
5.8.3	Ingenuity	Pathway	Analysis	(IPA®)	
	
IPA®	was	used	to	explore	potential	relationships	and	connections	between	the	proteins	of	
interest	 that	 we	 had	 explored	 in	 previous	 studies	 with	 STRING	 and	 Genevestigator®.	 The	 GWAS	
identified	 AD	 risk	 genes,	 those	 genes	 that	 encode	 the	 HS	 biosynthetic	 enzymes	 and	 those	 that	
encode	the	HS	core	proteins.	Finally,	the	heparin	interactome	list	was	also	added	to	searches	for	the	
sake	 of	 completion	 as	 this	 work	 was	 only	 at	 a	 preliminary	 stage	 and	 it	 was	 not	 known	 what	
connections	might	exist	between	proteins	of	interest.		
	
For	 this	work,	 the	GWAS	 identified	genes,	HS	biosynthetic	 genes,	 core	protein	genes	and	
heparin	 interactome	 lists	were	compiled	 into	one	 list	 into	 IPA®.	Search	results	 for	 this	query	were	
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Figure	5.4:	Hierarchal	clustering	of	expression	potential	of	genes	encoding	HS	related	enzymes	in	different	
anatomical	 locations	within	 the	brain	 as	 generated	by	 Genevestigator®	 software.	Anatomical	 regions	are	
listed	vertically	and	gene	names	horizontally.	Dark	red	colour	represents	high	expression	potential	and	paler	
squares,	lower	expression	potential.	The	number	of	samples	assayed	in	each	brain	region	is	listed	on	the	right	
vertically.	 Euclidian	 distance	 function	 was	 used	 to	 determine	 clustering	 of	 genes	 that	 shared	 similar	
expression	profiles.		
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Figure	 5.5:	 Hierarchal	 clustering	 of	 expression	 potential	 of	 genes	 encoding	 HS	 core	 proteins	 in	 different	
anatomical	 locations	 within	 the	 brain	 as	 generated	 by	 Genevestigator®	 software.	 Anatomical	 regions	 are	
listed	vertically	and	gene	names	horizontally.	Dark	red	colour	represents	high	expression	potential	and	paler	
squares,	lower	expression	potential.	The	number	of	samples	assayed	in	each	brain	region	is	listed	on	the	right	
vertically.	Euclidian	distance	function	was	used	to	determine	clustering	of	genes	that	shared	similar	expression	
profiles.		
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filtered	to	show	only	connection	evidence	 from	human	nervous	system	based	data,	not	any	other	
species	or	other	regions	of	the	body.	As	the	number	of	genes	was	so	high	and	the	main	focus	of	this	
work	AD,	it	was	decided	for	the	sake	of	simplification	to	only	include	that	data	generated	from	the	
human	CNS.	It	was	hoped	that	any	possible	networks	built	from	this	work	might	be	used	as	a	basis	
on	 which	 to	 form	 validation	 experiments	 within	 the	 lab.	 Database	 searching	 with	 these	 lists	
generated	a	number	of	canonical	pathways	associated	with	 the	search	proteins	uploaded	 into	 the	
IPA®	 software.	 The	 top	 scoring	 canonical	 pathways	 determined	with	 this	 search	 included	 hepatic	
fibrosis,	 granulocyte	 adhesion,	 bladder	 cancer	 signaling	 and	 the	 coagulation	 system.	 Interestingly,	
other	canonical	pathways	found	included	axonal	guidance,	the	neuroprotective	role	of	THOP1	in	AD,	
NFkB	signaling	and	amyloid	processing.	This	search	was	then	filtered	to	those	diseases	and	functions	
associated	with	the	list	of	proteins	of	interest.	Of	the	476	proteins	searched	for	on	IPA®,	200	of	them	
were	associated	with	neurological	disease	in	some	way.	Whilst	the	GWAS	identified	risk	protein	list	
would	naturally	be	associated	with	 the	onset	of	neurological	diseases,	 this	gene	 list	was	only	very	
short,	suggesting	a	number	of	interactions	came	from	the	heparin	interactome	list.	A	bar	chart	was	
generated	to	display	the	diseases	and	functions	associated	with	this	target	list	search	(Figure	5.6).		
	
In	 the	 bar	 chart	 generated	 to	 display	 all	 associated	 diseases	 and	 functions	 linked	 to	 the	
target	 gene	 list,	 immune	cell	 trafficking,	 inflammatory	 response,	 cell	 death,	 inflammatory	disease,	
neurological	 disease	 and	 psychological	 disorders	 scored	 highly	 and	 reached	 the	 set	 threshold	
(p<0.05)	for	significance.	This	search	 indicated	that	these	genes	were	associated	with	a	number	of	
canonical	 pathways	 and	 functional	 categories.	 This	 finding	 thus	 stressed	 a	 complexity	 of	 the	
functional	network	 that	underlies	 the	etiology	and	development	of	AD.	The	downstream	effectors	
associated	with	this	gene	list	was	large	and	varied	and	indicated	a	role	of	HS	associated	proteins	that	
may	 have	 functionality	 with	 other	 networks	 involved	 in	 the	 pathogenesis	 of	 AD,	 specifically	
inflammation,	 cell	 death	 and	 neurological	 dysfunction.	 Those	 genes	 encoding	 the	HS	 biosynthetic	
enzymes	 were	 not	 found	 to	 directly	 associate	 with	 these	 diseases	 but	 rather	 only	 the	 heparin	
interactome	and	GWAS	identified	AD	risk	factor	genes.		
	
No	details	 regarding	expression	potential	of	 these	proteins	were	 included	within	the	 IPA®	
search.	This	was	partly	because	there	was	not	a	complete	data	set	with	this	information	for	all	of	the	
target	 proteins	 investigated.	 As	 such,	 it	 was	 not	 possible	 to	 determine	 the	 downstream	
consequences	 of	 changes	 in	 the	 expression	 of	 specific	 proteins.	 Despite	 this,	 interactions	 and	
possible	networks	within	the	target	protein	lists	could	be	predicted	and	the	role	of	HS	and	heparin	
interacting	proteins	set	into	a	wider	context	for	AD	pathology.	Of	the	canonical	pathways	found	to	
be	associated	with	the	target	proteins,	all	were	found	to	 largely	 interact	and	displayed	substantial	
cross	over	with	respect	to	members	of	specific	pathways	and	their	functionality.	That	being	said,	the	
biosynthesis	of	HS	was	not	found	to	share	any	overlap	with	the	other	established	pathways	and	sat	
in	isolation	with	respect	to	other	physiological	function	within	the	body	(Figure	5.7).	This	figure		
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Figure	 5.6:	 Diseases	 and	 functions	 associated	with	 the	 target	 protein	 list	 as	 generated	 by	 IPA®	 software.	
Gene	 lists	 for	 HS	 biosynthetic	 enzymes,	 core	 proteins,	 GWAS	 identified	 AD	 risk	 genes	 and	 the	 heparin	
interactome	 were	 compiled	 into	 one	 target	 list	 and	 submitted	 to	 IPA®	 for	 network	 analysis.	 This	 bar	 chart	
displays	the	most	significant	diseases	and	functions	associated	wit	the	target	gene	list.	The	bigger	the	blue	bar,	
the	more	significant	the	association	was	found	to	be.	The	orange	line	depicts	the	threshold	of	significance	that	
set	 (p<0.05).	 Of	 the	 diseases	 and	 functions	 found	 to	 be	 represented,	 neurological	 disease,	 psychological	
disorder,	and	inflammatory	based	function	was	noted	for	their	associations	with	AD.			
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Figure	5.7:	Overlap	between	the	most	significant	canonical	pathways	associated	with	the	HS	biosynthetic	enzymes,	core	proteins;	GWAS	identified	risk	genes	and	heparin	interactome	
proteins.	Figure	as	generated	by	IPA®	shown	those	canonical	pathways	that	share	the	same	target	protein	members.	Blue	lines	between	red	nodes	depict	over	lap	and	the	number	above	
each	 blue	 line	 represents	 the	 number	 of	 overlapping	 components.	 Interestingly,	 the	 synthetic	 and	modification	 pathways	 of	 HS	 and	 CS	 do	 not	 overlap	 at	 all	 with	 any	 of	 the	 other	
established	canonical	pathways	but	rather	remain	in	isolation.		
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depicted	 the	 significant	 canonical	 pathways	 associated	 with	 the	 target	 gene	 list	 and	 the	 overlap	
between	 these	 pathways	 (the	 number	 above	 each	 line	 depicted	 the	 number	 of	 components	 that	
were	shared).	Whilst	there	was	no	shared	interaction	between	the	biosynthesis	of	HS	and	other	
physiological		functionality,	indirectly	the	biosynthesis	of	HS	is	hugely	important	for	interaction	with	
its	 ligand-binding	partners.	The	data	generated	 in	this	project	has	confirmed	the	 importance	of	HS	
biosynthesis,	 the	 resulting	 HS	 structures	 and	 the	 ways	 in	 which	 they	 interact	 with	 their	 binding	
partners.	 This	preliminary	work	 thus	highlighted	a	need	 to	update	network	associations	 such	 that	
the	 biosynthesis	 and	 modification	 of	 HS	 may	 be	 implicated	 in	 the	 downstream	 consequences	 of	
ligand	 interaction.	 In	 the	 context	 of	 AD,	 the	 lab	 work	 from	 this	 project	 has	 gone	 some	 way	 to	
validate	some	of	these	connections.	IPA®	was	used	in	combination	to	generate	a	predicted	model	of	
network	interactions	linking	AD	pathological	pathways	and	HS.	From	the	list	of	interactive	networks	
generated	 by	 the	 IPA®	 software,	 the	 top	 (most	 significant)	 was	 chosen	 for	 further	 work.	 This	
network	 was	 chosen	 as	 a	 base	 on	 which	 to	 generate	 a	 larger	 compilation	 of	 laboratory	 proven	
association	 and	 functionality	 alongside	 those	 interactions	 predicted	 by	 the	 literature	 and	 other	
experimental	data.		
	
IPA®	 interaction	 predictions	 were	 coupled	 with	 the	 data	 generated	 from	 this	 project	 to	
create	a	prediction	of	a	potential	 association	network	whereby	 the	 role	of	HS	 is	 implicated	 in	 the	
pathogenesis	of	AD	in	a	wider	context	to	that	already	established	with	its	 interaction	with	BACE-1.	
This	work	 is	preliminary	and	 further	work	 is	 required	 to	confirm	hypotheses	and	 further	elucidate	
the	many	other	nodes	of	 interaction	that	are	sure	to	exist	 in	this	somewhat	simplified	model.	 	For	
simplification,	 the	 interactions	as	predicted	by	 the	 IPA®	 software	 in	 the	 top	 scoring	network	have	
been	tabulated	below	to	detail	 the	 interaction	between	each	pair	of	nodes	 (Table	 5.3).	Figure	5.8	
was	generated	to	combine	the	IPA®	generated	connections	alongside	the	data	generated	from	this	
project	 within	 the	 lab.	 This	 is	 a	 working	 model	 and	 puts	 forward	 a	 hypothesis	 for	 a	 wider	
functionality	of	HS	in	the	pathogenesis	of	AD.	
	
This	network	pathway	as	generated	by	 the	 IPA®	software	 includes	nodes	 from	the	GWAS	
identified	 risk	 factor	 genes	 (PLAU)	 and	 several	 heparin	 interactome	 proteins	 (SERPINE2,	 FURIN,	
TGFB1).	This	network	also	allowed	the	integration	of	HS	biosynthetic	enzymes	themselves.	Coupled	
with	the	data	generated	within	the	lab	in	this	project,	a	model	for	some	of	the	pathways	that	could	
be	 involved	 in	 AD	 pathogenesis	 is	 hypothesised.	 As	 described	 previously,	 these	 interactions	
undoubtedly	 do	 not	 occur	 in	 isolation	 but	 rather	 within	 a	 much	 more	 complex	 framework	 of	
functional	and	regulatory	pathways.	Despite	this,	early	work	as	described	here	implicated	HS	in	AD	
not	 only	 in	 the	 context	 of	 its	 interaction	 with	 BACE-1	 but	 also	 perhaps	 for	 other	 roles	 in	 the	
pathogenesis	of	AD.		
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Table	 5.3:	 Interactions	 between	 nodes	 as	 predicted	 by	 the	 IPA®	 software.	 The	 top	 scoring	 network	 as	
generated	by	 IPA®	 following	search	of	protein	 lists	describing	HS	biosynthetic	enzymes,	 core	proteins,	GWAS	
associated	risk	factors	and	the	heparin	interactome	generated	a	network	scheme	for	the	below	proteins.	This	
network	incorporated	proteins	from	several	of	the	gene	lists	searched	against	and	predicted	the	relationships	
between	each	node	within	the	network.	
Node	1	 ç 	Interaction	è 	 Node	2	
PLAU	 Interaction	of	PLAU	with	SERPINE2	 SERPINE2	
SERPINE2	 SERPINE2	increases	inhibition	of	FURIN	 FURIN	
FURIN	 FURIN	increases	cleavage	of	pro-BACE-1	to	
BACE-1	
BACE-1	
BACE-1	 BACE-1	increases	expression	of	LRP1	 LRP1	
LRP1	 LRP1	plays	a	role	in	removal	of	Aβ	from	the	
brain	
Aβ	
Aβ	 Aβ	induces	increased	expression	of	IL6	 IL6	
FURIN	 FURIN	increases	cleavage	of	pro-TGFB1	to	
TGFB1	
TGFB1	
TGFB1	 TGFB1	induces	increased	expression	of	IL6	 IL6	
TGFB1	 TGFB1	induces	increased	levels	of	beta-
estradiol	
Bet-estradiol	
IL6	 IL6	decreases	levels	of	beta-estradiol	 Beta-estradiol	
Beta-estradiol	 Beta-estradiol	can	modulate	levels	of	HS	 Sulfotransferases	
Sulfotransferases	 Sulfotransferases	add	sulfate	groups	to	HS	 Heparan	sulfate	
TGFB1	 TGBF1	stimulates	microglial	activation	 Microglial	activation	
Microglial	activation	 Activated	microglia	co-localise	with	mature	
amyloid	plaques	
Mature	plaques	
	
5.9	Discussion	
	
5.9.1	STRING	
	
	 Analysis	 with	 STRING	 software	 revealed	 a	 strong	 interaction	 network	 between	 the	 HS	
biosynthetic	 enzymes	 and	 core	 proteins.	 This	 observed	 close	 interaction	was	 not	 surprising	 since	
these	proteins	all	share	common	functional	purpose	to	produce	proteoglycans.	Indeed,	the	majority	
of	interactions	observed	represented	interactions	based	on	text	mining	whereby	proteins	of	interest	
had	 appeared	 in	 the	 literature	 together.	 Again,	 this	 is	 expected	 with	 respect	 to	 these	 proteins	
appearing	in	the	same	mechanistic	pathway.	In	contrast	however,	there	were	very	few	interactions	
displayed	 that	 represented	 experimentally	 determined	 association.	 The	 observed	 experimentally	
derived	interaction	between	EXT1	and	EXT2	is	a	previously	established	interaction	between	the	two		
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Figure	5.8:	Predicted	model	of	interaction	between	HS	biosynthetic	machinery,	core	proteins,	GWAS	identified	risk	proteins	and	heparin	interactome	as	based	on	IPA	generated	interaction	
predictions	and	data	generated	within	the	lab	in	this	project.	The	above	network	depicts	a	model	generated	as	a	combination	of	lab	validated	data	and	interaction	predictions.	More	work	is	
needed	to	confirm	all	associations	as	shown	here	however	this	network	places	HS	structure	and	functionality	in	the	wider	context	of	AD,	not	 just	as	an	interactor	of	BACE-1	but	also	linking	
other	pathogenic	 pathways	 associated	with	AD	 such	 as	 inflammation.	 Colours:	 Blue;	 heparin	 interactome,	Green;	GWAS	 identified	AD	 risk	 genes,	 Red;	 lab	 validated	 findings,	 Purple;	 IPA®	
interactions.		
Altered	expression	of	genes	encoding	HS	
biosynthe6c	enzymes	
BACE-1	
HS	interacts	with	and	inhibits	BACE-1	
BACE-1	inhibi6on	by	HS	reduced	in	AD	(chapter	4)	
FURIN	
Increases	cleavage	of	pro-BACE-1	to	BACE-1	
SERPINE2	
Increases	inhibi9on	of	FURIN	
TGFB1	
Increases	cleavage	of	pro-TGFB1	to	TGFB1	
Beta-estradiol	
SULFOTRANSFERASES	
IGF1	
Cleavage	of		
pro-IGF1	to	IGF1	
BACE-1	cleaves	APP	
Mediates	cleavage		
of	APP	via	BACE-1	
LRP1	
Aβ	
MATURE		
AMYLOID	PLAQUES	
MICROGLIAL	ACTIVATION	
Beta-estradiol	levels	inﬂuence	levels	of	HS	
HEPARAN	SULFATE	
Interac9on	with	beta-estradiol	
Reduced	sulfa9on	=	less	eﬃcient	BACE-1	inhibi9on	HS	interacts	with	
mature	plaques	–	
protec9on	from	
degrada9on?	
HS	interacts	with	smaller	oligomers–	
sequester	into	“less	toxic”	plaques?	
AD	HS	=	less	UA-GlcNS(6S)	disaccharide	and	more	UA-GlcNAc(6s)	(p<0.05)	vs.	healthy	Ctrls	
Altered	structure	of	HS	with	AD	
Lower	total	HS	in	AD	vs.	Ctrls	(p<0.01)	
IL6	
TGFB1	induces	increased	
IL6	
Aβ1-42	induces	increased	in	IL6	
Via	intermediate	oligomers	
Decreases	
	beta-estradiol	
Ac9vated	microglia	associated	with	amyloid	plaques	
Increases		
expression	of	LRP1	
Role	in	clearance	of	Aβ	from	
the	brain	
PLAU	
Interac9on	with	SERPINE2	
Increased	levels	of	beta-estradiol?	
GENE	EXPRESSION	CHANGES	
Poten9al	as	treatment	for	AD	–	reduces	amyloid	burden	in	post	menopausal	women	
ALZHEIMER’S		DISEASE	
IL6	contributes	to	AD	pathogenesis	
HS/heparin	
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enzyme	 isoforms	and	describes	 the	 complex	 formed	by	 these	 to	 catalyse	 the	extension	of	 the	HS	
chain	during	biosynthesis	 (McCormick,	et	al.	2000).	 In	addition	an	 interaction	between	NDST1	and	
EXT2	was	 recorded	 in	mice	 in	embryonic	development	 research	whereby	 levels	of	 EXT1	and	EXT2	
were	shown	to	affect	the	 levels	of	NDST1	within	the	cell	and	ultimately	had	consequences	for	the	
final	 structure	 of	 HS	 that	 is	 generated	 (Presto,	 et	 al.	 2008).	Whilst	 this	 interaction	 has	 not	 been	
confirmed	in	humans	as	yet,	this	evidence	suggests	tight	regulation	of	the	synthesis	of	HS	and	the	
ways	in	which	its	final	structure	might	be	controlled.	It	was	already	previously	established	how	the	
role	of	each	family	of	enzymes	works	to	polymerise	and	modify	the	HS	chain.	However,	as	yet	there	
is	still	a	great	deal	to	learn	regarding	the	mechanisms	that	regulate	the	final	structure	of	HS	and	its	
ligand	binding	potential.	Whilst	we	would	expect	the	association	of	the	HS	biosynthetic	machinery	
components	 on	 account	 of	 their	 common	 functionality,	 the	 notion	 of	 direct	 association	 between	
enzymes	 of	 different	 families	 are	 suggestive	 of	 a	 very	 complex	 pathway	 to	 regulate	 the	 final	
outcome	in	terms	of	HS	structure.	Moreover,	the	absence	of	any	experimentally	derived	interaction	
data	 between	 more	 proteins	 within	 the	 HS	 biosynthetic	 pathway	 highlights	 the	 gaps	 in	 our	
understanding	of	this	pathway.		
		
With	 regard	 to	 the	 core	 proteins,	 experimentally	 determined	 interactions	 were	 also	
reported	 between	 all	members	 of	 the	 SDC	 family	 (protein-protein	 interactions	 in	 humans).	 These	
interactions	 are	 based	 upon	 the	 research	 by	 Dews	 and	 colleagues	 in	 2007	 whereby	 the	
transmembrane	 domains	 (TMDs)	 of	 the	 SDC	 family	 have	 been	 shown	 to	 display	 homotypic	 and	
heterotypic	 interactions.	 This	 work	 suggested	 that	 these	 TMDs	might	 play	 important	 roles	 in	 the	
interactions	of	full-length	SDC	family	members	(Dews	and	Mackenzie	2007).	As	before,	evidence	for	
interactions	 within	 a	 particular	 family	 may	 not	 be	 particularly	 surprising.	 That	 being	 said,	 this	
evidence	 does	 goes	 some	 way	 to	 further	 strengthen	 the	 notion	 of	 a	 more	 complex	 route	 of	 HS	
synthesis	whereby	the	activity	of	particular	enzymes	and	core	proteins	 is	not	achieved	 in	 isolation	
but	in	combination	with	other	factors.		
	
STRING	 analysis	 was	 also	 carried	 out	 with	 the	 addition	 of	 the	 GWAS	 identified	 AD	 risk	
proteins.	 With	 this	 list	 combined	 with	 the	 HS	 biosynthesis	 list,	 STRING	 did	 not	 reveal	 tight	
interaction	between	the	two	lists.	The	only	point	of	contact	between	the	two	groups	was	recorded	
between	the	SDC	family	and	APOE.	Kim	and	colleagues	in	2014	described	the	role	of	the	SDC	family	
in	 the	mediation	 of	 APOE	 isoform	 dependent	 neurite	 outgrowth	 and	 synaptic	 plasticity	 and	 their	
potential	 role	 in	 AD	 (Kim,	 et	 al.	 2014).	 Furthermore,	 SDC2	 has	 been	 reported	 to	 induce	 the	
maturation	 of	 dendritic	 spines	within	 the	 brain	 (Ethell	 and	 Yamaguchi	 1999),	 thus	 implicating	 the	
SDC	 family	 in	 the	 regulation	of	 synaptic	plasticity	and	demonstrating	a	direct	association	between	
the	two	gene	lists.		
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	 Taken	together,	the	use	of	STRING	software	on	this	occasion	did	not	highlight	a	great	deal	
of	 interaction	 between	 the	 proteins	 of	 interest.	 Naturally,	 that	 does	 not	mean	 to	 say	 that	 these	
interactions	do	not	exist	but	rather	highlights	a	gap	in	our	understanding	with	regard	to	the	ways	in	
which,	if	at	all,	HS	biosynthetic	machinery	components	interact	and	the	implications	this	may	have	
on	wider	AD	risk	factors.	This	search	was	somewhat	limited	in	that	the	HS	biosynthetic	machinery	is	
targeted	to	a	very	specific	function.	Indirectly,	the	role	of	these	enzymes	is	vastly	important	as	their	
activity	determines	the	final	structure	of	HS	that	in	turn	has	consequences	for	ligand	binding	affinity.	
Indeed,	 considering	 final	 HS	 structural	 outcomes	 will	 be	 key	 no	 doubt	 in	 understanding	 the	
functionality	of	many	downstream	components	associated	with	the	pathogenesis	of	AD.	Considering	
the	interaction	of	individual	components	of	the	synthesis	chain	is	likely	to	yield	less	interactive	data	
being	 that	 it	 is	 the	 collective	 outcome	 that	will	 have	 a	more	 considerable	 effect	 on	 downstream	
ligand	binders.		
	
	 It	is	worth	commenting	that	since	HS	is	not	a	protein	and	is	not	directly	encoded	by	a	gene,	
it	 is	 under-represented	 in	 this	 approach.	 There	 is	 direct	 evidence	 of	 HS	 interacting	 with,	 various	
proteins,	and	 this	could	also	be	 taken	 into	account	 in	 future	extension	of	 these	studies.	 Indeed	 in	
further	 work	 in	 the	 future	 it	 will	 be	 useful	 to	 study	 the	 potential	 interactions	 of	 the	 heparin	
interactome	 proteins	 to	 assess	 whether	 any	 wider	 pathways	 and	 connections	 can	 be	 drawn	
implicating	them	in	AD	pathogenesis	and	its	risk	factors.		
	
5.9.2	Genevestigator®			 The	 Genevestigator®	 software	 was	 used	 to	 determine	 how	 the	 presence	 of	 the	 AD	
phenotype	might	affect	the	expression	of	the	genes	that	encode	HS	biosynthetic	enzymes	and	core	
proteins.	It	should	be	noted	that	this	aspect	of	the	informatics	work	was	actually	carried	out	prior	to	
commencing	 any	 work	 within	 the	 lab	 as	 a	 way	 of	 preliminarily	 determining	 a)	 whether	 these	
changes	were	occurring	at	all	 in	 the	presence	of	AD	and	b)	which	 regions	of	 the	brain	were	most	
susceptible	 to	 these	 changes.	 Sampling	 of	 an	 appropriate	 brain	 region	 for	 this	 project	 was	
paramount	 and	 this	 aspect	 of	 the	 informatics	 work	 informed	 the	 choice	 that	 was	 made.	 The	
hippocampus	 is	the	brain	region	first	 implicated	 in	AD	pathogenesis	(Padurariu,	et	al.	2012)	yet	 its	
major	roles	in	memory	formation	and	consolidation	make	it	a	popular	region	to	study	and	as	such	it	
is	 very	 difficult	 to	 obtain	 samples.	 The	 Genevestigator®	 work	 as	 described	 here	 highlighted	 the	
significant	 expression	 changes	 that	 occur	 in	 the	middle	 temporal	 gyrus,	 a	 region	 of	 the	 temporal	
lobe	(one	of	the	4	lobes	of	the	cerebral	cortex)	and	is	an	area	key	in	the	formation	of	memory	and	
language	 known	 to	 be	 affected	 in	 AD	 (Convit,	 et	 al.	 2000).	 The	 changes	 in	 expression	 of	 the	 HS	
biosynthetic	 enzymes	 and	 core	 proteins	 as	 determined	 with	 this	 previously	 published	 study	
suggested	change	in	the	structure	of	HS	might	also	occur	in	the	presence	of	AD	and	as	such,	proved	
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to	be	a	suitable	region	of	 the	brain	 to	sample	 from	patients	 to	carry	out	 the	work	as	described	 in	
chapters	2-4.		
	
	 The	 changes	 in	 the	 expression	 of	 HS	 genes	 in	 the	 presence	 of	 the	 AD	 phenotype	 as	
determined	in	this	study	were	ultimately	largely	consistent	with	those	changes	established	in	the	lab	
in	 chapter	 3.	 As	 within	 any	 sampling	 from	 human	 sources,	 variability	 between	 individuals	 is	
significant	 and	 difficult	 to	 control.	 It	was	 therefore	 promising	 to	 replicate	most	 of	 the	 findings	 as	
displayed	 with	 the	 Genevestigator	 software.	 Strong	 up-regulation	 in	 the	 expression	 of	 the	 SULF	
genes	 across	 the	 brain	 regions	 studied	 was	 consistent	 with	 the	 TaqMan®	 array	 analysis	 as	
undertaken	 in	 chapter	 3	 and	 confirms	 the	 notion	 of	 a	 less	 sulfated	 HS	 in	 AD	 patients	 that	might	
display	 reduced	 inhibition	 of	 BACE-1	 and	 thus	 lead	 to	 the	 elevated	 generation	 of	 the	 toxic	 Aβ	
peptide.	 Down	 regulation	 of	 the	 HS6ST	 genes	 as	 displayed	 in	 this	 Genevestigator®	 search	 also	
strengthens	 our	 hypothesis	 that	 changes	 in	 the	 expression	 of	 HS	 biosynthetic	 genes	 could	 be	 an	
upstream	causation	of	HS	structural	changes	as	observed	in	AD	patient	brain	samples	compared	to	
healthy	controls.			
	
	 In	 addition,	 the	use	of	 the	Genevestigator®	 software	as	demonstrated	here	 allowed	easy	
scanning	of	the	different	brain	regions	and	the	variability	that	may	occur	in	HS	synthesis	regulation.	
As	 already	 hypothesised,	 it	 may	 be	 that	 variation	 in	 spatial	 vulnerability	 to	 AD	 pathogenesis	 as	
observed	 in	the	brain	may	be	at	 least	partly	explained	by	alterations	to	the	structure	of	HS.	These	
changes	will	 naturally	 be	 determined	 by	 expression	 profiles	 of	 the	 appropriate	 genes	 and	 as	 this	
informatics	work	 indicated,	may	be	very	different	 in	different	regions	of	 the	brain.	Future	work	to	
explore	 structural	 changes	 to	HS	 in	 different	 regions	 of	 the	 brain	would	 be	 interesting.	 Indeed,	 it	
would	be	 interesting	to	explore	whether	the	expression	profiles	 in	these	regions	can	be	“matched	
up”	to	their	downstream	effects.	 If	so,	expression	patterns	of	these	genes	may	prove	beneficial	as	
markers	for	vulnerability	to	AD	pathogenesis	in	individuals.		
	
With	respect	to	the	core	proteins,	a	much	more	substantial	up	regulation	of	expression	of	
the	 genes	 encoding	 core	 proteins	was	 observed	 in	 the	 presence	 of	 the	 AD	 phenotype	 relative	 to	
healthy	 controls	 with	 much	 fewer	 genes	 displaying	 decreased	 expression.	 Despite	 this,	 the	
hippocampus	 stood	out	as	displaying	 reasonably	prominent	down-regulation	of	 core	protein	gene	
expression	 vs.	 other	 brain	 regions	 studied.	 This	 might	 be	 indicative	 of	 variable	 regulation	 across	
different	brain	regions	and	may	go	some	way	to	explain	why	the	hippocampus	is	affected	first	in	AD	
disease	development.	Future	work	to	look	further	into	this	will	be	crucial	to	confirm	this;	however,	
differential	 patterns	 of	 gene	expression	 as	 observed	 in	 this	work	 creates	 a	 strong	 argument	 for	 a	
tightly	regulated	process	that	may	determine	vulnerability	to	onset	of	disease.		
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In	 a	 similar	manner,	 the	 expression	 of	 the	 genes	 encoding	 HS	 biosynthetic	 enzymes	 and	
core	proteins	was	investigated	in	different	brain	regions	in	a	physiological	non-diseased	state.	AD	is	
known	to	develop	 in	a	 temporal	and	spatial	 fashion	across	different	brain	regions	and	variation	 in	
healthy	 baseline	 expression	 of	 these	 genes,	 it	 was	 hypothesised,	 may	 go	 some	 way	 to	 predict	
susceptibility	to	AD	development,	and	indeed	other	neurological	diseases.	The	heat	map	generated	
from	 this	 search	 displayed	 strong	 expression	 differences	 across	 the	 different	 HS	 biosynthetic	
enzymes.	The	clustering	tool	was	also	used	to	group	genes	that	may	be	switched	on	and	off	together	
in	response	to	a	particular	anatomical	location	or	disease	state.	The	observation	on	this	occasion	of	
differential	expression	across	 the	 isoforms	of	different	enzyme	 families	was	suggestive	of	 regional	
specificity	and	offers	insight	into	the	ways	in	which	HS	synthesis	and	modification	may	be	regulated	
in	 different	 parts	 of	 the	 body.	 This	 finding	 was	 consistent	 with	 previous	 research	 that	 has	
established	 variable	 expression	 of	 HS	 enzyme	 isoforms	 (Lindahl,	 et	 al.	 1998,	Warda,	 et	 al.	 2006).	
Whilst	not	necessarily	surprising,	variable	expression	of	the	isoforms	as	observed	here	may	explain	
why	 AD	 pathogenesis	 develops	 in	 spatially	 variable	 fashion	 and	 does	 not	 develop	 ubiquitously	
throughout	the	brain	(Galton,	et	al.	2001).	
	
In	 addition,	 the	use	of	 the	 clustering	 tool	 allowed	grouping	of	 sets	of	 genes	 that	may	be	
switched	on	and	off	together	in	the	presence	of	the	AD	phenotype.	Whilst	a	great	deal	more	work	
would	be	needed	to	confirm	this,	the	notion	of	groups	of	genes	responding	to	a	certain	cellular	state	
may	 offer	 clues	 into	 ways	 in	 which	 the	 structure	 of	 HS	 is	 controlled.	 Future	 work	 to	 investigate	
shared	transcription	factors	for	example	between	these	groups	of	genes	may	offer	some	insight	into	
the	mechanisms	that	control	downstream	functionality	of	HS.	Whilst	we	did	not	have	time	to	 look	
into	this,	the	groups	of	genes	generated	with	this	tool	in	Genevestigator®	may	prove	an	interesting	
starting	point	for	future	studies.		
	
5.9.3	Ingenuity	Pathway	Analysis	(IPA®)		
IPA®	was	used	to	explore	potential	relationships	and	connections	between	the	proteins	of	
interest	 that	we	had	 identified	 in	our	previous	 studies	 -	 the	GWAS	 identified	AD	 risk	genes,	 those	
genes	that	encode	the	HS	biosynthetic	enzymes	and	those	that	encode	the	HS	core	proteins.	Finally	
the	heparin	interactome	list	was	also	added	to	searches	for	the	sake	of	completion	as	this	work	was	
only	at	a	preliminary	stage	and	it	was	not	known	what	connections	might	exist	between	proteins	of	
interest.		
	
The	top	scoring	canonical	pathways	determined	with	this	search	included	hepatic	fibrosis,	
granulocyte	 adhesion,	 bladder	 cancer	 signaling,	 axonal	 guidance	 and	 the	 coagulation	 system.	 The	
broad	spectrum	of	canonical	pathways	associated	with	 the	gene	 lists	used	 in	 this	search	were	not	
surprising	 on	 account	 of	 the	 heparin	 interactome	 being	 such	 a	 large	 list	 of	 proteins.	 HS	 is	 found	
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ubiquitously	all	over	the	body,	and	due	to	its	variable	structural	motifs	(as	described	previously),	the	
number	 of	 factors	 it	 is	 able	 to	 interact	 with	 is	 wide	 and	 varied.	 Indeed,	 HS	 is	 able	 to	 bind	 to	
chemokines,	 growth	 factors,	 coagulation	 cofactors,	 matrix	 proteins,	 and	 many	 more	 enzymes	
(Pomin	and	Mulloy	2015).	As	a	 result	 it	 is	not	 surprising	 that	 these	proteins	would	be	 involved	 in	
such	 a	wide	 variety	 of	 canonical	 pathways.	 	 Similarly,	 of	 the	 476	 proteins	 searched,	 200	 of	 them	
were	associated	with	neurological	diseases	 in	some	way.	Whilst	GWAS	 identified	risk	genes	would	
naturally	be	associated	with	neurological	disease,	this	list	was	relatively	short,	and	hence	a	number	
of	 heparin	 interactome	 and	 core	 proteins	 were	 also	 associated	 with	 neurological	 disease.	
Chemokines	 may	 be	 an	 obvious	 tie	 to	 neurological	 disease	 on	 account	 of	 the	 state	 of	 chronic	
inflammation	associated	with	a	number	of	neurological	disorders	(Samuels	2004).	The	finding	here	
that	a	number	of	already	established	canonical	pathways	are	associated	with	these	target	proteins,	
strengthened	 the	notion	of	a	very	 complex	association	network	between	 these	proteins	and	 their	
wider	 role	within	 the	body.	 Likewise,	whilst	we	have	 established	 a	 role	 for	HS	 in	 interaction	with	
BACE-1	 and	 amyloid	 pathology,	 this	work	 has	 indicated	 that	HS	may	be	 key	 in	 other	mechanisms	
that	contribute	to	the	pathogenesis	of	AD.		
	
Moreover,	the	crossover	between	established	canonical	pathways	confirms	the	complexity	
of	 the	 functionality	 exhibited	 by	 the	 HS-related	 proteins	 and	 the	 heparin	 interactome.	 The	 very	
nature	of	HS	and	its	ability	to	bind	numerous	ligands	makes	its	role	within	the	body,	particularly	in	
the	 context	 of	 disease,	 particularly	 challenging	 to	 fully	 elucidate.	 The	 synthesis	 of	 HS	 itself	 sat	 in	
isolation	 with	 respect	 to	 other	 physiological	 function	 within	 the	 body.	 This	 finding	 seemed	
somewhat	surprising	on	account	of	the	importance	of	synthesis	of	HS	and	the	consequences	this	has	
on	 ligand	 binding	 affinities	 and	 thus	 functions.	 Indirectly,	 the	 synthesis	 of	 HS	 is	 hugely	 important	
indeed	the	data	generated	in	this	project	has	confirmed	the	importance	of	HS	biosynthesis	and	the	
resulting	 HS	 structures	 and	 the	ways	 in	 which	 they	 interact	 with	 their	 binding	 partners.	 For	 that	
reason,	 this	 preliminary	 work	 highlighted	 a	 need	 to	 integrate	 the	 synthesis	 of	 GAGs	 and	 the	
downstream	 consequences	 this	 may	 have	 on	 the	 signaling	 and	 functionality	 of	 other	 associated	
proteins.	The	network	of	interactions	generated	here	thus	aimed	to	consolidate	data	as	gathered	in	
the	lab	in	this	project	and	the	predictions	of	interactions	made	by	the	IPA®	software.	The	resultant	
network	 therefore	 is	 only	 at	 this	 point	 a	 model	 that	 aims	 to	 predict	 the	 wider	 context	 of	 HS	
functionality	in	pathogenesis	and	development	of	AD.		
	
This	 model	 (Figure	 5.8)	 predicted	 a	 regulation	 of	 the	 BACE-1	 enzyme	 via	 SERPINE2	 and	
FURIN	 proteins.	 PLAU,	 a	 GWAS	 identified	 AD	 risk	 factor	 SNP	 is	 known	 to	 interact	 with	 SERPINE2	
(Ozturk,	 et	 al.	 2007)	 and	 one	 might	 predict	 that	 mutations	 within	 the	 PLAU	 gene	 may	 result	 in	
aberrant	 interaction	 with	 SERPINE2.	 Furthermore,	 SERPINE2,	 a	 serine	 protease	 inhibitor,	 is	 an	
inhibitor	of	FURIN,	a	protein	that	 is	able	to	activate	a	number	of	other	proteins	(including	BACE-1)	
via	cleavage.	Indeed,	FURIN	is	able	to	increase	the	activity	of	BACE-1	by	cleavage	of	the	Pro-BACE-1	
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pro-peptide.	As	such,	this	model	predicted	a	process	by	which	the	activity	of	BACE-1	(in	addition	to	
its	overexpression	with	AD	(Decourt	and	Sabbagh	2011))	may	be	enhanced	as	a	result	of	enhanced	
FURIN	activity.	Similarly,	SERPINE2	is	a	member	of	the	heparin	interactome	and	as	such,	one	might	
question	the	role	of	HS	in	attenuating	or	promoting	the	activity	of	this	protein.	FURIN	is	also	able	to	
activate	TGFB1,	via	cleavage	of	pro-TGFB1	(transforming	growth	factor	beta),	a	cytokine	belonging	
to	 the	 transforming	 growth	 factor	 superfamily	 of	 proteins.	 Previous	 research	 has	 reported	 that	
dysfunction	of	the	TGFB	signaling	pathway	may	contribute	to	AD	by	accelerating	the	deposition	and	
fibrilisation	of	 the	Aβ	peptide	 (Das	 and	Golde	2006).	 It	 is	 important	 to	 note	 that	 TGFB	 is	 another	
heparin	interactome	protein	and	its	functionality	may	be	perturbed	as	a	consequence	of	altered	HS	
structure.			
	
Downstream	 of	 TGFB,	 IL6	 was	 shown	 to	 interact	 with	 this	 cytokine	 and	 literature	 based	
searches	 indicated	 that	 TGFB	 is	 able	 to	 induce	 elevated	 levels	 of	 IL6	 (Turner,	 et	 al.	 1990).	 IL6	 is	
another	heparin	interactome	protein	and	is	consistently	implicated	in	AD	in	the	literature.	Aberrant	
immune	 regulation	 and	 inflammatory	 processes	 is	 tightly	 associated	 with	 the	 development	 and	
persistence	of	AD	(Akiyama,	et	al.	2000).	 Indeed,	elevated	 levels	of	 IL-6	have	been	reported	 in	AD	
patients	 (Khemka,	 et	 al.	 2014)	 and	 have	 been	 shown	 to	 stimulate	 the	 synthesis	 of	 APP.	 Purified	
interleukin-6	 receptor	 (sIL-6R)	 added	 together	 with	 IL-6	 has	 been	 shown	 to	 rapidly	 increase	 the	
levels	of	cell-associated	and	secreted	APP	(Ringheim,	et	al.	1998).	Chronic	inflammation	is	a	known	
component	of	AD	and	this	network	association	with	 IL-6	may	go	some	way	 to	predict	a	means	by	
with	an	inflammatory	state	is	imposed	within	the	brain	upon	development	of	AD.	Naturally,	we	do	
not	 know	 whether	 inflammatory	 states	 causes	 the	 AD	 pathology	 itself	 (as	 suggested	 above)	 or	
whether	it	exacerbates	the	pathology	(or	perhaps	a	combination	of	the	two);	however	interaction	of	
heparin	 interactome	 proteins	with	 other	 factors	 known	 to	 associate	with	 AD	 separate	 to	 BACE-1	
indicates	a	complex	functionality	of	HS	in	AD.		
	
Also	 downstream	 to	 TGFB	 activity,	 it	 has	 been	 suggested	 that	 this	 cytokine	 may	 induce	
elevated	 levels	 of	 beta-estradiol	 (estrogen).	 Indeed,	 recent	 research	 has	 suggested	 a	 cross	 talk	
between	 TGFB	 and	 beta-estradiol	 such	 that	 estrogen	 receptor	 signaling	 was	 enhanced	 by	 the	
expression	 of	 TGFB.	 This	 finding	 no	 doubt	 has	 numerous	 implications	 for	 a	 variety	 of	 diseases	
including	 kidney	 function,	 atherosclerosis	 and	 breast	 cancer	 (Matsuda,	 et	 al.	 2001)	 however	may	
also	be	important	in	the	context	of	AD.	Estrogens	in	particular	have	been	more	recently	studied	for	
their	 efficacy	 as	 treatments	 of	 AD	 in	 light	 of	 their	 potential	 neuroprotective	 roles.	 Indeed,	 beta-
estradiol	has	been	 shown	 to	protect	 central	nervous	cells	 from	oxidative	 stress	 (Behl,	 et	al.	 1995)	
including	 that	 induced	 by	 the	 presence	 of	 Aβ	 peptides	 and	 as	 such	 could	 prove	 beneficial	 in	 the	
treatment	of	AD	and	consequences	of	oxidative	stress	as	implicated	in	this	disease	(Simpkins,	et	al.	
2010).	This	 is	 thus	a	very	 interesting	pathway	to	study	 further,	not	 least	because	of	 its	potentially	
protective	 role	 in	 AD	 but	 also	 in	 light	 of	 its	 association	 with	 heparin	 interactome	 proteins.	
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Furthermore,	 the	 IPA®	 software	 predicted	 an	 interaction	 between	 beta-estradiol	 and	
sulfotransferases.	 Indeed,	 previous	 research	 confirmed	 that	 estradiol	 β-D-Xyloside	 is	 an	 efficient	
primer	 for	 the	 synthesis	 of	 HS	 and	 as	 such	may	 be	 a	modulator	 for	 the	 quantities	 of	 HS	 present	
within	 cells	 (Lugemwa	 and	 Esko	 1991).	 Xylosides	 containing	 an	 aromatic	 ring	 (p-nitrophenol,	 4-
methylumbelliferone,	and	estradiol)	primed	heparan	sulfate	most	efficiently.	It	has	been	suggested	
that	the	priming	of	HS	by	estradiol	β-D-xyloside	may	be	a	result	of	the	structural	similarities	between	
estradiol	 and	a	domain	within	 the	HSPG	core	proteins.	 	Data	generated	 in	 the	 lab	as	described	 in	
chapter	 2	 reported	 significantly	 reduced	 levels	 of	 total	HS	within	 brain	 samples	 from	AD	patients	
compared	 to	 healthy	 controls	 and	 this	 predicted	 interaction	 of	 TGFB	 and	 beta-estradiol,	 as	
established	by	IPA®,	may	go	some	way	to	explain	a	possible	mechanism.	These	network	components	
might	 also	 have	 implications	 on	 the	 level	 of	 sulfotransferase	 activity	 present	 along	 an	 HS	 chain;	
hence	it	is	still	largely	uncertain	how	HS	chain	modification	is	regulated.		
	
Based	on	a	combination	of	early	predictions	made	by	IPA®	and	the	data	generated	within	
the	 lab	 in	 this	 project,	 one	might	 predict	 that	 alteration	 to	 PLAU	 as	 initiated	 by	 AD,	may	 induce	
altered	SERPINE2	functionality	such	that	it	is	less	able	to	inhibit	FURIN.	Enhanced	FURIN	activity	may	
result	 in	elevated	BACE-1	activity	which	coupled	with	accelerated	activity	as	a	 result	of	altered	HS	
inhibition	efficacy	(as	established	in	chapter	4),	leads	to	an	initiation	of	inflammatory	pathways	that	
exacerbate	 the	effects	of	AD	pathology	and	perpetuate	 the	persistence	of	activated	microglia	and	
cytokines	such	as	IL-6	that	are	associated	with	AD.	This	all	may	be	accompanied	by	enhanced	beta-
estradiol	 signaling	 which	 may	 have	 downstream	 consequences	 on	 HS	 synthesis	 and	modification	
which	will	drive	the	aberrant	BACE-1	inhibition	and	aid	the	persistence	of	enhanced	APP	processing	
and	Aβ	turnover.		
	
The	 lab	 data	 as	 presented	 here	 that	 confirmed	 a	 change	 in	 the	 structure	 of	 HS	 in	 brain	
tissue	from	AD	patients	might	be	associated	with	some	of	the	upstream	factors	described	above.	It	
has	been	 shown	 that	 structural	 alterations	 to	HS	have	dramatic	 implications	 for	 its	 ability	 to	bind	
BACE-1	and	ultimately	 the	generation	of	Aβ	within	cells,	and	 the	 transfection	studies	 in	chapter	4	
implicate	 subtle	 changes	 in	 sulfatase	 and	 sulfotransferase	 expression	 in	 the	 modulation	 of	
generation	 of	 this	 peptide.	 As	 such,	 it	 would	 seem	 there	 is	 a	 strong	 argument	 for	 importance	 of	
synthesis	 of	 HS	 in	 a	 number	 of	 physiological	 and	 disease-state	 pathways	 within	 the	 body.	 The	
network	 as	 described	 here	 goes	 some	way	 to	 attempt	 to	 set	 the	 role	 of	 HS	 into	 a	wider	 disease	
mechanism	context.	Naturally,	this	work	is	only	preliminary	and	a	great	deal	more	work	is	required	
to	establish	how	the	role	of	HS	may	further	be	important	in	pathways	such	as	inflammation	that	are	
known	 to	exacerbate	AD,	and	also	 its	 interaction	with	 those	 risk	 factors	already	 identified	 for	 the	
onset	 of	 AD.	 Despite	 this,	 the	 integration	 of	 GWAS	 associated	 risk	 factor	 proteins;	 heparin	
interactome	proteins	and	data	from	the	lab	regarding	the	HS	biosynthetic	pathway	highlight	a	model	
by	which	a	better	understanding	of	the	complexity	of	AD	may	be	approached.			
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5.10	Conclusions	
	
	 There	is	no	doubt	that	the	use	of	informatics	still	requires	a	great	deal	more	work	to	make	
any	firm	conclusions	regarding	HS	and	a	wider	role	in	AD.	Despite	this,	the	studies	carried	out	here	
have	highlighted	the	sheer	complexity	of	any	HS	mediated	pathway	on	account	of	the	wide	variety	
of	ligands	that	it	may	bind	and	the	canonical	pathways	with	which	it	may	be	associated.	The	factors	
contributing	to	full-blown	pathogenesis	are	multiple	and	varied	and	as	such,	understanding	all	of	the	
mechanisms	that	underpin	AD	is	a	huge	challenge	in	itself.	That	being	said,	the	heparin	interactome,	
HS	biosynthetic	machinery	and	pre-established	GWAS	identified	risk	proteins	may	serve	as	a	useful	
tool	 in	elucidating	 some	of	 the	 crossover	points	between	 these	myriad	pathways.	 Inflammation	 it	
would	 seem	 is	 a	 particularly	 interesting	 area	 of	 cross	 talk	 between	 HS	 interacting	 proteins	 and	
amyloid	pathology	and	one	that	future	studies	will	need	to	further	 investigate.	Whilst	we	may	not	
have	had	time	to	explore	the	avenues	highlighted	with	this	work,	there	is	no	doubt	that	HS	is	a	key	
player	in	AD	pathology.	Furthermore,	if	we	are	to	think	of	HS	as	a	wide	acting,	ubiquitous	regulator	
within	 the	 body,	 one	 might	 consider	 it	 to	 function	 within	 an	 extremely	 “robust”	 system.	 In	 this	
sense,	robustness	may	refer	to	the	ability	of	HS	to	modulate	its	structure	such	that	it	may	efficiently	
bind	to	an	otherwise	unavailable	ligand	to	restore	baseline	conditions	without	risk	of	losing	binding	
efficacy	with	another	partner.	Re-establishing	“cellular	equilibrium”	following	challenge	is	mediated	
to	a	great	extent	by	HS	and	to	that	end,	a	great	deal	more	focus	on	the	regulation	of	HS	synthesis	
may	be	warranted.	Understanding	the	consequences	of	altered	HS	synthesis	and	modification	may	
prove	 vital	 in	 understanding	 the	 aberrant	 pathways	 that	may	 consequently	 be	 set	 into	motion	 to	
initiate	disease.	The	finding	that	HS	synthesis	is	so	poorly	represented	in	network	analysis	suggests	a	
need	for	a	much	greater	 focus	on	the	seemingly	subtle	yet	potentially	significant	alterations	 in	HS	
structure.	Moreover,	 the	 changes	 to	 HS	 as	 illustrated	 in	 this	 project	 in	 the	 context	 of	 AD	 and	 its	
amyloid	pathology	are	not	unique	and	could	serve	to	be	interesting	targets	of	research	for	a	number	
of	other	diseases.			
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6.	Conclusions	and	final	discussion	
	
6.1	HS	changes	in	AD	and	has	altered	BACE-1	inhibition	efficacy	
	
	 This	 project	 showed	 that	 the	 structure	 of	 HS	 purified	 from	 AD	 patient	 brain	 tissue	 is	
significantly	 less	 sulfated	 when	 compared	 to	 HS	 purified	 from	 healthy	 age-matched	 controls	
(chapter	2),	suggesting	that	structural	changes	to	HS	occur	as	a	consequence	of	the	AD	phenotype.	
In	addition,	 this	project	 showed	 that	 these	changes	 in	 the	composition	of	HS	are	 likely	a	 result	of	
altered	expression	of	the	genes	that	encode	HS-related	enzymes	responsible	for	the	modification	of	
the	 HS	 chain	 (chapter	 3).	 Finally,	 the	 changes	 in	 HS	 structure	 elucidated	 here	 are	 implicated	 in	
altered	BACE-1	 inhibition	efficacy	 (chapter	4)	and	as	 such	may	provide	a	mechanism	by	which	AD	
development	and	progression	is	exacerbated	within	the	brain	of	AD	patients.		
	
The	 changes	 in	 the	 structure	 of	 HS	 as	 observed	 in	 this	 project	 have	 confirmed	 the	
hypothesis	that	the	function	of	HS	as	a	naturally	occurring	“brake”	on	BACE-1	activity	is	attenuated	
by	 changes	 in	 its	 structure.	 This	 results	 in	 removal	 of	 the	 brake	 and	 potentially	 elevated	 APP	
processing	 as	 a	 consequence.	 In	 doing	 so,	 we	 have	 established	 a	 novel	mechanism	 by	 which	 AD	
pathology	may	be	initiated	and	exacerbated	within	the	brains	of	AD	patients.	In	addition,	this	work	
may	serve	to	explain	why	those	unaffected	by	AD	are	naturally	protected	from	the	onset	of	AD	-	if	
HS	structure	is	maintained	with	ageing	in	a	form	that	continues	to	put	a	brake	on	aberrant	BACE-1	
activity,	APP	processing	could	be	maintained	at	a	healthy	level.		
	
It	should	be	noted	that,	the	changes	in	the	structure	of	HS	as	reported	here	have	only	been	
pursued	with	specific	 reference	to	 function	 in	regard	to	 its	 interaction	with	the	BACE-1	enzyme.	 It	
has	already	been	shown	that	HS	also	interacts	with,	and	influences	in	some	cases,	other	features	of	
AD	pathology	including	interaction	with	the	mature	plaques	themselves	(Zhan,	et	al.	1995),	the	Aβ	
peptide	(Castillo,	et	al.	1997,	Cotman,	et	al.	2000).	As	such,	in	future	studies	it	may	be	interesting	to	
assess	 how	 the	 observed	 structural	 changes	 that	 occur	 with	 AD	may	 also	 affect	 these	 additional	
functions.	Previous	 research	has	 indicated	 that	 interaction	of	HS	with	mature	plaques	may	 indeed	
protect	 them	 from	 degradation	 (Biroc,	 et	 al.	 1993).	 Should	 this	 interaction	 be	 dependent	 upon	
sulfation	motifs	within	HS	(as	we	would	expect),	one	might	argue	that	AD	induced	structural	changes	
may	 also	 enhance/inhibit	 this	 functionality.	 Likewise,	 the	 role	 of	 HS	 and	HSPGs	 as	 a	 promoter	 of	
fibrilisation	of	smaller	oligomers	into	mature	fibrils	(Snow,	et	al.	1994)	may	also	be	dependent	upon	
structural	features	within	the	HS	chain.	 It	has	also	been	established	that	GAG-amyloid	 interactions	
occur	with	a	number	of	different	affinities,	all	of	which	depend	on	the	details	of	 the	amyloid	fibril	
architecture.	 As	 such,	 it	 would	 appear	 there	 is	 a	 complex	 relationship	 between	 GAGs	 and	 the	
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amyloid	species	with	regard	to	AD	pathology	development	(Stewart,	et	al.	2016).	Understanding	the	
implications	of	HS	structural	alterations	in	all	facets	of	its	role	in	AD	may	help	elucidate	the	ways	in	
which	AD	pathology	is	self	perpetuated.		
	
This	study	investigated	the	structure	of	HS	purified	from	the	middle	temporal	gyrus	region	
of	the	brain,	an	area	of	the	cortex	known	to	be	implicated	in	AD	and	the	spread	of	pathology.	This	
area	 was	 selected	 based	 on	 previously	 established	 changes	 in	 the	 expression	 of	 HS	 biosynthetic	
genes	in	this	region	with	AD,	alongside	known	vulnerability	of	this	region	to	AD	pathology.	Naturally,	
this	 study	 could	be	extended	 to	explore	possible	 changes	 in	 the	 structure	of	HS	 in	other	 affected	
brain	 regions,	 including	 the	 hippocampus.	 This	 is	 the	 first	 area	 known	 to	 be	 affected	 by	 AD	
pathology	and	is	also	the	key	region	implicated	in	memory	formation	and	consolidation	(Fox,	et	al.	
1996).	 As	 such,	 understanding	 the	 changes	 in	 HS	 that	 may	 occur	 here	 will	 prove	 particularly	
interesting	 and	 may	 offer	 insights	 into	 temporal	 and	 spatial	 changes	 in	 HS	 correlated	 with	 the	
spread	of	this	disease.	Procuring	samples	of	AD	hippocampus	is	particularly	challenging	in	light	of	its	
key	 functional	 roles	 in	a	number	of	 cognitive	 functions.	As	 such,	 selection	of	 the	middle	 temporal	
gyrus	was	an	appropriate	region	to	study	first	in	the	context	of	AD	pathology.	Now	this	preliminary	
study	 has	 uncovered	 significant	 changes	 in	 HS	 that	 occur	with	 AD,	 there	 is	 a	 strong	 argument	 to	
pursue	studies	on	other	regions	of	the	brain.	In	the	same	manner,	informatics	work	that	confirmed	
variable	baseline	expression	of	HS	biosynthetic	 genes	 in	different	 regions	of	 the	brain	 (chapter	 5)	
may	serve	 to	predict	 regional	vulnerability	 to	 the	 features	of	AD.	 It	would	be	 interesting	 in	 future	
studies	to	determine	whether	these	differences	in	baseline	expression	can	also	predict	HS	structural	
variability	and	ultimately	susceptibility	of	an	individual	to	the	onset	of	AD.		In	combination	with	this,	
establishing	 how	 BACE-1	 activity	 inhibition	 by	 HS	 is	 altered	 in	 the	 hippocampus	 would	 be	 an	
interesting	 avenue	 to	 pursue;	 is	 the	 activity	 of	 BACE-1	 in	 the	 presence	 of	 endogenous	 HS	 in	 this	
region	enhanced	to	an	even	greater	extent	in	AD	patients	vs.	healthy	controls?		
	
The	 changes	 in	 the	 expression	 of	 HS	 biosynthetic	 genes	 as	 confirmed	 in	 this	 study	 have	
offered	 an	 upstream	mechanism	 by	 which	 the	 reported	 changes	 in	 the	 structure	 of	 HS	 could	 be	
initiated.	Elevated	expression	of	the	SULF1	gene	as	reported	in	AD	patients	and	reduced	expression	
of	the	HS6ST2	and	HS6ST3	genes	 is	 indicative	of	reduced	sulfation	at	the	6-O	position.	This	finding	
was	supported	by	reduced	sulfation	of	HS	as	confirmed	with	compositional	analysis.	Further	work	is	
needed	to	establish	exactly	how	changes	in	HS	gene	expression	affect	downstream	regulation	of	HS	
structure.	 Indeed,	more	work	 is	also	necessary	to	determine	whether	there	 is	correlation	between	
expression	 and	 activity	 of	 these	 enzymes.	 Despite	 this	 however,	 these	 changes	 in	 AD	 patients	
strongly	 indicate	 a	mechanism	by	which	HS	 structure	 is	 altered	 and	 ultimately,	 via	modulation	 of	
BACE-1	 activity,	 regulates	 production	 of	 the	 toxic	 Aβ	 peptide.	 Moreover,	 changes	 in	 expression	
patterns	of	these	genes	may	serve	as	a	very	preliminary	biomarker	in	which	vulnerability	to	AD	could	
be	 predicted	 in	 patients.	 Recently,	 a	 significant	 SNP	 within	 the	 HS6ST1	 gene	 was	 linked	 with	
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albuminuria,	 associated	 with	 the	 onset	 of	 diabetes	 (Teumer,	 et	 al.	 2016).	Moreover,	 the	 HS6ST1	
gene	has	also	been	 implicated	 in	 idiopathic	hypogonadotrophic	hypogonadism	and	the	absence	of	
puberty	in	adolescents	(Tornberg,	et	al.	2011).	Other	HS	related	genes	implicated	in	disease	include	
GWAS	studies	to	implicate	the	NDST3	gene	in	schizophrenia	and	bipolar	disorder	(Lencz,	et	al.	2013)	
and	 SUMF1	 (sulfatase	 modifying	 factor	 1)	 in	 autism	 (Glessner,	 et	 al.	 2009).	 	 These	 findings	
strengthen	the	notion	of	HS	biosynthetic	genes	as	early	markers	 for	disturbances	 in	key	pathways	
associated	with	a	range	of	diseases.		
	
Interesting	 to	 note,	 Nagai	 and	 colleagues	 have	 previously	 reported	 regulation	 of	 the	
expression	 and	 cellular	 localisation	 of	 the	 HS6ST3	 enzyme	 by	 BACE-1	 (Nagai,	 et	 al.	 2007).	 It	 is	
unknown	as	yet	how	these	two	proteins	may	be	linked	however	it	has	been	postulated	that	BACE-1	
may	cleave	a	currently	unidentified	protein	that	HS6ST3	in	some	way	interacts	with,	or	that	BACE-1	
may	be	able	 to	 interact	with	and	regulate	 the	secretory	pathway	by	which	HS6ST3	 is	 transported.	
Interestingly	 this	 interaction	 was	 specific	 to	 HS6ST3	 and	 not	 the	 other	 HS6ST	 enzyme	 isoforms.	
Moreover,	 inhibition	 of	 BACE-1	 activity	 was	 able	 to	 increase	 the	 total	 levels	 of	 HS	 6-O	 sulfation.	
Elevated	 6-O	 sulfated	 in	 this	manner	may	 reflect	 a	 self	 perpetuating	 cycle	 by	 which	 effective	 HS	
mediated	 inhibition	of	 BACE-1	 can	be	 exploited	 to	maintain	 its	 own	 suppression.	 That	 being	 said,	
elevated	6-O	sulfation	may	also	serve	to	enhance	fibril	formation	and	stability	(Castillo,	et	al.	1997,	
Lindahl,	 et	 al.	 1999).	 Either	 way,	 the	 highly	 complex	 interaction	 between	 HS,	 its	 biosynthetic	
machinery,	and	the	BACE-1	enzyme	is	further	complicated	by	the	myriad	mechanisms	by	which	AD	
pathogenesis	 is	 perpetuated.	 Further	 understanding	 the	 interaction	 between	 BACE-1	 and	 HS6ST3	
may	prove	key	in	underpinning	BACE-1	regulation.	Furthermore,	our	observation	of	down-regulation	
of	 the	HS6ST3	 gene	with	AD	may	have	direct	 implications	 on	BACE-1	 regulation	 independently	 of	
gross	HS-mediated	affects.			
	
The	 established	 change	 in	 expression	 of	 the	 core	 proteins	 onto	which	HS	 chains	may	 be	
bound	 also	 calls	 into	 question	 their	 role	 in	 development	 of	 AD	 pathology.	 The	 significant	 up-
regulation	of	 the	AGRN	gene	sits	well	with	earlier	 research	 that	established	 its	 role	as	a	protector	
against	degradation	via	the	presence	of	protease	inhibitor	domains	(Gupta-Bansal,	et	al.	1995).	The	
role	 of	 the	HS	 chains	 that	may	 decorate	 the	AGRN	 core	 protein	 however	 is	 yet	 to	 be	 elucidated.	
Future	studies	to	purify	AGRN	proteins	from	brain	samples	of	AD	patients	and	extraction	of	the	HS	
chains	 that	 are	attached	may	offer	more	 information	about	HS	 covalently	bound	 to	 core	proteins	
and	the	ways	they	may	influence	functions	related	to	the	core	protein	itself.	The	structural	changes	
as	reported	here	do	not	distinguish	between	HS	chains	free	in	the	cell	and	those	attached	to	a	core	
protein.	Distinguishing	between	the	two	may	identify	important	changes	key	in	understanding	their	
respective	 functionalities.	 Variability	 between	 patients	 was	 expected	 and	 as	 such,	 larger	 sample	
sizes	in	the	future	may	be	necessary	to	smooth	out	variability	and	strengthen	some	of	the	trends	for	
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changes	in	expression	as	reported	in	chapter	3.	More	robust	changes	with	AD	may	become	apparent	
with	larger	group	sizes.		
	
In	 addition,	 this	 study	 confirmed	 that	 altered	 changes	 in	 the	 structure	 of	 HS	 in	 AD	 as	
induced	 (we	 hypothesise)	 by	 altered	 expression	 of	 the	 genes	 that	 encode	 the	 HS	 biosynthetic	
enzyme	 machinery	 results	 in	 reduced	 BACE-1	 inhibition	 efficacy.	 Elevated	 activity	 of	 the	 BACE-1	
enzyme	is	the	known	cause	of	elevated	production	of	the	Aβ	peptide.	This	study	has	verified	that	HS	
may	serve	as	the	“brake”	that	regulates	the	activity	of	BACE-1.	In	the	presence	of	the	AD	phenotype,	
this	 brake	 is	 less	 efficient	 (as	 a	 consequence	 of	 attenuated	 HS	 inhibition),	 resulting	 in	 elevated	
processing	of	the	APP	protein	to	form	the	Aβ	peptide.	This	finding	strengthens	the	notion	that	BACE-
1	 activity	 is	 a	 strong	 target	 for	 future	 design	 of	 therapeutics	 against	 AD	 and	 the	 role	 of	 HS;	 a	
physiologically	active	GAG	provides	the	optimal	template	on	which	to	create	future	therapies.	This	
study	 has	 gone	 some	 way	 to	 highlight	 the	 “ideal”	 structures	 necessary	 for	 efficacious	 BACE-1	
inhibition.	 Finding	 ways	 to	 mirror	 these	 structures,	 in	 combination	 with	 attenuation	 of	 the	
previously	 established	 anti-coagulant	 activities	 of	 heparin	 derivatives,	 may	 provide	 a	 route	 for	
development	 of	 small	 (important	 for	 crossing	 the	 BBB),	 non	 toxic,	 potent	 inhibitors	 of	 BACE-1,	
specific	 to	 only	 BACE-1	 and	 not	 other	 proteases,	 and	 these	 may	 have	 significant	 therapeutic	
potential.		
	
The	 somewhat	 preliminary	 in	 vitro	 work	 carried	 out	 in	 this	 project	 to	 assess	 how	
modulation	of	HS	biosynthesis	is	able	to	regulate	production	of	the	Aβ	peptide	has	gone	some	way	
to	address	the	hypothesis	of	a	“personalised”	heparin	derivative	to	treat	the	amyloid	pathologies	of	
AD.	The	knockdown	of	the	SULF1	and	SULF2	genes	in	cultured	HEKSweAPP	cells	resulted	in	reduced	
accumulation	 of	 the	 Aβ1-42	 peptide	 and	 offered	 a	 plausible	 mechanism	 by	 which	 toxic	 peptide	
formation	 could	 be	 halted	within	 cells	 (chapter	 4).	 Furthermore,	 the	 data	 collected	 here	 offers	 a	
strong	 argument	 for	 the	 role	 of	 the	 sulfatase	 enzymes,	 as	 key	 players	 in	 the	 fine-tuning	 of	 HS	
structure	with	consequences	on	overall	 functionality	of	HS.	 Indeed,	reduction	of	Aβ1-42	as	reported	
here	 confirms	 the	 notion	 of	 6-O	 sulfation	 being	 important	 for	 BACE-1	 interaction	 and	 inhibition	
(Scholefield,	et	al.	2003).	Furthermore,	the	significant	changes	as	reported	here	with	knockdown	of	
the	 SULF	 genes	may	 put	 forward	 an	 argument	 for	 the	 importance	 of	 fine	 tuning	 of	 the	 HS	 chain	
following	modification	over	gross	structural	changes.	Knockdown	of	the	HS6ST	genes	in	this	context	
produced	less	conclusive	results	regarding	affects	on	Aβ1-42	processing;	this	is	likely	due	to	issues	of	
redundancy	 among	 the	 3	 different	 isoforms.	 Combinatorial	 knockdown	 of	 HS6ST1,	 HS6ST2	 and	
HS6ST3	together	will	be	something	to	pursue	in	future	studies	to	explore	the	effects	of	more	robust	
gene	 knockdown	 to	 reduce	 6-O	 sulfation.	 It	may	 be	 that	 combination	 knockdown	will	 yield	more	
substantial	 results	with	 respect	 to	modulation	 of	 Aβ1-42	production.	 In	 addition	 a	 great	 deal	more	
research	 is	 needed	 to	 determine	 the	 functionality	 of	HS	 biosynthetic	 enzymes	 and	 the	ways	 they	
function	in	combination	with	each	other.	It	would	be	interesting	to	determine	whether	knockdown	
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of	HS6ST	gene	expression	completely	 for	example	 forces	the	compensatory	up-regulation	of	other	
genes	 and	 drives	 the	 equilibrium	of	 synthesis	 via	 a	 different	modification	 pathway	 e.g.	 enhanced	
activity	of	the	HS2ST	or	HS3ST	family	of	enzymes.	Furthermore	qRT-PCR	analysis	to	explore	potential	
expression	changes	of	other	gene	 families	 following	knockdown	of	 selected	HS	biosynthetic	genes	
may	 offer	 interesting	 information	 concerning	 the	 regulation	 of	 HS	 synthesis	 and	 modification.	 It	
seems	 likely	 that	 regulatory	mechanisms	 are	 in	 place	 to	 counter	 disturbances	 in	 the	 biosynthetic	
pathways	that	generate	HS.	
	
The	work	 carried	 out	 to	 assess	 BACE-1	 inhibition	 efficacy	 in	 the	 SULF	 KO	mouse	models	
went	some	way	to	recapitulate	more	exaggerated	modulated	structures	of	HS	as	discussed	above.	
Indeed,	this	work	reported	a	significant	improvement	in	BACE-1	inhibition	in	mice	in	the	absence	of	
SULF2	in	isolation,	as	well	as	those	lacking	both	the	Sulf1	and	Sulf2	gene	activity.	Future	studies	may	
utilise	other	mouse	knockout	models	as	a	way	of	generating	more	exaggerated	gene	knockdown	to	
assess	how	regulation	of	HS	synthesis	takes	place	and	the	implications	this	has	on	the	generation	of	
the	toxic	Aβ	species.	Such	animals	could	also	be	crossed	with	AD	model	mice	to	explore	the	effects	
on	development	of	amyloid	pathology.	
	
Understanding	 the	 spatial	 arrangement	 of	 sulfation	 in	 HS	 may	 also	 prove	 to	 be	 key	 in	
understanding	the	ways	in	which	it	is	able	to	interact	with	BACE-1	and	how	alterations	in	this	spatial	
arrangement	 are	 implicated	 in	 BACE-1	 inhibition	 efficacy.	 Developing	 other	 sequencing	
methodologies	may	help	to	 further	elucidate	structural	 features	of	HS	key	 in	the	 interaction	of	HS	
with	BACE-1.	Compositional	analysis	as	employed	in	this	study	allowed	comparison	of	the	ratios	of	
specific	 disaccharides	 within	 HS	 from	 AD	 and	 age-matched	 control	 brain	 samples.	 However	 the	
sequence	in	which	these	disaccharides	are	observed	in	the	HS	chains	could	not	be	determined.	In	a	
similar	manner,	 the	 structural	 analysis	 as	employed	 in	 this	 study	 (chapter	2)	 could	not	distinguish	
the	identity	of	the	uronic	acid	residue.	Changes	in	the	structure	of	HS	via	epimerisation	of	the	GlcA	
to	IdoA	residues	(via	the	action	of	the	C5	epimerase	enzyme)	have	been	postulated	to	have	dramatic	
effects	on	the	regulation	of	the	modification	events	that	occur	subsequently	(Rudd	and	Yates	2012).	
Changes	 in	 the	 expression	 of	 the	 GLCE	 gene	 as	 reported	 in	 chapter	 3	 with	 AD	 relative	 to	 age-
matched	healthy	controls	may	be	 indicative	of	additional	structural	changes	 to	a	proportion	of	HS	
chains	that	could	confer	significant	alterations	 in	the	subsequent	sulfation	motifs	that	are	created.		
Using	compositional	analysis	methods	that	can	 identify	the	 identity	of	the	uronic	acid	epimer	(e.g.	
nitrous	 acid	 cleavage)	would	 be	 of	 interest	 in	 future	 studies.	Understanding	 the	 consequences	 of	
epimerisation	 to	 the	HS	 chain	 in	 the	 context	 of	 AD	may	 further	 strengthen	 the	 findings	 reported	
here	 that	 confirm	 structural	 changes	 as	 key	 in	 the	 regulation	of	BACE-1	 and	processing	of	APP	 to	
form	 the	 Aβ1-42	 peptide.	 Enhanced	 epimerisation	 of	 AD	 HS	 as	 potentially	 indicated	 by	 the	 gene	
expression	 data	 described	 here	 may	 suggest	 further	 structural	 changes	 implicated	 in	 BACE-1	
inhibition	 efficacy	 and	disease	 development.	 Taken	 together,	 understanding	more	 about	 the	 “key	
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players”	in	terms	of	the	HS	biosynthetic	machinery	may	provide	ideas	for	reflecting	susceptibility	to	
the	onset	and	development	of	AD.		
	
This	project	has	established	 that	 the	compositional	profile	of	HS	derived	 from	AD	patient	
brain	tissue	is	different	to	that	of	healthy	age-matched	controls	and	as	such	offers	a	mechanism	by	
which	the	onset	of	AD	may	be	promoted	or	accelerated.	Furthermore,	the	known	interaction	of	HS	
with	 other	 features	 of	 AD	 in	 addition	 to	 BACE-1	 may	 serve	 to	 explain	 the	 persistence	 of	 this	
pathology	in	patient	brains	as	disease	development	continues.	This	work	coupled	with	review	of	the	
literature	 would	 suggest	 a	 “Yin-Yang”	 relationship	 whereby	 HS	may	 both	 enhance	 the	 pathology	
associated	 with	 AD	 and	 protect	 against	 some	 of	 its	 toxic	 affects.	 The	 interaction	 of	 BACE-1	 as	
investigated	here	is	undoubtedly	only	a	facet	of	the	much	wider	and	more	complex	role	that	HS	is	
known	 to	 play	 in	 AD.	 That	 being	 said,	 targeting	 the	 activity	 of	 BACE-1	 in	 this	manner	 is	 a	 central	
pathway	 eliciting	 the	 very	 early	 “seeds”	 of	 AD	 pathology.	 Understanding	 the	 role	 of	 HS	 in	 this	
pathway	thus	serves	as	a	strong	drug	design	target	in	the	future	by	nature	of	its	significant	position	
in	greater	disease	development.	 The	observed	changes	 in	HS	as	discussed	 in	 this	 study	will	 surely	
affect	several	downstream	ligand-binding	targets	of	HS,	 though	those	affecting	 its	 interaction	with	
the	BACE-1	enzyme	could	certainly	prove	the	most	efficacious	as	a	focus	for	drug	design.		
	
Targeting	this	key,	and	very	well	established,	pathway	in	AD	pathology	might	face	criticism	
in	 light	 of	 several	 failed	 pharmaceutical	 efforts	 to	 create	 clinically	 effective	 anti-amyloid	
therapeutics.	Despite	this,	the	approach	of	this	study	to	investigate	the	role	of	an	already	naturally	
occurring	 “brake”	 on	 BACE-1	 activity	 immediately	 overcomes	 several	 of	 the	 failures	 of	 those	
compounds	that	reached	but	failed	at	clinical	trials.	Designing	new	drug	strategies	based	on	natural	
products	already	well	tolerated	by	the	body	may	prove	to	be	key	in	treating	AD.		
	
6.2.	HS	changes	with	ageing	and	this	has	implications	for	BACE-1	inhibition	
efficacy	
	
As	a	side	issue,	this	project	also	aimed	to	investigate	the	variable	of	ageing	in	the	context	of	
HS	and	BACE-1	inhibition	efficacy.	This	work	was	carried	out	to	explore	whether	age,	the	biggest	risk	
factor	for	the	onset	of	AD,	initiated	similar	pathways	in	the	regulation	of	HS	and	its	interaction	with	
the	BACE-1	enzyme.	Somewhat	unexpectedly,	the	data	collected	from	this	work	indicated	a	separate	
mechanism	by	which	HS	is	regulated	with	normal	physiological	ageing.	Structural	changes	as	induced	
with	age	(as	discussed	in	chapter	2)	were	found	to	differ	greatly	from	those	recorded	in	AD	patient	
HS	samples	indicating	age	and	AD	induced	HS	changes	are	different.	Aged	mouse	HS	samples	were	
found	 to	 be	 more	 potent	 inhibitors	 of	 BACE-1	 activity	 vs.	 their	 younger	 control	 counterparts,	
whereas	one	might	have	expected	aged	HS	samples	to	display	reduced	BACE-1	inhibition	properties	
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similar	 to	 that	 of	 the	 AD	 samples.	 	 This	 contradictory	 result	 however	 may	 suggest	 a	 separate	
protective	 mechanism	 is	 initiated	 whereby	 normal	 physiological	 aging	 in	 healthy	 individuals	
maintains	 an	 appropriate	 level	 of	 BACE-1	 inhibition,	 thus	 avoiding	 elevated	 APP	 processing	 and	
enhanced	levels	of	Aβ.	Moreover,	when	studying	the	ageing	phenotype,	HS	at	lower	concentrations	
exhibited	the	most	potent	BACE-1	inhibition.	Future	studies	to	investigate	BACE-1	inhibition	potency	
at	even	lower	concentrations	may	prove	interesting	with	regard	to	exploring	the	potential	for	aged	
HS	to	both	inhibit	and	activate	BACE-1	at	varying	concentrations.			
	
Naturally	this	hypothesis	needs	a	great	deal	more	work	to	confirm	and	fully	elucidate,	not	
least	in	human	tissue.	This	early	data	however,	as	described	in	this	project,	would	suggest	that	there	
might	be	some	protective	regulatory	processes	that	may	actually	shape	HS	such	that	it	is	better	able	
to	modulate	the	activity	of	BACE-1	to	a	normal	physiological	level.	As	with	the	studies	in	human	AD	
tissue,	 gene	 expression	 studies	 to	 explore	 the	 potential	 upstream	 regulation	 of	 these	 structural	
changes	as	described	with	this	ageing	model	will	also	be	important.	Differences	in	gene	expression	
profiles	 with	 AD	 and	 with	 normal	 ageing	 may	 go	 some	 way	 to	 highlight	 separate	 regulatory	
pathways	by	which	physiological	ageing	and	disease	are	separated.	Moreover,	exploring	how	groups	
of	HS-related	genes	may	be	regulated,	 for	example	via	shared	transcriptional	 regulators	may	offer	
new	insight	into	how	separate	HS	structural	regulatory	pathways	may	be	maintained	and	balanced.	
We	might	 predict	 that	 enhanced	 BACE-1	 inhibition	 (as	 detailed	 in	 chapter	 4)	may	 be	 elicited	 via	
altered	HS	structures	distinct	to	those	observed	in	the	presence	of	the	AD	phenotype,	such	that	the	
ability	of	HS	to	interact	with	and	block	the	activity	of	BACE-1	is	significantly	altered.		
	
6.3.	Bioinformatics	tools	set	the	role	of	HS	in	the	wider	context	of	AD	
		
	 The	roles	of	HS	in	the	pathogenesis	of	and	progression	of	AD	are	undoubtedly	very	complex	
and	varied,	and	the	work	carried	out	here	with	bioinformatics	has	highlighted	the	need	 for	 future	
studies	to	 further	elucidate	the	pathways	associated	with	the	development	of	AD	and	the	ways	 in	
which	 these	 pathways	 are	 connected.	 In	 particular,	 the	 preliminary	 work	 as	 carried	 out	 here	
indicated	strong	association	with	the	HS	biosynthetic	machinery;	GWAS	identified	risk	genes	and	the	
heparin	 interactome	 with	 inflammatory	 pathways.	 Chronic	 inflammation	 is	 a	 known	 feature	 that	
accompanies	 AD	 pathology	 and	 finding	 ways	 to	 interconnect	 the	 numerous	 pathways	 associated	
with	 the	 development	 of	 this	 disease	 may	 be	 paramount	 in	 identifying	 key	 targets	 for	 potential	
therapeutic	 strategies.	 A	 great	 deal	 more	 work	 is	 needed	 before	 firm	 conclusions	 can	 be	 made	
regarding	the	role	of	heparin	binding	proteins	and	the	network	of	interactions	that	both	bring	about,	
and	aid	in	the	persistence	of,	AD	pathology.	Moreover,	the	informatics	work	as	carried	out	here	not	
only	 allowed	 preliminary	 identification	 of	 areas	 prone	 to	 change	 in	 HS	 (as	 determined	 by	
Genevestigator	 studies	 prior	 to	 lab	 work)	 but	 also	 highlighted	 the	 absence	 of	 HS	 structural	
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regulation	as	a	predictor	 for	altered	associations	between	proteins	within	a	network.	The	work	of	
this	project	has	implicated	the	structure	of	HS	and	the	way	in	which	it	is	synthesised	as	central	to	its	
downstream	affects	and	interaction	with	key	proteins	in	disease	mechanisms	pathways.	Whilst	the	
biosynthesis	of	HS	(and	the	means	by	which	 its	biosynthesis	 is	controlled)	was	not	associated	with	
the	 major	 canonical	 pathways	 as	 identified	 in	 this	 study,	 it	 seems	 unlikely	 that	 changes	 to	 this	
biosynthesis	could	not	have	significant	implications	on	these	pathways.	As	such,	one	might	propose	
that	a	greater	emphasis	needs	to	be	placed	upon	HS	biosynthesis	and	the	ways	in	which	its	structure	
might	be	modulated	and	the	consequences	this	could	have	on	 important	physiological	and	 indeed	
disease	 pathways.	 Whilst	 more	 work	 is	 needed	 to	 establish	 firm	 conclusions	 regarding	 the	
interactive	 networks	 that	 link	 the	heparin	 interactome,	HS	 synthesis	 and	GWAS	 identified	AD	 risk	
factors,	it	is	certain	that	these	associations	do	exist,	and	understanding	them,	may	shed	some	much	
needed	 light	 on	 disease	 progression	 and	 ways	 in	 which	 treatment	 of	 AD	 may	 be	 tackled	 in	 the	
future.		
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Appendix	A		
Optimisation	of	HS	 extraction	 and	purification	 steps	 for	 disaccharide	 analysis	with	 strong	 anion	
exchange	chromatography	
	
	 Initially,	 HS	 extraction	 and	 purification	 was	 carried	 out	 on	 mouse	 brain	 tissue	 and	 with	
commercially	 available	 disaccharide	 standards	 to	 ensure	 that	 the	 procedure	 could	 be	 carried	 out	
fully	without	loss	of	the	HS	material.	HS	extraction	and	purification	protocol	yielded	reasonably	low	
detection	of	disaccharides.	As	there	were	only	limited	quantities	of	brain	sample	available	from	the	
brain	 bank,	 optimisation	 was	 necessary	 to	 enhance	 detection	 of	 small	 quantities	 of	 HS	 so	 that	
multiple	 experiments	 could	be	 carried	out	with	 each	donated	 sample,	 as	well	 as	 generating	 large	
enough	peaks	so	as	to	be	accurately	analysed	without	error.		
	
	 The	protocol	steps	as	outlined	in	Chapter	2	were	necessary	for	appropriate	extraction	and	
purification	of	HS	 from	tissue.	Any	 issues/potential	 losses	of	material	 from	each	of	 the	main	steps	
were	highlighted	and	solutions	found	where	necessary.	These	are	outlined	below.	Importantly,	with	
exception	 of	 TLC	 optimisation	 that	 was	 carried	 out	 as	 a	 separate	 experiment,	 the	 other	
modifications	to	the	protocol	were	carried	out	in	combination	with	one	another.		
	
DEAE	step	optimisation		
	
There	 were	 difficulties	 with	 pelleting	 the	 beads	 appropriately	 and	 some	 were	 lost	 as	 a	
result,	 during	elution	 steps.	 This	would	have	negatively	 impacted	HS	product	 yield	 as	 the	 sugar	 is	
bound	 to	 the	 beads	 until	 the	 final	 elution	 steps.	 As	 such	 any	 beads	 lost	 in	 preceding	wash	 steps	
precluded	recovery	of	purified	HS	product.	To	solve	this,	beads	were	spun	at	a	greater	speed	(3000	
rpm)	for	a	longer	period	of	time	(5	min)	and	all	wash	steps	(10ml)	and	elution	steps	(1ml	x2)	were	
carried	out	 in	greater	volume	and	decanted	off	the	beads	rather	than	pipetted	off.	This	prevented	
loss	of	beads	and	as	a	result	improved	the	yield	of	HS	collected	at	this	step.		
	
Graphite	column	optimisation	
	
	 In	this	step	of	the	protocol,	there	was	some	graphite	contamination	in	the	final	sample	of	
HS	recovered.	In	addition	there	were	issues	removing	all	of	the	organic	solvents	used	to	elute	the	HS	
from	the	graphite	beads.	Graphite	contamination	was	shown	to	interfere	with	the	labeling	process	
that	 followed,	 as	 it	 could	 not	 be	 sufficiently	 dissolved	 in	 the	 DMSO:	 acetic	 acid	 mixture.	
Furthermore,	 graphite	 carried	 over	 in	 this	 manner	 resulted	 in	 a	 reduced	 product	 yield,	 as	 HS	
remained	bonded	to	the	graphite	beads	and	could	not	be	successfully	dissociated.	As	a	solution,	the	
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graphite	columns	were	spun	at	a	lower	speed	(1.5	x	g)	to	prevent	the	graphite	passing	through	the	
matrix	 filter	 at	 the	 bottom	 of	 the	 column	 into	 the	 sample.	 Furthermore	 an	 increased	 number	 of	
water	washes	and	speed	vac	steps	were	incorporated	into	the	protocol	to	ensure	complete	removal	
of	all	organic	solvents	that	would	otherwise	interrupt	the	successive	labeling	and	clean	up	steps.	
	
TLC	step	optimisation	
	
	 A	study	was	run	to	assess	efficiency	of	the	TLC	method	for	removing	free	BODIPY	label	that	
would	otherwise	saturate	the	fluorescence	detection	on	the	HPLC	system.	4	samples	of	HS	standards	
1-8	were	labeled	with	the	BODIPY	hydrazide	tag	(10μl)	of	160μg/ml	stock)	and	run	on	the	TLC	plates	
as	 described	 previously	 (Chapter	 2).	 Different	 sections	 of	 the	 plate	 relative	 to	 original	 sample	
placement	were	taken	 for	each	experiment	and	run	over	 the	Propac	PA-1	column	to	assess	which	
standards	were	collected	from	which	region	of	the	plate.		
	
Previously,	silica	 filings	 from	the	TLC	plate	were	taken	from	-2cm	of	sample	spot	to	+2cm	
(TLC1).	Results	of	this	study	however	found	that	a	high	proportion	of	standard	UA-GlcNAc	was	found	
within	 the	 region	 2-4cm	 from	 sample	 placement	 (TLC2)	 (Figure	 1).	 To	 ensure	 all	 of	 the	 standard	
disaccharides	were	 collected	without	 loss,	 a	 greater	 proportion	 of	 the	 silica	 filings	 from	 the	 plate	
must	 be	 collected.	 This	 prevented	 loss	 of	 final	 HS	 product	 at	 HPLC	 analysis.	 Together,	 the	
combination	 of	 these	 alterations	 to	 the	 protocol	 provided	 enhanced	 detection	 of	 the	 HS	
disaccharides	significantly	by	approximately	5	fold.	The	TLC	step	proved	to	be	the	most	significantly	
optimized	step	with	dramatic	increases	in	the	detection	of	HS	disaccharide	standard.	Optimisation	of	
this	protocol	therefore	improved	the	quality	of	the	chromatograms	for	each	sample	and	enhanced	
detection	of	even	very	small	quantities	of	individual	disaccharides.		
	
Ethanol	precipitation	optimisation		
	 The	last	step	is	included	in	this	protocol	to	ensure	final	removal	of	any	impurities	that	may	
have	 co-purified	 with	 the	 HS.	 Initially,	 there	 were	 some	 significant	 losses	 of	 the	 UA-GlcNAc	
disaccharides.	This	disaccharide	is	totally	unsulfated	and	as	such	only	binds	relatively	weakly	to	the	
positively	charged	strong	anion	exchange	column.	It	appeared	to	be	dissociated	almost	immediately	
from	 the	 column.	 This	 may	 have	 been	 a	 result	 of	 insufficient	 water	 wash	 steps	 after	 ethanol	
precipitation	 such	 that	 carry	 over	 of	 the	 sodium	 acetate	 meant	 the	 sample	 could	 be	 easily	
dissociated	from	the	column.	Increased	wash	steps	effectively	removed	the	salt	and	prevented	loss	
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of	 unsulfated	 HS	 disaccharides	 from	 the	 column	 inappropriately.	 This	 dramatically	 improved	 the	
yield	 of	 the	 UA-GlcNAc	 standard	 that	 could	 be	 detected	 and	 analysed	 as	 part	 of	 compositional	
analysis	studies.		
	
Results	
	
	 Together,	 these	 small	 changes	 to	 the	 protocol	 dramatically	 increased	 the	 detection	 of	
purified	HS	 after	 strong	 anion	 exchange	 chromatography.	Figure	 2	 shows	 data	 for	 preparation	 of	
disaccharides	 by	 the	 original	 or	 improved	 protocols.	 In	 some	 instances	 there	was	 nearly	 a	 5-fold	
improvement	in	the	amount	of	purified	HS	that	could	be	analysed.		
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Figure	A1:	Optimisation	of	TLC	step	in	compositional	analysis	of	purified	HS	from	human	AD	and	Ctrl	BA21	
brain	regions.	Different	regions	of	the	TLC	(as	shown)	were	taken	and	analysed	to	determine	how	labeled	HS	
disaccharide	standards	run	along	the	TLC	plate.	As	indicated	by	the	arrow	on	the	chromatogram,	a	great	deal	
of	 the	 UA-GlcNAc	 disaccharide	 is	 present	 within	 the	 “TLC2”	 region	 of	 the	 plate,	 a	 region	 previously	
uncollected	before	optimisation.	This	 is	 the	smallest	of	 the	disaccharides	and	hence	we	would	expect	 it	 to	
travel	further	up	the	plate.	In	future	HS	purifications	and	labeling,	filings	from	the	TLC	plate	were	collected	
as	far	as	6cm	from	the	bottom	of	the	plate	to	ensure	total	recovery	of	all	HS	disaccharides.		
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Figure	 A2:	 Original	 and	 optimised	 protocols	 for	 HS	 extraction	 and	 labeling	 of	 commercially	 available	
disaccharide	 standards	 (A)	 and	 HS	 derived	 from	 mouse	 brain	 samples	 (B).	 Fluorescence	 strong	 anion	
exchange	HPLC	of	commercially	available	disaccharide	standards	and	HS	derived	from	mouse	brain	samples.	
These	were	prepared	as	per	original	protocol	measures	and	injected	over	a	Propac	PA-1	column	and	eluted	
with	 a	 linear	 gradient	 of	 sodium	 chloride	 (0-1M	 over	 30min)	 and	 isocratic	 NaOH	 (150mM).	 Peaks	 were	
detected	 using	 an	 inline	 fluorimeter,	 λexc	 =	 488nm	 and	 λemm	 =	 520nm.	 From	 left	 to	 right	 disaccharides	
present	 a	 progressively	 greater	 level	 of	 sulfation.	 Chromatograms	 display	 improved	 profiles	 following	
optimisation	 of	 the	 original	 protocol.	 A	 much	 greater	 signal	 intensity	 was	 established	 following	
improvement	to	the	protocol.		
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Appendix	B	
SULF	KO	mouse	brain	compositional	analysis	data	
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Figure	B1:	Composition	of	HS	disaccharides	displaying	different	numbers	of	sulfate	groups	does	not	differ	
upon	knockdown	of	the	Sulf1	or	Sulf2	gene.	HS	isolated	from	control,	SULF1	KO,	SULF2	KO	and	DOUBLE	KO	
mouse	brain	samples	were	digested	with	 a	mixture	of	 heparin	 lyases	 (heparinase	 I,	 II	and	 III	mixture)	and	
resultant	 disaccharides	 were	 labeled	 with	 BODIPY	 hydrazide	 and	 subjected	 to	 strong	 anion	 exchange	
chromatography	on	a	Propac	PA-1	column	and	eluted	with	a	linear	gradient	of	sodium	chloride	(0-1M	over	
30	min)	 and	 isocratic	 sodium	 hydroxide	 (150mM).	 Peaks	were	detected	using	 an	 inline	 fluorimeter,	 λexc	 =	
488nm	 and	 λemm	 =	 520nm.	 Peak	 areas	 for	 each	 disaccharide	 were	 measure	 and	 disaccharide	 analysis	 is	
expressed	as	a	%	of	mono-	di-	and	tri-	sulfated	motifs	within	the	HS	analysed.	Data	shown	are	from	control	
(n=3),	SULF1	KO	(n=3),	SULF2	KO	(n=3)	and	DOUBLE	KO	(n=3).	Error	bars	represent	mean	(±S.E.M).		
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Figure	 B2:	 Total	 HS	 levels	 do	 not	 change	 upon	 knockdown	 of	 the	 Sulf1	 or	 Sulf2	 gene.	HS	 isolated	 from	
control,	SULF1	KO,	SULF2	KO	and	DOUBLE	KO	mouse	brain	samples	were	digested	with	a	mixture	of	heparin	
lyases	(heparinase	I,	II	and	III	mixture)	followed	by	exhaustive	clean	up	enzymatic	digestion	to	remove	other	
GAGs,	 DNA,	 RNA	 and	 protein.	 Resultant	 disaccharides	 were	 finally	 quantified	 and	 total	 HS	 levels	 were	
normalised	to	μg/100mg	of	wet	tissue	starting	material.	Data	shown	are	from	control	(n=3),	SULF1	KO	(n=3),	
SULF2	KO	(n=3)	and	DOUBLE	KO	(n=3).	Error	bars	represent	mean	(±S.E.M).	
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Figure	B3:	Composition	of	HS	disaccharides	sulfated	at	different	locations	do	not	differ	upon	knockdown	of	
the	Sulf1	or	Sulf2	gene.	HS	isolated	from	control,	SULF1	KO,	SULF2	KO	and	DOUBLE	KO	mouse	brain	samples	
were	 digested	with	 a	mixture	 of	 heparin	 lyases	 (heparinase	 I,	 II	 and	 III	mixture)	 and	 resultant	disaccharides	
were	labeled	with	BODIPY	hydrazide	and	subjected	to	strong	anion	exchange	chromatography	on	a	Propac	PA-
1	 column	 and	 eluted	 with	 a	 linear	 gradient	 of	 sodium	 chloride	 (0-1M	 over	 30	 min)	 and	 isocratic	 sodium	
hydroxide.	 Peaks	were	detected	using	 an	 inline	 fluorimeter,	 λexc	 =	488nm	and	λemm	=	520nm.	Peak	 areas	 for	
each	 disaccharide	were	measure	 and	 disaccharide	 analysis	 is	 expressed	 as	 a	%	 of	 N-,	 6-O	 and	 2-O	 sulfated	
motifs	 within	 the	 HS	 analysed.	 Data	 shown	 are	 from	 control	 (n=3),	 SULF1	 KO	 (n=3),	 SULF2	 KO	 (n=3)	 and	
DOUBLE	KO	(n=3).	Error	bars	represent	mean	±	S.E.M.		
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Figure	B4:	Composition	of	HS	disaccharides	changes	upon	knockdown	of	the	Sulf1	or	Sulf2	gene.	HS	isolated	
from	Ctrl,	SUlF1	KO,	SULF2	KO	and	double	KO	mouse	brain	samples	were	digested	with	a	mixture	of	heparin	
lyases	 (heparinase	 I,	 II	 and	 III	 mixture)	 and	 resultant	 disaccharides	 were	 labeled	 with	 BODIPY	 fluorescent	
hydrazide	and	subjected	to	strong	anion	exchange	chromatography	on	a	Propac	PA-1	column	and	eluted	with	a	
linear	gradient	of	sodium	hydroxide	(0-1M	over	30	min).	Peaks	were	detected	using	an	inline	fluorimeter,	λexc	=	
488nm	 and	 λemm	 =	 520nm.	 Peak	 areas	 for	 each	 disaccharide	 were	 measure	 and	 disaccharide	 analysis	 is	
expressed	as	a	%	of	 total	HS	analysed.	Data	shown	are	 from	Ctrl	 (n=3),	SULF1	KO	(n=3),	SULF2	KO	(n=3)	and	
Double	KO	(n=3).	Error	bars	represent	mean	±	S.E.M.	Student’s	t-test	*	p<0.05,	**	p<0.01,	***	p<0.001.	
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Appendix	C		
Gene/protein	lists	created	for	bioinformatics	work	
List	1:	HS	biosynthetic	enzymes	and	core	proteins	
	
This	 list	 included	 all	 HS	 biosynthetic	 enzymes	 including	 the	 core	 proteins	 onto	which	 HS	
chains	 may	 be	 covalently	 bound.	 This	 list	 was	 generated	 with	 the	 use	 of	 KEGG	 (Version	 80.1,	
Kaneshisa	laboratories,	Japan)	to	determine	the	established	pathway	for	the	synthesis	of	HS.	This	list	
also	included	the	HS	degradation	enzymes	including	HPSE	and	HPSE2	and	SULF1	and	2.	With	regard	
to	 core	 proteins,	 only	 the	 “full	 time”	 HSPGs	 were	 selected.	 The	 “part	 time”	 HSPGs,	 including	
betaglycan	and	Neuropilin-1	were	not	included	in	this	list	(Sarrazin,	et	al.	2011).	
	
EXT1	
EXT2	
EXTL1	
EXTL2	
EXTL3	
XYLT1	
XYLT2	
NDST1	
NDST2	
NDST3	
NDST4	
GLCE	
HS6ST1	
HS6ST2	
HS6ST3	
HS2ST1	
HS3ST1	
HS3ST2	
HS3ST3A1	
HS3ST3B1	
HS3ST4	
HS3ST5	
SULF1	
SULF2	
HPSE	
HPSE2	
GPC1	
GPC2	
GPC3	
GPC4	
GPC5	
GPC6	
SDC1	
SDC2	
SDC3	
SDC4	
HSPG2	
AGRN	
CD44	
COL18A1	
SRGN	
	
	
List	2:	GWAS	determined	AD	risk	proteins	
	
APOE	
LRAT	
FAM1138	
ATXN1	
CD33	
PCDH11X	
ACAN	
BCR	
CTSS	
EBF3	
FAM63A	
GALP	
LMNA	
LOC651924	
MYH13	
PCK1	
PGBD1	
TNK1	
TRAK2	
UBD	
CLU	
PICALM	
CHRNA7	
BIN1	
CD2AP	
CR1	
EPHAI	
MS4A4E	
MS4A6A	
GOLM1	
CELF2	
TMEM132C	
TRPC4AP	
ARSB	
CANDI	
EFNA5	
MAGI2	
PRUNE2	
TOMM40	
GAB2	
EXOC3L2	
AGPAT1	
ATP6VOA4	
GLOD4	
RG56	
	
List	3:	Heparin	interactome	proteins	
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	 This	list	was	obtained	from	the	work	of	Ori	et	al	in	2011	(Ori,	et	al.	2011).	The	interactome	
list	was	obtained	from	Supplementary	data,	Table	1.	All	details	of	functionality	of	these	proteins	can	
be	found	in	this	publication	also.		
 
 	
	
4F2	
5NTD	
A1AT	
A1BG	
A2MG	
A4	
AACT	
AAMP	
ABCBB	
ABCG2	
ABCG5	
ABP1	
ADA1B	
AGRP	
AIMP1	
ALDR	
AMBP	
AMRP	
ANGI	
ANGT	
ANT3	
ANXA1	
ANXA2	
ANXA3	
ANXA5	
ANXA6	
APLP1	
APLP2	
APOA5	
APOB	
APOE	
APOH	
AQP1	
ARGI1	
ARTN	
ASIP	
AT1A1	
AT1B1	
AT1B3	
AT2B1	
ATP7B	
ATPA	
ATRN	
ATS1	
ATS3	
ATS5	
ATS8	
ATS9	 	 	 	 	 	
B2MG	
B3AT	
B4E216	
BACE1	
BMP2	
BMP3	
BMP4	
BMP6	
BMP7	
BTC	
C1QA	
C1QB	
C1QC	
C4BPA	
CAC1S	
CADH8	
CAP7	
CATB	
CATG	
CBG	
CBPB2	
CBPD	
CC134	
CCD80	
CCL1	
CCL11	
CCL13	
CCL15	
CCL17	
CCL19	
CCL2	
CCL21	
CCL22	
CCL23	
CCL24	
CCL25	
CCL27	
CCL28	
CCL3	
CCL4	
CCL5	
CCL7	
CCL8	
CD031	
CD1D	
CD36	
CD47	
CEL	
CERU	
CF015	
CFAB	
CFAD	
CFAH	
CFAI	
CHRD	
CJ058	
CLUS	
CMA1	
CO1A1	
CO1A2	
CO2	
CO2A1	
CO3	
CO3A1	
CO4A	
CO4A1	
CO4A2	
CO5	
CO5A1	
CO5A3	
CO6	
CO6A3	
CO7	
CO8A	
CO8B	
CO8G	
CO9	
CO9A1	
COBA1	
COBA2	
COCA1	
CODA1	
COEA1	
COIA1	
COJA1	
COLQ	
COMP	
COMT	
CONA1	
COPA1	
CRCM1	
CRLD2	
CSF2	
CTGF	
CTR2	
CXB1	
CXCL2	
CXCL6	
CXCL7	
CXL10	
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CXL11	
CXL13	
CXL16	
CYC	
CYR61	
DCC	
DHB11	
DHB12	
DHB13	
DHB7	
DPP4	
ECE1	
ECM2	
EFNA1	
EFNA3	
EFNA5	
ELN	
ELNE	
ENOA	
ENPP1	
ENPP3	
ERBB2	
FA10	
FA11	
FA12	
FA55A	
FA9	
FBLN7	
FBN1	
FBN2	
FBS1	
FCGRN	
FETUB	
FGF1	
FGF10	
FGF12	
FGF14	
FGF16	
FGF17	
FGF18	
FGF2	
FGF20	
FGF22	
FGF3	
FGF4	
FGF5	
FGF6	
FGF7	
FGF8	
FGF9	
FGFP1	
FGFP3	
FGFR1	
FGFR2	
FGFR3	
FGFR4	
FIBA	
FIBB	
FIBG	
FINC	
FST	
FSTL1	
FURIN	
G6B	
GDN	
GDNF	
GELS	
GHR	
GP182	
GPNMB	
GROA	
GTR2	
HBEGF	
HDGF	
HEP2	
HFE	
HGF	
HMGB1	
HPT	
HRG	
IAPP	
IBP2	
IBP3	
IBP4	
IBP5	
IBP6	
IC1	
IFNG	
IHH	
IIGP5	
IL10	
IL12B	
IL2	
IL3	
IL4	
IL5	
IL6	
IL7	
IL8	
IMPG2	
INHBA	
INSR	
IPSP	
ITA1	
ITA5	
ITAM	
ITAV	
ITB1	
ITB3	
ITIH3	
ITM2B	
KALM	
KGFL1	
KGFL2	
KNG1	
LAMA1	
LAMA2	
LAMA3	
LAMA4	
LAMA5	
LAMC2	
LCAP	
LDLR	
LEG9	
LGR4	
LIFR	
LIPC	
LIPE	
LIPL	
LIS1	
LPHN2	
LTBP1	
LYAM1	
LYAM3	
MBL2	
MDR1	
MDR3	
MET	
MIF	
MK	
MMP14	
MMP2	
MMP7	
MMP9	
MOT1	
MOT8	
MRP6	
MYL9	
NAV2	
NCAM1	
NET1	
NICA	
NOGG	
NRG1	
NRP1	
NRTN	
NTCP	
OCLN	
OZF	
PA2G5	
PA2GA	
PAI1	
PAIRB	
PCFT	
PCOC2	
PCSK5	
PCSK6	
PDCD5	
PDGFA	
PDGFB	
PDIA1	
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PDIA6	
PEBP1	
PECA1	
PEDF	
PERM	
PF4V	
PGBM	
PGS1	
PIGR	
PLBL1	
PLF4	
PLGF	
PLMN	
PON1	
PON2	
PON3	
POSTN	
PPIB	
PRDX4	
PRELP	
PRG2	
PRIO	
PRL	
PROC	
PROP	
PSN1	
PTC1	
PTN	
PTPRC	
Q5IT36	
Q5JAR4	
Q8IV69	
Q9HCS8	
RL22	
RL29	
ROBO1	
RSPO1	
RSPO2	
RSPO3	
RSPO4	
RSSA	
S12A9	
S20A2	
S22A1	
S22A7	
S22AI	
S38A3	
S38A4	
S39A4	
S4A4	
SAA	
SAMP	
SCN5A	
SDF1	
SEM5A	
SEM5B	
SFRP1	
SHH	
SIAT1	
SLIT1	
SLIT2	
SLPI	
SNG1	
SODC	
SODE	
SORT	
SOST	
STAB2	
STEA4	
STIM1	
SYUA	
TAU	
TEN1	
TENA	
TENX	
TFPI1	
TFR1	
TFR2	
TGBR3	
TGFB1	
TGFB2	
TGM2	
THIO	
THRB	
THYG	
TIMP3	
TIP	
TNF13	
TNFA	
TPA	
TR11B	
TRFE	
TRFL	
TRY1	
TRYB1	
TRYB2	
TSG6	
TSP1	
TSP2	
TSP3	
TSP4	
TTHY	
UROK	
VEGFA	
VEGFB	
VGFR1	
VGFR2	
VTDB	
VTNC	
VWF	
WNT1	
X3CL1	
XCL1	
XDH	
ZNT1	
ZPI	
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Appendix	D	
Genevestigator	protocol	
	
Briefly,	33	AD	brain	samples	(15	males	and	18	females)	were	collected	at	three	Alzheimer’s	
disease	Centers	 (ADCs)	 in	America;	Washington	University,	Duke	University	and	Arizona	University	
ADCs.	 Alzheimer’s	 samples	 were	 taken	 from	 patients	 with	 a	mean	 age	 of	 79.9	 ±	 6.9yr	 and	were	
selected	 based	 on	 both	 clinical	 and	 neurological	 criteria.	 Post	 mortem	 at	 death	 allowed	
histopathological	 confirmation	 of	 AD	 and	 of	 the	 samples	 selected,	 CERAD	 scores	 ranged	 from	
moderate	to	frequent	and	Braak	stages	ranged	from	V	to	VI	(Braak	and	Braak	1991).	Control	samples	
were	 collected	 from	 the	 Sun	 Health	 research	 Institute,	 an	 ADC	 and	 were	 clinically	 classified	 as	
neurologically	 normal	 (Liang,	 et	 al.	 2007).	 10	 males	 and	 4	 females	 made	 up	 the	 healthy	 control	
sample	group	and	were	gender	and	age-matched	to	AD	samples	at	death.	Average	age	for	this	group	
was	79.8	±	9.1yr.	Post	mortem	at	death	confirmed	CERAD	scores	of	infrequent	and	Braak	staging	of	I	
to	II	(Liang,	et	al.	2007).		
	
Heterogeneity	within	 tissue	was	 eliminated	 prior	 to	 expression	 profiling	 by	 laser	 capture	
microscopy	on	all	brain	regions.	6	brain	regions	were	targeted	in	total,	with	14	biological	replicates	
taken	for	each	region.	The	entorhinal	cortex	(BA	28	and	34),	hippocampus,	middle	temporal	gyrus	
(BA	21	and	37),	posterior	cingulate	(BA	23	and	31),	primary	visual	cortex	(BA	17)	and	superior	frontal	
gyrus	(BA	10	and	11)	were	all	selected	as	regions	of	 interest	(Dunckley,	et	al.	2006).	The	6	regions	
chosen	were	based	on	 their	 vulnerability	 to	 the	pathological	processes	of	 associated	with	AD	and	
ageing.	 Sections	 were	 dissected,	 frozen	 and	 sectioned	 and	mounted	 onto	 slides	 (Dunckley,	 et	 al.	
2006).	 Approximately	 1,000	pyramidal	 neurons	were	 collected	 from	 the	 cortical	 layer	 III	 from	 the	
white	 matter	 of	 each	 brain	 region	 per	 brain	 sample	 by	 laser	 capture	 microdissection	 with	 the	
Arcturus	Autopix	Automated	 laser	Capture	Microdissection	System	(Mouse	View,	CA)	 (Liang,	et	al.	
2008).	 RNA	 was	 extracted	 according	 to	 manufacturer’s	 instructions	 (Pico	 Pure	 RNA	 Isolation	 Kit,	
Arcturus),	 and	DNA	 removed	 according	 to	manufacturer’s	 instructions	 (Qiagen	 RNAse	 free	DNase	
Set,	Valencia,	CA).	RNA	samples	underwent	double	 round	amplification	before	cleaning	and	biotin	
labeling	 as	 per	 manufacturer’s	 instructions	 (Affymetrix	 GeneChip	 Two-Cycle	 Target	 labeling	 kit,	
Santa	 Clara,	 CA)	 (Liang,	 et	 al.	 2007).	 For	 the	microarray	 analysis,	 cocktails	were	 hybridized	 to	 the	
Affymetrix	Human	Genome	U133	plus	2.0	Array	for	16h	at	45’C	in	the	Hybridization	Oven	640.	This	
array	 allowed	 the	 analysis	 over	 38,500	 pre-characterized	 human	 genes.	 After	 Incubation,	 arrays	
were	washed	 according	 to	manufacturer’s	 instructions	 and	 finally	 scanned	 for	 signal	 intensity.	 All	
target	gene	signal	 intensities	were	normalized	against	the	housekeeping	gene	GAPDH	(Liang,	et	al.	
2007).	
	
	
